[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2651885A1 - Anti-viral compounds - Google Patents

Anti-viral compounds

Info

Publication number
EP2651885A1
EP2651885A1 EP11806100.1A EP11806100A EP2651885A1 EP 2651885 A1 EP2651885 A1 EP 2651885A1 EP 11806100 A EP11806100 A EP 11806100A EP 2651885 A1 EP2651885 A1 EP 2651885A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
independently
occurrence
carbocycle
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP11806100.1A
Other languages
German (de)
French (fr)
Inventor
Allan C. Krueger
Warren M. Kati
William A. Carroll
John K. Pratt
Douglas K. Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of EP2651885A1 publication Critical patent/EP2651885A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to compounds effective in inhibiting replication of Hepatitis C virus ("HCV").
  • HCV Hepatitis C virus
  • the present invention also relates to compositions comprising these compounds and methods of using these compounds to treat HCV infection.
  • HCV is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family.
  • the enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame.
  • the open reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids.
  • the polyprotein comprises a core protein, envelope proteins El and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.
  • HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma.
  • Chronic hepatitis C may be treated with peginterferon-alpha in combination with ribavirin.
  • Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.
  • the present invention features compounds of Formulae I, I A , 3 ⁇ 4, Ic, I D , I E , I F or I G , and pharmaceutically acceptable salts thereof. These compounds and salts can inhibit the replication of HCV and therefore are useful for treating HCV infection.
  • compositions comprising the compounds or salts of the present invention.
  • the compositions can also include additional therapeutic agents, such as HCV helicase inhibitors, HCV polymerase inhibitors, HCV protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, cyclophilin inhibitors, or internal ribosome entry site (IRES) inhibitors.
  • additional therapeutic agents such as HCV helicase inhibitors, HCV polymerase inhibitors, HCV protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, cyclophilin inhibitors, or internal ribosome entry site (IRES) inhibitors.
  • the present invention further features methods of using the compounds or salts of the present invention to inhibit HCV replication.
  • the methods comprise contacting cells infected with HCV virus with a compound or salt of the present invention, thereby inhibiting the replication of HCV virus in the cells.
  • the present invention features methods of using the compounds or salts of the present invention, or compositions comprising the same, to treat HCV infection.
  • the methods comprise administering a compound or salt of the present invention, or a pharmaceutical composition comprising the same, to a patient in need thereof, thereby reducing the blood or tissue level of HCV virus in the patient.
  • the present invention also features use of the compounds or salts of the present invention for the manufacture of medicaments for the treatment of HCV infection.
  • the present invention features processes of making the compounds or salts of the invention.
  • the present invention features compounds having Formula I, and pharmaceutically acceptable salts thereof,
  • Li and L2 are each independently selected from bond; or Ci-Cealkylene, C 2 -C 6 alkenylene or C2-C 6 alkynylene, each of which is independently optionally substituted at each occurrence with one or more R L ;
  • L 3 is bond or -L S -K-L S '-, wherein K is selected from bond, -0-, -S-, -N(R B )-, -C(O)-, -S(0) 2 - -S(O)-, -OS(O)-, -OS(0) 2 - -S(0) 2 0- -S(0)0- -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(R B )-, -N(RB)C(0)-, -N(RB)C(0)0- -OC(0)N(R B )-, -N(R B )S(0)-, -N(RB)S(0) 2 - -S(0)N(R B )-, -S(0) 2 N(RB)-, -C(0)N(R B )C(0)-, -N(R B )C(0)N(RB')-, -N(R B )S0 2 N(RB')-, or
  • D is C 3 -Ci 2 carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle which is substituted with J and optionally substituted with one or more R A , where J is
  • Y is selected from -T'-C(R 1 R 2 )N(R 5 )-T-R D , -T'-C(R3R4)C(R 6 R 7 )-T-RD, -L K -T-R d , or Ri and R 2 are each independently R c , and R 5 is R B ; or Ri is Rc, and R 2 and R 5 , taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R A ;
  • R 3 , R4, R 6 , and R 7 are each independently R c ; or R 3 and R 6 are each independently R c , and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12- membered carbocycle or heterocycle which is optionally substituted with one or more R A ;
  • Z is selected from -T'-C(R 8 R 9 )N(R 12 )-T-R D , -T'-C(R 10 Rn)C(Ri3Ri4)-T-R D , L K — T— R D or
  • R 8 and R 9 are each independently R c , and Ri 2 is R B ; or R 8 is R c , and R 9 and Ri 2 , taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R A ;
  • Rio, Rn, Ri3, and R M are each independently Rc; or Ri 0 and R13 are each independently R c , and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
  • T and T are each independently selected at each occurrence from bond, -L s - -L s -M-L s '-, or -Ls-M-Ls'-M'-Ls"-, wherein M and M' are each independently selected at each occurrence from bond, -0-, -S-, N(R B )— , -C(O)-, -S(0) 2 - -S(O)-, -OS(O)-, -OS(0) 2 - -S(0) 2 0-, -S(0)0- -C(0)0- -OC(O)-, -OC(0)0-, -C(0)N(R B )-, -N(R B )C(0)-, -N(RB)C(0)0- -OC(0)N(R B )-, -N(R B )S(0)-, -N(R B )S(0) 2 - -S(0)N(R B )-, -S(0) 2 N(RB)-
  • L K is independently selected at each occurrence from bond, -L s -N(R B )C(0)-L s '- or -L s -C(0)N(R B )-L s '-; or Ci-Cealkylene, C 2 -Cealkenylene or C 2 -Cealkynylene, each of which is independently optionally substituted at each occurrence with one or more R L ; or C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more RA;
  • E is independently selected at each occurrence from C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is independently optionally substituted at each occurrence with one or more R A ;
  • R D is each independently selected at each occurrence from hydrogen or R A;
  • R A is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -RE, wherein two adjacent R A , taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle;
  • R B and R B ' are each independently selected at each occurrence from hydrogen; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R B or R B ' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 al
  • R c is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in Rc is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo,
  • R E is independently selected at each occurrence from -0-R s , -S-R s , -C(0)R s , -OC(0)R s , -C(0)OR s , -N(RsRs'), -S(0)R s , -S0 2 R s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(Rs)C(0)N(R s 'Rs"), -N(R s )S0 2 R s ', -S0 2 N(R s R s '), -N(R s )S0 2 N(R s 'R s "), -N(Rs)S(0)N(R s 'Rs"), -OS(0)-R s , -OS(0) 2 -R s , -S(0) 2 OR s , -S(0)OR s ,
  • each R Y is independently Ci-Cealkylene, C 2 -Cealkenylene or C 2 -C 6 alkynylene each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, and wherein each R Y ' is independently Ci-C 6 alkyl, C 2 -Ci 0 alkenyl or C 2 -Ci 0 alkynyl, each of which contains 0, 1, 2, 3, 4 or 5 heteroatoms selected from O, S or N and is independently optionally substituted with one or more R L ; or -(RX-RY)Q-(RX-RY'), wherein Q is 0, 1 , 2, 3 or 4, and each R x is independently O, S or N(R B ), wherein each R Y is independently Ci-Cealkylene, C 2 -Ce
  • L s ' and L s " are each independently selected at each occurrence from bond; or Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene, each of which is independently optionally substituted at each occurrence with one or more R L ; and
  • R s ' and R s " are each independently selected at each occurrence from hydrogen; Ci-C 6 alkyl, C 2 -Cealkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, -0-Ci-C 6 alkyl, -0-Ci-C 6 alkylene-0-Ci-C 6 alkyl, or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R s , R s ' or R s ' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy,
  • a and B preferably are independently selected from C 5 -C 6 carbocycle (e.g., phenyl), 5- to 6- membered heterocycle (e.g., pyridinyl or thiazolyl), or 8- to 12-membered bicycles such as where Zi is independently selected at each occurrence from O, S, NH or CH 2 , Z 2 is independently selected at each occurrence from N or CH, Z3 is independently selected at each occurrence from N or CH, Z4 is independently selected at each occurrence from O, S, NH or CH 2 , and Wi, W 2 , W 3 , W 4 , W 5 and W 6 are each independently selected at each occurrence from CH or N.
  • a and B are each independently optionally substituted with one or more R A .
  • A is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, and is optionally substituted with one or more RA ?
  • B is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or and is optionally substituted with one or more R A ; where Z Z 2 , Z 3 , Z 4 , Wi, W 2 ,
  • W 3 , W 4 , W 5 , W 6 are as defined above.
  • Z 3 is N and Z 4 is NH.
  • A can be selected from
  • both A and B are phenyl (e.g., both A and B ar Also highly preferably, A
  • D preferably is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more R A .
  • D can also be preferably selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more substituents selected from R L .
  • D is C 5 -C 6 carbocycle (e.g., phenyl), 5- to 6- membered heterocycle (e.g., pyridinyl, pyrimidinyl, thiazolyl), or 6- to 12-membered bicycles (e.g., indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l,3]dioxol-5-yl), and is substituted with one or more R M , where R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • D is phenyl, and is optionally substituted with one or more R A . More preferably, D is phenyl, and is substituted with one or more R M , wherein R M is as defined
  • D is wherein R M is as defined above, and each
  • R N is independently selected from R D and preferably is hydrogen.
  • One or more R N can also preferably be halo such as F.
  • D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R A . More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
  • D is , or , wherein is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[ xol-5-yl, and is substituted with one or more R M .
  • D is , or , wherein is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydro
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C
  • R M is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R M is -L S -R E , wherein L s is a bond or Ci-C 6 alkylene, and R E is -N(RsRs'), -O-Rs, -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S0 2 R s , -SRs, or -P(0)(OR s ) 2 , wherein R s and R s ' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C 6 alkyl optionally
  • R M is CF 3 , -C(CF 3 ) 2 -OH, -C(CH 3 ) 2 -CN, -C(CH 3 ) 2 -CH 2 OH, or -C(CH 3 ) 2 -CH 2 NH 2 .
  • R M is -L S -R E where L s is a bond and R E is -N(R S R S ), -0-R s , -N(R s )C(0)OR s ', -N(R s )S0 2 R s ', -S0 2 R s , or -SR S .
  • R E is -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ); -N(C C 6 alkylene-0-Ci-C 6 alkyl) 2 (e.g. -N(CH 2 CH 2 OMe) 2 );
  • -N(Ci-C 6 alkyl)(Ci-C 6 alkylene-0-Ci-C 6 alkyl) (e.g. -N(CH 3 )(CH 2 CH 2 OMe));— 0-Ci-C 6 alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-Ci-C 6 haloalkyl (e.g., -OCF 3 , -OCH 2 CF 3 ); -0-Ci-C 6 alkylene-piperidine (e.g., -0-CH 2 CH 2 -l-piperidyl);
  • -N(Ci-C 6 alkyl)C(0)OCi-C 6 alkyl e.g., -N(CH 3 )C(0)0-CH 2 CH(CH 3 ) 2
  • Ci-C 6 alkyl e.g., -N(CH 3 )S0 2 CH 3
  • -S0 2 Ci-C 6 alkyl e.g., -S0 2 Me
  • -S0 2 Ci-C 6 haloalkyl e.g., -S0 2 CF 3
  • -S-Ci-C 6 haloalkyl e.g., SCF 3
  • R M is -L S -R E where L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • R M is -Ci-C 6 alkylene-0-R s (e.g., -C(CH 3 ) 2 -CH 2 -OMe); -Ci-C 6 alkylene-C(0)OR s (e.g., -C(CH 3 ) 2 -C(0)OMe);
  • -Ci-C 6 alkylene-N(R s )C(0)ORs' e.g., -C(CH 3 ) 2 -CH 2 -NHC(0)OCH 3
  • -Ci-C 6 alkylene-P(0)(OR s ) 2 e.g., -CH 2 -P(0)(OEt) 2 ).
  • R M is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s , or -N(R S R S ').
  • R M is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl).
  • cycloalkyl e.g., cyclopropyl, 2,2-dichloro
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF 3 ).
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle, wherein said C 3 -C 6 carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S '), and J can also be optionally substituted with one or more R A .
  • substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA
  • J is C 3 -Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R)
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more R A
  • J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA.
  • D is phenyl and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or
  • D is , wherein each R N is independently selected from
  • R D and preferably is hydrogen or halogen
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or
  • D is , wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R S R S '), and J can also be optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S ').
  • X preferably is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyll and is optionally substituted with one or more RA.
  • X can also be C3-Cscycloalkyl or C 5 -Cscycloalkenyl which is optionally substituted with one or more RA, wherein two adjacent R A on X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F , wherein two adjacent R A on X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
  • Non-limiting examples of preferred X include the following cyclopropyl rings, each of which is optionally substituted with one or more R A or R F : As shown, the relative stereochemistry at the any of the positions of the above cyclopropyl ring may be either cis or trans. The stereochemistries of optional substituents R A or R F at any of the positions of the cyclopropyl may vary relative to any substituent at any other position on the cyclopropyl ring. Depending on the particular substituents attached to the cyclopropyl, the stereochemistry at any carbon may be either (R) or (S).
  • Non-limiting examples of preferred X include the following cyclopentyl or cyclopentenyl rings, each of which is optionally substituted with one or more R A or R F :
  • the relative stereochemistry at the any of the positions of the above cyclopentyl ring may be either cis or trans.
  • the stereochemistries of optional substituents R A or R F at any of the positions of the cyclopentyl or cyclopentenyl may vary relative to any substituent at any other position on the cyclopropyl ring.
  • the stereochemistry at any carbon may be either (R) or (S).
  • R F is Ci-Cioalkyl, C 2 -Cioalkenyl or C 2 -Cioalkynyl, each of which contains 0, 1 , 2, 3, 4 or 5 heteroatoms selected from O, S or N and is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • R F is Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl or C 2 -Cioalkynyl, each of which contains 0, 1 , 2, 3, 4 or 5 O and is independently optionally substituted with one or more R L .
  • R F is -(R X -RY)Q-(R X -RY'), wherein Q is 0, 1 , 2, 3 or 4; each R X is independently O, S or N(R B ); each R Y is independently Ci-C 6 alkylene, C 2 - Cealkenylene or C 2 -C 6 alkynylene each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; and each R Y ' is independently Ci-C 6 alkyl,
  • each R X is O. More preferably, X is optionally substituted with one or more RA or R F , each R F is independently selected from Ci-Cioalkyl,
  • C 2 -Cioalkenyl or C 2 -Cioalkynyl each of which contains 0, 1 , 2 or 3 O and is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • X is optionally substituted with one or more R A or R F , each R F is independently selected from
  • Li and L 2 are preferably independently bond or Ci-C 6 alkylene
  • L 3 is preferably selected from bond, Ci-C 6 alkylene or -C(O)-
  • L u L 2 and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each independently a bond or Ci-Cealkylene (e.g., -CH 2 - or -CH 2 CH 2 -), and are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each a bond.
  • Y is preferably selected from -L S -C(RiR2)N(R 5 )-T-R D; -L S -C(R 3 R4)C(R 6 R7)-T-RD,
  • G is C 5 -C 6 carbocycle
  • E preferably is a 7-
  • U is independently selected at each occurrence from -(CH 2 )- or -(NH)-;
  • V and Z 2 o are each independently selected from Ci-C4alkylene,
  • C2-C4alkenylene or C2-C4alkynylene in which at least one carbon atom can be independently optionally replaced with O, S or N), and is optionally substituted with one or more R A .
  • Ri is Rc, and R2 and R 5 , taken together with the atoms to which they are attached, form a
  • R A is optionally substituted with one or more R A (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)); and R 3 and R6 are each independently R c , and R4 and R 7 , taken together with the atoms to which they are attached, for carbocycle/heterocycle or 6- to 12-membered bicycle (e.g., is optionally substituted with one or more R A (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)).
  • R A such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -
  • Y can also be selected from -M-C(R 1 R 2 )N(R 5 )-C(0)-LY'-M'-R D ,
  • M preferably is bond, -C(0)N(R B )- or -N(R B )C(0)-, M' preferably is bond, -C(0)N(R B )-, -N(R B )C(0)- -N(R B )C(0)0- N(R B )C(0)N(R B ')-, -N(R B )S(0)- or -N(R B )S(0) 2 - and L Y ' preferably is C Cealkylene which is optionally substituted with one or more R L .
  • L Y ' is L s ' .
  • L Y ' for example, is a
  • Ci-C 6 alkylene such as, but not limited to, ' " , , , , or and the optional R L is a substituent such as, but not limited to phenyl, -SMe, or methoxy.
  • Any stereochemistry at a carbon within the group L Y ' can be either (R) or (S).
  • Ri is Rc, and R2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R A (e.g., one or more hydroxy); and R 3 and R 6 are each independently Rc, and R4 and R 7 , taken together with the atoms to which they are attached, form a 5- to 6-membered
  • carbocycle/heterocycle or 6- to 12-membered bicycle e.g., is optionally substituted with one or more R A .
  • Y is selected from -N(RB)CO-C(RIR2)N(R 5 )-C(0)-LY'-N(RB)C(0)0-R D , -N(RB)CO-C(R 1 R 2 )N(R 5 )-C(0)-L Y '-N(RB)C(0)-R D ,
  • L Y ' preferably is Ci-C 6 alkylene which is optionally substituted with one or more R L .
  • Ri may be Rc, and R 2 and R 5 , taken together with the atoms to which they are
  • R 3 and R6 may be each independently Rc, and R4 and R 7 , taken together with the atoms to which they are attached, may form 5- to 6-membered carbocycle/heterocycle or 6- to 12-membered bicycle (e is optionally substituted with one or more R A .
  • Y is selected from
  • R B is each independently R B .
  • R B " and Ri are each preferably hydrogen or Q-Cealkyl, and R2 and R 5 , taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or
  • 6- to 12-membered bicycle e.g., is optionally substituted with one or more R A (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)).
  • R A such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)).
  • L Y is each independently L s .
  • L Y is Ci-C 6 alkylene substituted with one or more R L such as a C3-Cecarbocycle 3- to 6-membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
  • R L is a Ci-Cealkylene such as a C3-Cecarbocycle 3- to 6-membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thio
  • L Y is optionally substituted with one or more
  • R L e.g., one or more phenyl or methoxy
  • G preferably is NJ
  • R B " is hydrogen
  • T and R D are as defined herein.
  • T for example, can be -L s -M-Ls'-M'-L s "- w L s is a bond;
  • M is C( ' is Ci-Cealkylene such as, but not limited to, ,
  • L s ' is optionally substituted with one or more R L ;
  • RL is a substituent such as, but not limited to phenyl or methoxy;
  • M' is -NHC(O)- or -NMeC(O)-; and
  • L s " is a bond.
  • Any stereochemistry at a carbon within the group L s ' can be either (R) or (S).
  • R D for example is
  • T-RD may also include certain stereochemical configurations; thus T-R D includes, but is not limited
  • preferred Y also include:
  • Z is preferably selected from -L S -C(R 8 R9)N(R 12 )-T-R D , -L s -C( ' Ri 0 Ri i)C(RuRi 4 )-T-R D , -G-C(R 8 R 9 )N(R 12 )-T-R D , -G-C(R 10 Ri i)C(R 13 R 14 )-T-R D , -N(R B )C(0)C(R 8 R 9 )N(R 12 )-T-R D , -N(R B )C(0)C(R 1 oRn)C(R 13 R 14 )-T-R D , -C(0)N(R B )C(R 8 R 9 )N(R 12 )-T-R D , -C(0)N(R B )C(R 8 R 9 )N(R 12 )-T-R D , -C(0)N(R B )C
  • E preferably is a 8- to 12-membered bicycle (such as wherein U is independently selected at each occurrence from -(CH 2 )- or -(NH)-; and V and Z 20 are each independently selected from Ci-C4alkylene, C2-C4alkenylene or C2-C4alkynylene, in which at least one carbon atom is independently optionally replaced with O, S or N), and is optionally substituted with one or more R A . More preferably, R 8 is Rc, and R9 and R12, taken together with the atoms to which they are attached,
  • R A such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl); and Rio and R13 are each independently R c , and Rn and R14, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocycle/heterocycle or 6- to 12-membered
  • bicycle e.g., is optionally substituted with one or more R A (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)).
  • R A such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C 6 alkyl (e.g., methyl), or C 2 -C 6 alkenyl (e.g., allyl)).
  • Z can also be selected from -M-C(R 8 R 9 )N(RI2)-C(0)-LY'-M'-RD, -M-C(R 8 R 9 )N(R 12 )-L Y '-M'-R D , -L S -C(R 8 R 9 )N(R 12 )-C(0)-L Y '-M'-R D , -L S -C(R 8 R 9 )N(R 12 )-L Y '-M'-R D , -M-C(R 10 RRON)C(R 13 R 14 )-C(O)-L Y '-M'-R D , -M-C(RioRn)C(Ri3Ri4)-L Y '-M'-R] -L S -C(R 10 R hinder)C(R 13 R 14 )-C(O)-L Y '-M'-R D , or -L S -
  • R L is a substituent such as, but not limited to phenyl, -SMe, or methoxy.
  • Any stereochemistry at a carbon within the group L Y ' can be either (R) or (S). More preferably, R 8 is Rc, and R 9 and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-
  • membered bicycle e.g., which is optionally substituted with one or more R A (e.g., one or more hydroxy); and Rio and R13 are each independently Rc, and Rn and R M , taken together with the atoms to which they are attached, form embered
  • carbocycle/heterocycle or 6- to 12-membered bicycle e.g., which is optionally substituted with one or more R A .
  • Z is selected from -N(R B )CO-C(R 8 R 9 )N(R 12 )-C(0)-L Y '-N(R B )C(0)0-R D , -N(R B )CO-C(R 8 R 9 )N(R 12 )-C(0)-L Y '-N(R B )C(0)-R D ,
  • L Y ' preferably is Ci-C 6 alkylene which is optionally substituted with one or more R L .
  • Rs may be Rc, and Rg and R12, taken together with the atoms to which they are
  • Z is selected from
  • L Y is C C 6 alkylene optionally substituted with one or more R L
  • R B " is each independently R B .
  • RB" and R ⁇ are each preferably hydrogen or Ci-C6alkyl, and R9 and R12, taken together with the atoms to which they are attached, preferably form
  • a 5- to 6-membered heterocycle or 6- to 12-membered bicycle e.g.,
  • L Y is each independently L s .
  • L Y is Ci-C 6 alkylene substituted with one or more R L such as a C 3 -C 6 carbocycle 3- to 6- membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloal or
  • L Y is a Q-Cealkylene such as, but not limited to, , or (stereochemistry at a carbon within the group L Y can be either (R) or (S)); L Y is optionally substituted with one or more R L (e.g., one or more phenyl or
  • G preferably is ti N ;
  • R B " is hydrogen; -C(R 8 R 9 )N(Ri 2 )- is 1 ⁇ TM v ⁇ ;
  • L s is a bond; and
  • R E is methoxy.
  • preferred Z include:
  • T and R D are as defined herein.
  • T for example, can be -L s -M-Ls'-M'-L s "- where L s is a bond; M is C( ' is Ci-Cealkylene such as, but not limited to, ,
  • L s ' is optionally substituted with one or more R L ; the optional R L is a substituent such as, but not limited to phenyl or methoxy; M' is -NHC(O)- or -NMeC(O)-; and L s " is a bond.
  • Any stereochemistry at a carbon within the group L s ' can be either (R) or (S).
  • R D for
  • T-R D may also include certain stereochemical configurations; thus T-RD includes, but is not limited
  • Non-limitin examples of preferred Z also include:
  • T can be, without limitation, independently selected at each occurrence from -C(0)-L s '-, -C(0)0-L S '-, -C(0)-L S '-N(RB)C(0)-L S ' '-, -C(0)-L S '-N(R B )C(0)0-L S "-, -N(RB)C(0)-L S '-N(RB)C(0)-LS"-, -N(R B )C(0)-L S '— N(R B )C(0)0-L s "-, or -N(R B )C(0)-L s '-N(R B )-L s "-.
  • T is independently selected at each occurrence from -C(0)-L s '-M'-L s "- or -N(R B )C(0)-L s '-M'-L s "-. More preferably, T is independently selected at each occurrence from -C(0)-L S '-N(R B )C(0)-L S ' '- or -C(0)-L S '-N(R B )C(0)0-L S ' '-.
  • T can also be, for example, -L s -M-L s '-M'-L s "- where L s is a bond; M is C(O); L s ' is Ci-C 6 alkylene (e.g., ), where L s ' is optionally substituted with R T ; the optional R T is a substituent selected from -Ci-C 6 alkyl, -C 2 -C 6 alkenyl, -Ci-C 6 alkyl-OH, -Ci-C 6 alkyl-0-Ci-C 6 alkyl, 3- to 6-membered heterocycle (e.g., tetrahydrofuranyl), or C 3 -C 6 carbocyclyl (e.g., phenyl, cyclohexyl); M' is -NHC(O)-, -N(Et)C(0)- or -N(Me)C(0)-; and L s " is a bond.
  • R D preferably is hydrogen, -Ci-C 6 alkyl (e.g., methyl), -0-Ci-C 6 alkyl (e.g., methoxy, tert-butoxy), methoxymethyl, or -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ).
  • T-RD can be either (R) or (S).
  • T can also be, without limitation, -L s -M-L s '- where L s is a bond; M is C(O); L s ' is
  • Ci-C 6 alkylene (e.g., ) where L s ' is optionally substituted with R T ; the optional R T is a substituent selected from -Ci-C 6 alkyl, -Ci-C 6 alkyl-OH, -Ci-C 6 alkyl-0-Ci-C 6 alkyl, or a C 3 -C 6 carbocyclyl (e.g., phenyl, cyclohexyl).
  • R D for example is -OH; -OC(0)Me; -NH(Ci-C 6 alkyl) (e.g., -NHMe, -NHEt); -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 , -NEt 2 ); a 3- to 10-membered heterocyclyl (e.g., pyrrolidinyl, imidazolidinyl, hexahydropyrimidinyl, mo holinyl, piperidinyl) optionally substituted with one or more halogen, oxo; C 3 -Ci 0 carbocycle (e.g., cyclopentyl) optionally substituted with -OH; -Ci-C 6 alkyl (e.g., isopropyl, 3-pentyl) optionally substituted with -OH; or NHR T where R T is a 3- to 6-membered heterocyclyl (e.g.,
  • stereochemistry at a carbon within the group T-RD can be either (R) or (S).
  • L K can also be independently selected at each occurrence from a bond; -L s '-N(R B )C(0)-L s -; -L s '-C(0)N(R B )-L s -; or C C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, C 3 -Ci 0 carbocycle or 3- to 10-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, R T> -0-R s , -S-R s , -N(R S R S '), -OC(0)R s , -C(0)OR s , nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, wherein Ls and Ls' are as defined above.
  • R A preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-Cealkyl, C 2 -Cealkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo,
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • L s , L s ' and L s " preferably are each independently selected at each occurrence from bond; or Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene.
  • a and B can be the same or different.
  • Li and L 2 , or Y and Z, or Y-A- and Z-B-, or -A-Li- and -B-L 2 - can be the same or different.
  • Y-A-Li- is identical to Z-B-L 2 -.
  • Y-A-Li- is different from Z-B-L 2 -.
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C3-C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S '), J can also be optionally substituted with one or more
  • R A Preferably , wherein R M and R N are as defined above. Also
  • D is wherein J and R N are as defined above.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • Y is -N(R B )C(0)C(RiR 2 )N(R 5 )-T-R D , or -N(R B )C(0)C(R 3 R4)C(R 6 R 7 )-T-RD
  • Z is -N(R B )C(0)C(R 8 R 9 )N(R 12 )-T-R D , or -N(R B )C(0)C(RioRn)C(Ri 3 Ri4)-T-RD.
  • Ri is Rc, and R 2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic
  • R3 and R6 are each independently R C , and R4 and R 7 , taken together with the atoms to which they are attached, form a 5-
  • RS is Rc, and R9 and R12, taken together with the atoms to which they are
  • heterocyclic ring ( ch is optionally substituted with one or more R A .
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, -C(0)-L Y '-N(R B )-L s "-, or -C(0)- '-N(R B )S(0) 2 -L s "-.
  • at least one of Y and Z is,
  • Y and Z are independently, wherein non-limiting examples of RD include (1) -0-Ci-C 6 alkyl, -0-C 2 -C 6 alkenyl, -0-C 2 -C 6 alkynyl, Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6-membered heterocycle; or (2) C3-C 6 carbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy,
  • A is nd is optionally substituted with one or more R A ; B is or and is optionally substituted with one or more R A .
  • Zi is independently selected at each occurrence from O, S, NH or CH 2 ; and Z 2 is independently selected at each occurrence from N or CH.
  • X is C 3 -Cscycloalkyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F .
  • X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C3-C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR s or -N(R S R S '), and J can also be
  • D is or , wherein R M
  • L L 2 , and L 3 are bond.
  • Y is -L s -C(RiR 2 )N(R 5 )-T-R D or -L S -C(R 3 R4)C(R 6 R 7 )-T-R D
  • Z is -L S -C(R 8 R 9 )N(R 12 )-T-R D or -L S -C(R 10 H)C(RI3RI 4 )-T-RD.
  • Ri is Rc, and R2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g., which is optionally substituted with one or more R A ;
  • R 3 and R6 are each independently R c , and R4 and R 7 , taken together with the atoms to which they are
  • RS is Rc, and R9 and R12, taken together with the atoms to
  • heterocyclic ring e.g., ch is optionally substituted with one or more R A .
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is independently Ci- C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, -C(0)-L Y '-N(R B )-Ls"-, or -C(0)-L Y '-N(R B )S(0) 2 -Ls"-.
  • at least one of Y and Z is,
  • R -]D include (1) -0-Ci-C 6 alkyl, -0-C 2 -C 6 alkenyl, -0-C 2 -C 6 alkynyl, Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6-membered heterocycle; or (2) C3-C6carbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo,
  • a and B are each independently 5- or 6-membered carbocycle or heterocycle (e.g., A and B are each independently phenyl, such as and are each independently optionally substituted with one or more RA.
  • X is C 3 -Cscycloaikyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D can be, for example, C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA.
  • C 5 -C 6 carbocycle or 5- to 6-membered heterocycle e.g., phenyl
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA.
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR S or -N(R S R S '), and J can also be optionally substituted with one or more R A .
  • D is
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 , and L 3 are bond.
  • Y is -G-C(RiR 2 )N(R 5 )-T-R D or -G-C(R 3 R4)C(R 6 R 7 )-T-RD
  • Z is -G-C(R 8 R 9 )N(R 12 )-T-R D or -G-C(RIORH)C(RI 3 RI4)-T-RD.
  • G is independently C 5 -C6carbocycle or 5- to 6-membered heterocycle, such as , and is independently optionally substituted with one or more R A .
  • Ri is Rc, and R2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g., which is optionally substituted with one or more R A ;
  • R 3 and R6 are each independently R c , and R4 and R 7 , taken together with the atoms to which they are
  • RS is Rc, and R9 and R12, taken together with the atoms to
  • heterocyclic ring e.g., ch is optionally substituted with one or more R A .
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, -C(0)-L Y '-N(R B )-Ls"-, or -C(0)-L '-N(R B )S(0) 2 -Ls"-.
  • at least one of Y and Z is,
  • R D include (1) -O-Ci-Cealkyl, -0-C 2 -C 6 alkenyl, -0-C2-C 6 alkynyl, Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6- membered heterocycle; or (2) C3-Cecarbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo,
  • a and B are each independently 5- or 6-membered carbocycle or heterocycle (e.g., A and B are each independently phenyl, such as and are each independently optionally substituted with one or more R A .
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D can be, for example, C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12- membered bicycle and is optionally substituted with one or more R A .
  • C 5 -C 6 carbocycle or 5- to 6-membered heterocycle e.g., phenyl
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR S or -N(R S R S '), and J can also be
  • R N are as defined above.
  • D is or , wherein J and R N are as defined above.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • , L 2 , and L 3 are bond.
  • Y is -N(R B )C(0)C(RiR 2 )N(R 5 )-T-R D or -N(RB)C(0)C(R 3 R4)C(R6R7)-T-RD
  • Z is -G-C(R 8 R 9 )N(Ri 2 )-T-R D or -G-C(RioRn)C(Ri 3 Ri 4 )-T-R D
  • Y is -G-C(RiR 2 )N(R 5 )-T-R D or -G-C(R 3 R4)C(R 6 R 7 )-T-RD
  • Z is -N(R B )C(0)C(R 8 R9)N(R 12 )-T-R D or -N(R B )C(0)C(RioRn)C(Ri 3 Ri4)-T-R D .
  • Ri is R c , and R 2 and R 5 , taken together with the atoms to which they
  • R 3 and R 6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 5-
  • RS is Rc, and R9 and R12, taken together with the atoms to which they are
  • heterocyclic ring ( ich is optionally substituted with one or more RA. independently C 5 -C 6 carbocycle or 5- to 6-membered heterocycle, such as
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, -C(0)-L Y '-N(R B )-L s "-, or '-N(RB)S(0) 2 -LS"-. In some cases, as described above,
  • A is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl
  • a and B are each independently optionally substituted with one or more R A .
  • Zi is independently selected at each occurrence from O, S, NH or CH 2 ; and Z 2 is independently selected at each occurrence from N or CH.
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F .
  • X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or '), and J can also be optionally substituted with one or more R A .
  • D is
  • D is
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L u L 2 , and L 3 are bond.
  • A is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as Y is -N(RB)C(0)C(R!R 2 )N(R 5 )-T-R D , -N(R b )C(0)C(R 3 R4)C(R 6 R 7 )-T-R D , -G-C(R!R 2 )N(R 5 )-T-R d or -G-C(R 3 R4)C(R6R 7 )-T-R D , and Z is -L S -C(R 8 R 9 )N(R 12 )-T-R D or -L S -C(R 10 RH)C(RI3RI4)-T-RD.
  • phenyl such as Y is -N(RB)C(0)C(R!R 2 )N(R 5 )-T-R D , -N(R b )C(0)C(R 3 R4)C(R 6
  • Y is -L S -C(R!R 2 )N(R5)-T-R D or -L S -C(R 3 R4)C(R 6 R 7 )-T-R D
  • Z is -N(R B )C(0)C(R 8 R 9 )N(R 12 )-T-R D , -N(R B )C(0)C(R 1 oRn)C(R 13 R 14 )-T-RD, -G-C(R 8 R 9 )N(R 12 )-T-R D or -G-C(R 10 Rn)C(R 13 R 14 )-T-RD.
  • Ri is Rc, and R 2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6-
  • membered heterocyclic ring e.g., which is optionally substituted with one or more R A ;
  • R 3 and R6 are each independently R c , and R4 and R 7 , taken together with the atoms to which they are
  • R 8 is Rc, and R 9 and Ri 2 , taken together with the atoms to
  • heterocyclic ring e.g., is optionally substituted with one or more RA.
  • G is independently C 5 -C 6 carbocycle or 5- to 6-membered heterocycle, such as
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-Ls"- or -C(0)-L Y '-N(R B )C(0)0-Ls"-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, -C(0)-L Y '-N(R B )-L s "-, or -C(0)-L Y '-N(R B )S(0) 2 -L s "-.
  • A is 5- or 6-membered carbocycle or heterocycle
  • B is 5- or 6-membered carbocycle or heterocycle e. . hen l such
  • the present invention also features compounds of Formulae I, I A , 3 ⁇ 4, Ic and I D as described herein (including each embodiment described hereunder) and pharmaceutically acceptable salts thereof, wherein:
  • D is C 3 -Ci 2 carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci 2 carbocycle or 3- to 12-membered heterocycle which is substituted with J and optionally substituted with one or more R A , where J is C 3 -Ci 5 carbocycle or 3- to 15 -membered heterocycle (e.g., a 3- to 6-membered monocycle, a 6- to 12-membered fused, bridged or spiro bicycle, a 10- to 15-memberd tricycle containing fused, bridged or spiro rings, or a 13- to 15-membered carbocycle or heterocycle) and is optionally substituted with one or more R A , or J is -SF 5 ; or D is hydrogen or R A ;
  • R E is independently selected at each occurrence from -0-R s , -S-R s , -C(0)R s , -OC(0)R s , -C(0)OR s , -N(RsRs'), -S(0)R s , -S0 2 R s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(Rs)C(0)N(R s 'Rs"), -N(R s )S0 2 R s ', -S0 2 N(R s R s '), -N(R s )S0 2 N(R s 'R s "), -N(Rs)S(0)N(R s 'Rs"), -OS(0)-R s , -OS(0) 2 -R s , -S(0) 2 OR s , -S(0)OR s ,
  • a and B are each independently 5- or 6-membered carbocycle or heterocycle (preferably, A and B are each independently phenyl such as and are each independently optionally substituted with one or more R A (preferably, A and B are each independently substituted with at least one halo such as F).
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F .
  • X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is a C 5 -C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle, or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR S or -N(R S R S '), or (2) trimethylsilyl, -0-R S , -S-R S , be optionally substituted with one or more R A .
  • D is
  • R D and preferably is hydrogen or halo such as F.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L u L 2 , and L 3 are bond.
  • Y is -N(RB)C(0)C(RIR 2 )N(R 5 )-T-R D , -N(R B )C(0)C(R 3 R4)C(R 6 R7)-T-RD, -G-C(RIR 2 )N(R 5 )-T-R d or -G-C(R 3 R4)C(R6R 7 )-T-R D .
  • Z is -N(R B )C(0)C(R 8 R 9 )N(R 12 )-T-R D ,
  • Ri is Rc; and R 2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g.,
  • R3 and R6 are each independently R C , and R4 and R 7 , taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
  • heterocyclic ring e.g., - to 12-membered bicycle which is optionally substituted with one or more R A .
  • R S is Rc; and R9 and R12, taken together with the atoms to which they are
  • R A (e.g., which is optionally substituted with one or more R A ; and Rio and R13 are each independently R c , and Rn and R14, taken together with the atoms to which they are attached, form a
  • 5- to 6-membered carbocyclic or heterocyclic ring e.g., or 6- to 12-membered bicycle which is optionally substituted with one or more R .
  • G is independently C 5 -C 6 carbocycle or 5- to 6- membered heterocycle, such as and is independently optionally substituted with one or more R A .
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-Ls"- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-,
  • A is nd is optionally substituted with one or more R A ; B is and is optionally substituted with one or more R A .
  • Zi is independently selected at each occurrence from O, S, NH or CH 2 ; and Z 2 is independently selected at each occurrence from N or CH.
  • a and B are each independently substituted with at least one halo such as F.
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is a C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and Li, L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • Y is -L S -C(RiR 2 )N(R 5 )-T-R D or -L S -C(R 3 R4)C(R 6 R7)-T-RD.
  • Z is -L S -C(R 8 R 9 )N(R 12 )-T-R D or -L s -C(RioRn)C(Ri3Ri4)-T-R D .
  • Ri is Rc; and R 2 and R 5 , taken together with the atoms to which they
  • 6-membered heterocyclic ring e.g., or 6- to 12-membered
  • R3 and R6 are each independently R C , and R4 and R 7 , taken together with the atoms to which they are attached, form a 5-
  • 6-membered carbocyclic or heterocyclic ring e.g., or 6- to 12-membered bicycle which is optionally substituted with one or more RA.
  • RS is Rc; and R9 and R12, taken together with the
  • Rio and R13 are each independently R c , and Rn and R14, taken together with the atoms to which they
  • T is preferably independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-Ls"- or -C(0)-L Y '-N(R B )C(0)0-L s "-.
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • T can also be, without limitation, selected from -C(0)-L Y '-L s "-, -C(0)-L Y '-0-L s "-, '-N(R B )-L s "-, or -C(0)-L Y '-N(R B )S(0) 2 -L s "-.
  • Y and Z are independently wherein non-limiting examples of R D include (1)
  • the present invention features compounds of Formula IA and pharmaceutically acceptable salts thereof.
  • R N B is each independently selected from R B ;
  • Rc' is each independently selected from R c ;
  • R D ' is each independently selected from R D ;
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • R 9 and R 12 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • A, B, D, X, Li, L 2 , L 3 , T, R A , RB, RC, and R D are as described above in Formula I.
  • D preferably is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 8- to 12- membered bicycles, and is optionally substituted with one or more RA.
  • D can also be preferably selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more R L .
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is substituted with one or more R M , where R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • D is phenyl, and is optionally substituted with one or more R A . More preferably, D is phenyl, and is substituted with one or more
  • R M wherein R M is as defined above.
  • D is wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
  • D is , wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA.
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l ,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l ,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l ,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R M is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is Ci-C 6 alkyl which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R M is -L S -R E , wherein L s is a bond or Ci-C 6 alkylene, and R E is -N(RsRs'), -0-R s , -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ' , -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S0 2 R s , -SRs, or -P(0)(OR s ) 2 , wherein R s and R s ' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-Cealkyl
  • R M is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy.
  • halogen e.g., fluoro, chloro, bromo, iodo
  • hydroxy, mercapto, amino, carboxy or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituent
  • R M is CF 3 , -C(CF 3 ) 2 -OH, -C(CH 3 ) 2 -CN, -C(CH 3 ) 2 -CH 2 OH, or -C(CH 3 ) 2 -CH 2 NH 2 .
  • R M is -L S -R E where L s is a bond and R E is -N(R S R S ), -0-R s , -N(R s )C(0)OR s ', -N(R s )S0 2 R s ', -S0 2 R s , or -SR S .
  • R E is -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ); -N(Ci-C 6 alkylene-0-Ci-C 6 alkyl) 2 (e.g. -N(CH 2 CH 2 OMe) 2 );
  • -N(Ci-C 6 alkyl)(Ci-C 6 alkylene-0-Ci-C 6 alkyl) (e.g. -N(CH 3 )(CH 2 CH 2 OMe));— 0-Ci-C 6 alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-C C 6 haloalkyl (e.g., -OCF 3 , -OCH 2 CF 3 ); -0-Ci-C 6 alkylene-piperidine (e.g., -0-CH 2 CH 2 -l-piperidyl);
  • -N(Ci-C 6 alkyl)C(0)OCi-C 6 alkyl e.g., -N(CH 3 )C(0)0-CH 2 CH(CH 3 ) 2
  • -N(Ci-C 6 alkyl)S0 2 Ci-C 6 alkyl (e.g., -N(CH 3 )S0 2 CH 3 );
  • -S0 2 Ci-C 6 alkyl e.g., -S0 2 Me);
  • -S0 2 Ci-C 6 haloalkyl e.g., -S0 2 CF 3 ); or -S-Ci-C 6 haloalkyl (e.g., SCF 3 ).
  • R M is -L S -R E where L s is Ci-C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 - -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)ORs', or -P(0)(OR s ) 2 .
  • L s is Ci-C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 - -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)ORs', or -P(0)(OR s ) 2 .
  • R M is -Ci-C 6 alkylene-0-R s (e.g., -C(CH 3 ) 2 -CH 2 -OMe); -Ci-C 6 alkylene-C(0)OR s (e.g., -C(CH 3 ) 2 -C(0)OMe);
  • R M is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s , or -N(R S R S ').
  • R M is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., mo holin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl).
  • cycloalkyl e.g., cyclopropyl, 2,2-dichlor
  • R M is Ci-Cealkyl which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert-butyl, CF 3 ).
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle, wherein said C 3 -C 6 carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R s Rs') > and J can also be optionally substituted with one or more RA.
  • substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA
  • J is C 3 -Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more R A
  • J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more R A .
  • D is phenyl and is substituted with J and optionally substituted with one or more RA
  • J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR S or
  • D is wherein each R N is independently selected from
  • R D and preferably is hydrogen or halogen
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR S or
  • D is wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl,
  • J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C2-C 6 haloalkynyl, C(0)OR s or -N(R s R s ').
  • X preferably is C 3 -Cscycloalkyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more R A . More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more RA or R F . Non-limiting examples of X are described hereinabove.
  • Li and L 2 are preferably independently bond or Ci-C 6 alkylene
  • L 3 is preferably selected from bond, Ci-C 6 alkylene or -C(O)-
  • L u L 2 and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 and L 3 are each independently bond or Ci-C 6 alkylene (e.g., -CH 2 - or -CH 2 CH 2 -), and are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each a bond.
  • R 2 and R 5 taken together with the atoms to which they are attached, preferably form a 5- to 6-
  • membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R A .
  • R 9 and Ri 2 taken together with the atoms to which they are attached, preferably form a 5- to
  • 6-membered heterocycle or 6- to 12-membered bicycle e.g., which is optionally substituted with one or more R A .
  • -T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-L Y '-R D ', -C(0)0-L Y '-R D ', -C(0)-L Y '-N(RB)C(0)-L S "-R D ' ,
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-M'-L s "-R D ' or -N(R B )C(0)-L Y '-M'-L s "-R D '. More preferably, -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "-R D ' or -C(0)-L Y '-N(R B )C(0)0-L s "-R D ' .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-R D ' or -C(0)-L Y '-N(R B )C(0)0-R D ', wherein L Y ' preferably is each independently Ci-Cealkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • R N B and Rc' are preferably hydrogen, and R D ' preferably is independently selected at each occurrence from R E . More preferably, R D ' is independently selected at each occurrence from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6- membered heterocycle; or C3-C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl,
  • R A preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • L s , L s ' and L s " preferably are each independently selected at each occurrence from bond; or Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene.
  • a and B can be the same or different.
  • Li and L 2 can be the same or different.
  • a and B are each independently phenyl, and are each independently optionally substituted with one or more R A ;
  • D is phenyl, and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R S R S '), J can also be optionally substituted with one or more
  • R A is or , wherein R M and R N are as defined above. Also
  • D is wherein J and R N are as defined above.
  • Li and L 2 are each independently bond or Ci-Cealkylene, and L 3 is bond, Ci-Cealkylene or -C(O)-, and Li, L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ', -C(0)-L Y '-0-L S "-R D ', -C(0)-L Y ' -N(R B )-L S "-R D ' , or -C(0)-L Y '-N(R B )S(0) 2 - "-R D ' .
  • R 2 and R 5 taken
  • X is C 3 -C 8 cycloalkyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • a and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more R A (preferably, A and B are each independently substituted with at least one halo such as F).
  • X is C 3 -Cscycloalkyl or C5-C 8 Cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or R F .
  • D is phenyl, and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s or -N(RsRs'), or (2) trimethylsilyl, -0-R s , -S-R s or -C(0)R s ; and J can also be optionally
  • D is wherein J is as defined above, and each R N is independently selected from R D and preferably is hydrogen or halo such as F.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and Li, L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-LY' -N(R B )C(0)-LS"-RD' or -C(0)-L Y '-N(RB)C(0)0-L S "-R d ', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ' , -C(0)-L Y '-0-L S "-R D ', -C(0)-L Y '-N(R B )-Ls"-R D ', or -C(0)-L Y '-N(R B )S(0) 2 -L S "-R D ' .
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic
  • ring e.g., or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R A ; and Rg and Ri 2 , taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g., or 6- to 12-membered bicycle
  • the present invention features compounds of Formula I B and pharmaceutically acceptable salts thereof:
  • R c ' is each independently selected from R c ;
  • R D ' is each independently selected from R D ;
  • R2 and R5 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • R 9 and R12 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • A, B, D, X, Li, L 2 , L 3 , T, R A , Rc, and R D are as described above in Formula I.
  • a and B preferably are independently selected from 8- to 12-membered
  • bicycles such as or where Zi is independently selected at each occurrence from O, S, NH or CH 2 ,
  • Z 2 is independently selected at each occurrence from N or CH
  • Z 3 is independently selected at each occurrence from N or CH
  • Z 4 is independently selected at each occurrence from O, S, NH or CH 2
  • Wi W 2 , W 3 , W 4 , W 5 and W 6 are each independently selected at each occurrence from CH or N.
  • a and B are each independently optionally substituted with one or more R A . More preferably, A is selected from is
  • B is selected from or d is optionally substituted with one or more R A , where Zi, Z 2 , Z 3 , Z 4 , Wi, W 2 ,
  • W 3 , W 4 , W 5 , W 6 are as defined above.
  • Z 3 is N and Z 4 is NH.
  • A can be
  • a and B are independently optionally substituted with one or more R A .
  • D preferably is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more R A .
  • D can also be preferably selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more substituents selected from R L .
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12-membered bicycles, and is substituted with one or more R M , where R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • D is phenyl, and is optionally substituted with one or more R A . More preferably, D is phenyl, and is substituted with one or more R M , wherein R M is as defined above.
  • D is R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • One or more R N can also preferably be halo such as F.
  • D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R A . More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
  • D is , wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA.
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • R M is substituted with one or more R M .
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 aikyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl
  • R M is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R M is -L S -R E , wherein L s is a bond or Ci-C 6 alkylene, and R E is -N(RsRs'), -O-Rs, -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S0 2 R s , -SRs, or -P(0)(OR s ) 2 , wherein R s and R s ' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C 6 alkyl optionally
  • R M is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy.
  • halogen e.g., fluoro, chloro, bromo, iodo
  • hydroxy, mercapto, amino, carboxy or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituent
  • R M is CF 3 , -C(CF 3 ) 2 -OH, -C(CH 3 ) 2 -CN, -C(CH 3 ) 2 -CH 2 OH, or -C(CH 3 ) 2 -CH 2 NH 2 .
  • R M is -L S -R E where L s is a bond and R E is -N(R S R S ), -0-R s , -N(R s )C(0)OR s ', -N(R s )S0 2 R s ', -S0 2 R s , or -SR S .
  • R E is -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ); -N(C C 6 alkylene-0-Ci-C 6 alkyl) 2 (e.g. -N(CH 2 CH 2 OMe) 2 ); -N(Ci-C 6 alkyl)(Ci-C 6 alkylene-0-Ci-C 6 alkyl) (e.g.
  • -N(Ci-C 6 alkyl)C(0)OCi-C 6 alkyl e.g., -N(CH 3 )C(0)0-CH 2 CH(CH 3 ) 2
  • Ci-C 6 alkyl e.g., -N(CH 3 )S0 2 CH 3
  • -S0 2 Ci-C 6 alkyl e.g., -S0 2 Me
  • -S0 2 Ci-C 6 haloalkyl e.g., -S0 2 CF 3
  • -S-Ci-C 6 haloalkyl e.g., SCF 3
  • R M is -L S -R E where L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • R M is -Ci-C 6 alkylene-0-R s (e.g., -C(CH 3 ) 2 -CH 2 -OMe); -Ci-C 6 alkylene-C(0)OR s (e.g., -C(CH 3 ) 2 -C(0)OMe);
  • -Ci-C 6 alkylene-N(R s )C(0)ORs' e.g., -C(CH 3 ) 2 -CH 2 -NHC(0)OCH 3
  • -Ci-C 6 alkylene-P(0)(OR s ) 2 e.g., -CH 2 -P(0)(OEt) 2 ).
  • R M is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s , or -N(R S R S ').
  • R M is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomo holin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl).
  • cycloalkyl e.g., cyclopropyl, 2,2-d
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF 3 ).
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more R A
  • J is C3-C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle, wherein said C 3 -C 6 carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R s Rs') > and J can also be optionally substituted with one or more RA.
  • substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA
  • J is C 3 -Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more R A
  • J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more R A .
  • D is phenyl and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or
  • D is , wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or
  • D is wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or S'), and J can also be optionally substituted with one or more R A . Also preferably, D is
  • J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C 2 -Cealkenyl, C 2 -C 6 alkynyl, Ci-Cehaloalkyl, C 2 -Cehaloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S ').
  • X preferably is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more R A or R F . Non-limiting examples of X are described hereinabove.
  • Li and L 2 are preferably independently bond or Ci-C 6 alkylene
  • L 3 is preferably selected from bond, Ci-C 6 alkylene or -C(O)-
  • L u L 2 and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 and L 3 are each independently bond or Ci-C 6 alkylene (e.g., -CH 2 - or -CH 2 CH 2 -), and are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each a bond.
  • R2 and R5 taken together with the atoms to which they are attached, preferably form a 5- to 6-
  • membered heterocycle or 6- to 12-membered bicycle e.g., which is optionally substituted with one or more RA.
  • R9 and R12 taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R A .
  • -T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-L Y ' -R D ', -C(0)0-L Y '-R D ' , -C(0)-L Y '-N(RB)C(0)-L S "-R D ' ,
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-M'-L S "-RD' or -N(R B )C(0)-L Y '-M'-L S "-RD'. More preferably, -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-R D ' or -C(0)-L Y '-N(R B )C(0)0-R D ', wherein L Y ' preferably is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • R C ' is preferably hydrogen, and R D ' preferably is independently selected at each occurrence from R E . More preferably, R D ' is independently selected at each occurrence from Ci-Cealkyl, C2-C 6 alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6-membered heterocycle; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-
  • R A preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • L s , L s ' and L s " preferably are each independently selected at each occurrence from bond; or Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene.
  • a and B can be the same or different.
  • Li and L 2 can be the same or different.
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or '), and J can also be optionally substituted with one or more R A .
  • D is
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-L Y '-N(R B )C(0)0-L S "-R D ' , wherein L Y ' is Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and Ls" preferably is bond.
  • -T-RD' can also be, without limitation, selected from -C(0)-L Y ' -L S " -R D ', -C(0)-L Y '-0-L S "-R D ' , -C(0)-L Y '-N(R B )-L S "-R D ', or
  • X is C 3 -C 8 cycloaikyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F .
  • X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • A is and optionally substituted
  • R A e.g., halogen
  • B is and is optionally substituted with one or more R A (e.g., halogen)
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12- membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C 2 -Cealkenyl, C 2 -Cealkynyl, Ci-Cehaloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(R s Rs') > an d J can also be
  • R N are as defined above. Also preferably, D is or , wherein J and R N are as defined above.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 , and L 3 are bond.
  • -T-R D ' is independently selected at each occurrence from -C(0)-L '-N(R )C(0)-L "-R d ' or -C(0)-L Y '-N(R B )C(0)0-L S "-R D ' , wherein L Y ' is Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and Ls" preferably is bond.
  • -T-R ' can also be, without limitation, selected from -C(0)-L Y ' -L S " -R D ', -C(0)-L Y '-0-L S "-R D ' , -C(0)-L Y '-N(R B )-L S "-R D ', or
  • 6- to 12-membered bicycle e.g., which is optionally substituted with one or more R preferably, R 2 and R 5 , taken together with the atoms to which they are
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • A is and optionally substituted with one or more R A (preferably, A is substituted with at least one halogen such as F); B is and is optionally substituted with one or more R A (preferably, B is substituted with at least one halogen such as F).
  • X is C 3 -Cscycloalkyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F .
  • X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is phenyl, and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s or -N(R S R S '), or (2) trimethylsilyl, -0-R s , -S-R s or -C(0)R s ; and J can also be optionally substituted with one or
  • R A is or , wherein J is as defined above, and each R N is independently selected from R D and preferably is hydrogen or halo such as F.
  • Li and L 2 are each independently bond or Ci-Cealkylene, and L 3 is bond, Ci-Cealkylene or -C(O)-, and Li, L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ', -C(0)-L Y '-0-L S "-R D ', -C(0)-L Y ' -N(R B )-L S "-R D ', or -C(0)-L Y '-N(R B )S(0) 2 -L S "-R D ' .
  • R 2 and R 5 taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12- membered bicycle (e.g., which is optionally substituted with one or more
  • RA- R9 and R12 taken together with the atoms to which they are attached, preferably form a 5- to 6-
  • the present invention further features compounds of Formula I c and pharmaceutically acceptable salts thereof.
  • R C ' is each independently selected from R C ;
  • R D ' is each independently selected from R D ;
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • R 9 and R12 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • A, B, D, X, Li, L 2 , L 3 , T, R A , RB, RC, and R D are as described above in Formula I.
  • A preferably is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle, and is optionally substituted with one or more R A ; and B preferably is 8- to 12-membered bicycle (such as or and is optionally substituted with one or more
  • Zi is O, S, NH or CH 2 ;
  • Z 2 is N or CH;
  • Z 3 is N or CH;
  • Z 4 is O, S, NH or CH 2 ;
  • Wi, W 2 , W 3 , W 4 , W 5 and W 6 are each independently selected from CH or N.
  • R A is N
  • A is C
  • a and B are independently optionally substituted with one or more R A .
  • D preferably is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more R A .
  • D can also be preferably selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more substituents selected from R L .
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12-membered bicycles, and is substituted with one or more R M , where R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -RE.
  • D is phenyl, and is optionally substituted with one or more R A . More preferably, D is phenyl, and is substituted with one or more R M , wherein R M is as defined above.
  • D is R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • One or more R N can also preferably be halo such as F.
  • D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R A . More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
  • D is , wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA.
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • R M is substituted with one or more R M .
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 aikyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl
  • R M is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R M is -L S -R E , wherein L s is a bond or Ci-C 6 alkylene, and R E is -N(RsRs'), -O-Rs, -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S0 2 R s , -SRs, or -P(0)(OR s ) 2 , wherein R s and R s ' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C 6 alkyl optionally
  • R M is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy.
  • halogen e.g., fluoro, chloro, bromo, iodo
  • hydroxy, mercapto, amino, carboxy or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituent
  • R M is CF 3 , -C(CF 3 ) 2 -OH, -C(CH 3 ) 2 -CN, -C(CH 3 ) 2 -CH 2 OH, or -C(CH 3 ) 2 -CH 2 NH 2 .
  • R M is -L S -R E where L s is a bond and R E is -N(R S R S ), -0-R s , -N(R s )C(0)OR s ', -N(R s )S0 2 R s ', -S0 2 R s , or -SR S .
  • R E is -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ); -N(C C 6 alkylene-0-Ci-C 6 alkyl) 2 (e.g. -N(CH 2 CH 2 OMe) 2 ); -N(Ci-C 6 alkyl)(Ci-C 6 alkylene-0-Ci-C 6 alkyl) (e.g.
  • -N(Ci-C 6 alkyl)C(0)OCi-C 6 alkyl e.g., -N(CH 3 )C(0)0-CH 2 CH(CH 3 ) 2
  • Ci-C 6 alkyl e.g., -N(CH 3 )S0 2 CH 3
  • -S0 2 Ci-C 6 alkyl e.g., -S0 2 Me
  • -S0 2 Ci-C 6 haloalkyl e.g., -S0 2 CF 3
  • -S-Ci-C 6 haloalkyl e.g., SCF 3
  • R M is -L S -R E where L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , — N(Rs)C(0)OR s ⁇ or -P(0)(OR s ) 2 .
  • L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , — N(Rs)C(0)OR s ⁇ or -P(0)(OR s ) 2 .
  • R M is -C C 6 alkylene-0-R s (e.g., -C(CH 3 ) 2 -CH 2 -OMe); -Ci-C 6 alkylene-C(0)OR s (e.g., -C(CH 3 ) 2 -C(0)OMe);
  • -Ci-C 6 alkylene-N(R s )C(0)ORs' e.g., -C(CH 3 ) 2 -CH 2 -NHC(0)OCH 3
  • -Ci-C 6 alkylene-P(0)(OR s ) 2 e.g., -CH 2 -P(0)(OEt) 2 ).
  • R M is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s , or -N(R S R S ').
  • R M is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., mo holin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl).
  • cycloalkyl e.g., cyclopropyl, 2,2-dichlor
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF 3 ).
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more R A
  • J is C3-C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle, wherein said C 3 -C 6 carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R s Rs') > and J can also be optionally substituted with one or more RA.
  • substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA
  • J is C 3 -Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more R A
  • J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more R A .
  • D is phenyl and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or
  • D is , wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or
  • D is wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or S'), and J can also be optionally substituted with one or more R A . Also preferably, D is
  • J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C 2 -Cealkenyl, C 2 -C 6 alkynyl, Ci-Cehaloalkyl, C 2 -Cehaloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S ').
  • X preferably is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more R A or R F . Non-limiting examples of X are described hereinabove.
  • Li and L 2 are preferably independently bond or Ci-C 6 alkylene
  • L 3 is preferably selected from bond, Ci-C 6 alkylene or -C(O)-
  • L u L 2 and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each independently a bond or Ci-Cealkylene (e.g., -CH 2 - or -CH 2 CH 2 -), and are each independently optionally substituted with one or more R L .
  • Li, L 2 and L 3 are each a bond.
  • Li and L 2 can be the same or different.
  • membered heterocycle or 6- to 12-membered bicycle e.g., which is optionally substituted with one or more RA.
  • R9 and R12 taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R A .
  • -T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-L Y '-R D ', -C(0)0-L Y '-R D ', -C(0)-L Y '-N(RB)C(0)-L S "-R D ' ,
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-M'-L S "-RD' or -N(R B )C(0)-L Y '-M'-L S "-RD'. More preferably, -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L s "-R D ' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' .
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-R D ' or -C(0)-L Y '-N(R B )C(0)0-R D ', wherein L Y ' preferably is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • RNB and Rc' are preferably hydrogen, and R D ' preferably is independently selected at each occurrence from R E . More preferably, R D ' is independently selected at each occurrence from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6- membered heterocycle; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl,
  • R A preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • L s , L s ' and L s " preferably are each independently selected at each occurrence from bond; or Ci-C 6 alkylene, C 2 -Cealkenylene or C 2 -C 6 alkynylene.
  • A is phenyl, and is optionally substituted with one or more
  • R A ; and B and is optionally substituted with one or more R A , wherein Z is O, S, NH or CH 2 ; and Z 2 is N or CH.
  • D is C 5 -C 6 carbocycle or 5- to 6- membered heterocycle (e.g., phenyl), and is optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to
  • 6-membered heterocycle or 6- to 12-membered bicycle is optionally substituted with one or more
  • J is substituted with a C3-C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R s Rs') > and J can also be optionally substituted with one or more R A .
  • D is
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 , and L 3 are bond.
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(O)— L Y '-N(R B )C(0)0-L S "-R D ', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L y '-0-L S "-R D ', -C(0)-L Y '-N(R B )-L S "-R D ', or -C(0)-L Y '-N(R B )S(0) 2 "-R D '.
  • R 2 and R 5 taken
  • X is C 3 -C 8 cycloalkyl or C 5 - Cscycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • B is , and is optionally substituted with one or more R A (preferably, B is substituted with at least one halogen such as F).
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is phenyl, and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR S or -N(R S R S '), or (2) trimethylsilyl, -0-R S , -S-R or -C 0 R and J can also be optionally substituted with one or more substituents selected from (1) halogen
  • R A Preferably, D is in J is as defined above, and each R N is independently selected from R D and preferably is hydrogen or halo such as F.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-LS"-RD' or -C(0)-L Y '-N(R B )C(0)0-L S "-R D ', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ', -C(0)-L Y '-0-L S "-R D ', -C(0)-L Y '-N(R B )-L S "-R D ', or -C(0)-L Y '-N(R B )S(0) 2 -L S "-R D '.
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g.,
  • 6- to 12-membered bicycle e.g., which is optionally substituted with r more R A ; R9 and Ri 2 , taken together with the atoms to which they are attached, form a 5- to 6-
  • membered heterocyclic ring e.g., or 6- to 12-membered bicycle (e.g.,
  • the present invention features compounds of Formula pharmaceutically acceptable salts thereof.
  • Gi and G 2 are each independently selected from C 5 -C 6 carbocycle or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more R A ;
  • R c ' is each independently selected from R c ;
  • R D ' is each independently selected from R D ;
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • Rg and R12 taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A ;
  • A, B, D, X, Li, L 2 , L 3 , T, R A , Rc, and R D are as described above in Formula I.
  • a and B preferably are independently selected from C 5 -C 6 carbocycle or 5- to 6- membered heterocycle, and are each independently optionally substituted with one or more R A . More preferably, at least one of A and B is phenyl (e.g., and is optionally substituted with one or more R A . Highly preferably, both A and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more R A .
  • D preferably is selected from C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 8- to 12- membered bicycles, and is optionally substituted with one or more R A .
  • D can also be preferably selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more R L .
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is substituted with one or more R M , where R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • R M is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E .
  • D is phenyl, and is optionally substituted with one or more R A . More preferably, D is phenyl, and is substituted with one or more
  • R M wherein R M is as defined above.
  • D is or , wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R A . More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
  • D is , wherein R M is as defined above, and each R N is independently selected from R D and preferably is hydrogen.
  • R N can also preferably be halo such as F.
  • D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more R A .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more R M .
  • R M is substituted with one or more R M .
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 aikyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl
  • R M is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
  • R M is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R M is -L S -R E , wherein L s is a bond or Ci-C 6 alkylene, and R E is -N(RsRs'), -O-Rs, -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S0 2 R s , -SRs, or -P(0)(OR s ) 2 , wherein R s and R s ' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C 6 alkyl optionally
  • R M is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy.
  • halogen e.g., fluoro, chloro, bromo, iodo
  • hydroxy, mercapto, amino, carboxy or Ci-C 6 alkyl (e.g., methyl, isopropyl, tert-butyl), C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituent
  • R M is CF 3 , -C(CF 3 ) 2 -OH, -C(CH 3 ) 2 -CN, -C(CH 3 ) 2 -CH 2 OH, or -C(CH 3 ) 2 -CH 2 NH 2 .
  • R M is -L S -R E where L s is a bond and R E is -N(R S R S ), -0-R s , -N(R s )C(0)OR s ', -N(R s )S0 2 R s ', -S0 2 R s , or -SR S .
  • R E is -N(Ci-C 6 alkyl) 2 (e.g., -NMe 2 ); -N(C C 6 alkylene-0-Ci-C 6 alkyl) 2 (e.g. -N(CH 2 CH 2 OMe) 2 ); -N(Ci-C 6 alkyl)(Ci-C 6 alkylene-0-Ci-C 6 alkyl) (e.g.
  • -N(Ci-C 6 alkyl)C(0)OCi-C 6 alkyl e.g., -N(CH 3 )C(0)0-CH 2 CH(CH 3 ) 2
  • Ci-C 6 alkyl e.g., -N(CH 3 )S0 2 CH 3
  • -S0 2 Ci-C 6 alkyl e.g., -S0 2 Me
  • -S0 2 Ci-C 6 haloalkyl e.g., -S0 2 CF 3
  • -S-Ci-C 6 haloalkyl e.g., SCF 3
  • R M is -L S -R E where L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • L s is C C 6 alkylene (e.g., -CH 2 - -C(CH 3 ) 2 -, -C(CH 3 ) 2 -CH 2 -) and R E is -0-R s , -C(0)OR s , -N(R s )C(0)OR s ', or -P(0)(OR s ) 2 .
  • R M is -Ci-C 6 alkylene-0-R s (e.g., -C(CH 3 ) 2 -CH 2 -OMe); -Ci-C 6 alkylene-C(0)OR s (e.g., -C(CH 3 ) 2 -C(0)OMe);
  • -Ci-C 6 alkylene-N(R s )C(0)ORs' e.g., -C(CH 3 ) 2 -CH 2 -NHC(0)OCH 3
  • -Ci-C 6 alkylene-P(0)(OR s ) 2 e.g., -CH 2 -P(0)(OEt) 2 ).
  • R M is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -C(0)OR s , or -N(R S R S ').
  • R M is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomo holin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl).
  • cycloalkyl e.g., cyclopropyl, 2,2-d
  • R M is Ci-C 6 alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF 3 ).
  • D is C 5 -C 6 carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more R A
  • J is C3-C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6- membered heterocycle, wherein said C 3 -C 6 carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R s Rs') > and J can also be optionally substituted with one or more RA.
  • substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA
  • J is C 3 -Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(
  • D is C 5 -C 6 carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more R A
  • J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more R A .
  • D is phenyl and is substituted with J and optionally substituted with one or more R A
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA
  • J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or
  • D is , wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or
  • D is wherein each R N is independently selected from R D and preferably is hydrogen or halogen, and J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or S'), and J can also be optionally substituted with one or more R A . Also preferably, D is
  • J is C 3 -C 6 carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more R A , and preferably J is at least substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C 2 -Cealkenyl, C 2 -C 6 alkynyl, Ci-Cehaloalkyl, C 2 -Cehaloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR S or -N(R S R S ').
  • X preferably is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl and is optionally substituted with one or more R A . More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more R A or R F . Non-limiting examples of X are described hereinabove.
  • Li and L 2 are preferably independently bond or Ci-C 6 alkylene
  • L 3 is preferably selected from bond, Ci-C 6 alkylene or -C(O)-
  • L u L 2 and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 and L 3 are each independently bond or Ci-C 6 alkylene (e.g., -CH 2 - or -CH 2 CH 2 -), and are each independently optionally substituted with one or more R L .
  • L L 2 and L 3 are bond.
  • R2 and R5 taken together with the atoms to which they are attached, preferably form a 5- to 6-
  • membered heterocycle or 6- to 12-membered bicycle (e.g., which optionally substituted with one or more R A .
  • R 9 and R12 taken together with the atoms to which they are attached, preferably form a 5-
  • nd G 2 preferably are each independently selected from
  • RA e.g., one or more chloro or bromo
  • Gi is N- (including any tautomer thereof), and G 2 is (including any tautomer thereof), and each Gi and G 2 is independently optionally substituted with one or more RA (e.g., one or more chloro or bromo).
  • -T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-L Y '-, -C(0)0-L Y '-R D ' , -C(0)-L Y '-N(RB)C(0)-L S "-R D ', -C(0)-L Y '-N(R B )C(0)0-L S "-R D ',
  • L Y ' is each independently L s ' and, preferably, is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-M'-Ls"-R D ' or -N(R B )C(0)-L Y '-M'-L S "-R D ' .
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-L Y ' -N(RB)C(0)0-L S "-RD'.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-R D ' or -C(0)-L Y '-N(R B )C(0)0-R D ', wherein L Y ' preferably is each independently Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L .
  • R C ' is preferably hydrogen, and R D ' preferably is independently selected at each occurrence from R E . More preferably, R D ' is independently selected at each occurrence from Ci-Cealkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3 -C 6 carbocycle or 3- to 6-membered heterocycle; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 3
  • R A preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C2-C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -Cecarbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C2-C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C
  • R A is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
  • L s , L s ' and L s " preferably are each independently selected at each occurrence from bond; or
  • a and B can be the same or different.
  • Li and L 2 can be the same or different.
  • a and B are each independently phenyl, and are each independently optionally substituted with one or more R A ;
  • D is phenyl, and is independently optionally substituted with one or more R A , or is substituted with J and optionally substituted with one or more R A , wherein J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C(0)OR s or -N(R S R S '), and J can also be optionally substituted with one or more R A ; and Gi is N , G 2 is , and each Gi and G 2 is independently optionally substituted with one or more R A (e.g., one or more chloro or bromo).
  • substituents selected from halogen, hydroxy,
  • D is ein J and R N are as defined above.
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • Li, L 2 , and L 3 are bond.
  • -T-RD' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein L Y ' is C C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ', -C(0)-L Y '-0-L S "-R D ', -C(0)-L Y ' -N(R B )-LS"-RD', or -C(0)-L Y '-N(R B )S(0) 2 "-RD'.
  • R 2 and R 5 taken
  • X is C 3 -C 8 cycloalkyl or C 5 - Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • a and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more R A (preferably, A and B are each independently substituted with at least one halogen such as F).
  • X is C 3 -Cscycloalkyl or C 5 -Cscycloalkenyl and is optionally substituted with one or more R A . Specific examples of X are described hereinabove.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A or R F . More preferably, X is cyclopropyl is and is optionally substituted with one or more R A or R F .
  • D is phenyl, and is substituted with J and optionally substituted with one or more R A .
  • J is C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more R A .
  • J is substituted with a C 3 -C 6 carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl,
  • D is wherein J is as defined above, and each R N is inde endentl selected from R D and preferably is hydrogen or halo such as F.
  • Gi is , and each Gi and G 2 is independently optionally substituted with one or more R A (e.g., one or more chloro or bromo).
  • Li and L 2 are each independently bond or Ci-C 6 alkylene, and L 3 is bond, Ci-C 6 alkylene or -C(O)-, and L u L 2 , and L 3 are each independently optionally substituted with one or more R L .
  • L L 2 , and L 3 are bond.
  • -T-R D ' is independently selected at each occurrence from -C(0)-L Y '-N(R B )C(0)-L S "-R D ' or -C(0)-LY' -N(R B )C(0)0-LS"-RD', wherein L Y ' is Ci-C 6 alkylene (e.g., -CH 2 -) and optionally substituted with one or more substituents selected from R L , and L s " preferably is bond.
  • -T-R D ' can also be, without limitation, selected from -C(0)-L Y '-L S "-R D ', -C(0)-L Y '-0-L S "-R D ', -C(0)-LY' -N(R B )-LS"-RD', or -C(0)-L Y '-N(RB)S(0) 2 -L S "-RD'.
  • R 2 and R 5 taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g.,
  • 6- to 12-membered bicycle e.g., which is optionally substituted with one or more RA; R9 and R12, taken together with the atoms to which they are attached, form a 5- to 6-
  • membered heterocyclic ring e.g., or 6- to 12-membered bicycle (e.g.,
  • the present invention features compounds having Formula I E and pharmaceutically acceptable salts thereof,
  • X is C 3 -C 8 cycloalkyl or C 5 -C 8 cycloalkenyl, and is optionally substituted with one or more R A ;
  • Li and L 2 are each independently selected from bond or Ci-Cealkylene which is independently optionally substituted at each occurrence with one or more halo, hydroxy, -O-Ci-Cealkyl, or -0-Ci-C 6 haloalkyl;
  • L 3 is bond or Ci-C 6 alkylene
  • a and B are each independently phenyl, pyridinyl, thiazolyl, Zi is independently selected at each occurrence from O, S, NH or CH 2 , Z 3 is independently selected at each occurrence from N or CH, and Wi, W 2 , and W 3 are each independently selected at each occurrence from CH or N; A and B are each independently optionally substituted with one or more R A .
  • D is C6-Ciocarbocycle or 5- to 12-membered heterocycle, each of which is optionally substituted with one or more R M ;
  • Y is -T'-C(R 1 R 2 )N(R 5 )-T-R D ;
  • Z is -T'-C(R 8 R 9 )N(R 12 )-T-R D ;
  • Ri is hydrogen, Ci-Cealkyl, Ci-Cehaloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl or -0-Ci-C 6 haloalkyl;
  • R 2 and R 5 are each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl or -0-Ci-C 6 haloalkyl; or R 2 and R 5 , taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more R A (e.g., 1, 2, 3, or 4 R A );
  • R A e.g., 1, 2, 3, or 4 R A
  • R 8 is hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl or -0-Ci-C 6 haloalkyl;
  • R 9 and R 12 are each independently hydrogen, Ci-Cealkyl, Ci-Cehaloalkyl, or 3- to 6- membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl or -O-Ci-Cehaloalkyl; or R 9 and R 12 , taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R A (e.g., 1, 2, 3, or 4 R A );
  • R A e.g., 1, 2, 3, or 4 R A
  • T is independently selected at each occurrence from bond or -C(0)-L s '-;
  • T' is independently selected at each occurrence from bond, -C(0)N(R B )-, -N(R B )C(0)-, or 3- to 12-membered heterocycle, wherein said 3- to 12-membered heterocycle is independently optionally substituted at each occurrence with one or more R A ;
  • R D is each independently selected at each occurrence from hydrogen or R A ;
  • R A is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E ;
  • R B and R B ' are each independently selected at each occurrence from hydrogen; or Ci-C 6 alkyl which is independently optionally substituted at each occurrence with one or more substituents selected from halogen or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R B or R B ' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, or -0-C C 6 haloalkyl;
  • R E is independently selected at each occurrence from -0-R s , -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)OR s , -N(RsRs'), -S(0)R s , -S0 2 R s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(Rs)C(0)N(R s 'Rs"), -N(R s )S0 2 R s ', -S0 2 N(R s R s '), -N(R s )S0 2 N(R s 'R s "), -N(Rs)S(0)N(R s 'Rs"), -OS(0)-R s , -OS(0) 2 -R s , -S(0) 2 OR s , -S(0)OR s , -OC(0)OR
  • Rs' and Rs" are each independently selected at each occurrence from hydrogen; Ci- Cealkyl, C 2 -Cealkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, or 3- to 12-membered carbocycle or heterocycle; or 3- to 12-membered carbocycle or heterocycle; wherein each 3- to 12- membered carbocycle or heterocycle in R s , R s ' or R s " is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phospho
  • s independently selected at each occurrence from: halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, SF 5 , -N(R S R S '), -0-R s , -OC(0)R s , -OC(0)OR s , -OC(0)N(R s R s '), -C(0)R s , -C(0)OR s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)OR s ', -N(R s )S0 2 Rs', -S(0)R s , -S0 2 R s , -S(0)N(R s R s '), -SR S , -Si(R s ) 3 , or -P(0)(OR
  • G 2 is a C 3 -Ci 2 carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more R G2 , and each R G2 is independently selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl,
  • L 4 is a bond, Ci-C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, -0-, -S-, -N(R B )-, -C(O)-, -S(0) 2 - -S(O)-, -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(R B )-, -N(RB)C(0)- -N(R B )C(0)0-, -OC(0)N(R B )-, -N(R B )S(0)-, -N(R B )S(0) 2 - -S(0)N(R B )-, -S(0) 2 N(R B )-, -N(RB)C(0)N(RB')- -N(R B )S0 2 N(R b ')-, or -N(R B )S(0)N(R B ')-;
  • G 3 is a C 3 -Ci 2 carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more R G3 ;
  • R G3 is each independently, at each occurrence, halogen, -Ci-C 6 alkyl, -C(0)Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, C 3 -C 6 carbocycle, or 3- to 6- membered heterocycle.
  • Z 3 is independently selected at each occurrence from N or CH, and Wi, W 2 , and W 3 are each independently selected at each occurrence from CH or N; A and B are each independently optionally substituted with one or more R A .
  • Pre thiazolyl e
  • both A and B are phenyl (e.g., both A and B are '); or A is
  • a and B are substituted by one or more R A , wherein each R A is independently selected from halogen (e.g., fluoro, chloro), L S -R E (where L S is bond and R E is -Ci-C 6 alkyl (e.g., methyl), -0-R S (e.g., -0-Ci-C 6 alkyl, -OCH 3 ), or -Ci-C 6 alkyl optionally substituted with one or more halogen (e.g., -CF 3 )), or L S -R E (where L S is Ci-C 6 alkylene and R E is -0-R S (e.g., -Ci-C 6 alk -0-Ci-C 6 alkyl, -CH 2 OCH 3 )).
  • halogen e.g., fluoro, chloro
  • L S -R E where L S is bond and R E is -Ci-C 6 alkyl (e.g.,
  • A is and B is as defined hereinabove. In certain other embodiments B is is as defined hereinabove. In certain other embodiments B is is as defined hereinabove.
  • D is C 6 -Ci 0 carbocycle or 3- to 12- membered heterocycle optionally substituted by one or more R M .
  • D is C 6 -Ci 0 aryl (e.g., phenyl, naphthyl, indanyl), or 5- to 10-membered heteroaryl (pyridinyl, thiazolyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l ,3]dioxol-5-yl), and D is substituted with one or more R M .
  • aryl e.g., phenyl, naphthyl, indanyl
  • 5- to 10-membered heteroaryl pyridinyl, thiazolyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl
  • D is preferably phenyl substituted by one or more R M , wherein each R M is independently halogen (e.g., fluoro, chloro, bromo); Ci-C 6 alkyl (e.g., tert-butyl); Ci-C 6 alkyl substituted with one or more halogen (e.g., CF 3 ); -0-R s such as -0-Ci-C 6 alkyl (e.g., -0-CH 2 CH 3 ); or -0-Ci-C 6 alkyl substituted at each occurrence with one or more halogen (e.g., -0-CF 3 , -0-CH 2 CHF 2 ) or -0-C C 6 alkyl (e.g., -0-CH 2 CH 2 OCH 3 ); -0-R s (e.g., -0-Ci-C 6 alkyl, such as -0-CH 2 ) substituted with 3- to 12-membered heterocycle (
  • D is preferably phenyl or pyridyl and is substituted by one or more R M where one R M is G 2 .
  • D is substituted by G 2
  • G 2 is 3- to 12-membered heterocycle (e.g., pyridinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazolyl) and is optionally substituted with one or more halogen (e.g., fluoro, chloro), hydroxy, oxo, cyano, Ci-C 6 alkyl (e.g., methyl), C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl (e.g., CF 3 ), C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl,
  • D is phenyl or pyridyl and G 2 is, for example, a monocyclic 3-8 membered carbocycle or monocyclic 4-8 membered heterocycle substituted with L 4 -G 3 and optionally substituted with one or more RG2 wherein L , G3 and RG2 are as defined herein.
  • L 4 for example is a bond, a Ci-C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH2CH2CH2-, etc.), -0-, or -S(0) 2 -.
  • G 3 is for example a C 3 -Ci 2 carbocycle optionally substituted with one or more RG3- RG2 and R G 3 are each independently at each occurrence halogen, -C(0)Ci-C 6 alkyl, -Ci-C 6 alkyl,
  • G2 is ,
  • a monocyclic 4-8 membered nitrogen-containing heterocycle e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl
  • a monocyclic 4-8 membered nitrogen-containing heterocycle e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl
  • R G 2 and G 3 is optionally substituted with R G 3.
  • ⁇ can be, for example, 3 -phenylazetidin- 1 -yl, 3-phenylpyrrolidin-l-yl, 4-phenylpiperazin-l-yl, 4-phenylpiperidin-l-yl, 4-phenyl-3,6- dihydropyridin- 1 (2H)-yl, 4,4-diphenylpiperidin- 1 -yl, 4-acetyl-4-phenylpiperidin- 1 -yl, 4-(4- methoxyphenyl)piperidin-l -yl, 4-(4-fluorophenyl)piperidin-l-yl, or 3-phenylpiperidin-l-yl, and wherein D can be further optionally substituted with one or more R M (e.g., fluoro, chloro, methyl, methoxy).
  • R M e.g., fluoro, chloro, methyl,
  • L i a -C6 alkylene, -0-, or
  • G 3 is as define d above and is optionally substituted with R G 3.
  • R G 3 can be, for example,
  • D is phenyl or pyridyl
  • D is substituted by G 2 and G 2 is a spiro, bridged, or fused bicyclic carbocycle or heterocycle optionally substituted with L 4 -G 3 and one or more RG2, wherein D is optionally substituted with one or more R M
  • R M , L 4 , G 3 , and R G 2 are as defined herein.
  • G 2 is ⁇ , N
  • ' ⁇ is a spiro, bridged, or fused bicyclic nitrogen-containing heterocycle (e.g., 3- azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, octahydro-2H- isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H-isoindol-2-yl, l ,4-dioxa-8-azaspiro[4.5]dec- 8-yl) attached to the parent molecular moiety through a nitrogen atom and optionally substituted with G 3 and one or more R G2 .
  • a nitrogen-containing heterocycle e.g., 3- azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azas
  • G 2 is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6- azaspiro[2.5]oct-6-yl, octahydro-2H-isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, or l ,4-dioxa-8-azaspiro[4.5]dec-8-yl; L 4 is a bond and D is optionally substituted with one or more R M (e.g., fluoro, chloro, methyl, methoxy).
  • R M e.g., fluoro, chloro, methyl, methoxy
  • D is wherein R M is as defined above in connection with Formula I E , and D is optionally substituted by one or more additional R M .
  • R M can be fluoro, chloro, tert-butyl, -0-CH 2 CH 3 , -0-CF 3 ,
  • R M selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C 6 alkyl (e.g., methyl).
  • D is wherein R M is fluoro, chloro, tert-butyl, -0-CH 2 CH 3 ,
  • R M selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C 6 alkyl (e.g., methyl).
  • D is wherein R M is cyclopropyl, cyclohexyl, or phenyl and D is optionally substituted by one or more additional R M selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C 6 alkyl (e.g., methyl).
  • R M is cyclopropyl, cyclohexyl, or phenyl and D is optionally substituted by one or more additional R M selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C 6 alkyl (e.g., methyl).
  • D is wherein R M is -0-CH 2 -(3-ethyloxetan-3-yl),
  • R M selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C 6 alkyl (e.g., methyl).
  • D is wherein G 2 is pyridinyl (e.g., pyridin-2-yl), piperidin-1- yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2- yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l - yl, 4-methylpiperidin-l-yl, 4-tert-butylpiperidin-l -yl, 2-oxopiperidin-l -yl, 3,3-dimethylazetidin-l -yl, or oxazolyl (e.g., l ,3-oxazol-2-yl) and D is optionally substituted by one or more additional pyridin
  • D is wherein Gi is N,
  • G 2 is a monocyclic 4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) attached to the parent molecular moiety through a nitrogen atom and substituted by L 4 -G 3 and optionally substituted with one or more R G2 ;
  • L 4 is a bond, Ci-C 6 alkylene, -0-, or -S(0) 2 -;
  • G 3 is aryl (e.g., phenyl), cycloalkyl (e.g., cyclohexyl), or heterocycle (e.g., thienyl) wherein each G 3 is optionally substituted with one or more RQ 3 ;
  • RG 2 and RQ3 at each occurrence are each independently halogen, -C(0)Ci-Cealkyl, -Ci-Cealkyl, -Ci-Cehaloalkyl, -O-
  • G3 is phenyl optionally substituted with one or two RG3; g is 0, 1, or 2; R M is each independently
  • G 3 is phenyl optionally substituted with one or two R G 3; RMI is each independently hydrogen, fluoro, chloro, or methyl; and R G 2 is an optional substituent as described herein.
  • RMI is each independently hydrogen, fluoro, chloro, or methyl; and R G 2 is an optional substituent as described herein.
  • D is wherein L 4 is Ci-C 6 alkylene, -0-, or
  • G 3 is phenyl optionally substituted with one or two RG3; g is 0, 1 , or 2; R M is each
  • D is wherein Gi is
  • D IS wherein g is 0, 1, or 2; R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • R M i is each independently hydrogen, fluoro, chloro, or methyl
  • ⁇ - is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2-yl, 2- azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl).
  • D is wherein is a monocyclic 4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) substituted with one or more RG2, wherein R G 2 at each occurrence is each independently halogen, -C(0)Ci-C 6 alkyl, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, or -0-Ci-C 6 haloalkyl; and R M is each independently halogen, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, or -0-Ci-C 6 haloalkyl.
  • R G 2 at each occurrence is each independently halogen, -C(0)Ci-C 6 alkyl, -Ci-C 6 alkyl, -Ci-C 6 haloal
  • R G 2 at each occurrence is each independently methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, or methyl.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more R A ; and Li, L 2 , and L 3 are each a bond.
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and Li and L 2 are each methylene (i.e. -CH 2 -), and L 3 is a bond.
  • Y is-T'-C(RiR2)N(R 5 )-T-R D and Z is -T'-C(RSR9) (RI2)-T-RD; wherein T' , Ri, R 2 , R5, Rs, R9, R12, T, and R D are as defined herein.
  • Ri, R 2 , R5, Rs, R9, and R12 are each independently hydrogen; Ci-C 6 alkyl; or 3- to 6- membered carbocycle or heterocycle, wherein each 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen or Ci-Cealkyl; wherein R 2 and R 5 , taken together with the atoms to which they are attached, optionally form a 3- to 12-membered heterocycle which is substituted with 0, 1, 2, 3, or 4 R A , and R 9 and R12 taken together with the atoms to which they are attached, optionally form a 3- to 12- membered heterocycle which is substituted with 0, 1, 2, 3, or 4 R A wherein R A is as defined herein.
  • Ri is hydrogen and R2 and R5, taken together with the atoms to which they are attached form a 3- to 12-membered heterocycle (e.g.,
  • R A is halogen (e.g., fluoro, chloro); cyano; L S -R E where L s is a single bond and R E is Ci-C 6 alkyl (e.g., methyl, ethyl), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy); or
  • R A is fluoro, methoxy, methyl, ethyl, or cyano.
  • R 5 taken together with the atoms to which they are
  • R 8 is hydrogen and R9 and R12, taken together with the atoms to which they are attached form a 3- to 12-membered heterocycle (e.g.,
  • a pyrrolidine ring i.e., substituted with 0 or 1 R A wherein R A is fluoro, methoxy, methyl, ethyl, or cyano.
  • R 9 and R 12 taken together with the atoms
  • a chiral carbon in any rings formed by joining R 2 and R 5 or R 9 and R 12 may
  • R 5 or R 9 and Ri 2 preferably possesses the (S) stereochemistry
  • R B is independently selected at each occurrence from a bond, -C(0)N(R B )-, -N(R B )C(0)-, or 3- to 12-membered heterocycle, and wherein said 3- to 12-membered heterocycle is each independently optionally substituted at each occurrence with one or more RA, and R A and R B are as described herein.
  • R B can be hydrogen (i.e., is -C(0)N(H)-).
  • T' is imidazolyl (i.e., , N— ) optionally substituted at each occurrence with one or more R A wherein R A is halogen (e.g., fluoro, chloro), Ci-Cealkyl (e.g., methyl, ethyl), or Ci-Cehaloalkyl (e.g., trifluoromethyl).
  • R A is halogen (e.g., fluoro, chloro), Ci-Cealkyl (e.g., methyl, ethyl), or Ci-Cehaloalkyl (e.g., trifluoromethyl).
  • R A is halogen (e.g., fluoro, chloro), Ci-Cealkyl (e.g., methyl, ethyl), or Ci-Cehaloalkyl (e.g., trifluoromethyl).
  • is imidazolyl i.e.,
  • This aspect of the invention contemplates particular combinations of A with Y and B with Z.
  • A is C 5 -C 6 carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl)
  • preferred Z when B is C 5 -C 6 carbocycle (e.g., phenyl) or
  • Y-A is and non-limiting examples of preferred Y, where T' is a bond, include: , wherein T and R D are as defined herein.
  • R A as described herein, or B
  • examples of preferred Z, where T' is a bond include: .
  • T and R D are as defined herein.
  • T at each occurrence is independently a bond or -C(0)-L s '-, wherein L s ' is as defined
  • L s ' is optionally substituted with one or more R L ; and R L is a substituent such as, but not limited to carbocycle (e.g., cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, phenyl), methoxy, or heterocycle (e.g., tetrahydrofuranyl, tetrahydropyranyl).
  • carbocycle e.g., cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, phenyl
  • heterocycle e.g., tetrahydrofuranyl, tetrahydropyranyl
  • R D is hydrogen or R A wherein R A is as defined herein.
  • R D includes, but is not limited to, R A wherein R A is L S -R E , and L S and R E are as defined herein.
  • R D includes, but is not limited to, LS-RE wherein L S is a bond and R E is-N(R s R s '), -N(R s )C(0)R s ', -N(R s )C(0)N(R s 'R s "), -N(R s )S0 2 Rs', — N(R s )S0 2 N(R s 'Rs"), -N(R s )S(0)N(R s 'R s "), -N(R s )C(0)OR s ', or -N(R s )S(0)-R s '; or C 3 -Ci 2 carbocycle or 3- to 12-membered heterocycle,
  • R D is L S -R E wherein L S is a bond and R E is -N(R s )C(0)OR s ' or 3- to 12-membered heterocycle (e.g., pyrrolidine, piperidine, azepanyl) wherein Rs and Rs' are as defined herein.
  • RD is preferably LS-RE wherein Ls is a bond and RE is -N(H)C(0)OMe.
  • T-R D includes, but is not limited to:
  • non-limiting examples of preferred Y when A is C 5 -C 6 carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl) and preferred Z when B is C 5 -C6carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl) include:
  • Y-A is :
  • the present invention features compounds of Formula Larmaceutically acceptable salts thereof:
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA
  • A is ally substituted with one or more R A ;
  • B is wherein B is optionally substituted with one or more R A ;
  • Y, Z, R A , and D are as described hereinabove (e.g., Y, Z, R A , and D as described for Formula I, I A , IB, IC, ID, or I E , preferably as described for Formula I E ).
  • A is wherein A is
  • B is wherein B is optionally substituted with one or more R A ;
  • D, R A , T and R D are as defined hereinabove (e.g., as described for Formula I, I A , 3 ⁇ 4, Ic, ID or I E , preferably as described for Formula
  • a or B are optionally substituted with one or more substituents selected from: R A wherein R A is each independently halogen (e.g., fluoro, chloro); L S -R E where L s is a single bond, and R E is -Ci-C 6 alkyl (e.g., methyl), -O-Rs (e.g., -0-Ci-C 6 alkyl, -OCH 3 ), or -Ci-C 6 alkyl optionally substituted with one or more halogen (e.g., -CF 3 ); or L S -R E where L s is a Ci-C 6 alkylene and R E is -O-Rs (e.g., -Ci-C 6 alkyl-0-Ci-C 6 alkyl, -CH 2 OCH 3 ).
  • R A is each independently halogen (e.g., fluoro, chloro)
  • L S -R E where L s is a single bond
  • This embodiment includes compounds where A and B are both substituted by one R A ; compounds where A and B are both substituted by zero R A ; compounds where A is substituted by one R A and B is substituted by zero R A ; and compounds where A is substituted by zero R A and B is
  • T-R D is independently selected at
  • this aspect of the invention features compound of Formula I F and pharmaceutically acceptable salts thereof, wherein:
  • A is wherein A is optionally substituted with one o mo e RA ?
  • B is wherein B is optionally substituted with one or more R A ;
  • Y is D
  • R D are as defined hereinabove.
  • a particular subgroup according to this embodiment includes
  • this aspect of the invention features compounds of Formula I F and pharmaceuticall acceptable salts thereof, wherein: A and B are each Y and Z are each independently
  • Rr or ; and D, T and R D are as defined hereinabove.
  • a particular subgroup according to this embodiment includes compounds where T-R D is each independently selected from ; and D is as defined hereinabove.
  • D is , where R M is fluoro, chloro, tert-butyl,
  • R M is optionally substituted by one or more additional R M , selected from the group consisting of halogen (e.g., fluoro, chloro) or Ci-C 6 alkyl (e.g., methyl).
  • D is wherein G 2 is pyridinyl (e.g., pyridin-2-yl), piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6-dimethylpiperidin-l-yl, 4- (propan-2-yl)piperidin-l-yl, 4-fluoropiperidin-l-yl, 3,5-dimethylpiperidin-l-yl, 4-
  • G 2 is pyridinyl (e.g., pyridin-2-yl), piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6-dimethylpiperidin-l-yl, 4- (propan-2-yl)piperidin-l-yl, 4-fluoropiperidin-l-yl, 3,5-dimethylpiperidin-l-yl, 4-
  • G 2 is piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6- dimethylpiperidin-1 -yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin- 1 -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l-yl, 4-tert-butylpiperidin-l-yl, 2- oxopiperidin-l-yl, or 3,3-dimethylazetidin-l-yl; and R M i is each independently hydrogen, fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • G 2 is ⁇ ;
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2.
  • L 4 is Ci-C 6 alkylene, -0-, or -S(0) 2 -; G 2 is ; R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy
  • g is 0, 1 , or
  • G 3 is phenyl optionally substituted with one or two RG3; g is 0, 1, or 2; R M is each independently fluoro, chloro, methyl, methoxy,
  • compounds D is in L 4 is Ci-C 6 alkylene, -0-, or -S(0) 2 -; G 3 is phenyl optionally substituted with one or two R G 3; g is 0, 1 , or 2; R M is each independently fluoro, chloro, methyl,
  • G 3 is phenyl optionally substituted with one or two R G 3 as defined hereinabove;
  • R M i is each independently hydrogen, fluoro, chloro, or methyl;
  • R G 2 is an optional substituent, as described above, selected from the group consisting of -C(0)C C 6 alkyl, -Ci-C 6 alkyl, -d-Cghaloalkyl, -0-C C 6 alkyl, and -0-Ci-C 6 haloalkyl.
  • D is wherein Gi is N, C-H, or C-R M ; G 2 is , R M , and g are as defined hereinabove.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • g is 0, 1, or 2; and is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-
  • R M is each independently fluoro, chloro, methyl, methoxy,
  • compounds D is each independently hydrogen, fluoro, chloro, or N
  • methyl and is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2- yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl).
  • D is , wherein ⁇ is a monocyclic
  • RG2 at each occurrence is each independently halogen, -C(0)C C 6 alkyl, -C C 6 alkyl, -C C 6 haloalkyl, -0-C C 6 alkyl, or -0-C C 6 haloalkyl; and R M is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, - ⁇ -Ci-Cealkyl, or -O-Ci-Cehaloalkyl.
  • RG2 at each occurrence is each independently halogen, -C(0)C C 6 alkyl, -C C 6 alkyl, -C C 6 haloalkyl, -0-C C 6 alkyl, or -0-C C 6 haloalkyl
  • R M is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, - ⁇ -Ci-Cealkyl, or
  • each group of compounds according to the foregoing embodiments is azetidinyl, pyrrolidinyl, or piperidinyl substituted with one or two RG2, wherein R G2 at each occurrence is each methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or trifluoromethyl; and R M is each independently
  • fluoro, chloro, or methyl For example is 4,4-dimethylpiperidin-l -yl, 4,4- difluoropiperidin-1 -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l - yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l -yl, 4-tert- butylpiperidin-l-yl, 2-oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl.
  • the present invention features compounds of Formula I G and pharmaceutically acceptable salts thereof,
  • X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA A is substituted with one or more R A ;
  • B is or , wherein B is optionally substituted with one or more R A ;
  • Y, Z, R A , and D are as described hereinabove (e.g., as described for Formula I, I A , 3 ⁇ 4, Ic, I D , I E or I F , preferably as described for Formula I E ).
  • this aspect of the invention features compounds of Formula I G and
  • Y and Z are each independently
  • Rr , or Rr T-R D is each independently and D is as defined hereinabove.
  • this aspect of the invention features compounds of Formula I G and
  • L S -R E where L s is a single bond and R E is -Ci-C 6 alkyl (e.g., methyl), -O-Rs (e.g., -O-Ci-Cealkyl, -OCH 3 ), or -Ci-Cealkyl optionally substituted with one or more halogen (e.g., -CF 3 ); or L S -R E where L s is a Ci-C 6 alkylene and R E is -0-R s (e.g., -Ci-C 6 alkyl-0-Ci-C 6 alkyl,
  • T-R D is each independently
  • This subgroup includes compounds where A and B are both substituted by one R A ; compounds where A and B are both substituted by zero R A ; compounds where A is substituted by one R A and B is substituted by zero R A ; and compounds where A is substituted by zero R A and B is substituted by one R A .
  • This subgroup includes compounds where A and B are both substituted by one R A ; compounds where A and B are both substituted by zero R A ; compounds where A is substituted by one R A and B is substituted by zero R A ; and compounds where A is substituted by zero R A and B is substituted by one R A .
  • Groups of compounds according to this aspect of the invention include compounds where D is C 6 -Ci 0 aryl (e.g., phenyl, naphthyl, indanyl), or 5- to 10-membered heteroaryl (pyridinyl, thiazolyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l,3]dioxol-5-yl), and D is substituted with one or more R M .
  • D is C 6 -Ci 0 aryl (e.g., phenyl, naphthyl, indanyl), or 5- to 10-membered heteroaryl (pyridinyl, thiazolyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l,3]diox
  • R M is halogen (e.g., fluoro, chloro, bromo); Ci-C 6 aikyl (e.g., tert-butyl); Ci-Cealkyl substituted with one or more halogen (e.g., CF 3 ); - ⁇ -Ci-Cealkyl (e.g., -0-CH 2 CH 3 ); -0-Ci-C 6 alkyl substituted at each occurrence with one or more halogen (e.g., -0-CF 3 , -0-CH 2 CHF 2 ) or -0-C C 6 alkyl (-0-CH 2 CH 2 OCH 3 ); -0-C C 6 alkyl (e.g., -0-CH 2 ) substituted with an optionally substituted 3- to 12-membered heterocycle (e.g., 3-ethyloxetan-3-yl, 1,3-dioxolan- 4-yl
  • R M is halogen (e.g., flu
  • Other subgroups according to this embodiment include compounds wherein D is phenyl substituted by G 2 and optionally substituted by one or more R M , wherein G 2 is a 3- to 12-membered heterocycle (e.g., pyridinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazolyl) wherein the heterocycle is optionally substituted with one or more substituents selected from halogen, hydroxy, oxo, cyano, Ci-C 6 alkyl (e.g., methyl), C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl (e.g., CF 3 ), C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0-Ci-C 6 alkyl (e.g., -O-CH3), -C(0)OR s (e.g.
  • D is , where R M is fluoro, chloro, tert-butyl, -0-CH 2 CH 3 , -0-CF 3 , -0-CH 2 CHF 2 , -0-CH 2 CH 2 OCH 3 , -0-CH 2 -(3-ethyloxetan-3-yl), -0-CH 2 -(l,3-dioxolan-4-yl), -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, -0-(l ,3-dioxan-5-yl), cyclopropyl, cyclohexyl, phenyl, SF 5 , -S0 2 Me, or -N(t-Bu)C(0)Me and D is optionally substituted by one or more additional R M , selected from the group consisting of halogen (e.g., fluoro, chloro) or C C 6 alkyl (e
  • D is wherein G 2 is pyridinyl (e.g., pyridin-2-yl), piperidin-l-yl, 4,4-dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l -yl, 2,6-dimethylpiperidin-l-yl, 4- (propan-2-yl)piperidin-l-yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin-l-yl, 4- (trifluoromethyl)piperidin-l -yl, 4-methylpiperidin-l -yl, 4-tert-butylpiperidin-l-yl, 2-oxopiperidin-l- yl, 3,3-dimethylazetidin-l-yl, or oxazolyl (e.g., l ,3-oxazol-2-yl) and D is optionally substituted by one or more additional R
  • G 2 is piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6- dimethylpiperidin-l -yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin- l -yl, 4-(trifluoromethyl)piperidin-l -yl, 4-methylpiperidin-l -yl, 4-tert-butylpiperidin-l-yl, 2- oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl; and R M i is each independently hydrogen, fluoro, chloro, or methyl.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • G 2 is ⁇ ;
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • ⁇ is 3-phenylazetidin-l -yl, 3- phenylpyrrolidin- 1 -yl, 4-phenylpiperazin- 1 -yl, 4-phenylpiperidin- 1 -yl, 4-phenyl-3 ,6-dihydropyridin- 1 (2H)-yl, 4,4-diphenylpiperidin- 1 -yl, 4-acetyl-4-phenylpiperidin- 1 -yl, 4-(4-methoxyphenyl)piperidin- 1 -yl, 4-(4-fluorophenyl)piperidin-l-yl, or 3-phenylpiperidin-l-yl; R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1 , or 2. In other subgroups, R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • L 4 is Ci-C 6 alkylene, -0-, or -S(0) 2 -; G 2 is ; R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2.
  • G 2 is ; R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2.
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy
  • g is 0, 1 , or
  • compounds D is 6 alkylene, -0-, or -S(0) 2 -;
  • G 3 is phenyl optionally substituted with one or two R G 3;
  • g is 0, 1 , or 2;
  • R M is each independently fluoro, chloro, methyl,
  • G 3 is phenyl optionally substituted with one or two R G 3 as defined hereinabove;
  • R M i is each independently hydrogen, fluoro, chloro, or methyl;
  • R G 2 is an optional substituent, as described above, selected from the group consisting of -C(0)Ci-C 6 alkyl, -Ci-C 6 alkyl, -Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, and -0-Ci-C 6 haloalkyl.
  • D is wherein Gi is N, C-H, or C-R M ; G2 is
  • R M is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
  • g is 0, 1 , or 2; and is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-
  • R M is each independently fluoro, chloro, methyl, methoxy,
  • compounds D is each independently hydrogen, fluoro, chloro, or
  • methyl and is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2- yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl).
  • D is is a monocyclic
  • R G 2 at each occurrence is each independently halogen, -C(0)C C 6 alkyl, -C C 6 alkyl, -C C 6 haloalkyl, -0-C C 6 alkyl, or -0-C C 6 haloalkyl; and R M is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, - ⁇ -Ci-Cealkyl, or -O-Ci-Cehaloalkyl.
  • R G 2 at each occurrence is each independently halogen, -C(0)C C 6 alkyl, -C C 6 alkyl, -C C 6 haloalkyl, -0-C C 6 alkyl, or -0-C C 6 haloalkyl
  • R M is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, - ⁇ -Ci-Cealkyl, or
  • each group of compounds according to the foregoing embodiments is azetidinyl, pyrrolidinyl, or piperidinyl substituted with one or two RG2, wherein R G2 at each occurrence is each methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or trifluoromethyl; and R M is each independently
  • G2 fluoro, chloro, or methyl For example is 4,4-dimethylpiperidin-l -yl, 4,4- difluoropiperidin-1 -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l - yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l -yl, 4-tert- butylpiperidin-l-yl, 2-oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl.
  • the present invention also features compounds of Formulae I E , IF and IG as described herein (including each embodiment described hereunder) and pharmaceutically acceptable salts thereof, wherein:
  • R E is independently selected at each occurrence from -0-R s , -S-R s , -C(0)R s , -OC(0)R s , -C(0)OR s , -N(RsRs'), -S(0)R s , -S0 2 R s , -C(0)N(R s R s '), -N(R s )C(0)R s ', -N(Rs)C(0)N(R s 'Rs"), -N(R s )S0 2 R s ', -S0 2 N(R s R s '), -N(R s )S0 2 N(R s 'R s "), -N(Rs)S(0)N(R s 'Rs"), -OS(0)-R s , -OS(0) 2 -R s , -S(0) 2 OR s , -S(0)OR s ,
  • the compounds of the present invention can be used in the form of salts.
  • a salt of a compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability under certain conditions or desired solubility in water or oil.
  • a salt of a compound may be useful for the isolation or purification of the compound.
  • the salt preferably is pharmaceutically acceptable.
  • Pharmaceutically acceptable salts include, but are not limited to, acid addition salts, base addition salts, and alkali metal salts.
  • Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids.
  • suitable inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroionic, nitric, carbonic, sulfuric, and phosphoric acid.
  • suitable organic acids include, but are not limited to, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic, and sulfonic classes of organic acids.
  • suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylammosulfonate, algenic acid, b-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, buty
  • Pharmaceutically acceptable base addition salts include, but are not limited to, metallic salts and organic salts.
  • suitable metallic salts include alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and other pharmaceutically acceptable metal salts.
  • Such salts may be made, without limitation, from aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc.
  • suitable organic salts can be made from tertiary amines and quaternary amine, such as tromethamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
  • Basic nitrogen-containing groups can be quaternized with agents such as alkyl halides (e.g., methyl, ethyl, propyl, butyl, decyl, lauryl, myristyl, and stearyl chlorides/bromides/iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
  • alkyl halides e.g., methyl, ethyl, propyl, butyl, decyl, lauryl, myristyl, and stearyl chlorides/bromides/iodides
  • dialkyl sulfates e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates
  • the compounds or salts of the present invention may exist in the form of solvates, such as with water (i.e., hydrates), or with organic solvents (e.g., with methanol, ethanol or acetonitrile to form, respectively, methanolate, ethanolate or acetonitrilate).
  • solvates such as with water (i.e., hydrates), or with organic solvents (e.g., with methanol, ethanol or acetonitrile to form, respectively, methanolate, ethanolate or acetonitrilate).
  • the compounds or salts of the present invention may also be used in the form of prodrugs.
  • Some prodrugs are aliphatic or aromatic esters derived from acidic groups on the compounds of the invention. Others are aliphatic or aromatic esters of hydroxyl or amino groups on the compounds of the invention. Phosphate prodrugs of hydroxyl groups are preferred prodrugs.
  • the compounds of the invention may comprise asymmetrically substituted carbon atoms known as chiral centers. These compounds may exist, without limitation, as single stereoisomers (e.g., single enantiomers or single diastereomer), mixtures of stereoisomers (e.g. a mixture of enantiomers or diastereomers), or racemic mixtures.
  • Individual stereoisomers of the compounds of this invention can be prepared using a variety of methods known in the art. These methods include, but are not limited to, stereospecific synthesis, chromatographic separation of diastereomers, chromatographic resolution of enantiomers, conversion of enantiomers in an enantiomeric mixture to diastereomers followed by chromatographically separation of the diastereomers and regeneration of the individual enantiomers, and enzymatic resolution.
  • Stereospecific synthesis typically involves the use of appropriate optically pure (enantiomerically pure) or substantial optically pure materials and synthetic reactions that do not cause racemization or inversion of stereochemistry at the chiral centers.
  • Mixtures of stereoisomers of compounds, including racemic mixtures, resulting from a synthetic reaction may be separated, for example, by chromatographic techniques as appreciated by those of ordinary skill in the art. Chromatographic resolution of enantiomers can be accomplished by using chiral chromatography resins, many of which are commercially available.
  • racemate is placed in solution and loaded onto the column containing a chiral stationary phase. Enantiomers can then be separated by HPLC.
  • Resolution of enantiomers can also be accomplished by converting enantiomers in a mixture to diastereomers by reaction with chiral auxiliaries.
  • the resulting diastereomers can be separated by column chromatography or crystallization/re-crystallization. This technique is useful when the compounds to be separated contain a carboxyl, amino or hydroxyl group that will form a salt or covalent bond with the chiral auxiliary.
  • suitable chiral auxiliaries include chirally pure amino acids, organic carboxylic acids or organosulfonic acids.
  • Enzymes such as esterases, phosphatases or lipases, can be useful for the resolution of derivatives of enantiomers in an enantiomeric mixture.
  • an ester derivative of a carboxyl group in the compounds to be separated can be treated with an enzyme which selectively hydrolyzes only one of the enantiomers in the mixture.
  • the resulting enantiomerically pure acid can then be separated from the unhydrolyzed ester.
  • salts of enantiomers in a mixture can be prepared using any suitable method known in the art, including treatment of the carboxylic acid with a suitable optically pure base such as alkaloids or phenethylamine, followed by precipitation or crystallization/re-crystallization of the enantiomerically pure salts.
  • a suitable optically pure base such as alkaloids or phenethylamine
  • Methods suitable for the resolution/separation of a mixture of stereoisomers, including racemic mixtures can be found in ENANTIOMERS, RACEMATES, AND RESOLUTIONS (Jacques et al, 1981, John Wiley and Sons, New York, NY).
  • a compound of this invention may possess one or more unsaturated carbon-carbon double bonds. All double bond isomers, such as the cis (Z) and trans (E) isomers, and mixtures thereof are intended to be encompassed within the scope of a recited compound unless otherwise specified. In addition, where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms.
  • Certain compounds of the invention may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotations about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers.
  • the invention encompasses each conformational isomer of these compounds and mixtures thereof.
  • Certain compounds of the invention may also exist in zwitterionic form and the invention encompasses each zwitterionic form of these compounds and mixtures thereof.
  • the compounds of the present invention are generally described herein using standard nomenclature. For a recited compound having asymmetric center(s), it should be understood that all of the stereoisomers of the compound and mixtures thereof are encompassed in the present invention unless otherwise specified. Non-limiting examples of stereoisomers include enantiomers, diastereomers, and cis-transisomers. Where a recited compound exists in various tautomeric forms, the compound is intended to encompass all tautomeric forms. Certain compounds are described herein using general formulas that include variables (e.g., A, B, D, X, Li, L 2 , L 3 , Y, Z, T, R A or R B ).
  • variables e.g., A, B, D, X, Li, L 2 , L 3 , Y, Z, T, R A or R B ).
  • each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently at each occurrence. If moieties are described as being "independently" selected from a group, each moiety is selected independently from the other. Each moiety therefore can be identical to or different from the other moiety or moieties.
  • C x -C y The number of carbon atoms in a hydrocarbyl moiety can be indicated by the prefix "C x -C y ,” where x is the minimum and y is the maximum number of carbon atoms in the moiety.
  • Ci-Cealkyl refers to an alkyl substituent containing from 1 to 6 carbon atoms.
  • C3-Cecycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms.
  • a prefix attached to a multiple-component substituent only applies to the first component that immediately follows the prefix.
  • the term "carbocyclylalkyl” contains two components: carbocyclyl and alkyl.
  • C 3 -C 6 carbocyclylCi-C 6 alkyl refers to a C 3 -C 6 carbocyclyl appended to the parent molecular moiety through a Ci-Cealkyl group.
  • a linking element links two other elements in a depicted chemical structure
  • the leftmost-described component of the linking element is bound to the left element in the depicted structure
  • the rightmost-described component of the linking element is bound to the right element in the depicted structure.
  • the chemical structure is -Ls-M-Ls'- and M is -N(R B )S(0)-
  • the chemical structure is -L s -N(R B )S(0)-L s '-.
  • a linking element in a depicted structure is a bond
  • the element left to the linking element is joined directly to the element right to the linking element via a covalent bond.
  • a chemical structure is depicted as -L s -M-L s '- and M is selected as bond
  • the chemical structure will be -L s -L s '-.
  • two or more adjacent linking elements in a depicted structure are bonds, then the element left to these linking elements is joined directly to the element right to these linking elements via a covalent bond.
  • the dash(s) indicates the portion of the moiety that has the free valence(s).
  • a moiety is described as being “optionally substituted", the moiety may be either substituted or unsubstituted. If a moiety is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that moiety may be either unsubstituted, or substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the moiety, whichever is less. Thus, for example, if a moiety is described as a heterocycle optionally substituted with up to three non-hydrogen radicals, then any heterocycle with less than three substitutable positions will be optionally substituted by up to only as many non- hydrogen radicals as the heterocycle has substitutable positions.
  • alkenyl means a straight or branched hydrocarbyl chain containing one or more double bonds. Each carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety, relative to groups substituted on the double bond carbons.
  • Non-limiting examples of alkenyl groups include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl.
  • alkenylene refers to a divalent unsaturated hydrocarbyl chain which may be linear or branched and which has at least one carbon-carbon double bond.
  • alkyl means a straight or branched saturated hydrocarbyl chain.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, iso-amyl, and hexyl.
  • alkylene denotes a divalent saturated hydrocarbyl chain which may be linear or branched.
  • Representative examples of alkylene include, but are not limited to, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, and -CH 2 CH(CH 3 )CH 2 -.
  • alkynyl means a straight or branched hydrocarbyl chain containing one or more triple bonds.
  • Non-limiting examples of alkynyl include ethynyl, 1-propynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
  • alkynylene refers to a divalent unsaturated hydrocarbon group which may be linear or branched and which has at least one carbon-carbon triple bonds.
  • Representative alkynylene groups include, by way of example, — C ⁇ C— , — C ⁇ C— CH 2 — , — C ⁇ C— CH 2 — CH 2 — , -CH 2 -C ⁇ C-CH 2 - -C ⁇ C-CH(CH 3 )-, and -CH 2 -C ⁇ C-CH(CH 2 CH 3 )-.
  • Carbocycle or “carbocyclic” or “carbocyclyl” refers to a saturated (e.g., “cycloalkyl"), partially saturated (e.g., “cycloalkenyl” or “cycloalkynyl") or completely unsaturated (e.g., "aryl”) ring system containing zero heteroatom ring atom.
  • Ring atoms or “ring members” are the atoms bound together to form the ring or rings.
  • a carbocyclyl may be, without limitation, a single ring, two fused rings, or bridged or spiro rings.
  • a substituted carbocyclyl may have either cis or trans geometry.
  • carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclopentadienyl, cyclohexadienyl, adamantyl, decahydro-naphthalenyl, octahydro-indenyl, cyclohexenyl, phenyl, naphthyl, indanyl, 1,2,3,4-tetrahydro-naphthyl, indenyl, isoindenyl, decalinyl, and norpinanyl.
  • a carbocycle group can be attached to the parent molecular moiety through any substitutable carbon ring atom.
  • a carbocycle group is a divalent moiety linking two other elements in a depicted chemical structure (such as A in Formula I)
  • the carbocycle group can be attached to the two other elements through any two substitutable ring atoms.
  • a carbocycle group is a trivalent moiety linking three other elements in a depicted chemical structure (such as X in Formula I)
  • the carbocycle group can be attached to the three other elements through any three substitutable ring atoms, respectively.
  • Carbocyclylalkyl refers to a carbocyclyl group appended to the parent molecular moiety through an alkylene group.
  • C3-C6carbocyclylCi-C6alkyl refers to a C 3 -C 6 carbocyclyl group appended to the parent molecular moiety through Ci-C 6 alkylene.
  • cycloalkenyl refers to a non-aromatic, partially unsaturated carbocyclyl moiety having zero heteroatom ring member.
  • Representative examples of cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, and octahydronaphthalenyl.
  • cycloalkyl refers to a saturated carbocyclyl group containing zero heteroatom ring member.
  • Non-limiting examples of cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decalinyl and norpinanyl.
  • Ci-Cehaloalkyl means a Ci-C6alkyl substituent wherein one or more hydrogen atoms are replaced with independently selected halogen radicals.
  • Non-limiting examples of Ci-Cehaloalkyl include chloromethyl, 1-bromoethyl, fluorom ethyl, difluoromethyl, trifluorom ethyl, and 1,1 ,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
  • heterocycle or “heterocyclo” or “heterocyclyl” refers to a saturated (e.g., “heterocycloalkyl"), partially unsaturated (e.g., “heterocycloalkenyl” or “heterocycloalkynyl”) or completely unsaturated (e.g., “heteroaryl”) ring system where at least one of the ring atoms is a heteroatom (i.e., nitrogen, oxygen or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur.
  • a heterocycle may be, without limitation, a single ring, two fused rings, or bridged or spiro rings.
  • a heterocycle group can be linked to the parent molecular moiety via any substitutable carbon or nitrogen atom(s) in the group.
  • a heterocycle group is a divalent moiety that links two other elements in a depicted chemical structure (such as A in Formula I)
  • the heterocycle group can be attached to the two other elements through any two substitutable ring atoms.
  • a heterocycle group is a trivalent moiety that links three other elements in a depicted chemical structure (such as X in Formula I)
  • the heterocycle group can be attached to the three other elements through any three substitutable ring atoms, respectively.
  • a heterocyclyl may be, without limitation, a monocycle which contains a single ring.
  • monocycles include furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl
  • a heterocyclyl may also be, without limitation, a bicycle containing two fused rings, such as, for example, naphthyridinyl (including [1,8] naphthyridinyl, and [1,6] naphthyridinyl), thiazolpyrimidinyl, thienopyrimidinyl, pyrimidopyrimidinyl, pyridopyrimidinyl, pyrazolopyrimidinyl, indolizinyl, pyrindinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, and pyrido[4,3-b]-pyridinyl), pyridopyrimidine, and pteridinyl.
  • naphthyridinyl including [1,8]
  • fused-ring heterocycles include benzo-fused heterocyclyls, such as indolyl, isoindolyl, indoleninyl (also known as “pseudoindolyl”), isoindazolyl (also known as “benzpyrazolyl” or indazolyl), benzazinyl (including quinolinyl (also known as “1- benzazinyl”) and isoquinolinyl (also known as “2 -benzazinyl”)), benzimidazolyl, phthalazinyl, quinoxalinyl, benzodiazinyl (including cinnolinyl (also known as “1,2-benzodiazinyl”) and quinazolinyl (also known as "1,3 -benzodiazinyl”)), benzopyranyl (including “chromenyl” and “isochromenyl”), benzothiopyranyl (also known as "thiochromenyl”)
  • a heterocyclyl may also be, without limitation, a spiro ring system, such as, for example, 1 ,4- dioxa-8-azaspiro[4.5]decanyl.
  • a heterocyclyl may comprise one or more sulfur atoms as ring members; and in some cases, the sulfur atom(s) is oxidized to SO or SO 2 .
  • the nitrogen heteroatom(s) in a heterocyclyl may or may not be quaternized, and may or may not be oxidized to N-oxide. In addition, the nitrogen heteroatom(s) may or may not be N-protected.
  • pharmaceutically acceptable is used adjectivally to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product.
  • terapéuticaally effective amount refers to the total amount of each active substance that is sufficient to show a meaningful patient benefit, e.g. a reduction in viral load.
  • prodrug refers to derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become, by solvolysis or under physiological conditions, the compounds of the invention which are pharmaceutically active in vivo.
  • a prodrug of a compound may be formed in a conventional manner by reaction of a functional group of the compound (such as an amino, hydroxy or carboxy group).
  • Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in mammals (see, Bungard, H., DESIGN OF PRODRUGS, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine.
  • Examples of prodrugs include, but are not limited to, acetate, formate, benzoate or other acylated derivatives of alcohol or amine functional groups within the compounds of the invention.
  • solvate refers to the physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, and methanolates.
  • N-protecting group or “N-protected” refers to those groups capable of protecting an amino group against undesirable reactions. Commonly used N-protecting groups are described in Greene and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (3 rd ed., John Wiley & Sons, NY (1999).
  • N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, or 4-nitrobenzoyl; sulfonyl groups such as benzenesulfonyl or p-toluenesulfonyl; sulfenyl groups such as phenylsulfenyl (phenyl-S-) or triphenylmethylsulfenyl (trityl-S-); sulfinyl groups such as p-methylphenylsulfinyl (p- methylphenyl-S(O)-)
  • N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
  • the compounds of the present invention can be prepared as shown in Scheme I.
  • the diamine (1-1) may be reacted with a suitably protected proline acid [i-butoxycarbonyl (Boc) is shown, although benzyloxycarbonyl (Cbz), 2,2,2-trichloroethoxycarbonyl (Troc), or 9-fluorenylmethoxycarbonyl (Fmoc) may be substituted] in the presence of a peptide coupling reagent, such as A ⁇ 3-dimethylaminopropyl)-A ⁇ -ethylcarbodiimide hydrochloride/1 - hydroxybenzotriazole [EDAC/HOBT], (benzotriazol- 1 -yl-oxy)tripyrrolidinophosphonium hexafluorophosphate [PyBOP®], 0-(7-azabenzotriazol-l -yl)-A ⁇ ,A ⁇ ,A ⁇ ',A'-tetra
  • the alkene (1-2) may be reacted with 1 to 5 equivalents or more of compounds of formula (1-4) in the presence of a suitable acid such as toluene sulfonic acid or other reagents such as boron trifluoride etherate in organic solvents such as dichloromethane or toluene to give cyclopropane compounds of formula (1-5) [Sugawara, M.; et al. J. Am. Chem. Soc. 1997, 1 19, 11986]. Removal of the i-butoxycarbonyl (Boc) protecting groups to give (1-6) may be accomplished by treatment with an acid, such as trifluoroacetic acid, HC1, or formic acid.
  • Compounds of the present invention (1-7) wherein T and R D are as described above, may be prepared by coupling of (1-6) with an acid of choice using the standard peptide coupling reagents and conditions described above.
  • Dibromostilbene (II- 1) can be reacted with bis(pinacolato)diboron with potassium acetate in solvents such as, but not limited to, toluene at temperatures from about 80 °C to about 120 °C to give alkene ( ⁇ -2).
  • the alkene ( ⁇ -2) may be reacted with 1 to 5 equivalents or more of compounds of formula (1-4) in the presence of a suitable acid such as toluene sulfonic acid or other reagents such as boron trifluoride etherate in organic solvents such as dichloromethane or toluene to give cyclopropane compounds of formula (II-3).
  • the cyclopropane compounds ( ⁇ -3) can be reacted with bromoimidazoles ( ⁇ -4), wherein Pi is a nitrogen-protecting group, using Suzuki reaction conditions to give the phenylimidazole ( ⁇ -5).
  • Suzuki reaction conditions A variety of reaction conditions are well known to those of skill in the art to be effective in mediating the Suzuki reaction.
  • the reaction of ( ⁇ -3) with (II-4) to produce ( ⁇ -5) can be performed with [l,l '-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [Pd(dppf)Cl 2 ] catalyst and potassium carbonate in a mixture of toluene and water and with heating to about 100 °C.
  • Alcohols (III-l) can be oxidized to aldehydes ( ⁇ -2) using well-known methods such as, for example, reacting the alcohols (III-l) with Dess-Martin periodinane in the presence of sodium bicarbonate in a solvent such as, but not limited to, dichloromethane.
  • Compounds ( ⁇ -2) can be reacted with glyoxal and ammonium hydroxide in methanol/water to give (III-3).
  • Compounds ( ⁇ -3) in turn can be brominated using ⁇ -bromosuccinimide in solvents such as, but not limited to, dichloromethane at temperatures from 0 °C to room temperature to give ( ⁇ -4).
  • Compounds ( ⁇ -4) can be mono-debrominated by reaction with sodium sulfite (Na 2 S0 3 ) in a mixture of dioxane and water with heating to reflux to give intermediates ( ⁇ -4). Although no particular stereochemistry is designated for intermediate ( ⁇ -4), the foregoing chemical methods can be used to prepare ( ⁇ -4) as a racemate or a single enantiomer (R or S stereochemistry). The choice of (R) or (S) stereochemistry in the starting alcohol (III-l) will lead to compounds of the invention having a single absolute stereochemistry at the corresponding carbon of the final compound.
  • Benzimidazole derivatives of general structural formula (VI-2) can be prepared by synthetic sequences summarized in Schemes IV- VI.
  • the requisite stilbene derivative (IV-6) can be prepared starting by treatment of bromide (IV- 1) with di-teri-butyl dicarbonate in the presence of a suitable base such as, but not limited to, aqueous sodium bicarbonate solution, to afford bis-i-butoxycarbonyl protected (IV-2).
  • Bromide (IV-2) is reacted with an acetylene derivative such as trimethylsilylacetylene under Sonogashira conditions using a suitable palladium catalyst such as bis(triphenylphosphine)palladium (II) chloride in the presence of a copper salt, such as, but not limited to, copper (I) iodide, and a suitable amine base, such as triethylamine or diisopropyl amine.
  • a suitable palladium catalyst such as bis(triphenylphosphine)palladium (II) chloride
  • a copper salt such as, but not limited to, copper (I) iodide
  • a suitable amine base such as triethylamine or diisopropyl amine.
  • Acetylene (IV-3) so obtained is then deprotected by treatment with a suitable alcoholic base, such as potassium carbonate or potassium hydroxide, or by treatment with fluoride ion, in the form of tetrabutylammonium fluoride to afford acetylene derivative (IV-4).
  • a suitable alcoholic base such as potassium carbonate or potassium hydroxide
  • fluoride ion in the form of tetrabutylammonium fluoride
  • acetylene derivative (IV-4) acetylene derivative
  • Boronate (IV-5) is prepared by hydroboration of (IV-4) with diisopmocampheylborane followed by reaction of the resulting trialkylborane with an aldehyde, such as acetaldehyde, and aqueous hydrolysis of the dialkyl borate to afford boronic acid (IV-5).
  • Stilbene (IV-6) can then be obtained from the Suzuki-Miyaura coupling of boronic acid (IV-5) with bromide (IV-2), catalyzed by either a palladium (II) salt or a palladium (0) source, such as tris(dibenzylideneacetone)dipalladium (0) or the like in conjunction with a phosphine ligand, preferably with a Cytec® phenyl phosphaadamantyl ligand (PA-Ph) (Adjabeng, J., et al. Org. Lett. 2003, 5, 953; Adjabeng, J., et al. J. Org. Chem.
  • a palladium (II) salt or a palladium (0) source such as tris(dibenzylideneacetone)dipalladium (0) or the like in conjunction with a phosphine ligand, preferably with a Cytec® phenyl pho
  • aqueous base such as tribasic potassium phosphate, potassium carbonate, or the like
  • a suitable solvent such as tetrahydrofuran, dimethoxyethane, or the like.
  • Tetraamine (V-2) can be coupled with two equivalents of a suitably protected proline acid (i-butoxycarbonyl (Boc) is shown, other protecting groups such as benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl would also be useful) using preferably coupling agent 0-(7-azabenzotriazol-l-yl)-A ⁇ ,A ⁇ ,A ⁇ ',A ⁇ '-tetramethyluronium hexafluorophosphate (HATU) in the presence of an amine base such as diisopropylethylamine or Af-methylmorpholine, or other coupling agents known to those skilled in the art, to afford the two regioisomeric anilides (V-3) and (V-4).
  • i-butoxycarbonyl (Boc) i-butoxycarbonyl (Boc)
  • other protecting groups such as benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl would also be useful
  • the regioisomeric anilides are not separated, but directly cyclized to (V-6) by treatment with 5-10 equivalents of glacial acetic acid in toluene or tetrahydrofuran (or mixtures thereof) at a temperature in the range of 50-85 °C.
  • Benzimidazole (V-6) can be transformed to representative compounds of this invention by the sequence of transformations shown in Scheme VI. As shown, treatment of (V-6) with a suitable acid removes the two t-butoxycarbonyl (Boc) protecting groups to afford diamine (VI-1). Diamine (VI- 1) can then be coupled with two equivalents of an appropriately functionalized amino acid derivative, by use of amino acid coupling methods known to those skilled in the art to afford final benzimidazole derivative (VI-2), wherei I and n, R D and T are as defined above.
  • Compounds (VII-2) can be converted to compounds (VII-3) by reaction with a triflating source such as triflic anhydride.
  • a triflating source such as triflic anhydride.
  • Compounds (VII-3) may be converted to further compounds of the invention using well- known organic transformations of aromatic triflates such as Suzuki, Sonogashira, or Buchwald reactions.
  • (VII-3) may be converted to compounds (VII-4), wherein R 00 is group such as alkenyl, aryl, heteroaryl, or cycloalkenyl, by reaction with a suitable boronic acid or ester Ri 0 oB(OR') 2 , wherein R' is hydrogen, alkyl, or together with the oxygen atoms and adjacent boron atom to which they are attached form a dioxaborolane or a dioxaborinane, such as, but not limited to, 1-cyclohexen-yl-boronic acid pinacol ester or other boronic acids/esters, in the presence of a source of palladium and phosphine ligand (e.g., PdCl 2 [dppfj 2 ) and base (e.g., triethylamine, sodium carbonate, potassium carbonate, potassium phosphate, sodium bicarbonate), in solvents such as, but not limited to, DME and water at
  • the compounds (VII-4) derived from Suzuki reaction with an alkeneboronic acid/ester or cycloalkenylboronic acid/ester and having an alkene in the R100 group may be further elaborated to compounds of the invention by reaction of the alkene present in R100 (e.g. reduction by catalytic hydrogenation).
  • reaction conditions are well known to those of skill in the art to be effective in mediating the Suzuki reaction.
  • Other substrates utilized in the Suzuki reaction such as aromatic, heteroaromatic, or heterocyclic boronates or boronic acids may provide compounds (VII-4) having heteroaryl, heterocyclic, or aryl groups at Rioo.
  • Suitably substituted amines may combine with a triflate (VII-3) in a Buchwald-type reaction to provide compounds (VII-5), wherein R101 and R102 are each alkyl or taken together with the nitrogen atom to which they are attached form a heterocycloalkyl.
  • Suitable conditions for effecting this transformation may be found in the following references: Wolfe and Buchwald, J. Org. Chem. 1997, 1264-1267; Louie et al, J. Org. Chem. 1997, 1268-1273; Peng, T.; Yang, D. Organic Lett. 2010, 12, 496-499; Hartwig, J. F. in Handbook of Organopalladium
  • substituted alkynes may couple in a Sonogashira reaction with (VII-3) to provide compounds (VII-6), wherein R103 is aryl or heteroaryl.
  • compounds (VIII-3) can be converted to compounds (VIII -4) by reaction with PBr 3 .
  • Compounds (VIII-4) may be converted to compounds (VIII-5) by reaction with 4-(teri-butoxycarbonylamino)phenylboronic acid or teri-butyl 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenylcarbamate using Suzuki reaction conditions (see for example: J. Chem. Soc. Chem. Commun. (1994) 2305-2306; Org. Lett. (1999) 1839-1842).
  • Compounds (VIII-5) may be converted to compounds (VIII-6) by catalytic hydrogenation using Pt0 2 or Pd/C as described for enone reduction in Aust. J. Chem. (1997) 149-152; J. Med. Chem. (1976) 414-419 (see bottom of table III on page 417); and Org. Lett. (2009) 5450-5453 and supporting information.
  • Compounds (VIII-6) may be converted to compounds (VIII-7) by treatment with base (e.g., NaH, LiHMDS, KHMDS) followed by reaction with (Tf) 2 NPh as shown in the following references: Ang. Chem. Int. Ed. Eng. (2005) 403-406 and supporting information; J. Med. Chem.
  • compounds (VIII-5) may be converted directly to compounds (VIII-7) by reduction with L-selectride or sodium selectride followed by trapping of the in-situ formed enolate with (Tf) 2 NPh or Comins' reagent as described in the following references: see J. Org. Chem. (2007) 4616 and supporting information on page S33; also WO2007144174 on page 25; see also http://en.wikipedia.org/wiki/L-selectride.
  • Compounds (VIII-7) may be converted to compounds (VIII-8) by a Suzuki reaction with an appropriate boronic acid or ester as described above or as generally known in the art.
  • Compounds (VIII-8) may be converted to compounds (VIII-9) by Boc removal using standard conditions such as TFA/CH 2 CI 2 or HC1 in dioxane.
  • Compounds (VIII-9) may be converted to compounds (VIII- 10) by reaction with (.S)-l-(teri-butoxycarbonyl)pyrrolidine-2-carboxylic acid using standard amide bond forming techniques such as the use of a peptide coupling reagent (e.g., EDAC/HOBT, PyBOP®, HATU, T3P, or DEPBT), in a solvent such as THF, DMF, dichloromethane, or DMSO, with or without the addition of an amine base such as A-methylmorpholine, Hunig's base, pyridine, 2,6- lutidine, or triethylamine.
  • a peptide coupling reagent e.g., EDAC/HOBT, PyBOP®, HATU, T3P,
  • Compounds (VIII- 10) may be converted to compounds (VIII- 11) using the Boc removal conditions referred to above.
  • Compounds (VIII- 11) may be converted to compounds (VIII-12) by reaction with an appropriate carboxylic acid such, but not limited to, 2- (methoxycarbonylamino)-3-methylbutanoic acid, 2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid, 2-cyclohexyl-2-(methoxycarbonylamino)acetic acid, 2-(methoxycarbonylamino)-2-(tetrahydro- 2//-pyran-4-yl)acetic acid, etc., using the standard amide bond forming conditions referred to above.
  • Compounds (VIII-12) may be converted to compounds (VIII- 13) by catalytic hydrogenation using catalysts such as Pt0 2 or Pd/C under 1-4 atmospheres of hydrogen in typical organic solvents (e.g., ethyl acetate, methanol, etc).
  • catalysts such as Pt0 2 or Pd/C under 1-4 atmospheres of hydrogen in typical organic solvents (e.g., ethyl acetate, methanol, etc).
  • Scheme VIII By analogy with the methods outlined in Scheme VIII, further compounds of the invention may be prepared according to the methods outlined in Scheme IX.
  • Compounds (VIII-4) may be reacted with compound (IX- 1) under standard Suzuki conditions to give compounds (IX-2).
  • Compounds (IX-2) may be converted to compounds (IX-3) using conditions and steps analogous to those in Scheme VIII used to convert (VIII-5) to (VIII-8).
  • the benzimidazole of (IX-1) and (IX-2) may be protected as a SEM derivative.
  • Schemes VIII-X may also be modified to produce compounds of the invention bearing different groups flanking the central core by appropriate choice of a distinct boronic acid or ester for each Suzuki reaction.
  • compounds may be prepared having a benzimidazole moiety on one side and a
  • Compounds (XI-1), where X13 is alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxycarbonyl, etc., can be coupled with an acid (e.g., (5)-l-(te ⁇ butoxycarbonyl)pyrrolidine-2-carboxylic acid) using peptide coupling procedures described above to give an amide that can be heated in acetic acid to about 100 °C to give (XI-2).
  • Compounds (XI-2) can be reacted with SEM-C1 and
  • Compound (VIII-2) may react with a variety of boronic acids or esters as mentioned above.
  • Certain boronic acids suitable for reaction with (VIII-2) may be prepared as outlined in Scheme XII, where q is 0, 1, or 2; R A is halo, alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, etc.; and n is 0, 1, 2, 3, or 4.
  • Bromoanilines may be reacted with a dihaloalkane (e.g., 1,5-dibromopentane) generally in solvents such as benzene, toluene, DMF, etc.
  • a dihaloalkane e.g., 1,5-dibromopentane
  • compounds of formula (XIII-4) can be treated with hydroxylamine hydrochloride in the presence of potassium hydroxide in a heated mixture of ethanol and water to remove the 2,4- dimethylpyrrole. Then treatment with acid under conditions known to one skilled in the art removes the teri-butoxycarbonyl protecting group to deliver compounds of formula (VIII-9).
  • Compounds of formula (VIII-9) can be coupled with compounds of formula (XIII-5) under standard amide bond coupling procedures to give compounds of formula (VIII-12).
  • Compounds of formula (VIII-12) can be further transformed as described in Scheme VIII.
  • a moiety described herein e.g., -NH 2 or -OH
  • the moiety may be protected with a suitable protecting group that is stable to the reaction conditions used in the methods.
  • the protecting group may be removed at a suitable point in the reaction sequence to provide a desired intermediate or target compound.
  • Suitable protecting groups and methods for protecting or deprotecting moieties are well know in the art, examples of which can be found in Greene and Wuts, supra.
  • Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants employed and substituents present in the reactants used. Solvents, temperatures and other reaction conditions may be readily selected by one of ordinary skill in the art based on the present invention.
  • Example compounds below were named using either ChemDraw version 9.0 or ACD/Name release 12.00 12 (ACD vl2). Final compounds for Examples 1-8 were named using ChemDraw unless otherwise indicated as being named using ACD vl2. Intermediates were named using ChemDraw, unless otherwise indicated as being named using ACD vl2.
  • Example compounds below were named using ACD Name version 12 (ACD Name vl2).
  • Certain compounds in the Examples below can be purified using normal phase silica gel chromatography including traditional flash chromatography or an automated purification system (e.g., Isco CombiFlash®, Analogix Intelliflash) using pre-packed silica gel columns (55 or 35 ⁇ silica gel, Isco gold columns). Compounds can also be purified by preparative thin-layer chromatography.
  • normal phase silica gel chromatography including traditional flash chromatography or an automated purification system (e.g., Isco CombiFlash®, Analogix Intelliflash) using pre-packed silica gel columns (55 or 35 ⁇ silica gel, Isco gold columns).
  • Compounds can also be purified by preparative thin-layer chromatography.
  • Typical solvents for silica gel chromatography include: Ethyl acetate in hexanes, diethyl ether in hexanes, tetrahydrofuran in hexanes, ethyl acetate in methylene chloride, methanol in methylene chloride, methanol in methylene chloride with ammonium hydroxide, acetone in hexanes, and methylene chloride in hexanes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Description

ANTI-VIRAL COMPOUNDS
This application incorporates by reference the entire content of U.S. Patent Application Pub. No. 2010/0317568, U.S. Patent Application Pub. No. 2011/0092415, U.S. Patent Application Pub. No. 2011/0207699, U.S. Patent Application No. 13/100,827 filed May 4, 2011, and U.S. Provisional Application No. 61/446,800 filed February 25, 2011.
FIELD
The present invention relates to compounds effective in inhibiting replication of Hepatitis C virus ("HCV"). The present invention also relates to compositions comprising these compounds and methods of using these compounds to treat HCV infection.
BACKGROUND
HCV is an RNA virus belonging to the Hepacivirus genus in the Flaviviridae family. The enveloped HCV virion contains a positive stranded RNA genome encoding all known virus-specific proteins in a single, uninterrupted, open reading frame. The open reading frame comprises approximately 9500 nucleotides and encodes a single large polyprotein of about 3000 amino acids. The polyprotein comprises a core protein, envelope proteins El and E2, a membrane bound protein p7, and the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.
HCV infection is associated with progressive liver pathology, including cirrhosis and hepatocellular carcinoma. Chronic hepatitis C may be treated with peginterferon-alpha in combination with ribavirin. Substantial limitations to efficacy and tolerability remain as many users suffer from side effects, and viral elimination from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.
SUMMARY
The present invention features compounds of Formulae I, IA, ¾, Ic, ID, IE, IF or IG, and pharmaceutically acceptable salts thereof. These compounds and salts can inhibit the replication of HCV and therefore are useful for treating HCV infection.
The present invention also features compositions comprising the compounds or salts of the present invention. The compositions can also include additional therapeutic agents, such as HCV helicase inhibitors, HCV polymerase inhibitors, HCV protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, cyclophilin inhibitors, or internal ribosome entry site (IRES) inhibitors.
The present invention further features methods of using the compounds or salts of the present invention to inhibit HCV replication. The methods comprise contacting cells infected with HCV virus with a compound or salt of the present invention, thereby inhibiting the replication of HCV virus in the cells.
In addition, the present invention features methods of using the compounds or salts of the present invention, or compositions comprising the same, to treat HCV infection. The methods comprise administering a compound or salt of the present invention, or a pharmaceutical composition comprising the same, to a patient in need thereof, thereby reducing the blood or tissue level of HCV virus in the patient.
The present invention also features use of the compounds or salts of the present invention for the manufacture of medicaments for the treatment of HCV infection.
Furthermore, the present invention features processes of making the compounds or salts of the invention.
Other features, objects, and advantages of the present invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating preferred embodiments of the invention, are given by way of illustration only, not limitation. Various changes and modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.
DETAILED DESCRIPTION
The present invention features compounds having Formula I, and pharmaceutically acceptable salts thereof,
D
Y— A— L-i— X— L2— B— Z
I
wherein:
-Cscycloalkyl or C5-C8cycloalkenyl, and is optionally substituted with one or more RA or RF;
Li and L2 are each independently selected from bond; or Ci-Cealkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL;
L3 is bond or -LS-K-LS'-, wherein K is selected from bond, -0-, -S-, -N(RB)-, -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20- -S(0)0- -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0- -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2- -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-, -N(RB)S02N(RB')-, or -N(RB)S(0)N(RB')-; A and B are each independently C3-Ci2carbocycle or 3- to 12-membered heterocycle, and are each independently optionally substituted with one or more RA;
D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle which is substituted with J and optionally substituted with one or more RA, where J is
C3-Ci2carbocycle or 3- to 12-membered heterocycle and is optionally substituted with one or more RA, or J is -SF5; or D is hydrogen or RA;
Y is selected from -T'-C(R1R2)N(R5)-T-RD, -T'-C(R3R4)C(R6R7)-T-RD, -LK-T-Rd, or Ri and R2 are each independently Rc, and R5 is RB; or Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
R3, R4, R6, and R7 are each independently Rc; or R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12- membered carbocycle or heterocycle which is optionally substituted with one or more RA;
Z is selected from -T'-C(R8R9)N(R12)-T-RD, -T'-C(R10Rn)C(Ri3Ri4)-T-RD, LK— T— RD or
R8 and R9 are each independently Rc, and Ri2 is RB; or R8 is Rc, and R9 and Ri2, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
Rio, Rn, Ri3, and RM are each independently Rc; or Ri0 and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
T and T are each independently selected at each occurrence from bond, -Ls- -Ls-M-Ls'-, or -Ls-M-Ls'-M'-Ls"-, wherein M and M' are each independently selected at each occurrence from bond, -0-, -S-, N(RB)— , -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20-, -S(0)0- -C(0)0- -OC(O)-, -OC(0)0-, -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0- -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2- -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-,
-N(RB)S02N(RB')-, -N(RB)S(0)N(RB')-, C3-Ci2carbocycle or 3- to 12-membered heterocycle, and wherein said C3-Ci2carbocycle and 3- to 12-membered heterocycle are each independently optionally substituted at each occurrence with one or more RA;
LK is independently selected at each occurrence from bond, -Ls-N(RB)C(0)-Ls'- or -Ls-C(0)N(RB)-Ls'-; or Ci-Cealkylene, C2-Cealkenylene or C2-Cealkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; or C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more RA;
E is independently selected at each occurrence from C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is independently optionally substituted at each occurrence with one or more RA;
RD is each independently selected at each occurrence from hydrogen or RA;
RA is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE, wherein two adjacent RA, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle;
RB and RB' are each independently selected at each occurrence from hydrogen; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RB or RB' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-Cehaloalkenyl or C2-Cehaloalkynyl;
Rc is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in Rc is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl;
RE is independently selected at each occurrence from -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RsRs'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), -P(0)(ORs)2, or -C(0)N(Rs)C(0)-Rs'; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs, or -N(RsRs');
is independently selected at each occurrence from Ci-Ci0alkyl, C2-Ci0alkenyl or C2-Ci0alkynyl, each of which contains 0, 1, 2, 3, 4 or 5 heteroatoms selected from O, S or N and is independently optionally substituted with one or more RL; or -(RX-RY)Q-(RX-RY'), wherein Q is 0, 1 , 2, 3 or 4, and each Rx is independently O, S or N(RB), wherein each RY is independently Ci-Cealkylene, C2-Cealkenylene or C2-C6alkynylene each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, and wherein each RY' is independently Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs') or -N(Rs)C(0)Rs'; or C3-C6carbocycle 3- to 6- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; wherein two adjacent RL, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle;
Ls' and Ls" are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; and
Rs' and Rs" are each independently selected at each occurrence from hydrogen; Ci-C6alkyl, C2-Cealkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, -0-Ci-C6alkyl, -0-Ci-C6alkylene-0-Ci-C6alkyl, or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in Rs , Rs' or Rs' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl.
A and B preferably are independently selected from C5-C6carbocycle (e.g., phenyl), 5- to 6- membered heterocycle (e.g., pyridinyl or thiazolyl), or 8- to 12-membered bicycles such as where Zi is independently selected at each occurrence from O, S, NH or CH2, Z2 is independently selected at each occurrence from N or CH, Z3 is independently selected at each occurrence from N or CH, Z4 is independently selected at each occurrence from O, S, NH or CH2, and Wi, W2, W3, W4, W5 and W6 are each independently selected at each occurrence from CH or N. A and B are each independently optionally substituted with one or more RA.
More preferably, A is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, and is optionally substituted with one or more RA? B is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or and is optionally substituted with one or more RA; where Z Z2, Z3, Z4, Wi, W2,
W3, W4, W5, W6 are as defined above. Preferably, Z3 is N and Z4 is NH. For instance, A can be selected from
and is optionally substituted with one or more RA; and B can be selected from phenyl (e.g., ^ \= ^), pyridinyl (e.g., ^ ^), thiazolyl (e.g., and is optionally substituted with one or more RA. Highly p referably, both A and B are phenyl (e.g., both A and B ar Also highly preferably, A
substituted with one or more RA
D preferably is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more RA. D can also be preferably selected from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, and is optionally substituted with one or more substituents selected from RL. More preferably, D is C5-C6carbocycle (e.g., phenyl), 5- to 6- membered heterocycle (e.g., pyridinyl, pyrimidinyl, thiazolyl), or 6- to 12-membered bicycles (e.g., indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l,3]dioxol-5-yl), and is substituted with one or more RM, where RM is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE. Also preferably, D is phenyl, and is optionally substituted with one or more RA. More preferably, D is phenyl, and is substituted with one or more RM, wherein RM is as defined
above. Highly preferably, D is wherein RM is as defined above, and each
RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
more RM. Highly preferably, D is , or , wherein is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F. D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[ xol-5-yl, and is substituted with one or more RM. Highly preferably, D
is ? an(j jg optionally substituted with one or more RM.
Preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. More preferably, RM is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy. Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or RM is -LS-RE, wherein Ls is a bond or Ci-C6alkylene, and RE is -N(RsRs'), -O-Rs, -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, -SRs, or -P(0)(ORs)2, wherein Rs and Rs' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C6alkyl optionally substituted at each occurrence with one or more halogen, hydroxy, -O-Q-Cealkyl or 3- to 6-membered heterocycle; or RM is Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RsRs')- More preferably, RM is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C6alkyl (e.g., methyl, isopropyl, tert-butyl), C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example RM is CF3, -C(CF3)2-OH, -C(CH3)2-CN, -C(CH3)2-CH2OH, or -C(CH3)2-CH2NH2. Also preferably RM is -LS-RE where Ls is a bond and RE is -N(RSRS ), -0-Rs, -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, or -SRS. For example where Ls is a bond, RE is -N(Ci-C6alkyl)2 (e.g., -NMe2); -N(C C6alkylene-0-Ci-C6alkyl)2 (e.g. -N(CH2CH2OMe)2);
-N(Ci-C6alkyl)(Ci-C6alkylene-0-Ci-C6alkyl) (e.g. -N(CH3)(CH2CH2OMe));— 0-Ci-C6alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-Ci-C6haloalkyl (e.g., -OCF3, -OCH2CF3); -0-Ci-C6alkylene-piperidine (e.g., -0-CH2CH2-l-piperidyl);
-N(Ci-C6alkyl)C(0)OCi-C6alkyl (e.g., -N(CH3)C(0)0-CH2CH(CH3)2),
-N(Ci-C6alkyl)S02Ci-C6alkyl (e.g., -N(CH3)S02CH3); -S02Ci-C6alkyl (e.g., -S02Me); -S02Ci-C6haloalkyl (e.g., -S02CF3); or -S-Ci-C6haloalkyl (e.g., SCF3). Also preferably RM is -LS-RE where Ls is C C6alkylene (e.g., -CH2- -C(CH3)2-, -C(CH3)2-CH2-) and RE is -0-Rs, -C(0)ORs, -N(Rs)C(0)ORs', or -P(0)(ORs)2. For example RM is -Ci-C6alkylene-0-Rs (e.g., -C(CH3)2-CH2-OMe); -Ci-C6alkylene-C(0)ORs (e.g., -C(CH3)2-C(0)OMe);
-Ci-C6alkylene-N(Rs)C(0)ORs' (e.g., -C(CH3)2-CH2-NHC(0)OCH3); or -Ci-C6alkylene-P(0)(ORs)2 (e.g., -CH2-P(0)(OEt)2). Also more preferably RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). For example RM is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl). Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF3).
More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle, wherein said C3-C6carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS'), and J can also be optionally substituted with one or more RA. Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably, J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS'). Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA. More preferably, D is phenyl and is substituted with J and optionally substituted with one or more RA, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Highly preferably, D is , wherein each RN is independently selected from
RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Also preferably, D is , wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'), and J can also be optionally substituted with one or more RA. Also preferably, D is
, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS').
X preferably is C3-C8cycloalkyl or C5-C8cycloalkenyll and is optionally substituted with one or more RA. X can also be C3-Cscycloalkyl or C5-Cscycloalkenyl which is optionally substituted with one or more RA, wherein two adjacent RA on X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle. More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF, wherein two adjacent RA on X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
Non-limiting examples of preferred X include the following cyclopropyl rings, each of which is optionally substituted with one or more RA or RF: As shown, the relative stereochemistry at the any of the positions of the above cyclopropyl ring may be either cis or trans. The stereochemistries of optional substituents RA or RF at any of the positions of the cyclopropyl may vary relative to any substituent at any other position on the cyclopropyl ring. Depending on the particular substituents attached to the cyclopropyl, the stereochemistry at any carbon may be either (R) or (S).
Non-limiting examples of preferred X include the following cyclopentyl or cyclopentenyl rings, each of which is optionally substituted with one or more RA or RF:
As shown, the relative stereochemistry at the any of the positions of the above cyclopentyl ring may be either cis or trans. The stereochemistries of optional substituents RA or RF at any of the positions of the cyclopentyl or cyclopentenyl may vary relative to any substituent at any other position on the cyclopropyl ring. Depending on the particular substituents attached to the cyclopentyl or cyclopentenyl, the stereochemistry at any carbon may be either (R) or (S). Preferably, RF is Ci-Cioalkyl, C2-Cioalkenyl or C2-Cioalkynyl, each of which contains 0, 1 , 2, 3, 4 or 5 heteroatoms selected from O, S or N and is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano. Also preferably, RF is Ci-Ci0alkyl, C2-Ci0alkenyl or C2-Cioalkynyl, each of which contains 0, 1 , 2, 3, 4 or 5 O and is independently optionally substituted with one or more RL. Also preferably, RF is -(RX-RY)Q-(RX-RY'), wherein Q is 0, 1 , 2, 3 or 4; each RX is independently O, S or N(RB); each RY is independently Ci-C6alkylene, C2- Cealkenylene or C2-C6alkynylene each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; and each RY' is independently Ci-C6alkyl,
C2-C6alkenyl or C2-Cealkynyl each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano. Preferably, each RX is O. More preferably, X is optionally substituted with one or more RA or RF, each RF is independently selected from Ci-Cioalkyl,
C2-Cioalkenyl or C2-Cioalkynyl, each of which contains 0, 1 , 2 or 3 O and is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano. Also preferably, X is optionally substituted with one or more RA or RF, each RF is independently selected from
-(0-Ci-C6alkylene)Q-(0-Ci-C6alkyl), wherein Q preferably is 0, 1 , 2 or 3.
Li and L2 are preferably independently bond or Ci-C6alkylene, L3 is preferably selected from bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. More preferably, Li, L2 and L3 are each independently a bond or Ci-Cealkylene (e.g., -CH2- or -CH2CH2-), and are each independently optionally substituted with one or more RL. Highly preferably, Li, L2 and L3 are each a bond.
Y is preferably selected from -LS-C(RiR2)N(R5)-T-RD; -LS-C(R3R4)C(R6R7)-T-RD,
-G-C(R1R2)N(R5)-T-RD; -G-C(R3R4)C(R6R7)-T-RD, -N(RB)C(0)C(R1R2)N(R5)-T-RD;
-N(RB)C(0)C(R3R4)C(R6R7)-T-RD, -C(0)N(RB)C(R1R2)N(R5)-T-RD;
-C(0)N(RB)C(R3R4)C(R6R7)-T-RD, -N(RB)C(0)-LS-E, or -C(0)N(RB)-LS-E. G is C5-C6carbocycle
or 5- to 6-membered heterocycle, such as , and is optionally substituted with one or more RA (e.g., one or more chloro or bromo). E preferably is a 7-
wherein U is independently selected at each occurrence from -(CH2)- or -(NH)-; V and Z2o are each independently selected from Ci-C4alkylene,
C2-C4alkenylene or C2-C4alkynylene, in which at least one carbon atom can be independently optionally replaced with O, S or N), and is optionally substituted with one or more RA. More preferably, Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a
is optionally substituted with one or more RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl)); and R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, for carbocycle/heterocycle or 6- to 12-membered bicycle (e.g., is optionally substituted with one or more RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl)).
Y can also be selected from -M-C(R1R2)N(R5)-C(0)-LY'-M'-RD,
-M-C(R1R2)N(R5)-LY' -M'-RD, -LS-C(R1R2)N(R5)-C(0)-LY'-M'-RD, -LS-C(R1R2)N(R5)-LY'-M'-RD, -M-C(R3R4)C(R6R7)-C(0)-LY'-M'-RD, -M-C(R3R4)C(R6R7)-LY'-M'-RD,
-LS-C(R3R4)C(R6R7)-C(0)-LY'-M'-Rd, or -LS-C(R3R4)C(R6R7)-LY'-M'-Rd, wherein M preferably is bond, -C(0)N(RB)- or -N(RB)C(0)-, M' preferably is bond, -C(0)N(RB)-, -N(RB)C(0)- -N(RB)C(0)0- N(RB)C(0)N(RB')-, -N(RB)S(0)- or -N(RB)S(0)2- and LY' preferably is C Cealkylene which is optionally substituted with one or more RL. LY' is Ls' . LY', for example, is a
Ci-C6alkylene such as, but not limited to, ' " , , , , or and the optional RL is a substituent such as, but not limited to phenyl, -SMe, or methoxy. Any stereochemistry at a carbon within the group LY' can be either (R) or (S). More preferably, Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA (e.g., one or more hydroxy); and R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered
carbocycle/heterocycle or 6- to 12-membered bicycle (e.g., is optionally substituted with one or more RA.
Also preferably, Y is selected from -N(RB)CO-C(RIR2)N(R5)-C(0)-LY'-N(RB)C(0)0-RD, -N(RB)CO-C(R1R2)N(R5)-C(0)-LY'-N(RB)C(0)-RD,
-N(RB)CO-C(R1R2)N(R5)-C(0)-LY'-N(RB)S(0)2-RD,
-N(RB)CO-C(R1R2)N(R5)-C(0)-LY'-N(RBRB')-RD, -N(RB)CO-C(R1R2)N(R5)-C(0)-LY'-0-RD, -N(RB)CO-C(R1R2)N(R5)-C(0)-LY'-RD, -N(RB)CO-C(R!R2)N(R5)-RD,
-LS-C(RIR2)N(R5)-C(0)-LY'-N(RB)C(0)0-RD, -LS-C(RIR2)N(R5)-C(0)-LY'-N(RB)C(0)-RD, -LS-C(R1R2)N(R5)-C(0)-LY'-N(RB)S(0)2-RD, -LS-C(R1R2)N(R5)-C(0)-LY'-N(RBRB')-RD, -LS-C(R1R2)N(R5)-C(0)-LY'-0-RD, -LS-C(R1R2)N(R5)-C(0)-LY'-RD, -LS-C(R1R2)N(R5)-RD, -N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)C(0)0-RD,
-N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)C(0)-RD,
-N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)S(0)2-RD,
-N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-N(RBRB')-RD, -N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-0-RD, -N(RB)CO-C(R3R4)C(R6R7)-C(0)-LY'-RD, -N(RB)CO-C(R3R4)C(R6R7)-RD,
-LS-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)C(0)0-RD, -LS-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)C(0)-RD, -LS-C(R3R4)C(R6R7)-C(0)-LY'-N(RB)S(0)2-RD, -LS-C(R3R4)C(R6R7)-C(0)-LY'-N(RBRB')-RD, -Ls-C(R3R4)C(R6R7)-C(0)-LY'-0-RD, -Ls-C(R3R4)C(R6R7)-C(0)-LY'-RD, or
-LS-C(R3R4)C(R6R7)-RD, wherein LY' preferably is Ci-C6alkylene which is optionally substituted with one or more RL. Ri may be Rc, and R2 and R5, taken together with the atoms to which they are
attached, may form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA; and R3 and R6 may be each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, may form 5- to 6-membered carbocycle/heterocycle or 6- to 12-membered bicycle (e is optionally substituted with one or more RA.
Highly preferably, Y is selected from
-N(RB")CO-C(R1R2)N(R5)-C(0)-LY-N(RB")C(0)-LS-Re or -C(RIR2)N(R5)-C(0)-LY-N(RB")C(0)-LS-Re, or Y is -G-C(RIR2)N(R5)-C(0)-LY-N(RB")C(0)-LS-RE, wherein LY is Q-Cealkylene optionally substituted with one or more RL, and RB" is each independently RB. RB" and Ri are each preferably hydrogen or Q-Cealkyl, and R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or
6- to 12-membered bicycle (e.g., is optionally substituted with one or more RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl)). LY is each independently Ls. Preferably, LY is Ci-C6alkylene substituted with one or more RL such as a C3-Cecarbocycle 3- to 6-membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. Highly preferably, LY is a Ci-Cealkylene such
as, but not limited to, , , , 1 , or (stereochemistry at a carbon within the group LY can be either (R) or (S)), LY is optionally substituted with one or more
H
RL (e.g., one or more phenyl or methoxy), G preferably is NJ , RB" is hydrogen;
-C(RiR2)N(R5)- is ; Ls is a bond; and RE is methoxy.
wherein T and RD are as defined herein. T, for example, can be -Ls-M-Ls'-M'-Ls"- w Ls is a bond; M is C( ' is Ci-Cealkylene such as, but not limited to, ,
, or , where Ls' is optionally substituted with one or more RL; RL is a substituent such as, but not limited to phenyl or methoxy; M' is -NHC(O)- or -NMeC(O)-; and Ls" is a bond. Any stereochemistry at a carbon within the group Ls' can be either (R) or (S). RD, for example is
or T-RD may also include certain stereochemical configurations; thus T-RD includes, but is not limited
-limiting examples of preferred Y also include:
Z is preferably selected from -LS-C(R8R9)N(R12)-T-RD, -Ls-C('Ri0Ri i)C(RuRi4)-T-RD, -G-C(R8R9)N(R12)-T-RD, -G-C(R10Ri i)C(R13R14)-T-RD, -N(RB)C(0)C(R8R9)N(R12)-T-RD, -N(RB)C(0)C(R1oRn)C(R13R14)-T-RD, -C(0)N(RB)C(R8R9)N(R12)-T-RD, -C(0)N(RB)C(R1oRn)C(R13R14)-T-RD, -N(RB)C(0)-Ls-E, or -C(0)N(RB)-Ls-E. G is or , and is optionally substituted with one or more RA (e.g., one or more chloro or bromo).
E preferably is a 8- to 12-membered bicycle (such as wherein U is independently selected at each occurrence from -(CH2)- or -(NH)-; and V and Z20 are each independently selected from Ci-C4alkylene, C2-C4alkenylene or C2-C4alkynylene, in which at least one carbon atom is independently optionally replaced with O, S or N), and is optionally substituted with one or more RA. More preferably, R8 is Rc, and R9 and R12, taken together with the atoms to which they are attached,
RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl); and Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocycle/heterocycle or 6- to 12-membered
bicycle (e.g., is optionally substituted with one or more RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl)).
Z can also be selected from -M-C(R8R9)N(RI2)-C(0)-LY'-M'-RD, -M-C(R8R9)N(R12)-LY'-M'-RD, -LS-C(R8R9)N(R12)-C(0)-LY'-M'-RD, -LS-C(R8R9)N(R12)-LY'-M'-RD, -M-C(R10R„)C(R13R14)-C(O)-LY'-M'-RD, -M-C(RioRn)C(Ri3Ri4)-LY'-M'-R] -LS-C(R10R„)C(R13R14)-C(O)-LY'-M'-RD, or -LS-C(RIORII)C(RI3RI4)-LY'-M'-RD, wherein M preferably is bond, -C(0)N(RB)- or -N(RB)C(0)-, M' preferably is bond, -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0-, N(RB)C(0)N(RB')-, -N(RB)S(0)- or -N(RB)S(0)2-, and LY' preferably is Ci-C6alkylene which is optionally substituted with one or more RL. LY' is each independently LS'. LY', for example, is a Ci-C6alkylene such as, but
not limited to, ' " , , , , or ; and the optional RL is a substituent such as, but not limited to phenyl, -SMe, or methoxy. Any stereochemistry at a carbon within the group LY' can be either (R) or (S). More preferably, R8 is Rc, and R9 and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-
membered bicycle (e.g., which is optionally substituted with one or more RA (e.g., one or more hydroxy); and Rio and R13 are each independently Rc, and Rn and RM, taken together with the atoms to which they are attached, form embered
carbocycle/heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA.
Also preferably, Z is selected from -N(RB)CO-C(R8R9)N(R12)-C(0)-LY'-N(RB)C(0)0-RD, -N(RB)CO-C(R8R9)N(R12)-C(0)-LY'-N(RB)C(0)-RD,
-N(RB)CO-C(R8R9)N(R12)-C(0)-LY'-N(RB)S(0)2-RD,
-N(RB)CO-C(R8R9)N(R12)-C(0)-LY'-N(RBRB')-RD, -N(RB)CO-C(R8R9)N(R12)-C(0)-Ly'-0-RD,
-N(RB)CO-C(R8R9)N(R12)-C(0)-LY'-RD, -N(RB)CO-C(R8R9)N(R12)-RD,
-Ls-C(R8R9)N(R12)-C(0)-LY'-N(RB)C(0)0-RD, -Ls-C(R8R9)N(R12)-C(0)-LY'-N(RB)C(0)-RD, -LS_-C(R8R9)N(R12)-C(0)-LY'-N(RB)S(0)2-RD, -LS-C(R8R9)N(R12)-C(0)-LY'-N(RBRB')-RD,
-Ls-C(R8R9)N(R12)-C(0)-LY'-0-RD, -Ls-C(R8R9)N(R12)-C(0)-LY'-RD, -LS-C(R8R9)N(R12)-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)C(O)O-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)C(O)-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)S(O)2-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-N(RBRB')-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-O-RD, -N(RB)CO-C(R10Rn)C(R13R14)-C(O)-LY'-RD,
-N(RB)CO-C(R10Rn)C(R13R14)-RD, -Ls-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)C(O)O-RD,
-Ls-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)C(O)-RD,
-Ls-C(R10Rn)C(R13R14)-C(O)-LY'-N(RB)S(O)2-RD, -LS-C(R10R„)C(R13R14)-C(O)-LY'-N(RBRB')-RD, -LS-C(RIORII)C(RI3RI4)-C(0)-LY'-0-RD, -LS-C(RIORH)C(RI3RI4)-C(0)-LY'-RD, or
-Ls-C(RioRn)C(Ri3Ri4)-RD, wherein LY' preferably is Ci-C6alkylene which is optionally substituted with one or more RL. Rs may be Rc, and Rg and R12, taken together with the atoms to which they are
attached, may form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e optionally substituted with one or more RA; and Rio and R13 may be each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, may
or 6- to 12-membered bicycle or one or more RA.
Highly preferably, Z is selected from
-N(RB")CO-C(R8R9)N(R12)-C(0)-LY-N(RB")C(0)-LS-Re or -C(R8R9)N(R12)-C(0)-LY-N(RB")C(0)-LS-RE, or Z is
-G-C(R8R9)N(R12)-C(0)-LY-N(RB")C(0)-LS-Re, wherein LY is C C6alkylene optionally substituted with one or more RL, and RB" is each independently RB. RB" and R§ are each preferably hydrogen or Ci-C6alkyl, and R9 and R12, taken together with the atoms to which they are attached, preferably form
a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g.,
which is optionally substituted with one or more RA (such as, but not limited to hydroxy, halo (e.g., fluoro), Ci-C6alkyl (e.g., methyl), or C2-C6alkenyl (e.g., allyl)). LY is each independently Ls. Preferably, LY is Ci-C6alkylene substituted with one or more RL such as a C3-C6carbocycle 3- to 6- membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloal or
C2-C6haloalkynyl. Highly preferably, LY is a Q-Cealkylene such as, but not limited to, , or (stereochemistry at a carbon within the group LY can be either (R) or (S)); LY is optionally substituted with one or more RL (e.g., one or more phenyl or
methoxy); G preferably is ti N ; RB" is hydrogen; -C(R8R9)N(Ri2)- is 1 ·™ v~ ; Ls is a bond; and RE is methoxy. -limiting examples of preferred Z include:
wherein T and RD are as defined herein. T, for example, can be -Ls-M-Ls'-M'-Ls"- where Ls is a bond; M is C( ' is Ci-Cealkylene such as, but not limited to, ,
, or , where Ls' is optionally substituted with one or more RL; the optional RL is a substituent such as, but not limited to phenyl or methoxy; M' is -NHC(O)- or -NMeC(O)-; and Ls" is a bond. Any stereochemistry at a carbon within the group Ls' can be either (R) or (S). RD, for
T-RD may also include certain stereochemical configurations; thus T-RD includes, but is not limited Non-limitin examples of preferred Z also include:
T can be, without limitation, independently selected at each occurrence from -C(0)-Ls'-, -C(0)0-LS'-, -C(0)-LS'-N(RB)C(0)-LS' '-, -C(0)-LS'-N(RB)C(0)0-LS"-, -N(RB)C(0)-LS'-N(RB)C(0)-LS"-, -N(RB)C(0)-LS'— N(RB)C(0)0-Ls"-, or -N(RB)C(0)-Ls'-N(RB)-Ls"-. Preferably, T is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"- or -N(RB)C(0)-Ls'-M'-Ls"-. More preferably, T is independently selected at each occurrence from -C(0)-LS'-N(RB)C(0)-LS' '- or -C(0)-LS'-N(RB)C(0)0-LS' '-.
T can also be, for example, -Ls-M-Ls'-M'-Ls"- where Ls is a bond; M is C(O); Ls' is Ci-C6alkylene (e.g., ), where Ls' is optionally substituted with RT; the optional RT is a substituent selected from -Ci-C6alkyl, -C2-C6alkenyl, -Ci-C6alkyl-OH, -Ci-C6alkyl-0-Ci-C6alkyl, 3- to 6-membered heterocycle (e.g., tetrahydrofuranyl), or C3-C6carbocyclyl (e.g., phenyl, cyclohexyl); M' is -NHC(O)-, -N(Et)C(0)- or -N(Me)C(0)-; and Ls" is a bond. RD preferably is hydrogen, -Ci-C6alkyl (e.g., methyl), -0-Ci-C6alkyl (e.g., methoxy, tert-butoxy), methoxymethyl, or -N(Ci-C6alkyl)2 (e.g., -NMe2).
T-RD can be either (R) or (S).
T can also be, without limitation, -Ls-M-Ls'- where Ls is a bond; M is C(O); Ls' is
Ci-C6alkylene (e.g., ) where Ls' is optionally substituted with RT; the optional RT is a substituent selected from -Ci-C6alkyl, -Ci-C6alkyl-OH, -Ci-C6alkyl-0-Ci-C6alkyl, or a C3-C6carbocyclyl (e.g., phenyl, cyclohexyl). RD, for example is -OH; -OC(0)Me; -NH(Ci-C6alkyl) (e.g., -NHMe, -NHEt); -N(Ci-C6alkyl)2 (e.g., -NMe2, -NEt2); a 3- to 10-membered heterocyclyl (e.g., pyrrolidinyl, imidazolidinyl, hexahydropyrimidinyl, mo holinyl, piperidinyl) optionally substituted with one or more halogen, oxo; C3-Ci0carbocycle (e.g., cyclopentyl) optionally substituted with -OH; -Ci-C6alkyl (e.g., isopropyl, 3-pentyl) optionally substituted with -OH; or NHRT where RT is a 3- to 6-membered heterocyclyl (e.g., thiazolyl, pyrimidinyl). T-RD includes, but is not limited to:
, wherein the stereochemistry at a carbon within the group T-RD can be either (R) or (S).
For each compound of Formula I, LK can also be independently selected at each occurrence from a bond; -Ls'-N(RB)C(0)-Ls-; -Ls'-C(0)N(RB)-Ls-; or C C6alkylene, C2-C6alkenylene, C2-C6alkynylene, C3-Ci0carbocycle or 3- to 10-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, RT> -0-Rs, -S-Rs, -N(RSRS'), -OC(0)Rs, -C(0)ORs, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, wherein Ls and Ls' are as defined above.
For Formula I as well as Formulae IA, Ic, ID, IE, IF or IG described below, including each and every embodiment described thereunder, RA preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-Cealkyl, C2-Cealkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl C2-C6haloalkynyl, C(0)ORs or RF; or -LA-0-Rs, -LA-S-RS, -LA-C(0)Rs, -LA-OC(0)Rs, -LA-C(0)ORs, -LA-N(RSRS'), -LA-S(0)Rs, -LA-S02Rs, -LA-C(0)N(RsRs'), -LA-N(Rs)C(0)Rs', -LA-N(Rs)C(0)N(Rs'Rs"), -LA-N(Rs)S02Rs', -LA-S02N(RsRs'), -LA-N(Rs)S02N(Rs'Rs"), -LA-N(Rs)S(0)N(Rs'Rs"), -LA-OS(0)-Rs, -LA-OS(0)2-Rs, -LA-S(0)2ORs, -LA-S(0)ORs, -LA-OC(0)ORs, -LA-N(Rs)C(0)ORs', -LA-OC(0)N(RsRs'), -LA-N(Rs)S(0)-Rs', -LA-S(0)N(RsRs') or -LA-C(0)N(Rs)C(0)-Rs', wherein LA is bond, Ci-Cealkylene, C2-Cealkenylene or C2-Cealkynylene.
More preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl C2-C6haloalkynyl, C(0)ORs or RF. Highly preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and Ls" preferably are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
A and B can be the same or different. Likewise, Li and L2, or Y and Z, or Y-A- and Z-B-, or -A-Li- and -B-L2-, can be the same or different. In some instances, Y-A-Li- is identical to Z-B-L2-. In some other instances, Y-A-Li- is different from Z-B-L2-.
In one embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as \=/ ¾), and are each independently optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS'), J can also be optionally substituted with one or more
RA. Preferably , wherein RM and RN are as defined above. Also
preferably, D is wherein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. Y is -N(RB)C(0)C(RiR2)N(R5)-T-RD, or -N(RB)C(0)C(R3R4)C(R6R7)-T-RD, and Z is -N(RB)C(0)C(R8R9)N(R12)-T-RD, or -N(RB)C(0)C(RioRn)C(Ri3Ri4)-T-RD. Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic
ring (e.g., which is optionally substituted with one or more RA; R3 and R6 are each independently RC, and R4 and R7, taken together with the atoms to which they are attached, form a 5-
to 6-membered carbocyclic or heterocyclic ring (e.g., which is optionally substituted with one or more RA. RS is Rc, and R9 and R12, taken together with the atoms to which they are
attached, form a 5- to 6-membered heterocyclic ring (e.g., which is optionally substituted with one or more RA; and Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring ( ch is optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or -C(0)- '-N(RB)S(0)2-Ls"-. In some cases, at least one of Y and Z is,
or both Y and Z are independently, , wherein non-limiting examples of RD include (1) -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6-membered heterocycle; or (2) C3-C6carbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-Cehaloalkynyl; and non-limiting examples of LY' include Ci-C6alkylene optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, or 3- to 6- membered carbocycle or heterocycle, said 3- to 6-membered carbocycle or heterocycle being optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-Cealkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
In another embodiment, A is nd is optionally substituted with one or more RA; B is or and is optionally substituted with one or more RA. Zi is independently selected at each occurrence from O, S, NH or CH2; and Z2 is independently selected at each occurrence from N or CH. X is C3-Cscycloalkyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'), and J can also be
optionally substituted with one or more RA. Preferably, D is or , wherein RM
and RN are as defined above. Also preferably, D is wherein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Li, L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. Y is -Ls-C(RiR2)N(R5)-T-RD or -LS-C(R3R4)C(R6R7)-T-RD, and Z is -LS-C(R8R9)N(R12)-T-RD or -LS-C(R10 H)C(RI3RI4)-T-RD. Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g., which is optionally substituted with one or more RA;
R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are
attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (e.g., which is optionally substituted with one or more RA. RS is Rc, and R9 and R12, taken together with the atoms to
which they are attached, form a 5- to 6-membered heterocyclic ring (e.g., which is optionally substituted with one or more RA; and Rio and R13 are each independently Rc, and Rn and Ri4, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring (e.g., ch is optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is independently Ci- C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or -C(0)-LY'-N(RB)S(0)2-Ls"-. In some cases, at least one of Y and Z is,
or both Y and Z are independently, , wherein non-limiting examples of R -]D include (1) -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6-membered heterocycle; or (2) C3-C6carbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-Cehaloalkynyl; and non-limiting examples of LY' include Ci-C6alkylene optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, or 3- to 6- membered carbocycle or heterocycle, said 3- to 6-membered carbocycle or heterocycle being optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C2-C6alkenyl, C2-Cealkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
In still yet another embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (e.g., A and B are each independently phenyl, such as and are each independently optionally substituted with one or more RA. X is C3-Cscycloaikyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D can be, for example, C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS'), and J can also be optionally substituted with one or more RA. Preferably, D is
s wherein RM and RN are as defined above. Also preferably, D is
herein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and L L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. Y is -G-C(RiR2)N(R5)-T-RD or -G-C(R3R4)C(R6R7)-T-RD, and Z is -G-C(R8R9)N(R12)-T-RD or -G-C(RIORH)C(RI3RI4)-T-RD. G is independently C5-C6carbocycle or 5- to 6-membered heterocycle, such as , and is independently optionally substituted with one or more RA. Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g., which is optionally substituted with one or more RA;
R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are
attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (e.g., which is optionally substituted with one or more RA. RS is Rc, and R9 and R12, taken together with the atoms to
which they are attached, form a 5- to 6-membered heterocyclic ring (e.g., which is optionally substituted with one or more RA; and Rio and R13 are each independently Rc, and Rn and Ri4, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring (e.g., ch is optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or -C(0)-L '-N(RB)S(0)2-Ls"-. In some cases, at least one of Y and Z is,
or both Y and Z are independently,
wherein non-limiting examples of RD include (1) -O-Ci-Cealkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6- membered heterocycle; or (2) C3-Cecarbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; and non-limiting examples of LY' include Ci-Cealkylene optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, or 3- to 6-membered carbocycle or heterocycle, said 3- to 6-membered carbocycle or heterocycle being optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
In yet another embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (e.g., A and B are each independently phenyl, such as and are each independently optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D can be, for example, C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12- membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS'), and J can also be
RN are as defined above. Also preferably, D is or , wherein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, , L2, and L3 are bond. Y is -N(RB)C(0)C(RiR2)N(R5)-T-RD or -N(RB)C(0)C(R3R4)C(R6R7)-T-RD, and Z is -G-C(R8R9)N(Ri2)-T-RD or -G-C(RioRn)C(Ri3Ri4)-T-RD; or Y is -G-C(RiR2)N(R5)-T-RD or -G-C(R3R4)C(R6R7)-T-RD, and Z is -N(RB)C(0)C(R8R9)N(R12)-T-RD or -N(RB)C(0)C(RioRn)C(Ri3Ri4)-T-RD. Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic
ring (e.g., which is optionally substituted with one or more RA; R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 5-
to 6-membered carbocyclic or heterocyclic ring (e.g., which is optionally substituted with one or more RA. RS is Rc, and R9 and R12, taken together with the atoms to which they are
attached, form a 5- to 6-membered heterocyclic ring (e.g., which is optionally substituted with one or more RA; and Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring ( ich is optionally substituted with one or more RA. independently C5-C6carbocycle or 5- to 6-membered heterocycle, such as
and is independently optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or '-N(RB)S(0)2-LS"-. In some cases, as described above,
In still another embodiment, A is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl
is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as * \=) ). A and B are each independently optionally substituted with one or more RA. Zi is independently selected at each occurrence from O, S, NH or CH2; and Z2 is independently selected at each occurrence from N or CH. X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or '), and J can also be optionally substituted with one or more RA. Preferably, D is
defined above. Also preferably, D is
above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and L L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Lu L2, and L3 are bond. When A is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as Y is -N(RB)C(0)C(R!R2)N(R5)-T-RD, -N(Rb)C(0)C(R3R4)C(R6R7)-T-RD, -G-C(R!R2)N(R5)-T-Rd or -G-C(R3R4)C(R6R7)-T-RD, and Z is -LS-C(R8R9)N(R12)-T-RD or -LS-C(R10RH)C(RI3RI4)-T-RD.
When B is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as \==/ ? ), Y is -LS-C(R!R2)N(R5)-T-RD or -LS-C(R3R4)C(R6R7)-T-RD, and Z is -N(RB)C(0)C(R8R9)N(R12)-T-RD, -N(RB)C(0)C(R1oRn)C(R13R14)-T-RD, -G-C(R8R9)N(R12)-T-RD or -G-C(R10Rn)C(R13R14)-T-RD. Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-
membered heterocyclic ring (e.g., which is optionally substituted with one or more RA;
R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are
attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (e.g., which is optionally substituted with one or more RA. R8 is Rc, and R9 and Ri2, taken together with the atoms to
which they are attached, form a 5- to 6-membered heterocyclic ring (e.g., which is optionally substituted with one or more RA; and Rio and Ri3 are each independently Rc, and Rn and Ri4, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring (e.g., is optionally substituted with one or more RA. G is independently C5-C6carbocycle or 5- to 6-membered heterocycle, such as
and is independently optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or -C(0)-LY'-N(RB)S(0)2-Ls"-. In some cases when A is 5- or 6-membered carbocycle or heterocycle
or as described above, and Z is as described above. In some other cases when B is 5- or 6-membered carbocycle or heterocycle e. . hen l such
described above.
The present invention also features compounds of Formulae I, IA, ¾, Ic and ID as described herein (including each embodiment described hereunder) and pharmaceutically acceptable salts thereof, wherein:
D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle which is substituted with J and optionally substituted with one or more RA, where J is C3-Ci5carbocycle or 3- to 15 -membered heterocycle (e.g., a 3- to 6-membered monocycle, a 6- to 12-membered fused, bridged or spiro bicycle, a 10- to 15-memberd tricycle containing fused, bridged or spiro rings, or a 13- to 15-membered carbocycle or heterocycle) and is optionally substituted with one or more RA, or J is -SF5; or D is hydrogen or RA;
RE is independently selected at each occurrence from -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RsRs'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), -P(0)(ORs)2, =C(RSRS'), or -C(0)N(Rs)C(0)-Rs'; or C C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-Ci2carbocycle or 3- to 12- membered heterocycle (e.g., 7- to 12-membered carbocycle or heterocycle), each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, trimethylsilyl, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -0-Rs, -S-Rs, -C(0)Rs, -C(0)ORs, or -N(RSRS').
In one embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (preferably, A and B are each independently phenyl such as and are each independently optionally substituted with one or more RA (preferably, A and B are each independently substituted with at least one halo such as F). X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is a C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle, or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORS or -N(RSRS'), or (2) trimethylsilyl, -0-RS, -S-RS, be optionally substituted with one or more RA. Preferably, D is
wherein J is as defined above, and each RN is independently selected from
RD and preferably is hydrogen or halo such as F. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Lu L2, and L3 are bond. Y is -N(RB)C(0)C(RIR2)N(R5)-T-RD, -N(RB)C(0)C(R3R4)C(R6R7)-T-RD, -G-C(RIR2)N(R5)-T-Rd or -G-C(R3R4)C(R6R7)-T-RD. Z is -N(RB)C(0)C(R8R9)N(R12)-T-RD,
-N(RB)C(0)C(R1oRn)C(R13R14)-T-RD, -G-C(R8R9)N(R12)-T-RD or -G-C(R10Rn)C(R13R14)-T-RD. Ri is Rc; and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6- membered heterocyclic ring (e.g.,
which is optionally substituted with one or more RA; R3 and R6 are each independently RC, and R4 and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or
heterocyclic ring (e.g., - to 12-membered bicycle which is optionally substituted with one or more RA. RS is Rc; and R9 and R12, taken together with the atoms to which they are
attached, form a 5- to 6-membered heterocyclic ring (e.g., to 12-membered bicycle
(e.g., which is optionally substituted with one or more RA; and Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a
5- to 6-membered carbocyclic or heterocyclic ring (e.g., or 6- to 12-membered bicycle which is optionally substituted with one or more R . G is independently C5-C6carbocycle or 5- to 6- membered heterocycle, such as and is independently optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-,
'-0-Ls"-, -C(0)-LY'-N(RB)-Ls"-, or -C(0)-LY'-N(RB)S(0)2-Ls"-. In some cases, Y
escribed above, and Z is or as described above.
In another embodiment, A is nd is optionally substituted with one or more RA; B is and is optionally substituted with one or more RA. Zi is independently selected at each occurrence from O, S, NH or CH2; and Z2 is independently selected at each occurrence from N or CH. Preferably, A and B are each independently substituted with at least one halo such as F. X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is a C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to
12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl,
C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs or -N(RsRs'), or (2) trimethylsilyl, -0-Rs, -S-Rs, or -C(0)Rs; and J can also be optionally substituted with one or more RA. Preferably, D is
wherein J is as defined above, and each RN is independently selected from RD and preferably is hydrogen or halo such as F. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Li, L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. Y is -LS-C(RiR2)N(R5)-T-RD or -LS-C(R3R4)C(R6R7)-T-RD. Z is -LS-C(R8R9)N(R12)-T-RD or -Ls-C(RioRn)C(Ri3Ri4)-T-RD. Ri is Rc; and R2 and R5, taken together with the atoms to which they
are attached, to 6-membered heterocyclic ring (e.g., or 6- to 12-membered
bicycle (e.g., which is optionally substituted with one or more RA; R3 and R6 are each independently RC, and R4 and R7, taken together with the atoms to which they are attached, form a 5-
to 6-membered carbocyclic or heterocyclic ring (e.g., or 6- to 12-membered bicycle which is optionally substituted with one or more RA. RS is Rc; and R9 and R12, taken together with the
atoms to which they are attach a 5- to 6-membered heterocyclic ring (e.g., or 6-
to 12-membered bicycle (e.g., which is optionally substituted with one or more RA; and
Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they
are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (e.g., or 6- to
12-membered bicycle which is optionally substituted with one or more RA. T is preferably independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"- or -C(0)-LY'-N(RB)C(0)0-Ls"-. LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. T can also be, without limitation, selected from -C(0)-LY'-Ls"-, -C(0)-LY'-0-Ls"-, '-N(RB)-Ls"-, or -C(0)-LY'-N(RB)S(0)2-Ls"-. In some cases, Y and Z are independently wherein non-limiting examples of RD include (1)
-0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6-membered heterocycle; or (2) C3-C6carbocycle or 3- to 6-membered heterocycle each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; and non-limiting examples of LY' include Ci-C6alkylene optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -0-Ci-C6alkyl, -0-C2-C6alkenyl, -0-C2-C6alkynyl, or 3- to 6-membered carbocycle or heterocycle, said 3- to 6-membered carbocycle or heterocycle being optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
In another aspect, the present invention features compounds of Formula IA and pharmaceutically acceptable salts thereof.
IA
wherein:
RNB is each independently selected from RB;
Rc' is each independently selected from Rc;
RD' is each independently selected from RD;
R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
R9 and R12, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
A, B, D, X, Li, L2, L3, T, RA, RB, RC, and RD are as described above in Formula I.
In this aspect, A and B preferably are independently selected from C5-C6carbocycle or 5- to 6- membered heterocycle, and are each independently optionally substituted with one or more RA. More preferably, at least one of A and B is phenyl (e.g., and is optionally substituted with one or more RA. Highly preferably, both A and B are each independently phenyl (e.g., \=/ ¾), and are each independently optionally substituted with one or more RA.
D preferably is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or 8- to 12- membered bicycles, and is optionally substituted with one or more RA. D can also be preferably selected from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, and is optionally substituted with one or more RL. More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is substituted with one or more RM, where RM is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE. Also preferably, D is phenyl, and is optionally substituted with one or more RA. More preferably, D is phenyl, and is substituted with one or more
RM, wherein RM is as defined above. Highly preferably, D is wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
more RM. Highly preferably, D is , wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F. D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l ,3]dioxol-5-yl, and is substituted with one or more RM. Highly preferably, D
is s an(j js optionally substituted with one or more RM.
Preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. More preferably, RM is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy. Highly preferably, RM is Ci-C6alkyl which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or RM is -LS-RE, wherein Ls is a bond or Ci-C6alkylene, and RE is -N(RsRs'), -0-Rs, -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, -SRs, or -P(0)(ORs)2, wherein Rs and Rs' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-Cealkyl optionally substituted at each occurrence with one or more halogen, hydroxy, -O-Q-Cealkyl or 3- to 6-membered heterocycle; or RM is Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). More preferably, RM is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C6alkyl (e.g., methyl, isopropyl, tert-butyl), C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example RM is CF3, -C(CF3)2-OH, -C(CH3)2-CN, -C(CH3)2-CH2OH, or -C(CH3)2-CH2NH2. Also preferably RM is -LS-RE where Ls is a bond and RE is -N(RSRS ), -0-Rs, -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, or -SRS. For example where Ls is a bond, RE is -N(Ci-C6alkyl)2 (e.g., -NMe2); -N(Ci-C6alkylene-0-Ci-C6alkyl)2 (e.g. -N(CH2CH2OMe)2);
-N(Ci-C6alkyl)(Ci-C6alkylene-0-Ci-C6alkyl) (e.g. -N(CH3)(CH2CH2OMe));— 0-Ci-C6alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-C C6haloalkyl (e.g., -OCF3, -OCH2CF3); -0-Ci-C6alkylene-piperidine (e.g., -0-CH2CH2-l-piperidyl);
-N(Ci-C6alkyl)C(0)OCi-C6alkyl (e.g., -N(CH3)C(0)0-CH2CH(CH3)2), -N(Ci-C6alkyl)S02Ci-C6alkyl (e.g., -N(CH3)S02CH3); -S02Ci-C6alkyl (e.g., -S02Me); -S02Ci-C6haloalkyl (e.g., -S02CF3); or -S-Ci-C6haloalkyl (e.g., SCF3). Also preferably RM is -LS-RE where Ls is Ci-C6alkylene (e.g., -CH2- -C(CH3)2- -C(CH3)2-CH2-) and RE is -0-Rs, -C(0)ORs, -N(Rs)C(0)ORs', or -P(0)(ORs)2. For example RM is -Ci-C6alkylene-0-Rs (e.g., -C(CH3)2-CH2-OMe); -Ci-C6alkylene-C(0)ORs (e.g., -C(CH3)2-C(0)OMe);
-Ci-C6alkylene-N(Rs)C(0)ORs' (e.g., -C(CH3)2-CH2-NHC(0)OCH3); or -Ci-C6alkylene-P(0)(ORs)2 (e.g., -CH2-P(0)(OEt)2). Also more preferably RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). For example RM is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., mo holin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl). Highly preferably, RM is Ci-Cealkyl which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert-butyl, CF3).
More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle, wherein said C3-C6carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be optionally substituted with one or more RA. Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably, J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'). Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA. More preferably, D is phenyl and is substituted with J and optionally substituted with one or more RA, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Highly preferably, D is wherein each RN is independently selected from
RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Also preferably, D is wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl,
C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or
-N(RSRS'), and J can also be optionally substituted with one or more RA. Also preferably, D is
and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs'). X preferably is C3-Cscycloalkyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more RA or RF. Non-limiting examples of X are described hereinabove.
Li and L2 are preferably independently bond or Ci-C6alkylene, L3 is preferably selected from bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. More preferably, L L2 and L3 are each independently bond or Ci-C6alkylene (e.g., -CH2- or -CH2CH2-), and are each independently optionally substituted with one or more RL. Highly preferably, Li, L2 and L3 are each a bond.
R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-
membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA.
R9 and Ri2, taken together with the atoms to which they are attached, preferably form a 5- to
6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA.
-T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-LY'-RD', -C(0)0-LY'-RD', -C(0)-LY'-N(RB)C(0)-LS"-RD' ,
-C(0)-LY' -N(RB)C(0)0-LS" -RD', -N(RB)C(0)-LY'-N(RB)C(0)-LS"-RD', -N(RB)C(0)-LY'-N(RB)C(0)0-Ls"-RD', or -N(RB)C(0)-LY'— N(RB)-LS"-RD', wherein LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. Preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-M'-Ls"-RD' or -N(RB)C(0)-LY'-M'-Ls"-RD'. More preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"-RD' or -C(0)-LY'-N(RB)C(0)0-Ls"-RD' . Highly preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-RD' or -C(0)-LY'-N(RB)C(0)0-RD', wherein LY' preferably is each independently Ci-Cealkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL.
RNB and Rc' are preferably hydrogen, and RD' preferably is independently selected at each occurrence from RE. More preferably, RD' is independently selected at each occurrence from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6- membered heterocycle; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl.
RA preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; or -LA-O-RS, -LA-S-RS, -LA-C(0)RS, -LA-OC(0)RS, -LA-C(0)ORS, -LA-N(RSRS'), -LA-S(0)RS, -LA-S02Rs, -LA-C(0)N(RSRS'), -LA-N(RS)C(0)RS', -LA-N(RS)C(0)N(RS'RS"), -LA-N(RS)S02RS' , -LA-S02N(RSRS'), -LA-N(RS)S02N(RS'RS"), -LA-N(RS)S(0)N(RS'RS"), -LA-OS(0)-RS, -LA-OS(0)2-RS, -LA-S(0)2ORS, -LA-S(0)ORS, -LA-OC(0)ORS, -LA-N(RS)C(0)ORS' , -LA-OC(0)N(RSRS'), -LA-N(RS)S(0)-RS', -LA-S(0)N(RSRS'), -LA-C(0)N(RS)C(0)-Rs', or -LA-P(0)(ORS)2, wherein LA is bond, Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
More preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
Highly preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and Ls" preferably are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
A and B can be the same or different. Likewise, Li and L2 can be the same or different. In one embodiment of this aspect, A and B are each independently phenyl, and are each independently optionally substituted with one or more RA; D is phenyl, and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'), J can also be optionally substituted with one or more
RA. Preferably, D is or , wherein RM and RN are as defined above. Also
preferably, D is wherein J and RN are as defined above. Li and L2 are each independently bond or Ci-Cealkylene, and L3 is bond, Ci-Cealkylene or -C(O)-, and Li, L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD', -C(0)-LY'-0-LS"-RD', -C(0)-LY' -N(RB)-LS"-RD' , or -C(0)-LY'-N(RB)S(0)2- "-RD' . Preferably, R2 and R5, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA; Rg and Ri2, taken together with the atoms to which they are attached, form which is optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. ther embodiment of this aspect, A and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more RA (preferably, A and B are each independently substituted with at least one halo such as F). X is C3-Cscycloalkyl or C5-C8Cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is phenyl, and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs or -N(RsRs'), or (2) trimethylsilyl, -0-Rs, -S-Rs or -C(0)Rs; and J can also be optionally
substituted with one or more RA. Preferably, D is wherein J is as defined above, and each RN is independently selected from RD and preferably is hydrogen or halo such as F. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Li, L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY' -N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-Rd', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD' , -C(0)-LY'-0-LS"-RD', -C(0)-LY'-N(RB)-Ls"-RD', or -C(0)-LY'-N(RB)S(0)2-LS"-RD' . R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic
ring (e.g., or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA; and Rg and Ri2, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g., or 6- to 12-membered bicycle
which is optionally substituted with one or more RA.
In still another aspect, the present invention features compounds of Formula IB and pharmaceutically acceptable salts thereof:
wherein:
Rc' is each independently selected from Rc;
RD' is each independently selected from RD;
R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
R9 and R12, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
A, B, D, X, Li, L2, L3, T, RA, Rc, and RD are as described above in Formula I.
In this aspect, A and B preferably are independently selected from 8- to 12-membered
bicycles such as or where Zi is independently selected at each occurrence from O, S, NH or CH2,
Z2 is independently selected at each occurrence from N or CH, Z3 is independently selected at each occurrence from N or CH, Z4 is independently selected at each occurrence from O, S, NH or CH2, and Wi, W2, W3, W4, W5 and W6 are each independently selected at each occurrence from CH or N. A and B are each independently optionally substituted with one or more RA. More preferably, A is selected from is
optionally substituted with one or more RA; B is selected from or d is optionally substituted with one or more RA, where Zi, Z2, Z3, Z4, Wi, W2,
W3, W4, W5, W6 are as defined above. Preferably, Z3 is N and Z4 is NH. For instance, A can be
e.g., , an is wherein A' and B' are independently selected from
C5-C6carbocycle or 5- to 6-membered heterocycle, and A and B are independently optionally substituted with one or more RA.
D preferably is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more RA. D can also be preferably selected from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, and is optionally substituted with one or more substituents selected from RL. More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12-membered bicycles, and is substituted with one or more RM, where RM is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE. Also preferably, D is phenyl, and is optionally substituted with one or more RA. More preferably, D is phenyl, and is substituted with one or more RM, wherein RM is as defined above. Highly preferably, D is RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
more RM. Highly preferably, D is , wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F. D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more RM. Highly preferably, D
is s an(j js optionally substituted with one or more RM.
Preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6aikyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. More preferably, RM is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy. Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or RM is -LS-RE, wherein Ls is a bond or Ci-C6alkylene, and RE is -N(RsRs'), -O-Rs, -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, -SRs, or -P(0)(ORs)2, wherein Rs and Rs' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C6alkyl optionally substituted at each occurrence with one or more halogen, hydroxy, -Ο-Ci-Cealkyl or 3- to 6-membered heterocycle; or RM is Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). More preferably, RM is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C6alkyl (e.g., methyl, isopropyl, tert-butyl), C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example RM is CF3, -C(CF3)2-OH, -C(CH3)2-CN, -C(CH3)2-CH2OH, or -C(CH3)2-CH2NH2. Also preferably RM is -LS-RE where Ls is a bond and RE is -N(RSRS ), -0-Rs, -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, or -SRS. For example where Ls is a bond, RE is -N(Ci-C6alkyl)2 (e.g., -NMe2); -N(C C6alkylene-0-Ci-C6alkyl)2 (e.g. -N(CH2CH2OMe)2); -N(Ci-C6alkyl)(Ci-C6alkylene-0-Ci-C6alkyl) (e.g. -N(CH3)(CH2CH2OMe));— 0-Ci-C6alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-C C6haloalkyl (e.g., -OCF3, -OCH2CF3); -0-Ci-C6alkylene-piperidine (e.g., -0-CH2CH2-l-piperidyl);
-N(Ci-C6alkyl)C(0)OCi-C6alkyl (e.g., -N(CH3)C(0)0-CH2CH(CH3)2),
-N(Ci-C6alkyl)S02Ci-C6alkyl (e.g., -N(CH3)S02CH3); -S02Ci-C6alkyl (e.g., -S02Me); -S02Ci-C6haloalkyl (e.g., -S02CF3); or -S-Ci-C6haloalkyl (e.g., SCF3). Also preferably RM is -LS-RE where Ls is C C6alkylene (e.g., -CH2- -C(CH3)2-, -C(CH3)2-CH2-) and RE is -0-Rs, -C(0)ORs, -N(Rs)C(0)ORs', or -P(0)(ORs)2. For example RM is -Ci-C6alkylene-0-Rs (e.g., -C(CH3)2-CH2-OMe); -Ci-C6alkylene-C(0)ORs (e.g., -C(CH3)2-C(0)OMe);
-Ci-C6alkylene-N(Rs)C(0)ORs' (e.g., -C(CH3)2-CH2-NHC(0)OCH3); or -Ci-C6alkylene-P(0)(ORs)2 (e.g., -CH2-P(0)(OEt)2). Also more preferably RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). For example RM is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomo holin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl). Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF3).
More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle, wherein said C3-C6carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be optionally substituted with one or more RA. Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably, J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'). Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA. More preferably, D is phenyl and is substituted with J and optionally substituted with one or more RA, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or
-N(RSRS'). Highly preferably, D is , wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Also preferably, D is wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or S'), and J can also be optionally substituted with one or more RA. Also preferably, D is
, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS').
X preferably is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more RA or RF. Non-limiting examples of X are described hereinabove.
Li and L2 are preferably independently bond or Ci-C6alkylene, L3 is preferably selected from bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. More preferably, L L2 and L3 are each independently bond or Ci-C6alkylene (e.g., -CH2- or -CH2CH2-), and are each independently optionally substituted with one or more RL. Highly preferably, Li, L2 and L3 are each a bond. R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-
membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA. R9 and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA.
-T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-LY' -RD', -C(0)0-LY'-RD' , -C(0)-LY'-N(RB)C(0)-LS"-RD' ,
-C(0)-LY' -N(RB)C(0)0-LS" -RD', -N(RB)C(0)-LY'-N(RB)C(0)-LS"-RD', -N(RB)C(0)-LY' -N(RB)C(0)0-LS"-RD', or -N(RB)C(0)-LY'— N(RB)-LS"-RD', wherein LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. Preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-M'-LS"-RD' or -N(RB)C(0)-LY'-M'-LS"-RD'. More preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' . Highly preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-RD' or -C(0)-LY'-N(RB)C(0)0-RD', wherein LY' preferably is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL.
RC' is preferably hydrogen, and RD' preferably is independently selected at each occurrence from RE. More preferably, RD' is independently selected at each occurrence from Ci-Cealkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6-membered heterocycle; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
RA preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; or -LA-0-Rs, -LA-S-RS, -LA-C(0)Rs, -LA-OC(0)Rs, -LA-C(0)ORs, -LA-N(RSRS'), -LA-S(0)Rs, -LA-S02Rs, -LA-C(0)N(RsRs'), -LA-N(Rs)C(0)Rs', -LA-N(Rs)C(0)N(Rs'Rs"), -LA-N(Rs)S02Rs', -LA-S02N(RsRs'), -LA-N(Rs)S02N(Rs'Rs"), -LA-N(Rs)S(0)N(Rs'Rs"), -LA-OS(0)-Rs, -LA-OS(0)2-Rs, -LA-S(0)2ORs, -LA-S(0)ORs, -LA-OC(0)ORs, -LA-N(Rs)C(0)ORs', -LA-OC(0)N(RsRs'), -LA-N(Rs)S(0)-Rs', -LA-S(0)N(RsRs'), -LA-C(0)N(Rs)C(0)-Rs', or -LA-P(0)(ORs)2 wherein LA is bond, Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
More preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
Highly preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and Ls" preferably are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
A and B can be the same or different. Likewise, Li and L2 can be the same or different.
In one embodiment of this aspect,
optionally substituted with one or more RA; B is optionally substituted with one or more RA; and D is C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or '), and J can also be optionally substituted with one or more RA. Preferably, D is
s wherein RM and RN are as defined above. Also preferably, D is
s wherein and RN are as defined above. Zi is independently selected at each occurrence from O, S, NH or CH2; and Z2 is independently selected at each occurrence from N or CH. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and L L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' , wherein LY' is Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY' -LS" -RD', -C(0)-LY'-0-LS"-RD' , -C(0)-LY'-N(RB)-LS"-RD', or
-C(0)-LY' -N(RB)S(0)2-LS"-RD' . X is C3-C8cycloaikyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF.
More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF.
In another embodiment of this aspect, A is and optionally substituted
with one or more RA (e.g., halogen); B is and is optionally substituted with one or more RA (e.g., halogen); and D is C5-C6carbocycle or 5- to 6-membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12- membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-Cealkynyl, Ci-Cehaloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be
RN are as defined above. Also preferably, D is or , wherein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-L '-N(R )C(0)-L "-Rd' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' , wherein LY' is Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-R ' can also be, without limitation, selected from -C(0)-LY' -LS" -RD', -C(0)-LY'-0-LS"-RD' , -C(0)-LY'-N(RB)-LS"-RD', or
-C(0)-LY' -N(RB)S(0)2-LS"-R R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R R9 and Ri2, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or
6- to 12-membered bicycle (e.g., which is optionally substituted with one or more R preferably, R2 and R5, taken together with the atoms to which they are
attached, form which is optionally substitut one or more R R9 and Ri2, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF.
In still another embodiment of this aspect, A is and optionally substituted with one or more RA (preferably, A is substituted with at least one halogen such as F); B is and is optionally substituted with one or more RA (preferably, B is substituted with at least one halogen such as F). X is C3-Cscycloalkyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is phenyl, and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs or -N(RSRS'), or (2) trimethylsilyl, -0-Rs, -S-Rs or -C(0)Rs; and J can also be optionally substituted with one or more
RA. Preferably, D is or , wherein J is as defined above, and each RN is independently selected from RD and preferably is hydrogen or halo such as F. Li and L2 are each independently bond or Ci-Cealkylene, and L3 is bond, Ci-Cealkylene or -C(O)-, and Li, L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD', -C(0)-LY'-0-LS"-RD', -C(0)-LY' -N(RB)-LS"-RD', or -C(0)-LY'-N(RB)S(0)2-LS"-RD' . R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12- membered bicycle (e.g., which is optionally substituted with one or more
RA- R9 and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-
membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA. More preferably, R2 and R5, taken together with the
atoms to which they are attached, form which is optionally substituted with one or more
RA; R9 and R12, taken together with the atoms to which they are attache which is optionally substituted with one or more RA.
In yet another aspect, the present invention further features compounds of Formula Ic and pharmaceutically acceptable salts thereof.
Ic
wherein:
RC' is each independently selected from RC;
RD' is each independently selected from RD;
R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
R9 and R12, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA; A, B, D, X, Li, L2, L3, T, RA, RB, RC, and RD are as described above in Formula I.
In this aspect, A preferably is C5-C6carbocycle or 5- to 6-membered heterocycle, and is optionally substituted with one or more RA; and B preferably is 8- to 12-membered bicycle (such as or and is optionally substituted with one or more
RA. Zi is O, S, NH or CH2; Z2 is N or CH; Z3 is N or CH; Z4 is O, S, NH or CH2; and Wi, W2, W3, W4, W5 and W6 are each independently selected from CH or N.
More preferably, A is phenyl (e.g., \=/ ), and is optionally substituted with one or
more RA; and and is optionally substituted with one or more RA, where Zi, Z2, Z3, Z4, Wi, W2, W3, W , W5, W6 are as defined above. Preferably, Z3 is N
and is optionally substituted with one or more RA.
Also preferably, A is C
membered heterocycle; and B is
from C5-C6carbocycle or 5- to 6-membered heterocycle. A and B are independently optionally substituted with one or more RA.
D preferably is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is optionally substituted with one or more RA. D can also be preferably selected from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, and is optionally substituted with one or more substituents selected from RL. More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12-membered bicycles, and is substituted with one or more RM, where RM is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE. Also preferably, D is phenyl, and is optionally substituted with one or more RA. More preferably, D is phenyl, and is substituted with one or more RM, wherein RM is as defined above. Highly preferably, D is RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
more RM. Highly preferably, D is , wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F. D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more RM. Highly preferably, D
is s an(j js optionally substituted with one or more RM.
Preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6aikyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. More preferably, RM is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy. Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or RM is -LS-RE, wherein Ls is a bond or Ci-C6alkylene, and RE is -N(RsRs'), -O-Rs, -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, -SRs, or -P(0)(ORs)2, wherein Rs and Rs' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C6alkyl optionally substituted at each occurrence with one or more halogen, hydroxy, -Ο-Ci-Cealkyl or 3- to 6-membered heterocycle; or RM is Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). More preferably, RM is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C6alkyl (e.g., methyl, isopropyl, tert-butyl), C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example RM is CF3, -C(CF3)2-OH, -C(CH3)2-CN, -C(CH3)2-CH2OH, or -C(CH3)2-CH2NH2. Also preferably RM is -LS-RE where Ls is a bond and RE is -N(RSRS ), -0-Rs, -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, or -SRS. For example where Ls is a bond, RE is -N(Ci-C6alkyl)2 (e.g., -NMe2); -N(C C6alkylene-0-Ci-C6alkyl)2 (e.g. -N(CH2CH2OMe)2); -N(Ci-C6alkyl)(Ci-C6alkylene-0-Ci-C6alkyl) (e.g. -N(CH3)(CH2CH2OMe));— 0-Ci-C6alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-C C6haloalkyl (e.g., -OCF3, -OCH2CF3); -0-Ci-C6alkylene-piperidine (e.g., -0-CH2CH2-l-piperidyl);
-N(Ci-C6alkyl)C(0)OCi-C6alkyl (e.g., -N(CH3)C(0)0-CH2CH(CH3)2),
-N(Ci-C6alkyl)S02Ci-C6alkyl (e.g., -N(CH3)S02CH3); -S02Ci-C6alkyl (e.g., -S02Me); -S02Ci-C6haloalkyl (e.g., -S02CF3); or -S-Ci-C6haloalkyl (e.g., SCF3). Also preferably RM is -LS-RE where Ls is C C6alkylene (e.g., -CH2- -C(CH3)2-, -C(CH3)2-CH2-) and RE is -0-Rs, -C(0)ORs, — N(Rs)C(0)ORs\ or -P(0)(ORs)2. For example RM is -C C6alkylene-0-Rs (e.g., -C(CH3)2-CH2-OMe); -Ci-C6alkylene-C(0)ORs (e.g., -C(CH3)2-C(0)OMe);
-Ci-C6alkylene-N(Rs)C(0)ORs' (e.g., -C(CH3)2-CH2-NHC(0)OCH3); or -Ci-C6alkylene-P(0)(ORs)2 (e.g., -CH2-P(0)(OEt)2). Also more preferably RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). For example RM is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., mo holin-4-yl, l,l -dioxidothiomorpholin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl). Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF3).
More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle, wherein said C3-C6carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be optionally substituted with one or more RA. Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably, J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'). Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA. More preferably, D is phenyl and is substituted with J and optionally substituted with one or more RA, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or
-N(RSRS'). Highly preferably, D is , wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Also preferably, D is wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or S'), and J can also be optionally substituted with one or more RA. Also preferably, D is
, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS').
X preferably is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more RA or RF. Non-limiting examples of X are described hereinabove.
Li and L2 are preferably independently bond or Ci-C6alkylene, L3 is preferably selected from bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. More preferably, Li, L2 and L3 are each independently a bond or Ci-Cealkylene (e.g., -CH2- or -CH2CH2-), and are each independently optionally substituted with one or more RL. Highly preferably, Li, L2 and L3 are each a bond. Li and L2 can be the same or different. R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-
membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA. R9 and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA.
-T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-LY'-RD', -C(0)0-LY'-RD', -C(0)-LY'-N(RB)C(0)-LS"-RD' ,
-C(0)-LY' -N(RB)C(0)0-LS" -RD', -N(RB)C(0)-LY'-N(RB)C(0)-LS"-RD', -N(RB)C(0)-LY' -N(RB)C(0)0-LS"-RD', or -N(RB)C(0)-LY'— N(RB)-LS"-RD', wherein LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. Preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-M'-LS"-RD' or -N(RB)C(0)-LY'-M'-LS"-RD'. More preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-Ls"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD' . Highly preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-RD' or -C(0)-LY'-N(RB)C(0)0-RD', wherein LY' preferably is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL.
RNB and Rc' are preferably hydrogen, and RD' preferably is independently selected at each occurrence from RE. More preferably, RD' is independently selected at each occurrence from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6- membered heterocycle; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl.
RA preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; or -LA-0-Rs, -LA-S-RS, -LA-C(0)Rs, -LA-OC(0)Rs, -LA-C(0)ORs, -LA-N(RSRS'), -LA-S(0)Rs, -LA-S02Rs, -LA-C(0)N(RsRs'), -LA-N(Rs)C(0)Rs', -LA-N(Rs)C(0)N(Rs'Rs"), -LA-N(Rs)S02Rs', -LA-S02N(RsRs'), -LA-N(Rs)S02N(Rs'Rs"), -LA-N(Rs)S(0)N(Rs'Rs"), -LA-OS(0)-Rs, -LA-OS(0)2-Rs, -LA-S(0)2ORs, -LA-S(0)ORs, -LA-OC(0)ORs, -LA-N(Rs)C(0)ORs', -LA-OC(0)N(RsRs'), -LA-N(Rs)S(0)-Rs', -LA-S(0)N(RsRs'), -LA-C(0)N(Rs)C(0)-Rs', or -LA-P(0)(ORs)2, wherein LA is bond, Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
More preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
Highly preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and Ls" preferably are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-Cealkenylene or C2-C6alkynylene.
In one embodiment of this aspect, A is phenyl, and is optionally substituted with one or more
RA; and B , and is optionally substituted with one or more RA, wherein Z is O, S, NH or CH2; and Z2 is N or CH. D is C5-C6carbocycle or 5- to 6- membered heterocycle (e.g., phenyl), and is optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to
6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more
RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be optionally substituted with one or more RA. Preferably, D is
s wherein RM and RN are as defined above. Also preferably, D is
herein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and L L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(O)— LY'-N(RB)C(0)0-LS"-RD', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-Ly'-0-LS"-RD', -C(0)-LY'-N(RB)-LS"-RD', or -C(0)-LY'-N(RB)S(0)2 "-RD'. Preferably, R2 and R5, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA; R9 and Ri2, taken together with the atoms to which they are attached, form which is optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5- Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF.
In another embodiment of this aspect, A is phenyl (e.g., \=/ ), and is optionally substituted with one or more RA (preferably, A is substituted with at least one halogen such as F); and
B is , and is optionally substituted with one or more RA (preferably, B is substituted with at least one halogen such as F). X is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is phenyl, and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORS or -N(RSRS'), or (2) trimethylsilyl, -0-RS, -S-R or -C 0 R and J can also be optionally substituted with one or more
RA. Preferably, D is in J is as defined above, and each RN is independently selected from RD and preferably is hydrogen or halo such as F. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD', -C(0)-LY'-0-LS"-RD', -C(0)-LY'-N(RB)-LS"-RD', or -C(0)-LY'-N(RB)S(0)2-LS"-RD'. Preferably, R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g.,
or 6- to 12-membered bicycle (e.g., which is optionally substituted with r more RA; R9 and Ri2, taken together with the atoms to which they are attached, form a 5- to 6-
membered heterocyclic ring (e.g., or 6- to 12-membered bicycle (e.g.,
which is optionally substituted with one or more RA.
In yet another aspect, the present invention features compounds of Formula pharmaceutically acceptable salts thereof.
wherein:
Gi and G2 are each independently selected from C5-C6carbocycle or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more RA; Rc' is each independently selected from Rc;
RD' is each independently selected from RD;
R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
Rg and R12, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA;
A, B, D, X, Li, L2, L3, T, RA, Rc, and RD are as described above in Formula I.
In this aspect, A and B preferably are independently selected from C5-C6carbocycle or 5- to 6- membered heterocycle, and are each independently optionally substituted with one or more RA. More preferably, at least one of A and B is phenyl (e.g., and is optionally substituted with one or more RA. Highly preferably, both A and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more RA.
D preferably is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or 8- to 12- membered bicycles, and is optionally substituted with one or more RA. D can also be preferably selected from Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, and is optionally substituted with one or more RL. More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 12- membered bicycles, and is substituted with one or more RM, where RM is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE. Also preferably, D is phenyl, and is optionally substituted with one or more RA. More preferably, D is phenyl, and is substituted with one or more
RM, wherein RM is as defined above. Highly preferably, D is or , wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more RA. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or
more RM. Highly preferably, D is , wherein RM is as defined above, and each RN is independently selected from RD and preferably is hydrogen. One or more RN can also preferably be halo such as F. D is also preferably indanyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, or indazolyl, and is optionally substituted with one or more RA. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, or benzo[d][l,3]dioxol-5-yl, and is substituted with one or more RM. Highly preferably, D
is s an(j js optionally substituted with one or more RM.
Preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6aikyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl. More preferably, RM is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy. Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, RM is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or RM is -LS-RE, wherein Ls is a bond or Ci-C6alkylene, and RE is -N(RsRs'), -O-Rs, -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, -SRs, or -P(0)(ORs)2, wherein Rs and Rs' can be, for example, each independently selected at each occurrence from (1) hydrogen or (2) Ci-C6alkyl optionally substituted at each occurrence with one or more halogen, hydroxy, -Ο-Ci-Cealkyl or 3- to 6-membered heterocycle; or RM is Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). More preferably, RM is halogen (e.g., fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or Ci-C6alkyl (e.g., methyl, isopropyl, tert-butyl), C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example RM is CF3, -C(CF3)2-OH, -C(CH3)2-CN, -C(CH3)2-CH2OH, or -C(CH3)2-CH2NH2. Also preferably RM is -LS-RE where Ls is a bond and RE is -N(RSRS ), -0-Rs, -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S02Rs, or -SRS. For example where Ls is a bond, RE is -N(Ci-C6alkyl)2 (e.g., -NMe2); -N(C C6alkylene-0-Ci-C6alkyl)2 (e.g. -N(CH2CH2OMe)2); -N(Ci-C6alkyl)(Ci-C6alkylene-0-Ci-C6alkyl) (e.g. -N(CH3)(CH2CH2OMe));— 0-Ci-C6alkyl (e.g., -O-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-n-hexyl); -0-C C6haloalkyl (e.g., -OCF3, -OCH2CF3); -0-Ci-C6alkylene-piperidine (e.g., -0-CH2CH2-l-piperidyl);
-N(Ci-C6alkyl)C(0)OCi-C6alkyl (e.g., -N(CH3)C(0)0-CH2CH(CH3)2),
-N(Ci-C6alkyl)S02Ci-C6alkyl (e.g., -N(CH3)S02CH3); -S02Ci-C6alkyl (e.g., -S02Me); -S02Ci-C6haloalkyl (e.g., -S02CF3); or -S-Ci-C6haloalkyl (e.g., SCF3). Also preferably RM is -LS-RE where Ls is C C6alkylene (e.g., -CH2- -C(CH3)2-, -C(CH3)2-CH2-) and RE is -0-Rs, -C(0)ORs, -N(Rs)C(0)ORs', or -P(0)(ORs)2. For example RM is -Ci-C6alkylene-0-Rs (e.g., -C(CH3)2-CH2-OMe); -Ci-C6alkylene-C(0)ORs (e.g., -C(CH3)2-C(0)OMe);
-Ci-C6alkylene-N(Rs)C(0)ORs' (e.g., -C(CH3)2-CH2-NHC(0)OCH3); or -Ci-C6alkylene-P(0)(ORs)2 (e.g., -CH2-P(0)(OEt)2). Also more preferably RM is C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -C(0)ORs, or -N(RSRS'). For example RM is cycloalkyl (e.g., cyclopropyl, 2,2-dichloro-l-methylcycloprop-l -yl, cyclohexyl), phenyl, heterocyclyl (e.g., morpholin-4-yl, l,l -dioxidothiomo holin-4-yl, 4-methylpiperazin-l-yl, 4- methoxycarbonylpiperazin-l-yl, pyrrolidin-l-yl, piperidin-l -yl, 4-methylpiperidin-l-yl, 3,5- dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimethylamino)pyridin-3-yl). Highly preferably, RM is Ci-C6alkyl which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g., tert- butyl, CF3).
More preferably, D is C5-C6carbocycle, 5- to 6-membered heterocycle or 6- to 12-membered bicycle and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6- membered heterocycle, wherein said C3-C6carbocycle or 3- to 6-membered heterocycle is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs')> and J can also be optionally substituted with one or more RA. Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably, J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'). Also preferably, D is C5-C6carbocycle or 5- to 6-membered heterocycle and is substituted with J and optionally substituted with one or more RA, and J is 6- to 12-membered bicycle (e.g., a 7- to 12-membered fused, bridged or spiro bicycle comprising a nitrogen ring atom through which J is covalently attached to D) and is optionally substituted with one or more RA. More preferably, D is phenyl and is substituted with J and optionally substituted with one or more RA, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or
-N(RSRS'). Highly preferably, D is , wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORS or
-N(RSRS'). Also preferably, D is wherein each RN is independently selected from RD and preferably is hydrogen or halogen, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or S'), and J can also be optionally substituted with one or more RA. Also preferably, D is
, and J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA, and preferably J is at least substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl, C2-C6haloalkynyl, C(0)ORS or -N(RSRS').
X preferably is C3-C8cycloalkyl or C5-C8cycloalkenyl and is optionally substituted with one or more RA. More preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl and is optionally substituted with one or more RA or RF. Non-limiting examples of X are described hereinabove.
Li and L2 are preferably independently bond or Ci-C6alkylene, L3 is preferably selected from bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. More preferably, L L2 and L3 are each independently bond or Ci-C6alkylene (e.g., -CH2- or -CH2CH2-), and are each independently optionally substituted with one or more RL. Highly preferably, L L2 and L3 are bond. R2 and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-
membered heterocycle or 6- to 12-membered bicycle (e.g., which optionally substituted with one or more RA.
R9 and R12, taken together with the atoms to which they are attached, preferably form a 5-
6-membered heterocycle or 6- to 12-membered bicycle (e
optionally substituted with one or more RA. nd G2 preferably are each independently selected from
or , and are each independently optionally substituted with one or more
H
RA (e.g., one or more chloro or bromo). More preferably, Gi is N- (including any tautomer thereof), and G2 is (including any tautomer thereof), and each Gi and G2 is independently optionally substituted with one or more RA (e.g., one or more chloro or bromo).
-T-RD' can be, without limitation, independently selected at each occurrence from -C(0)-LY'-, -C(0)0-LY'-RD' , -C(0)-LY'-N(RB)C(0)-LS"-RD', -C(0)-LY'-N(RB)C(0)0-LS"-RD',
-N(RB)C(0)-LY'-N(RB)C(0)-LS"-R] -N(RB)C(0)-LY'— N(RB)C(0)0-LS"-R] or
-N(RB)C(0)-LY'— (RB)-LS"-RD', wherein LY' is each independently Ls' and, preferably, is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL. Preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-M'-Ls"-RD' or -N(RB)C(0)-LY'-M'-LS"-RD' . More preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY' -N(RB)C(0)0-LS"-RD'. Highly preferably, -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-RD' or -C(0)-LY'-N(RB)C(0)0-RD', wherein LY' preferably is each independently Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL.
RC' is preferably hydrogen, and RD' preferably is independently selected at each occurrence from RE. More preferably, RD' is independently selected at each occurrence from Ci-Cealkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C3-C6carbocycle or 3- to 6-membered heterocycle; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
RA preferably is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-Cecarbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl; or -LA-0-Rs, -LA-S-RS, -LA-C(0)Rs, -LA-OC(0)Rs, -LA-C(0)ORs, -LA-N(RSRS'), -LA-S(0)Rs, -LA-S02Rs, -LA-C(0)N(RsRs'), -LA-N(Rs)C(0)Rs', -LA-N(Rs)C(0)N(Rs'Rs"), -LA-N(Rs)S02Rs', -LA-S02N(RsRs'), -LA-N(Rs)S02N(Rs'Rs"), -LA-N(Rs)S(0)N(Rs'Rs"), -LA-OS(0)-Rs, -LA-OS(0)2-Rs, -LA-S(0)2ORs, -LA-S(0)ORs, -LA-OC(0)ORs, -LA-N(Rs)C(0)ORs', -LA-OC(0)N(RsRs'), -LA-N(Rs)S(0)-Rs', -LA-S(0)N(RsRs') -LA-C(0)N(Rs)C(0)-Rs', or -LA-P(0)(ORs)2, wherein LA is bond, Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene.
More preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
Highly preferably, RA is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and Ls" preferably are each independently selected at each occurrence from bond; or
Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene. A and B can be the same or different. Likewise, Li and L2 can be the same or different.
In one embodiment of this aspect, A and B are each independently phenyl, and are each independently optionally substituted with one or more RA; D is phenyl, and is independently optionally substituted with one or more RA, or is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle, 3- to 6-membered heterocycle or 6- to 12-membered bicycle and is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle or 3- to 6-membered heterocycle which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'), and J can also be optionally substituted with one or more RA; and Gi is N , G2 is , and each Gi and G2 is independently optionally substituted with one or more RA (e.g., one or more chloro or bromo).
wherein
preferably, D is ein J and RN are as defined above. Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, Li, L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY'-N(RB)C(0)0-LS"-RD', wherein LY' is C C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD', -C(0)-LY'-0-LS"-RD', -C(0)-LY' -N(RB)-LS"-RD', or -C(0)-LY'-N(RB)S(0)2 "-RD'. Preferably, R2 and R5, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA; R9 and Ri2, taken together with the atoms to which they are attached, form which is optionally substituted with one or more RA. X is C3-C8cycloalkyl or C5- Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF.
ther embodiment of this aspect, A and B are each independently phenyl (e.g., and are each independently optionally substituted with one or more RA (preferably, A and B are each independently substituted with at least one halogen such as F). X is C3-Cscycloalkyl or C5-Cscycloalkenyl and is optionally substituted with one or more RA. Specific examples of X are described hereinabove. Preferably, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA or RF. More preferably, X is cyclopropyl is and is optionally substituted with one or more RA or RF. D is phenyl, and is substituted with J and optionally substituted with one or more RA. J is C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12- membered bicycle, 10- to 15-membered tricycle or 13- to 15-membered carbocycle/heterocycle, and J is optionally substituted with one or more RA. Preferably, J is substituted with a C3-C6carbocycle, 3- to 6-membered heterocycle, 6- to 12-membered bicycle or 7- to 12-membered carbocycle/heterocycle, which is independently optionally substituted with one or more substituents selected from (1) halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl,
-C(0)ORs or -N(RSRS'), or (2) trimethylsilyl, -0-Rs, -S-Rs or -C(0)Rs; and J can also be optionally
substituted with one or more RA. Preferably, D is wherein J is as defined above, and each RN is inde endentl selected from RD and preferably is hydrogen or halo such as F.
Gi is , and each Gi and G2 is independently optionally substituted with one or more RA (e.g., one or more chloro or bromo). Li and L2 are each independently bond or Ci-C6alkylene, and L3 is bond, Ci-C6alkylene or -C(O)-, and Lu L2, and L3 are each independently optionally substituted with one or more RL. Preferably, L L2, and L3 are bond. -T-RD' is independently selected at each occurrence from -C(0)-LY'-N(RB)C(0)-LS"-RD' or -C(0)-LY' -N(RB)C(0)0-LS"-RD', wherein LY' is Ci-C6alkylene (e.g., -CH2-) and optionally substituted with one or more substituents selected from RL, and Ls" preferably is bond. -T-RD' can also be, without limitation, selected from -C(0)-LY'-LS"-RD', -C(0)-LY'-0-LS"-RD', -C(0)-LY' -N(RB)-LS"-RD', or -C(0)-LY'-N(RB)S(0)2-LS"-RD'. Preferably, R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (e.g.,
or 6- to 12-membered bicycle (e.g., which is optionally substituted with one or more RA; R9 and R12, taken together with the atoms to which they are attached, form a 5- to 6-
membered heterocyclic ring (e.g., or 6- to 12-membered bicycle (e.g.,
which is optionally substituted with one or more RA.
In another aspect, the present invention features compounds having Formula IE and pharmaceutically acceptable salts thereof,
D I
L3
I
Y— A— L— X— L2— B— Z
wherein:
X is C3-C8cycloalkyl or C5-C8cycloalkenyl, and is optionally substituted with one or more RA; Li and L2 are each independently selected from bond or Ci-Cealkylene which is independently optionally substituted at each occurrence with one or more halo, hydroxy, -O-Ci-Cealkyl, or -0-Ci-C6haloalkyl;
L3 is bond or Ci-C6alkylene;
A and B are each independently phenyl, pyridinyl, thiazolyl, Zi is independently selected at each occurrence from O, S, NH or CH2, Z3 is independently selected at each occurrence from N or CH, and Wi, W2, and W3 are each independently selected at each occurrence from CH or N; A and B are each independently optionally substituted with one or more RA.
D is C6-Ciocarbocycle or 5- to 12-membered heterocycle, each of which is optionally substituted with one or more RM;
Y is -T'-C(R1R2)N(R5)-T-RD;
Z is -T'-C(R8R9)N(R12)-T-RD;
Ri is hydrogen, Ci-Cealkyl, Ci-Cehaloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C6alkyl, Ci-C6haloalkyl, -0-Ci-C6alkyl or -0-Ci-C6haloalkyl;
R2 and R5 are each independently hydrogen, Ci-C6alkyl, Ci-C6haloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C6alkyl, Ci-C6haloalkyl, -0-Ci-C6alkyl or -0-Ci-C6haloalkyl; or R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12- membered heterocycle which is optionally substituted with one or more RA (e.g., 1, 2, 3, or 4 RA);
R8 is hydrogen, Ci-C6alkyl, Ci-C6haloalkyl, or 3- to 6-membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C6alkyl, Ci-C6haloalkyl, -0-Ci-C6alkyl or -0-Ci-C6haloalkyl;
R9 and R12 are each independently hydrogen, Ci-Cealkyl, Ci-Cehaloalkyl, or 3- to 6- membered carbocycle or heterocycle, wherein each said 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen, Ci-C6alkyl, Ci-C6haloalkyl, -0-Ci-C6alkyl or -O-Ci-Cehaloalkyl; or R9 and R12, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA (e.g., 1, 2, 3, or 4 RA);
T is independently selected at each occurrence from bond or -C(0)-Ls'-;
T' is independently selected at each occurrence from bond, -C(0)N(RB)-, -N(RB)C(0)-, or 3- to 12-membered heterocycle, wherein said 3- to 12-membered heterocycle is independently optionally substituted at each occurrence with one or more RA;
RD is each independently selected at each occurrence from hydrogen or RA;
RA is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE;
RB and RB' are each independently selected at each occurrence from hydrogen; or Ci-C6alkyl which is independently optionally substituted at each occurrence with one or more substituents selected from halogen or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RB or RB' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, Ci-C6alkyl, Ci-C6haloalkyl, -0-Ci-C6alkyl, or -0-C C6haloalkyl;
RE is independently selected at each occurrence from -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RsRs'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), -C(0)N(Rs)C(0)-Rs', or =C(RSRS'); or C C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-Ci2carbocycle or 3- to 12- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), or -N(Rs)C(0)Rs'; or C3-Ci2carbocycle or 3- to 12- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; is independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each independently optionally substituted with halogen;
is independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-Cealkynylene, each of which is independently optionally substituted at each occurrence with one or more RL;
Rs' and Rs" are each independently selected at each occurrence from hydrogen; Ci- Cealkyl, C2-Cealkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, -0-Ci-C6alkyl, -0-Ci-C6haloalkyl, or 3- to 12-membered carbocycle or heterocycle; or 3- to 12-membered carbocycle or heterocycle; wherein each 3- to 12- membered carbocycle or heterocycle in Rs , Rs' or Rs" is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl or C2-Cehaloalkynyl;
s independently selected at each occurrence from: halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, SF5, -N(RSRS'), -0-Rs, -OC(0)Rs, -OC(0)ORs, -OC(0)N(RsRs'), -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S(0)Rs, -S02Rs, -S(0)N(RsRs'), -SRS, -Si(Rs)3, or -P(0)(ORs)2; Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, -N(RSRS'), -0-Rs, -OC(0)Rs, -OC(0)ORs, -OC(0)N(RsRs'), -C(0)Rs, -C(0)ORs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)ORs', -N(Rs)S02Rs', -S(0)Rs, -S02Rs, -S(0)N(RsRs'), -SRS, or -P(0)(ORs)2; or
G2, wherein G2 is a C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more RG2, and each RG2 is independently selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl,
-0-Rs, -C(0)ORs, -C(0)Rs, -N(RSRS'), or -L4-G3;
L4 is a bond, Ci-C6alkylene, C2-C6alkenylene, C2-C6alkynylene, -0-, -S-, -N(RB)-, -C(O)-, -S(0)2- -S(O)-, -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)- -N(RB)C(0)0-, -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2- -S(0)N(RB)-, -S(0)2N(RB)-, -N(RB)C(0)N(RB')- -N(RB)S02N(Rb')-, or -N(RB)S(0)N(RB')-;
G3 is a C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RG3; and
RG3 is each independently, at each occurrence, halogen, -Ci-C6alkyl, -C(0)Ci-C6alkyl, -Ci-C6haloalkyl, -0-Ci-C6alkyl, -0-Ci-C6haloalkyl, C3-C6carbocycle, or 3- to 6- membered heterocycle.
As described hereinabove for compounds of Formula IE A and B are each phenyl, pyridinyl,
thiazolyl, or where Zi is independently selected at each occurrence from O, S,
NH or CH2, Z3 is independently selected at each occurrence from N or CH, and Wi, W2, and W3 are each independently selected at each occurrence from CH or N; A and B are each independently optionally substituted with one or more RA. Pre thiazolyl (e
optionally substituted with one or more RA.
Prefera thiazolyl (e.g.,
is optionally substituted with one or more RA.
Highly preferably, both A and B are phenyl (e.g., both A and B are '); or A is
substituted with one or more RA.
In certain embodiments of this aspect of the invention, A and B are substituted by one or more RA, wherein each RA is independently selected from halogen (e.g., fluoro, chloro), LS-RE (where LS is bond and RE is -Ci-C6alkyl (e.g., methyl), -0-RS (e.g., -0-Ci-C6alkyl, -OCH3), or -Ci-C6alkyl optionally substituted with one or more halogen (e.g., -CF3)), or LS-RE (where LS is Ci-C6alkylene and RE is -0-RS (e.g., -Ci-C6alk -0-Ci-C6alkyl, -CH2OCH3)). For example, in certain
embodiments A is and B is as defined hereinabove. In certain other embodiments B is is as defined hereinabove. In
As described hereinabove for compounds of Formula IE D is C6-Ci0carbocycle or 3- to 12- membered heterocycle optionally substituted by one or more RM. Preferably, D is C6-Ci0aryl (e.g., phenyl, naphthyl, indanyl), or 5- to 10-membered heteroaryl (pyridinyl, thiazolyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l ,3]dioxol-5-yl), and D is substituted with one or more RM. For example, in certain embodiments D is preferably phenyl substituted by one or more RM, wherein each RM is independently halogen (e.g., fluoro, chloro, bromo); Ci-C6alkyl (e.g., tert-butyl); Ci-C6alkyl substituted with one or more halogen (e.g., CF3); -0-Rs such as -0-Ci-C6alkyl (e.g., -0-CH2CH3); or -0-Ci-C6alkyl substituted at each occurrence with one or more halogen (e.g., -0-CF3, -0-CH2CHF2) or -0-C C6alkyl (e.g., -0-CH2CH2OCH3); -0-Rs (e.g., -0-Ci-C6alkyl, such as -0-CH2) substituted with 3- to 12-membered heterocycle (e.g., 3-ethyloxetan-3-yl, l ,3-dioxolan-4-yl); -0-Rs where Rs is an optionally substituted 3- to 12- membered carbocycle or heterocycle (e.g., cyclopentyl, cyclohexyl, phenyl, l,3-dioxan-5-yl); -N(Rs)C(0)Rs' wherein Rs and Rs' are each independently C C6alkyl (e.g., -N(t-Bu)C(0)Me); SF5; -S02Rs wherein Rs is Ci-C6alkyl (e.g., -S02Me); or C3-Ci2carbocycle (e.g., cyclopropyl, cyclohexyl, phenyl).
In certain embodiments of this aspect of the invention, D is preferably phenyl or pyridyl and is substituted by one or more RM where one RM is G2. In certain embodiments where D is phenyl or pyridyl, D is substituted by G2, G2 is 3- to 12-membered heterocycle (e.g., pyridinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazolyl) and is optionally substituted with one or more halogen (e.g., fluoro, chloro), hydroxy, oxo, cyano, Ci-C6alkyl (e.g., methyl), C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl (e.g., CF3), C2-C6haloalkenyl, C2-C6haloalkynyl, -0-C C6alkyl (e.g., -0-CH3), -C(0)ORs (e.g., -C(0)OCH3), -C(0)Rs (e.g., -C(0)CH3), or -N(RSRS'); and D is further optionally substituted by one or more RM where RM is halogen (e.g., fluoro, chloro), Ci-C6alkyl (e.g., methyl), Ci-C6haloalkyl (e.g., CF3), or -0-Ci-C6alkyl (e.g., -0-CH3). In certain other embodiments D is phenyl or pyridyl and G2 is, for example, a monocyclic 3-8 membered carbocycle or monocyclic 4-8 membered heterocycle substituted with L4-G3 and optionally substituted with one or more RG2 wherein L , G3 and RG2 are as defined herein. L4, for example is a bond, a Ci-C6 alkylene (e.g., -CH2- -CH2CH2-, -CH2CH2CH2-, etc.), -0-, or -S(0)2-. G3 is for example a C3-Ci2carbocycle optionally substituted with one or more RG3- RG2 and RG3 are each independently at each occurrence halogen, -C(0)Ci-C6alkyl, -Ci-C6alkyl,
-Ci-Cehaloalkyl, -O-Ci-Cealkyl, or -O-Ci-Cehaloalkyl. In certain embodiments G2 is ,
wherein is a monocyclic 4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl) attached to the parent molecular moiety through a nitrogen atom and substituted with one or two L4-G3 and optionally substituted with one or more RG2- Thus, in
certain embodiments where L4 is a bond G2 is is optionally substituted with
RG2 and G3 is optionally substituted with RG3. Thus, ^ can be, for example, 3 -phenylazetidin- 1 -yl, 3-phenylpyrrolidin-l-yl, 4-phenylpiperazin-l-yl, 4-phenylpiperidin-l-yl, 4-phenyl-3,6- dihydropyridin- 1 (2H)-yl, 4,4-diphenylpiperidin- 1 -yl, 4-acetyl-4-phenylpiperidin- 1 -yl, 4-(4- methoxyphenyl)piperidin-l -yl, 4-(4-fluorophenyl)piperidin-l-yl, or 3-phenylpiperidin-l-yl, and wherein D can be further optionally substituted with one or more RM (e.g., fluoro, chloro, methyl, methoxy).
In certain other embodiments of this as ect of the invention L i a -C6 alkylene, -0-, or
-S(0)2- and G2 is substituted with RG
and G3 is as define d above and is optionally substituted with RG3. Thus, can be, for example,
4-tosylpiperazin-l-yl, 4-phenoxypiperidin-l-yl, 3-phenoxypyrrolidin-l -yl, 4-benzylpiperidin-l-yl, 4- phenethylpiperidin-l-yl, or 3-phenylpropyl)piperidin-l-yl. In certain other embodiments of this aspect of the invention, D is phenyl or pyridyl, D is substituted by G2 and G2 is a spiro, bridged, or fused bicyclic carbocycle or heterocycle optionally substituted with L4-G3 and one or more RG2, wherein D is optionally substituted with one or more RM
N
and RM, L4, G3, and RG2 are as defined herein. In certain embodiments G2 is ^ , N
wherein '^ is a spiro, bridged, or fused bicyclic nitrogen-containing heterocycle (e.g., 3- azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, octahydro-2H- isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H-isoindol-2-yl, l ,4-dioxa-8-azaspiro[4.5]dec- 8-yl) attached to the parent molecular moiety through a nitrogen atom and optionally substituted with G3 and one or more RG2. Thus, G2 is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6- azaspiro[2.5]oct-6-yl, octahydro-2H-isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, or l ,4-dioxa-8-azaspiro[4.5]dec-8-yl; L4 is a bond and D is optionally substituted with one or more RM (e.g., fluoro, chloro, methyl, methoxy).
In certain embodiments of this aspect of the invention, D is wherein RM is as defined above in connection with Formula IE, and D is optionally substituted by one or more additional RM.
For instance, where D is , RM can be fluoro, chloro, tert-butyl, -0-CH2CH3, -0-CF3,
-0-CH2CHF2, -0-CH2CH2OCH3, -0-CH2-(3-ethyloxetan-3-yl), -0-CH2-(l ,3-dioxolan-4-yl), -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, -0-(l,3-dioxan-5-yl), cyclopropyl, cyclohexyl, phenyl, SF5, -S02Me, or -N(t-Bu)C(0)Me and D can be optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C6alkyl (e.g., methyl).
In certain embodiments, D is wherein RM is fluoro, chloro, tert-butyl, -0-CH2CH3,
-O-CF3, -0-CH2CHF2, -0-CH2CH2OCH3, SF5, -S02Me, or -N(t-Bu)C(0)Me and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C6alkyl (e.g., methyl). In certain embodiments, D is wherein RM is cyclopropyl, cyclohexyl, or phenyl and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C6alkyl (e.g., methyl).
In certain embodiments, D is wherein RM is -0-CH2-(3-ethyloxetan-3-yl),
-0-CH2-(l,3-dioxolan-4-yl), -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, or -0-(l,3-dioxan-5-yl) and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C6alkyl (e.g., methyl).
In certain embodiments, D is wherein G2 is pyridinyl (e.g., pyridin-2-yl), piperidin-1- yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2- yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l - yl, 4-methylpiperidin-l-yl, 4-tert-butylpiperidin-l -yl, 2-oxopiperidin-l -yl, 3,3-dimethylazetidin-l -yl, or oxazolyl (e.g., l ,3-oxazol-2-yl) and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro) and Ci-C6alkyl (e.g., methyl).
In another embodiment of this as ect of the invention, D is wherein Gi is N,
C-H, or C-RM; G2 is a monocyclic 4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) attached to the parent molecular moiety through a nitrogen atom and substituted by L4-G3 and optionally substituted with one or more RG2; L4 is a bond, Ci-C6 alkylene, -0-, or -S(0)2-; G3 is aryl (e.g., phenyl), cycloalkyl (e.g., cyclohexyl), or heterocycle (e.g., thienyl) wherein each G3 is optionally substituted with one or more RQ3 ; RG2 and RQ3 at each occurrence are each independently halogen, -C(0)Ci-Cealkyl, -Ci-Cealkyl, -Ci-Cehaloalkyl, -O-Ci-Cealkyl, or -O-Ci-Cehaloalkyl; g is 0, 1 , 2, or 3; and RM is as defined above in connection with
Formula IE. In one group of compounds according to this embodiment, D is wherein
G3 is phenyl optionally substituted with one or two RG3; g is 0, 1, or 2; RM is each independently
fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and and RG3 are as
defined above. In a further subgroup of compounds of this embodiment, D is
wherein G3 is phenyl optionally substituted with one or two RG3; RMI is each independently hydrogen, fluoro, chloro, or methyl; and RG2 is an optional substituent as described herein. In another group of
compounds according to this embodiment, D is wherein L4 is Ci-C6 alkylene, -0-, or
-S(0)2-; G3 is phenyl optionally substituted with one or two RG3; g is 0, 1 , or 2; RM is each
independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and and RG3 are as defined above. In yet another embodiment of this aspect of the invention, D is wherein Gi is
N, C-H, or C-RM; G2 wherein is a spiro, bridged, or fused bicyclic nitrogen- containing heterocycle (e.g., 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-2-yl, 6- azaspiro[2.5]oct-6-yl, octahydro-2H-isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl) attached to the parent molecular moiety through a nitrogen atom and optionally substituted with L4-G3 and one or more RG2; L4 is a bond, Ci-C6 alkylene, -0-, or -S(0)2-; G3 is aryl (e.g., phenyl), cycloalkyl (e.g., cyclohexyl), or heterocycle (e.g., thienyl) wherein each G3 is optionally substituted with one or more RG3; RG2 and RG3 at each occurrence are each independently halogen, -C(0)Ci-C6alkyl, -Ci-C6alkyl, -Ci-C6haloalkyl, -0-Ci-C6alkyl, or -0-Ci-C6haloalkyl; g is 0, 1 , 2, or 3; and RM is as defined above in connection with
Formula IE. In one group of compounds according to this embodiment, D IS wherein g is 0, 1, or 2; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
trifluoromethoxy; and as defined above. In a further subgroup of compounds D is
wherein RMi is each independently hydrogen, fluoro, chloro, or methyl, and
"^- is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2-yl, 2- azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl). till another embodiment of this aspect of the invention, D is wherein is a monocyclic 4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) substituted with one or more RG2, wherein RG2 at each occurrence is each independently halogen, -C(0)Ci-C6alkyl, -Ci-C6alkyl, -Ci-C6haloalkyl, -0-Ci-C6alkyl, or -0-Ci-C6haloalkyl; and RM is each independently halogen, -Ci-C6alkyl, -Ci-C6haloalkyl, -0-Ci-C6alkyl, or -0-Ci-C6haloalkyl. In one group of compounds according to this embodiment, is azetidinyl, pyrrolidinyl, or piperidinyl substituted with one or two RG2, wherein RG2 at each occurrence is each independently methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or
trifluoromethyl; and RM is each independently fluoro, chloro, or methyl. For example is 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2- yl)piperidin- 1 -yl, 4-fluoropiperidin- 1 -yl, 3 ,5 -dimethylpiperidin- 1 -yl, 4-(trifluoromethyl)piperidin- 1 - yl, 4-methylpiperidin-l -yl, 4-tert-butylpiperidin-l-yl, 2-oxopiperidin-l-yl, or 3,3-dimethylazetidin-l- yl-
In certain preferred embodiments of this aspect of the invention, X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA; and Li, L2, and L3 are each a bond. In another embodiment, X is cyclopropyl, cyclopentyl or cyclopentenyl, and Li and L2 are each methylene (i.e. -CH2-), and L3 is a bond.
In compounds of Formula IE, Y is-T'-C(RiR2)N(R5)-T-RD and Z is -T'-C(RSR9) (RI2)-T-RD; wherein T' , Ri, R2, R5, Rs, R9, R12, T, and RD are as defined herein.
Preferably Ri, R2, R5, Rs, R9, and R12 are each independently hydrogen; Ci-C6alkyl; or 3- to 6- membered carbocycle or heterocycle, wherein each 3- to 6-membered carbocycle or heterocycle is independently optionally substituted at each occurrence with one or more substituents selected from halogen or Ci-Cealkyl; wherein R2 and R5, taken together with the atoms to which they are attached, optionally form a 3- to 12-membered heterocycle which is substituted with 0, 1, 2, 3, or 4 RA, and R9 and R12 taken together with the atoms to which they are attached, optionally form a 3- to 12- membered heterocycle which is substituted with 0, 1, 2, 3, or 4 RA wherein RA is as defined herein. In certain embodiments of this aspect of the invention, Ri is hydrogen and R2 and R5, taken together with the atoms to which they are attached form a 3- to 12-membered heterocycle (e.g.,
RA is halogen (e.g., fluoro, chloro); cyano; LS-RE where Ls is a single bond and RE is Ci-C6alkyl (e.g., methyl, ethyl), -0-Ci-C6alkyl (e.g., methoxy), or -0-Ci-C6haloalkyl (e.g., trifluoromethoxy); or
K CH
LS-RE where Ls is a double bond and RE is =C(RsRs') (e.g., H H 3 ). In a preferred embodim R5, taken together with the atoms to which they are attached form a pyrrolidine
ring (i.e., substituted with 0 or 1 RA wherein RA is fluoro, methoxy, methyl, ethyl, or cyano. In another preferred embodi and R5, taken together with the atoms to which they are
attached form a pyrrolidine ring (i.e.,
In certain other embodiments of this aspect of the invention, R8 is hydrogen and R9 and R12, taken together with the atoms to which they are attached form a 3- to 12-membered heterocycle (e.g.,
RA wherein RA is halogen (e.g., fluoro, chloro); cyano; LS-RE where LS is a single bond and RE is Ci-C6alkyl (e.g., methyl, ethyl), -0-Ci-C6alkyl (e.g., methoxy), or -0-Ci-C6halo (e.g., trifluoromethoxy); or LS-RE where LS is a double bond and RE is =C(RSRS') (e.g., M , In a preferred embodime and R12, taken together with the atoms to which they are attached form
a pyrrolidine ring (i.e., substituted with 0 or 1 RA wherein RA is fluoro, methoxy, methyl, ethyl, or cyano. In another preferred embodiment R9 and R12, taken together with the atoms
to which they are attached form a pyrrolidine ring (i.e.,
As used herein, a chiral carbon in any rings formed by joining R2 and R5 or R9 and R12 may
possess either (R) or (S) stereochemistry. A pyrrolidine ring (i.e.,
and R5 or R9 and Ri2 preferably possesses the (S) stereochemistry
In this aspect of the invention, is independently selected at each occurrence from a bond, -C(0)N(RB)-, -N(RB)C(0)-, or 3- to 12-membered heterocycle, and wherein said 3- to 12-membered heterocycle is each independently optionally substituted at each occurrence with one or more RA, and RA and RB are as described herein. In particular, where T is -C(0)N(RB)-, RB can be hydrogen (i.e., is -C(0)N(H)-). In certain embodiments, T' is imidazolyl (i.e., , N— ) optionally substituted at each occurrence with one or more RA wherein RA is halogen (e.g., fluoro, chloro), Ci-Cealkyl (e.g., methyl, ethyl), or Ci-Cehaloalkyl (e.g., trifluoromethyl). In certain embodiments, is imidazolyl (i.e.,
This aspect of the invention contemplates particular combinations of A with Y and B with Z. Non-limiting examples of preferred Y when A is C5-C6carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl) and preferred Z when B is C5-C6carbocycle (e.g., phenyl) or
In certain embodiments of this aspect of the inventio optionally substituted with one or more RA as described herein, or Y-A is and non-limiting examples of preferred Y, where T' is a bond, include: , wherein T and RD are as defined herein. In certain embodiments of this aspect of the inventi optionally substituted with one or more RA as described herein, or B
examples of preferred Z, where T' is a bond, include: .
wherein T and RD are as defined herein.
T at each occurrence is independently a bond or -C(0)-Ls'-, wherein Ls' is as defined
includes, but is not limited to, , or , where Ls' is optionally substituted with one or more RL; and RL is a substituent such as, but not limited to carbocycle (e.g., cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, phenyl), methoxy, or heterocycle (e.g., tetrahydrofuranyl, tetrahydropyranyl).
RD is hydrogen or RA wherein RA is as defined herein. Thus RD includes, but is not limited to, RA wherein RA is LS-RE, and LS and RE are as defined herein. Thus RD includes, but is not limited to, LS-RE wherein LS is a bond and RE is-N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', — N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -N(Rs)C(0)ORs', or -N(Rs)S(0)-Rs'; or C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, or Ci-C6haloalkyl.
In one embodiment of this aspect of the invention, RD is LS-RE wherein LS is a bond and RE is -N(Rs)C(0)ORs' or 3- to 12-membered heterocycle (e.g., pyrrolidine, piperidine, azepanyl) wherein Rs and Rs' are as defined herein. For example RD is preferably LS-RE wherein Ls is a bond and RE is -N(H)C(0)OMe.
Thus according to the foregoing description T-RD includes, but is not limited to:
etc.
According to this aspect of the invention, non-limiting examples of preferred Y when A is C5-C6carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl) and preferred Z when B is C5-C6carbocycle (e.g., phenyl) or 5- to 6-membered heterocycle (e.g., pyridinyl or thiazolyl) include:
one or more RA as described herein and Y-A is :
99
In still another aspect, the present invention features compounds of Formula Larmaceutically acceptable salts thereof:
wherein:
X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA
A is ally substituted with one or more RA;
B is wherein B is optionally substituted with one or more RA; and
Y, Z, RA, and D are as described hereinabove (e.g., Y, Z, RA, and D as described for Formula I, IA, IB, IC, ID, or IE, preferably as described for Formula IE).
In one embodiment of this aspect of the invention, A is wherein A is
optionally substituted with one or more RA; B is wherein B is optionally
substituted with one or more RA; Y is
or ; and D, RA, T and RD are as defined hereinabove (e.g., as described for Formula I, IA, ¾, Ic, ID or IE, preferably as described for Formula
In another embodiment according to this aspect of the invention, A or B are optionally substituted with one or more substituents selected from: RA wherein RA is each independently halogen (e.g., fluoro, chloro); LS-RE where Ls is a single bond, and RE is -Ci-C6alkyl (e.g., methyl), -O-Rs (e.g., -0-Ci-C6alkyl, -OCH3), or -Ci-C6alkyl optionally substituted with one or more halogen (e.g., -CF3); or LS-RE where Ls is a Ci-C6alkylene and RE is -O-Rs (e.g., -Ci-C6alkyl-0-Ci-C6alkyl, -CH2OCH3). This embodiment includes compounds where A and B are both substituted by one RA; compounds where A and B are both substituted by zero RA; compounds where A is substituted by one RA and B is substituted by zero RA; and compounds where A is substituted by zero RA and B is
In a further embodiment of this aspect of the invention, T-RD is independently selected at
each occurrence from the group consisting of -
preferred and wherein D is as defined hereinabove.
In another embodiment, this aspect of the invention features compound of Formula IF and pharmaceutically acceptable salts thereof, wherein:
A is wherein A is optionally substituted with one o mo e RA? B is wherein B is optionally substituted with one or more RA; Y is D
and RD are as defined hereinabove. A particular subgroup according to this embodiment includes
compounds where A is Y is ; Z is or ; T-RD is each independently
; and D is as defined hereinabove.
In yet another embodiment, this aspect of the invention features compounds of Formula IF and pharmaceuticall acceptable salts thereof, wherein: A and B are each Y and Z are each independently
Rr , or ; and D, T and RD are as defined hereinabove. A particular subgroup according to this embodiment includes compounds where T-RD is each independently selected from ; and D is as defined hereinabove.
According to each of the foregoing embodiments and description of this aspect of the invention of Formula IF are groups and subgroups of compounds having particular values for D. Included in each of the foregoing embodiments are groups and subgroups of compounds with the following particular values for D:
In certain groups of compounds according t Formula IF and the foregoing embodiments and
description of this aspect of the invention, D is , where RM is fluoro, chloro, tert-butyl,
-0-CH2CH3, -0-CF3, -0-CH2CHF2, -0-CH2CH2OCH3, -0-CH2-(3-ethyloxetan-3-yl), -0-CH2-(l,3-dioxolan-4-yl), -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, -0-(l,3-dioxan-5-yl), cyclopropyl, cyclohexyl, phenyl, SF5, -S02Me, or -N(t-Bu)C(0)Me and D is optionally substituted by one or more additional RM, selected from the group consisting of halogen (e.g., fluoro, chloro) or Ci-C6alkyl (e.g., methyl).
In other groups of compounds accordi Formula IF and the foregoing embodiments and
description of this aspect of the invention, D is wherein G2 is pyridinyl (e.g., pyridin-2-yl), piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6-dimethylpiperidin-l-yl, 4- (propan-2-yl)piperidin-l-yl, 4-fluoropiperidin-l-yl, 3,5-dimethylpiperidin-l-yl, 4-
(trifluoromethyl)piperidin- 1 -yl, 4-methylpiperidin- 1 -yl, 4-tert-butylpiperidin- 1 -yl, 2-oxopiperidin- 1 - yl, 3,3-dimethylazetidin-l-yl, or oxazolyl (e.g., l,3-oxazol-2-yl) and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro), or Ci-C6alkyl (e.g., methyl). In particular according to these groups are compounds where D is ; G2 is piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6- dimethylpiperidin-1 -yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin- 1 -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l-yl, 4-tert-butylpiperidin-l-yl, 2- oxopiperidin-l-yl, or 3,3-dimethylazetidin-l-yl; and RMi is each independently hydrogen, fluoro, chloro, or methyl.
In other groups of compounds according Formula IF and the foregoing embodiments and
description of this aspect of the invention, D wherein Gi is N, C-H, or C-RM; G2 is
RM, and g are as defined hereinabove. In particular according to these groups, RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
G3
L4
trifluoromethoxy; g is 0, 1, or 2; and ^ is as defined hereinabove. In further subgroups L4 is a
N
bond; G2 is ^ ; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
trifluoromethoxy; and g is 0, 1, or 2. In particular subgroups, is 3-phenylazetidin-l-yl, 3- phenylpyrrolidin- 1 -yl, 4-phenylpiperazin- 1 -yl, 4-phenylpiperidin- 1 -yl, 4-phenyl-3 ,6-dihydropyridin- 1 (2H)-yl, 4,4-diphenylpiperidin- 1 -yl, 4-acetyl-4-phenylpiperidin- 1 -yl, 4-(4-methoxyphenyl)piperidin- 1 -yl, 4-(4-fluorophenyl)piperidin-l-yl, or 3-phenylpiperidin-l-yl; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2. In other subgroups L4 is Ci-C6 alkylene, -0-, or -S(0)2-; G2 is ; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2. In particular subgroups,
is 4-tosylpiperazin-l -yl, 4-phenoxypiperidin-l-yl, 3-phenoxypyrrolidin-l -yl, 4- benzylpiperidin-l-yl, 4-phenethylpiperidin-l-yl, or 3-phenylpropyl)piperidin-l -yl; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1 , or
2. In further subgroups of compounds D is wherein G3 is phenyl optionally substituted with one or two RG3; g is 0, 1, or 2; RM is each independently fluoro, chloro, methyl, methoxy,
trifluoromethyl, or trifluoromethox and and RG3 are as defined above. In other groups of
compounds D is in L4 is Ci-C6 alkylene, -0-, or -S(0)2-; G3 is phenyl optionally substituted with one or two RG3; g is 0, 1 , or 2; RM is each independently fluoro, chloro, methyl,
methoxy, trifluoromethyl, or trifluoromethoxy; and and RG3 are as defined above. In further subgroups of compounds D is wherein G3 is phenyl optionally substituted with one or two RG3 as defined hereinabove; RMi is each independently hydrogen, fluoro, chloro, or methyl; and RG2 is an optional substituent, as described above, selected from the group consisting of -C(0)C C6alkyl, -Ci-C6alkyl, -d-Cghaloalkyl, -0-C C6alkyl, and -0-Ci-C6haloalkyl.
In other groups of compounds according Formula IF and the foregoing embodiments and
description of this aspect of the invention, D is wherein Gi is N, C-H, or C-RM; G2 is , RM, and g are as defined hereinabove. In particular according to these subgroups, RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
N
trifluoromethoxy; g is 0, 1, or 2; and is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-
2-yl, 6-azaspiro[2.5]oct-6-yl, octahydro-2H-isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l,3-dihydro-2H- isoindol-2-yl, or l,4-dioxa-8-azaspiro[4.5]dec-8-yl. In further subgroups of compounds D is
wherein g is 0, 1, or 2; RM is each independently fluoro, chloro, methyl, methoxy,
trifluoromethyl, is as defined above. In further subgroups of
compounds D is is each independently hydrogen, fluoro, chloro, or N
methyl and is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2- yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl).
In other groups of compounds according Formula IF and the foregoing embodiments and
description of this aspect of the invention, D is , wherein ^ is a monocyclic
4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) substituted with one or more RG2, wherein RG2 at each occurrence is each independently halogen, -C(0)C C6alkyl, -C C6alkyl, -C C6haloalkyl, -0-C C6alkyl, or -0-C C6haloalkyl; and RM is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ο-Ci-Cealkyl, or -O-Ci-Cehaloalkyl. In
each group of compounds according to the foregoing embodiments is azetidinyl, pyrrolidinyl, or piperidinyl substituted with one or two RG2, wherein RG2 at each occurrence is each methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or trifluoromethyl; and RM is each independently
fluoro, chloro, or methyl. For example is 4,4-dimethylpiperidin-l -yl, 4,4- difluoropiperidin-1 -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l - yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l -yl, 4-tert- butylpiperidin-l-yl, 2-oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl.
In still another aspect, the present invention features compounds of Formula IG and pharmaceutically acceptable salts thereof,
wherein:
X is cyclopropyl, cyclopentyl or cyclopentenyl, and is optionally substituted with one or more RA A is substituted with one or more RA;
B is or , wherein B is optionally substituted with one or more RA; and
Y, Z, RA, and D are as described hereinabove (e.g., as described for Formula I, IA, ¾, Ic, ID, IE or IF, preferably as described for Formula IE).
In one embodiment, this aspect of the invention features compounds of Formula IG and
pharmaceutically acceptable salts thereof, wherein: A is or
wherein A is optionally substituted with one RA; B is wherein B is optionally substituted with one RA; RA is halogen (e.g., fluoro, chloro); LS-RE where Ls is a single bond and RE is -Ci-Cealkyl (e.g., methyl), -O-Rs (e.g., -O-Ci-Cealkyl, -OCH3), or -Ci-Cealkyl optionally substituted with one or more halogen (e.g., -CF3); or LS-RE where Ls is a Ci-C6alkylene
-O-Rs (e.g., -Ci-C6alkyl-0-Ci-C6alkyl, -CH2OCH3); Y and Z are each independently
Rr , or Rr T-RD is each independently and D is as defined hereinabove.
In another embodiment, this aspect of the invention features compounds of Formula IG and
pharmaceutically acceptable salts thereof, wherein A is wherein A is optionally
substituted with one RA; B is , wherein B is optionally substituted with one RA; RA is halogen (e.g., fluoro, chloro); LS-RE where Ls is a single bond and RE is -Ci-C6alkyl (e.g., methyl), -O-Rs (e.g., -O-Ci-Cealkyl, -OCH3), or -Ci-Cealkyl optionally substituted with one or more halogen (e.g., -CF3); or LS-RE where Ls is a Ci-C6alkylene and RE is -0-Rs (e.g., -Ci-C6alkyl-0-Ci-C6alkyl,
- ently
, or , T-RD is each independently
, or wherein compounds having (S) stereochemistry (e.g., are particularly contemplated; and D is as defined hereinabove. This subgroup includes compounds where A and B are both substituted by one RA; compounds where A and B are both substituted by zero RA; compounds where A is substituted by one RA and B is substituted by zero RA; and compounds where A is substituted by zero RA and B is substituted by one RA. In particular, according to this subgroup
According to each of the foregoing embodiments and description of this aspect of the invention of Formula IG are groups and subgroups of compounds having particular values for D. Included in each of the foregoing embodiments are groups and subgroups of compounds with the following particular values for D:
Groups of compounds according to this aspect of the invention include compounds where D is C6-Ci0aryl (e.g., phenyl, naphthyl, indanyl), or 5- to 10-membered heteroaryl (pyridinyl, thiazolyl, 4,5,6,7-tetrahydrobenzo[d]thiazolyl, benzo[d]thiazolyl, indazolyl, benzo[d][l,3]dioxol-5-yl), and D is substituted with one or more RM. Particular subgroups according to this aspect and these embodiments include compounds wherein RM is halogen (e.g., fluoro, chloro, bromo); Ci-C6aikyl (e.g., tert-butyl); Ci-Cealkyl substituted with one or more halogen (e.g., CF3); -Ο-Ci-Cealkyl (e.g., -0-CH2CH3); -0-Ci-C6alkyl substituted at each occurrence with one or more halogen (e.g., -0-CF3, -0-CH2CHF2) or -0-C C6alkyl (-0-CH2CH2OCH3); -0-C C6alkyl (e.g., -0-CH2) substituted with an optionally substituted 3- to 12-membered heterocycle (e.g., 3-ethyloxetan-3-yl, 1,3-dioxolan- 4-yl); -0-Rs where Rs is an optionally substituted 3- to 12-membered carbocycle or heterocycle (e.g., cyclopentyl, cyclohexyl, phenyl, l,3-dioxan-5-yl); -N(Rs)C(0)Rs' wherein Rs and Rs' are each independently Ci-C6alkyl (e.g., -N(t-Bu)C(0)Me); SF5; -S02Rs wherein Rs is Ci-C6alkyl (e.g., -S02Me); or C3-Ci2carbocycle (e.g., cyclopropyl, cyclohexyl, phenyl). Other subgroups according to this embodiment include compounds wherein D is phenyl substituted by G2 and optionally substituted by one or more RM, wherein G2 is a 3- to 12-membered heterocycle (e.g., pyridinyl, piperidinyl, pyrrolidinyl, azetidinyl, oxazolyl) wherein the heterocycle is optionally substituted with one or more substituents selected from halogen, hydroxy, oxo, cyano, Ci-C6alkyl (e.g., methyl), C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl (e.g., CF3), C2-C6haloalkenyl, C2-C6haloalkynyl, -0-Ci-C6alkyl (e.g., -O-CH3), -C(0)ORs (e.g., -C(0)OC¾), -C(0)Rs (e.g., -C(0)CH3), -N(RSRS'), or L4-G3; RM is halogen (e.g., fluoro, chloro), alkyl (e.g., methyl), haloalkyl (e.g., CF3), or -0-Ci-C6alkyl (e.g., -O-CH3); and L4, G3, Rs, and Rs' are as defined hereinabove.
In certain groups of compounds according t Formula IG and the foregoing embodiments and
description of this aspect of the invention, D is , where RM is fluoro, chloro, tert-butyl, -0-CH2CH3, -0-CF3, -0-CH2CHF2, -0-CH2CH2OCH3, -0-CH2-(3-ethyloxetan-3-yl), -0-CH2-(l,3-dioxolan-4-yl), -O-cyclopentyl, -O-cyclohexyl, -O-phenyl, -0-(l ,3-dioxan-5-yl), cyclopropyl, cyclohexyl, phenyl, SF5, -S02Me, or -N(t-Bu)C(0)Me and D is optionally substituted by one or more additional RM, selected from the group consisting of halogen (e.g., fluoro, chloro) or C C6alkyl (e.g., methyl).
In other groups of compounds accordi Formula IG and the foregoing embodiments and
description of this aspect of the invention, D is wherein G2 is pyridinyl (e.g., pyridin-2-yl), piperidin-l-yl, 4,4-dimethylpiperidin-l -yl, 4,4-difluoropiperidin-l -yl, 2,6-dimethylpiperidin-l-yl, 4- (propan-2-yl)piperidin-l-yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin-l-yl, 4- (trifluoromethyl)piperidin-l -yl, 4-methylpiperidin-l -yl, 4-tert-butylpiperidin-l-yl, 2-oxopiperidin-l- yl, 3,3-dimethylazetidin-l-yl, or oxazolyl (e.g., l ,3-oxazol-2-yl) and D is optionally substituted by one or more additional RM selected from the group consisting of halogen (e.g., fluoro, chloro), or methyl). In particular according to these groups are compounds where D is
; G2 is piperidin-l-yl, 4,4-dimethylpiperidin-l-yl, 4,4-difluoropiperidin-l-yl, 2,6- dimethylpiperidin-l -yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l -yl, 3,5-dimethylpiperidin- l -yl, 4-(trifluoromethyl)piperidin-l -yl, 4-methylpiperidin-l -yl, 4-tert-butylpiperidin-l-yl, 2- oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl; and RMi is each independently hydrogen, fluoro, chloro, or methyl. In other groups of compounds according Formula IG and the foregoing embodiments and
description of this aspect of the invention, D wherein Gi is N, C-H, or C-RM; G2 is
RM, and g are as defined hereinabove. In particular according to these groups, RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
trifluoromethoxy; g is 0, 1 , or 2; and is as defined hereinabove. In further subgroups L4 is a
bond; G2 is ^ ; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
trifluoromethoxy; and g is 0, 1 , or 2. In particular subgroups, ^ is 3-phenylazetidin-l -yl, 3- phenylpyrrolidin- 1 -yl, 4-phenylpiperazin- 1 -yl, 4-phenylpiperidin- 1 -yl, 4-phenyl-3 ,6-dihydropyridin- 1 (2H)-yl, 4,4-diphenylpiperidin- 1 -yl, 4-acetyl-4-phenylpiperidin- 1 -yl, 4-(4-methoxyphenyl)piperidin- 1 -yl, 4-(4-fluorophenyl)piperidin-l-yl, or 3-phenylpiperidin-l-yl; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1 , or 2. In other subgroups
L4 is Ci-C6 alkylene, -0-, or -S(0)2-; G2 is ; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1, or 2. In particular subgroups,
is 4-tosylpiperazin-l -yl, 4-phenoxypiperidin-l-yl, 3-phenoxypyrrolidin-l -yl, 4- benzylpiperidin-l-yl, 4-phenethylpiperidin-l-yl, or 3-phenylpropyl)piperidin-l -yl; RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or trifluoromethoxy; and g is 0, 1 , or
2. In further subgroups of compounds D is wherein G3 is phenyl optionally substituted with one or tw is each independently fluoro, chloro, methyl, methoxy,
trifluoromethyl, and RG3 are as defined above. In other groups of
compounds D is 6 alkylene, -0-, or -S(0)2-; G3 is phenyl optionally substituted with one or two RG3; g is 0, 1 , or 2; RM is each independently fluoro, chloro, methyl,
methoxy, trifluoromethyl, or trifluoromethoxy; and and RG3 are as defined above. In further
subgroups of compounds D is wherein G3 is phenyl optionally substituted with one or two RG3 as defined hereinabove; RMi is each independently hydrogen, fluoro, chloro, or methyl; and RG2 is an optional substituent, as described above, selected from the group consisting of -C(0)Ci-C6alkyl, -Ci-C6alkyl, -Ci-C6haloalkyl, -0-Ci-C6alkyl, and -0-Ci-C6haloalkyl.
In other groups of compounds accord IG and the foregoing embodiments and
description of this aspect of the invention, D is wherein Gi is N, C-H, or C-RM; G2 is
subgroups, RM is each independently fluoro, chloro, methyl, methoxy, trifluoromethyl, or
N
trifluoromethoxy; g is 0, 1 , or 2; and is 3-azabicyclo[3.2.0]hept-3-yl, 2-azabicyclo[2.2.2]oct-
2-yl, 6-azaspiro[2.5]oct-6-yl, octahydro-2H-isoindol-2-yl, 3-azaspiro[5.5]undec-3-yl, l ,3-dihydro-2H- isoindol-2-yl, or l ,4-dioxa-8-azaspiro[4.5]dec-8-yl. In further subgroups of compounds D is
wherein g is 0, 1 , or 2; RM is each independently fluoro, chloro, methyl, methoxy,
trifluoromethyl, is as defined above. In further subgroups of
compounds D is is each independently hydrogen, fluoro, chloro, or
N
methyl and is as defined above (e.g., 3-azabicyclo[3.2.0]hept-3-yl, octahydro-2H-isoindol-2- yl, 2-azabicyclo[2.2.2]oct-2-yl, 6-azaspiro[2.5]oct-6-yl, 3-azaspiro[5.5]undec-3-yl, l,3-dihydro-2H- isoindol-2-yl, l,4-dioxa-8-azaspiro[4.5]dec-8-yl).
In other groups of compounds according Formula IG and the foregoing embodiments and
description of this aspect of the invention, D is is a monocyclic
4-8 membered nitrogen-containing heterocycle (e.g., azetidinyl, pyrrolidinyl, piperidinyl) substituted with one or more RG2, wherein RG2 at each occurrence is each independently halogen, -C(0)C C6alkyl, -C C6alkyl, -C C6haloalkyl, -0-C C6alkyl, or -0-C C6haloalkyl; and RM is each independently halogen, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ο-Ci-Cealkyl, or -O-Ci-Cehaloalkyl. In
each group of compounds according to the foregoing embodiments is azetidinyl, pyrrolidinyl, or piperidinyl substituted with one or two RG2, wherein RG2 at each occurrence is each methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or trifluoromethyl; and RM is each independently
G2 fluoro, chloro, or methyl. For example is 4,4-dimethylpiperidin-l -yl, 4,4- difluoropiperidin-1 -yl, 2,6-dimethylpiperidin-l-yl, 4-(propan-2-yl)piperidin-l -yl, 4-fluoropiperidin-l - yl, 3,5-dimethylpiperidin-l -yl, 4-(trifluoromethyl)piperidin-l-yl, 4-methylpiperidin-l -yl, 4-tert- butylpiperidin-l-yl, 2-oxopiperidin-l-yl, or 3,3-dimethylazetidin-l -yl.
The present invention also features compounds of Formulae IE, IF and IG as described herein (including each embodiment described hereunder) and pharmaceutically acceptable salts thereof, wherein:
RE is independently selected at each occurrence from -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RsRs'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), -P(0)(ORs)2, =C(RsRs'), or -C(0)N(Rs)C(0)-Rs'; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-Ci2carbocycle or 3- to 12- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, trimethylsilyl, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, -0-Rs, -S-Rs, -C(0)Rs, -C(0)ORs, or -N(RSRS').
The compounds of the present invention can be used in the form of salts. Depending on the particular compound, a salt of a compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability under certain conditions or desired solubility in water or oil. In some instances, a salt of a compound may be useful for the isolation or purification of the compound. Where a salt is intended to be administered to a patient, the salt preferably is pharmaceutically acceptable. Pharmaceutically acceptable salts include, but are not limited to, acid addition salts, base addition salts, and alkali metal salts.
Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Examples of suitable inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroionic, nitric, carbonic, sulfuric, and phosphoric acid. Examples of suitable organic acids include, but are not limited to, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic, and sulfonic classes of organic acids. Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylammosulfonate, algenic acid, b-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate.
Pharmaceutically acceptable base addition salts include, but are not limited to, metallic salts and organic salts. Non-limiting examples of suitable metallic salts include alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and other pharmaceutically acceptable metal salts. Such salts may be made, without limitation, from aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc. Non-limiting examples of suitable organic salts can be made from tertiary amines and quaternary amine, such as tromethamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine. Basic nitrogen-containing groups can be quaternized with agents such as alkyl halides (e.g., methyl, ethyl, propyl, butyl, decyl, lauryl, myristyl, and stearyl chlorides/bromides/iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
The compounds or salts of the present invention may exist in the form of solvates, such as with water (i.e., hydrates), or with organic solvents (e.g., with methanol, ethanol or acetonitrile to form, respectively, methanolate, ethanolate or acetonitrilate).
The compounds or salts of the present invention may also be used in the form of prodrugs. Some prodrugs are aliphatic or aromatic esters derived from acidic groups on the compounds of the invention. Others are aliphatic or aromatic esters of hydroxyl or amino groups on the compounds of the invention. Phosphate prodrugs of hydroxyl groups are preferred prodrugs. The compounds of the invention may comprise asymmetrically substituted carbon atoms known as chiral centers. These compounds may exist, without limitation, as single stereoisomers (e.g., single enantiomers or single diastereomer), mixtures of stereoisomers (e.g. a mixture of enantiomers or diastereomers), or racemic mixtures. Compounds identified herein as single stereoisomers are meant to describe compounds that are present in a form that is substantially free from other stereoisomers (e.g., substantially free from other enantiomers or diastereomers). By "substantially free," it means that at least 80% of the compound in a composition is the described stereoisomer; preferably, at least 90%> of the compound in a composition is the described stereoisomer; and more preferably, at least 95%>, 96%>, 97%>, 98%o or 99%o of the compound in a composition is the described stereoisomer. Where the stereochemistry of a chiral carbon is not specified in the chemical structure of a compound, the chemical structure is intended to encompass compounds containing either stereoisomer of the chiral center.
Individual stereoisomers of the compounds of this invention can be prepared using a variety of methods known in the art. These methods include, but are not limited to, stereospecific synthesis, chromatographic separation of diastereomers, chromatographic resolution of enantiomers, conversion of enantiomers in an enantiomeric mixture to diastereomers followed by chromatographically separation of the diastereomers and regeneration of the individual enantiomers, and enzymatic resolution.
Stereospecific synthesis typically involves the use of appropriate optically pure (enantiomerically pure) or substantial optically pure materials and synthetic reactions that do not cause racemization or inversion of stereochemistry at the chiral centers. Mixtures of stereoisomers of compounds, including racemic mixtures, resulting from a synthetic reaction may be separated, for example, by chromatographic techniques as appreciated by those of ordinary skill in the art. Chromatographic resolution of enantiomers can be accomplished by using chiral chromatography resins, many of which are commercially available. In a non-limiting example, racemate is placed in solution and loaded onto the column containing a chiral stationary phase. Enantiomers can then be separated by HPLC.
Resolution of enantiomers can also be accomplished by converting enantiomers in a mixture to diastereomers by reaction with chiral auxiliaries. The resulting diastereomers can be separated by column chromatography or crystallization/re-crystallization. This technique is useful when the compounds to be separated contain a carboxyl, amino or hydroxyl group that will form a salt or covalent bond with the chiral auxiliary. Non-limiting examples of suitable chiral auxiliaries include chirally pure amino acids, organic carboxylic acids or organosulfonic acids. Once the diastereomers are separated by chromatography, the individual enantiomers can be regenerated. Frequently, the chiral auxiliary can be recovered and used again. Enzymes, such as esterases, phosphatases or lipases, can be useful for the resolution of derivatives of enantiomers in an enantiomeric mixture. For example, an ester derivative of a carboxyl group in the compounds to be separated can be treated with an enzyme which selectively hydrolyzes only one of the enantiomers in the mixture. The resulting enantiomerically pure acid can then be separated from the unhydrolyzed ester.
Alternatively, salts of enantiomers in a mixture can be prepared using any suitable method known in the art, including treatment of the carboxylic acid with a suitable optically pure base such as alkaloids or phenethylamine, followed by precipitation or crystallization/re-crystallization of the enantiomerically pure salts. Methods suitable for the resolution/separation of a mixture of stereoisomers, including racemic mixtures, can be found in ENANTIOMERS, RACEMATES, AND RESOLUTIONS (Jacques et al, 1981, John Wiley and Sons, New York, NY).
A compound of this invention may possess one or more unsaturated carbon-carbon double bonds. All double bond isomers, such as the cis (Z) and trans (E) isomers, and mixtures thereof are intended to be encompassed within the scope of a recited compound unless otherwise specified. In addition, where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms.
Certain compounds of the invention may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotations about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The invention encompasses each conformational isomer of these compounds and mixtures thereof.
Certain compounds of the invention may also exist in zwitterionic form and the invention encompasses each zwitterionic form of these compounds and mixtures thereof.
The compounds of the present invention are generally described herein using standard nomenclature. For a recited compound having asymmetric center(s), it should be understood that all of the stereoisomers of the compound and mixtures thereof are encompassed in the present invention unless otherwise specified. Non-limiting examples of stereoisomers include enantiomers, diastereomers, and cis-transisomers. Where a recited compound exists in various tautomeric forms, the compound is intended to encompass all tautomeric forms. Certain compounds are described herein using general formulas that include variables (e.g., A, B, D, X, Li, L2, L3, Y, Z, T, RA or RB). Unless otherwise specified, each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently at each occurrence. If moieties are described as being "independently" selected from a group, each moiety is selected independently from the other. Each moiety therefore can be identical to or different from the other moiety or moieties.
The number of carbon atoms in a hydrocarbyl moiety can be indicated by the prefix "Cx-Cy," where x is the minimum and y is the maximum number of carbon atoms in the moiety. Thus, for example, "Ci-Cealkyl" refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C3-Cecycloalkyl means a saturated hydrocarbyl ring containing from 3 to 6 carbon ring atoms. A prefix attached to a multiple-component substituent only applies to the first component that immediately follows the prefix. To illustrate, the term "carbocyclylalkyl" contains two components: carbocyclyl and alkyl. Thus, for example, C3-C6carbocyclylCi-C6alkyl refers to a C3-C6carbocyclyl appended to the parent molecular moiety through a Ci-Cealkyl group.
Unless otherwise specified, when a linking element links two other elements in a depicted chemical structure, the leftmost-described component of the linking element is bound to the left element in the depicted structure, and the rightmost-described component of the linking element is bound to the right element in the depicted structure. To illustrate, if the chemical structure is -Ls-M-Ls'- and M is -N(RB)S(0)-, then the chemical structure is -Ls-N(RB)S(0)-Ls'-.
If a linking element in a depicted structure is a bond, then the element left to the linking element is joined directly to the element right to the linking element via a covalent bond. For example, if a chemical structure is depicted as -Ls-M-Ls'- and M is selected as bond, then the chemical structure will be -Ls-Ls'-. If two or more adjacent linking elements in a depicted structure are bonds, then the element left to these linking elements is joined directly to the element right to these linking elements via a covalent bond. For instance, if a chemical structure is depicted as -Ls-M-Ls'-M'-Ls"-, and M and Ls' are selected as bonds, then the chemical structure will be -Ls-M'-Ls"-. Likewise, if a chemical structure is depicted as -Ls-M-Ls'-M'-Ls"-, and M, Ls' and M' are bonds, then the chemical structure will be -Ls-Ls"-.
When a chemical formula is used to describe a moiety, the dash(s) indicates the portion of the moiety that has the free valence(s).
If a moiety is described as being "optionally substituted", the moiety may be either substituted or unsubstituted. If a moiety is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that moiety may be either unsubstituted, or substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the moiety, whichever is less. Thus, for example, if a moiety is described as a heterocycle optionally substituted with up to three non-hydrogen radicals, then any heterocycle with less than three substitutable positions will be optionally substituted by up to only as many non- hydrogen radicals as the heterocycle has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) will be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to two non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to two non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only one non-hydrogen radical. The term "alkenyl" means a straight or branched hydrocarbyl chain containing one or more double bonds. Each carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety, relative to groups substituted on the double bond carbons. Non-limiting examples of alkenyl groups include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl.
The term "alkenylene" refers to a divalent unsaturated hydrocarbyl chain which may be linear or branched and which has at least one carbon-carbon double bond. Non-limiting examples of alkenylene groups include -C(H)=C(H)-, -C(H)=C(H)-CH2- -C(H)=C(H)-CH2-CH2- -CH2-C(H)=C(H)-CH2- -C(H)=C(H)-CH(CH3)-, and -CH2-C(H)=C(H)-CH(CH2CH3)-.
The term "alkyl" means a straight or branched saturated hydrocarbyl chain. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, iso-amyl, and hexyl.
The term "alkylene" denotes a divalent saturated hydrocarbyl chain which may be linear or branched. Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-.
The term "alkynyl" means a straight or branched hydrocarbyl chain containing one or more triple bonds. Non-limiting examples of alkynyl include ethynyl, 1-propynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
The term "alkynylene" refers to a divalent unsaturated hydrocarbon group which may be linear or branched and which has at least one carbon-carbon triple bonds. Representative alkynylene groups include, by way of example, — C≡C— , — C≡C— CH2— , — C≡C— CH2— CH2— , -CH2-C≡C-CH2- -C≡C-CH(CH3)-, and -CH2-C≡C-CH(CH2CH3)-.
The term "carbocycle" or "carbocyclic" or "carbocyclyl" refers to a saturated (e.g., "cycloalkyl"), partially saturated (e.g., "cycloalkenyl" or "cycloalkynyl") or completely unsaturated (e.g., "aryl") ring system containing zero heteroatom ring atom. "Ring atoms" or "ring members" are the atoms bound together to form the ring or rings. A carbocyclyl may be, without limitation, a single ring, two fused rings, or bridged or spiro rings. A substituted carbocyclyl may have either cis or trans geometry. Representative examples of carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclopentadienyl, cyclohexadienyl, adamantyl, decahydro-naphthalenyl, octahydro-indenyl, cyclohexenyl, phenyl, naphthyl, indanyl, 1,2,3,4-tetrahydro-naphthyl, indenyl, isoindenyl, decalinyl, and norpinanyl. A carbocycle group can be attached to the parent molecular moiety through any substitutable carbon ring atom. Where a carbocycle group is a divalent moiety linking two other elements in a depicted chemical structure (such as A in Formula I), the carbocycle group can be attached to the two other elements through any two substitutable ring atoms. Likewise, where a carbocycle group is a trivalent moiety linking three other elements in a depicted chemical structure (such as X in Formula I), the carbocycle group can be attached to the three other elements through any three substitutable ring atoms, respectively.
The term "carbocyclylalkyl" refers to a carbocyclyl group appended to the parent molecular moiety through an alkylene group. For instance, C3-C6carbocyclylCi-C6alkyl refers to a C3-C6carbocyclyl group appended to the parent molecular moiety through Ci-C6alkylene.
The term "cycloalkenyl" refers to a non-aromatic, partially unsaturated carbocyclyl moiety having zero heteroatom ring member. Representative examples of cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, and octahydronaphthalenyl.
The term "cycloalkyl" refers to a saturated carbocyclyl group containing zero heteroatom ring member. Non-limiting examples of cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decalinyl and norpinanyl.
The prefix "halo" indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, "Ci-Cehaloalkyl" means a Ci-C6alkyl substituent wherein one or more hydrogen atoms are replaced with independently selected halogen radicals. Non-limiting examples of Ci-Cehaloalkyl include chloromethyl, 1-bromoethyl, fluorom ethyl, difluoromethyl, trifluorom ethyl, and 1,1 ,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
The term "heterocycle" or "heterocyclo" or "heterocyclyl" refers to a saturated (e.g., "heterocycloalkyl"), partially unsaturated (e.g., "heterocycloalkenyl" or "heterocycloalkynyl") or completely unsaturated (e.g., "heteroaryl") ring system where at least one of the ring atoms is a heteroatom (i.e., nitrogen, oxygen or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur. A heterocycle may be, without limitation, a single ring, two fused rings, or bridged or spiro rings. A heterocycle group can be linked to the parent molecular moiety via any substitutable carbon or nitrogen atom(s) in the group. Where a heterocycle group is a divalent moiety that links two other elements in a depicted chemical structure (such as A in Formula I), the heterocycle group can be attached to the two other elements through any two substitutable ring atoms. Likewise, where a heterocycle group is a trivalent moiety that links three other elements in a depicted chemical structure (such as X in Formula I), the heterocycle group can be attached to the three other elements through any three substitutable ring atoms, respectively.
A heterocyclyl may be, without limitation, a monocycle which contains a single ring. Non- limiting examples of monocycles include furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl (also known as "azoximyl"), 1,2,5-oxadiazolyl (also known as "furazanyl"), and 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4- oxatriazolyl and 1,2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2- dioxazolyl, and 1,3,4-dioxazolyl), oxathiolanyl, pyranyl (including 1,2-pyranyl and 1,4-pyranyl), dihydropyranyl, pyridinyl, piperidinyl, diazinyl (including pyridazinyl (also known as "1,2-diazinyl"), pyrimidinyl (also known as "1,3 -diazinyl"), and pyrazinyl (also known as "1,4-diazinyl")), piperazinyl, triazinyl (including s-triazinyl (also known as "1,3,5-triazinyl"), as-triazinyl (also known 1,2,4-triazinyl), and v-triazinyl (also known as "1,2,3-triazinyl), oxazinyl (including 1,2,3-oxazinyl, 1,3,2-oxazinyl, 1,3,6-oxazinyl (also known as "pentoxazolyl"), 1,2,6-oxazinyl, and 1,4-oxazinyl), isoxazinyl (including o-isoxazinyl and p-isoxazinyl), oxazolidinyl, isoxazolidinyl, oxathiazinyl (including 1,2, 5 -oxathiazinyl or 1,2,6-oxathiazinyl), oxadiazinyl (including 1,4,2-oxadiazinyl and 1,3,5,2-oxadiazinyl), mo holinyl, azepinyl, oxepinyl, thiepinyl, thiomorpholinyl, and diazepinyl.
A heterocyclyl may also be, without limitation, a bicycle containing two fused rings, such as, for example, naphthyridinyl (including [1,8] naphthyridinyl, and [1,6] naphthyridinyl), thiazolpyrimidinyl, thienopyrimidinyl, pyrimidopyrimidinyl, pyridopyrimidinyl, pyrazolopyrimidinyl, indolizinyl, pyrindinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, and pyrido[4,3-b]-pyridinyl), pyridopyrimidine, and pteridinyl. Other non-limiting examples of fused-ring heterocycles include benzo-fused heterocyclyls, such as indolyl, isoindolyl, indoleninyl (also known as "pseudoindolyl"), isoindazolyl (also known as "benzpyrazolyl" or indazolyl), benzazinyl (including quinolinyl (also known as "1- benzazinyl") and isoquinolinyl (also known as "2 -benzazinyl")), benzimidazolyl, phthalazinyl, quinoxalinyl, benzodiazinyl (including cinnolinyl (also known as "1,2-benzodiazinyl") and quinazolinyl (also known as "1,3 -benzodiazinyl")), benzopyranyl (including "chromenyl" and "isochromenyl"), benzothiopyranyl (also known as "thiochromenyl"), benzoxazolyl, indoxazinyl (also known as "benzisoxazolyl"), anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl (also known as "coumaronyl"), isobenzofuranyl, benzothienyl (also known as "benzothiophenyl", "thionaphthenyl", and "benzothiofuranyl"), isobenzothienyl (also known as "isobenzothiophenyl", "isothionaphthenyl", and "isobenzothiofuranyl"), benzothiazolyl, 4,5,6,7- tetrahydrobenzo[d]thiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl (including 1,3,2-benzoxazinyl, 1,4,2-benzoxazinyl, 2,3,1 -benzoxazinyl, and 3,1,4-benzoxazinyl), benzisoxazinyl (including 1,2-benzisoxazinyl and 1 ,4-benzisoxazinyl), and tetrahydroisoquinolinyl.
A heterocyclyl may also be, without limitation, a spiro ring system, such as, for example, 1 ,4- dioxa-8-azaspiro[4.5]decanyl.
A heterocyclyl may comprise one or more sulfur atoms as ring members; and in some cases, the sulfur atom(s) is oxidized to SO or SO2. The nitrogen heteroatom(s) in a heterocyclyl may or may not be quaternized, and may or may not be oxidized to N-oxide. In addition, the nitrogen heteroatom(s) may or may not be N-protected.
in a chemical formula refers to a single or double bond.
The term "pharmaceutically acceptable" is used adjectivally to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product.
The term "therapeutically effective amount" refers to the total amount of each active substance that is sufficient to show a meaningful patient benefit, e.g. a reduction in viral load.
The term "prodrug" refers to derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become, by solvolysis or under physiological conditions, the compounds of the invention which are pharmaceutically active in vivo. A prodrug of a compound may be formed in a conventional manner by reaction of a functional group of the compound (such as an amino, hydroxy or carboxy group). Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in mammals (see, Bungard, H., DESIGN OF PRODRUGS, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Examples of prodrugs include, but are not limited to, acetate, formate, benzoate or other acylated derivatives of alcohol or amine functional groups within the compounds of the invention.
The term "solvate" refers to the physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, and methanolates.
The term "N-protecting group" or "N-protected" refers to those groups capable of protecting an amino group against undesirable reactions. Commonly used N-protecting groups are described in Greene and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (3rd ed., John Wiley & Sons, NY (1999). Non-limiting examples of N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, or 4-nitrobenzoyl; sulfonyl groups such as benzenesulfonyl or p-toluenesulfonyl; sulfenyl groups such as phenylsulfenyl (phenyl-S-) or triphenylmethylsulfenyl (trityl-S-); sulfinyl groups such as p-methylphenylsulfinyl (p- methylphenyl-S(O)-) or t-butylsulfinyl (t-Bu-S(O)-); carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p- nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4- dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5- trimethoxybenzyloxycarbonyl, 1 -(p-biphenylyl)- 1 -methylethoxycarbonyl, dimethyl-3,5- dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2 -trichloro-ethoxy-carbonyl, phenoxycarbonyl, 4-nitro-phenoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, or phenylthiocarbonyl; alkyl groups such as benzyl, p-methoxybenzyl, triphenylmethyl, or benzyloxymethyl; p- methoxyphenyl; and silyl groups such as trimethylsilyl. Preferred N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
Abbreviations which have been used in the descriptions of the Schemes, Intermediates and Examples that follow are: Ac for acetyl;aq or aq. for aqueous; Boc for i-butoxycarbonyl; Bu for butyl; «-Bu or «-butyl; t-Bu or teri-butyl or tertiary-butyl; Cbz for benzyloxycarbonyl; DCI for desorption chemical ionization; DEPBT for 3 -(diethoxyphosphoryloxy )- 1 , 2, 3 -benzotriazin-4(3/fS- one; DME for 1,2-dimethoxy ethane; DMF for AyV-dimethylformamide; DMSO for dimethyl sulfoxide; dppf for l,l '-bis(diphenylphosphino)ferrocene; EDC, ED AC or EDCI for /V-(3- dimethylaminopropyl)-A '-ethylcarbodiimide hydrochloride; ESI for electrospray ionization; Et for ethyl; EtOAc for ethyl acetate; EtOH for ethanol; Et20 for diethyl ether; eq or equiv for equivalents; Fmoc for 9-fluorenylmethoxycarbonyl; HATU for 0-(7-azabenzotriazol-l-yl)-/V,/V,/V',/V'- tetramethyluronium hexafluorophosphate; HMDS for hexamethyldisilazane; HOBt for 1 - hydroxybenzotriazole; HPLC for high performance liquid chromatography; LCMS for liquid chromatography /mass spectrometry; Me for methyl; MeOH for methanol; NBS for N- bromosuccinimide; OAc for acetate; OTf for triflate or trifluoromethanesulfonate; PA-Ph for 1,3,5,7- tetramethyl-2,4,8-trioxa-6-phenyl-6-phosphaadamantane; Ph for phenyl; psi or psig for pounds per square inch (gas); PyBOP® for (benzotriazol-l-yloxy)tripyrrolidinophosphonium
hexafluorophosphate; SEM for 2-(trimethylsilyl)ethoxymethyl; T3P for propane phosphonic acid anhydride; Tf for trifluorosulfonyl; TFA for trifluoroacetic acid; THF for tetrahydrofuran; Troc for 2,2,2-trichloroethoxycarbonyl; v/v for volume/volume; wt% for weight percent; and w/v for weight/volume.
As another non-limiting example, the compounds of the present invention can be prepared as shown in Scheme I. The diamine (1-1) may be reacted with a suitably protected proline acid [i-butoxycarbonyl (Boc) is shown, although benzyloxycarbonyl (Cbz), 2,2,2-trichloroethoxycarbonyl (Troc), or 9-fluorenylmethoxycarbonyl (Fmoc) may be substituted] in the presence of a peptide coupling reagent, such as A^3-dimethylaminopropyl)-A^-ethylcarbodiimide hydrochloride/1 - hydroxybenzotriazole [EDAC/HOBT], (benzotriazol- 1 -yl-oxy)tripyrrolidinophosphonium hexafluorophosphate [PyBOP®], 0-(7-azabenzotriazol-l -yl)-A^,A^,A^',A''-tetrametriyluronium hexafluorophosphate [HATU], or 3-(diethoxyphosphoryioxy)- 1 ,2,3-benzotriazin-4(3H)-one [DEPBTj, in a solvent such as tetrahydrofuran, Λ^,Λ^-dimethylformamide, dichloromethane, or dimethyl sulfoxide, with or without the addition of an amine base such as Hunig's base, pyridine, 2,6- lutidine, 4-methylmorpholine, or triethylamine, to give (1-2). Reaction of an aldehydes of formula (I- 3) with the anion of trialkyltin such as tri-n-butyltin, followed by reaction with a chloroformate such as methyl chloroformate, in organic solvents such as tetrahydrofuran, dioxane or dichloromethane wherein RP is non-electron-withdrawing substituent such as alkyl (methyl, ethyl, etc.), benzyl (e.g., benzyl, 4-methoxybenxyl, etc.), trialkylsilyl (e.g., triisopropylsilyl); R1 is an alkyl group; RA is alkyl, alkoxy, halo, haloalkyl, or haloalkoxy, and n is 0, 1 , 2, 3, or 4 can give compounds of formula (1-4). The alkene (1-2) may be reacted with 1 to 5 equivalents or more of compounds of formula (1-4) in the presence of a suitable acid such as toluene sulfonic acid or other reagents such as boron trifluoride etherate in organic solvents such as dichloromethane or toluene to give cyclopropane compounds of formula (1-5) [Sugawara, M.; et al. J. Am. Chem. Soc. 1997, 1 19, 11986]. Removal of the i-butoxycarbonyl (Boc) protecting groups to give (1-6) may be accomplished by treatment with an acid, such as trifluoroacetic acid, HC1, or formic acid. Compounds of the present invention (1-7), wherein T and RD are as described above, may be prepared by coupling of (1-6) with an acid of choice using the standard peptide coupling reagents and conditions described above.
Scheme I Certain compounds of the invention (II-7) optionally substituted with 1, 2, 3, or 4 groups RA; where RA and Rp are as defined in Scheme I: and RD and T are as described above, can be prepared according to the general method illustrated in Scheme II.
Dibromostilbene (II- 1) can be reacted with bis(pinacolato)diboron with potassium acetate in solvents such as, but not limited to, toluene at temperatures from about 80 °C to about 120 °C to give alkene (Π-2). The alkene (Π-2) may be reacted with 1 to 5 equivalents or more of compounds of formula (1-4) in the presence of a suitable acid such as toluene sulfonic acid or other reagents such as boron trifluoride etherate in organic solvents such as dichloromethane or toluene to give cyclopropane compounds of formula (II-3). The cyclopropane compounds (Π-3) can be reacted with bromoimidazoles (Π-4), wherein Pi is a nitrogen-protecting group, using Suzuki reaction conditions to give the phenylimidazole (Π-5). A variety of reaction conditions are well known to those of skill in the art to be effective in mediating the Suzuki reaction. In particular, the reaction of (Π-3) with (II-4) to produce (Π-5) can be performed with [l,l '-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [Pd(dppf)Cl2] catalyst and potassium carbonate in a mixture of toluene and water and with heating to about 100 °C. Removal of the protecting groups to give (Π-6) may be accomplished using methodologies known to one skilled in the art and dependent upon the particular protecting group used. Compounds of the present invention (II-7), wherein T, and RD are as described above, may be prepared by coupling of (Π-6) with an appropriately functionalized amino acid derivative using the standard peptide coupling reagents and conditions described above. The intermediate of general formula (Π-4), wherein Pi is a nitrogen protecting group as described hereinabove, can be prepared using the general method in Scheme III.
Scheme III Alcohols (III-l) can be oxidized to aldehydes (ΙΠ-2) using well-known methods such as, for example, reacting the alcohols (III-l) with Dess-Martin periodinane in the presence of sodium bicarbonate in a solvent such as, but not limited to, dichloromethane. Compounds (ΙΠ-2) can be reacted with glyoxal and ammonium hydroxide in methanol/water to give (III-3). Compounds (ΙΠ-3), in turn can be brominated using Λ^-bromosuccinimide in solvents such as, but not limited to, dichloromethane at temperatures from 0 °C to room temperature to give (ΙΠ-4). Compounds (ΙΠ-4) can be mono-debrominated by reaction with sodium sulfite (Na2S03) in a mixture of dioxane and water with heating to reflux to give intermediates (Π-4). Although no particular stereochemistry is designated for intermediate (Π-4), the foregoing chemical methods can be used to prepare (Π-4) as a racemate or a single enantiomer (R or S stereochemistry). The choice of (R) or (S) stereochemistry in the starting alcohol (III-l) will lead to compounds of the invention having a single absolute stereochemistry at the corresponding carbon of the final compound.
Benzimidazole derivatives of general structural formula (VI-2) can be prepared by synthetic sequences summarized in Schemes IV- VI. As shown in Scheme IV, the requisite stilbene derivative (IV-6) can be prepared starting by treatment of bromide (IV- 1) with di-teri-butyl dicarbonate in the presence of a suitable base such as, but not limited to, aqueous sodium bicarbonate solution, to afford bis-i-butoxycarbonyl protected (IV-2). Bromide (IV-2) is reacted with an acetylene derivative such as trimethylsilylacetylene under Sonogashira conditions using a suitable palladium catalyst such as bis(triphenylphosphine)palladium (II) chloride in the presence of a copper salt, such as, but not limited to, copper (I) iodide, and a suitable amine base, such as triethylamine or diisopropyl amine. Acetylene (IV-3) so obtained is then deprotected by treatment with a suitable alcoholic base, such as potassium carbonate or potassium hydroxide, or by treatment with fluoride ion, in the form of tetrabutylammonium fluoride to afford acetylene derivative (IV-4). Boronate (IV-5) is prepared by hydroboration of (IV-4) with diisopmocampheylborane followed by reaction of the resulting trialkylborane with an aldehyde, such as acetaldehyde, and aqueous hydrolysis of the dialkyl borate to afford boronic acid (IV-5). Stilbene (IV-6) can then be obtained from the Suzuki-Miyaura coupling of boronic acid (IV-5) with bromide (IV-2), catalyzed by either a palladium (II) salt or a palladium (0) source, such as tris(dibenzylideneacetone)dipalladium (0) or the like in conjunction with a phosphine ligand, preferably with a Cytec® phenyl phosphaadamantyl ligand (PA-Ph) (Adjabeng, J., et al. Org. Lett. 2003, 5, 953; Adjabeng, J., et al. J. Org. Chem. 2004, 69, 5082) in the presence of an aqueous base, such as tribasic potassium phosphate, potassium carbonate, or the like, in a suitable solvent, such as tetrahydrofuran, dimethoxyethane, or the like.
(IV-1) (IV-2)
(IV-5) (IV-6)
Scheme IV As shown in Scheme V, stilbene (IV-6) can then be reacted with stannane (1-4) in the presence of a Lewis acid such as boron trifluoride etherate in solvents such as toluene or dichloromethane (or mixtures thereof) to afford cyclopropane (V-l). Cyclopropane derivative (V-l) can be transformed to the benzimidazole ring system by the sequence of transformations summarized in Schemes V and VI. Treatment of (V-l) with a number of acid conditions known to those skilled in the art affords the tetraamine (V-2). Tetraamine (V-2) can be coupled with two equivalents of a suitably protected proline acid (i-butoxycarbonyl (Boc) is shown, other protecting groups such as benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl would also be useful) using preferably coupling agent 0-(7-azabenzotriazol-l-yl)-A^,A^,A^',A^'-tetramethyluronium hexafluorophosphate (HATU) in the presence of an amine base such as diisopropylethylamine or Af-methylmorpholine, or other coupling agents known to those skilled in the art, to afford the two regioisomeric anilides (V-3) and (V-4). The regioisomeric anilides are not separated, but directly cyclized to (V-6) by treatment with 5-10 equivalents of glacial acetic acid in toluene or tetrahydrofuran (or mixtures thereof) at a temperature in the range of 50-85 °C.
Scheme V
Benzimidazole (V-6) can be transformed to representative compounds of this invention by the sequence of transformations shown in Scheme VI. As shown, treatment of (V-6) with a suitable acid removes the two t-butoxycarbonyl (Boc) protecting groups to afford diamine (VI-1). Diamine (VI- 1) can then be coupled with two equivalents of an appropriately functionalized amino acid derivative, by use of amino acid coupling methods known to those skilled in the art to afford final benzimidazole derivative (VI-2), wherei I and n, RD and T are as defined above.
(VI-2)
Scheme VI
Further compounds of the invention may be prepared according to the methods outlined in Scheme VII. Compounds (VII-1), where R is a group such as benzyl, 4-methoxybenzyl, 3, 4- dimethoxybenzyl, methyl, triisopropylsilyl, etc., may be converted to compounds (VII -2) using standard conditions known to remove these groups from a phenolic oxygen. For example, where R is benzyl or methyl, (VII-1) may be converted to (VII-2) by treatment with BBr3. Where R is triisopropylsilyl, (VII-1) may be converted to (VII-2) by reaction with a fluoride source. Compounds (VII-2) can be converted to compounds (VII-3) by reaction with a triflating source such as triflic anhydride. Compounds (VII-3) may be converted to further compounds of the invention using well- known organic transformations of aromatic triflates such as Suzuki, Sonogashira, or Buchwald reactions. Using a Suzuki reaction, (VII-3) may be converted to compounds (VII-4), wherein R 00 is group such as alkenyl, aryl, heteroaryl, or cycloalkenyl, by reaction with a suitable boronic acid or ester Ri0oB(OR')2, wherein R' is hydrogen, alkyl, or together with the oxygen atoms and adjacent boron atom to which they are attached form a dioxaborolane or a dioxaborinane, such as, but not limited to, 1-cyclohexen-yl-boronic acid pinacol ester or other boronic acids/esters, in the presence of a source of palladium and phosphine ligand (e.g., PdCl2[dppfj2) and base (e.g., triethylamine, sodium carbonate, potassium carbonate, potassium phosphate, sodium bicarbonate), in solvents such as, but not limited to, DME and water at temperatures from about 80 °C to about 100 °C. The compounds (VII-4) derived from Suzuki reaction with an alkeneboronic acid/ester or cycloalkenylboronic acid/ester and having an alkene in the R100 group may be further elaborated to compounds of the invention by reaction of the alkene present in R100 (e.g. reduction by catalytic hydrogenation). A variety of reaction conditions are well known to those of skill in the art to be effective in mediating the Suzuki reaction. Other substrates utilized in the Suzuki reaction such as aromatic, heteroaromatic, or heterocyclic boronates or boronic acids may provide compounds (VII-4) having heteroaryl, heterocyclic, or aryl groups at Rioo. Suitably substituted amines may combine with a triflate (VII-3) in a Buchwald-type reaction to provide compounds (VII-5), wherein R101 and R102 are each alkyl or taken together with the nitrogen atom to which they are attached form a heterocycloalkyl. Suitable conditions for effecting this transformation may be found in the following references: Wolfe and Buchwald, J. Org. Chem. 1997, 1264-1267; Louie et al, J. Org. Chem. 1997, 1268-1273; Peng, T.; Yang, D. Organic Lett. 2010, 12, 496-499; Hartwig, J. F. in Handbook of Organopalladium
Chemistry for Organic Synthesis; Negishi, E., Ed. Wiley-Interscience: New York, 2002; pp 1051- 1096; Muci, A. R.; Buchwald, S. L. Top. Curr. Chem. 2002, 219, 131-209; Jiang, L.; Buchwald, S. L. In Metal-Catalyzed Cross-Coupling Reactions; De Meijere, A., Diederich, F., Eds.; Wiley-VCH: New York, 2004; pp 699-760 and references cited therein. Additionally, substituted alkynes may couple in a Sonogashira reaction with (VII-3) to provide compounds (VII-6), wherein R103 is aryl or heteroaryl.
(VI 1-4)
Scheme VII
Further compounds of the invention may be prepared according to the methods outlined in Scheme VIII. Compound (VIII- 1) can be converted to compound (VIII-2) as described in J. Org. Chem. 2002, 5993-6000. Compound (VIII-2) can be converted to compounds (VIII-3) by a Suzuki reaction with an appropriate boronic acid or ester using conditions such as those described in J. Org. Chem. 2002, 5993-6000 or as generally known in the art. Either an aryl or heteroaryl boronic acid or ester may be used (product of reaction with a phenyl boronic acid is shown in Scheme VIII). As further described in J. Org. Chem. 2002, 5993-6000, compounds (VIII-3) can be converted to compounds (VIII -4) by reaction with PBr3. Compounds (VIII-4) may be converted to compounds (VIII-5) by reaction with 4-(teri-butoxycarbonylamino)phenylboronic acid or teri-butyl 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenylcarbamate using Suzuki reaction conditions (see for example: J. Chem. Soc. Chem. Commun. (1994) 2305-2306; Org. Lett. (1999) 1839-1842). Compounds (VIII-5) may be converted to compounds (VIII-6) by catalytic hydrogenation using Pt02 or Pd/C as described for enone reduction in Aust. J. Chem. (1997) 149-152; J. Med. Chem. (1976) 414-419 (see bottom of table III on page 417); and Org. Lett. (2009) 5450-5453 and supporting information. Compounds (VIII-6) may be converted to compounds (VIII-7) by treatment with base (e.g., NaH, LiHMDS, KHMDS) followed by reaction with (Tf)2NPh as shown in the following references: Ang. Chem. Int. Ed. Eng. (2005) 403-406 and supporting information; J. Med. Chem. (2008) 8077-8087 (see Scheme 2 step iv) and supporting information. Alternatively, compounds (VIII-5) may be converted directly to compounds (VIII-7) by reduction with L-selectride or sodium selectride followed by trapping of the in-situ formed enolate with (Tf)2NPh or Comins' reagent as described in the following references: see J. Org. Chem. (2007) 4616 and supporting information on page S33; also WO2007144174 on page 25; see also http://en.wikipedia.org/wiki/L-selectride. Compounds (VIII-7) may be converted to compounds (VIII-8) by a Suzuki reaction with an appropriate boronic acid or ester as described above or as generally known in the art. Compounds (VIII-8) may be converted to compounds (VIII-9) by Boc removal using standard conditions such as TFA/CH2CI2 or HC1 in dioxane. Compounds (VIII-9) may be converted to compounds (VIII- 10) by reaction with (.S)-l-(teri-butoxycarbonyl)pyrrolidine-2-carboxylic acid using standard amide bond forming techniques such as the use of a peptide coupling reagent (e.g., EDAC/HOBT, PyBOP®, HATU, T3P, or DEPBT), in a solvent such as THF, DMF, dichloromethane, or DMSO, with or without the addition of an amine base such as A-methylmorpholine, Hunig's base, pyridine, 2,6- lutidine, or triethylamine. Compounds (VIII- 10) may be converted to compounds (VIII- 11) using the Boc removal conditions referred to above. Compounds (VIII- 11) may be converted to compounds (VIII-12) by reaction with an appropriate carboxylic acid such, but not limited to, 2- (methoxycarbonylamino)-3-methylbutanoic acid, 2-(methoxycarbonylamino)-3,3-dimethylbutanoic acid, 2-cyclohexyl-2-(methoxycarbonylamino)acetic acid, 2-(methoxycarbonylamino)-2-(tetrahydro- 2//-pyran-4-yl)acetic acid, etc., using the standard amide bond forming conditions referred to above. Compounds (VIII-12) may be converted to compounds (VIII- 13) by catalytic hydrogenation using catalysts such as Pt02 or Pd/C under 1-4 atmospheres of hydrogen in typical organic solvents (e.g., ethyl acetate, methanol, etc).
Scheme VIII By analogy with the methods outlined in Scheme VIII, further compounds of the invention may be prepared according to the methods outlined in Scheme IX. Compounds (VIII-4) may be reacted with compound (IX- 1) under standard Suzuki conditions to give compounds (IX-2). Compounds (IX-2) may be converted to compounds (IX-3) using conditions and steps analogous to those in Scheme VIII used to convert (VIII-5) to (VIII-8). Alternatively, the benzimidazole of (IX-1) and (IX-2) may be protected as a SEM derivative. Compounds (IX-3) may be converted to compounds (IX-4) by deprotection and reaction with an appropriate acid to give compounds in analogy with the methods of Scheme VIII converting (VIII- 10) to (VIII- 12). Analogously to the conversion of (VIII- 12) to (VIII- 13), compounds (IX-4) may be converted to (IX-5) by catalytic hydrogenation.
Scheme IX
By analogy with the methods outlined in Schemes VIII and IX, further compounds of the invention may be prepared according to the methods outlined in Scheme X. Compounds (VIII-4) may be reacted with compound (X-l) under standard Suzuki conditions to give compounds (X-2). Compounds (X-2) may be converted to compounds (X-3) using conditions and steps analogous to those in Scheme VIII used to convert (VIII-5) to (VIII-8). Compounds (X-3) may be converted to compounds (X-4), having either a cyclopentene or cyclopentane core in analogy with the methods of Schemes VIII and IX.
Scheme X
The foregoing Schemes VIII, IX, and X show, by way of example, the synthesis of compounds of the invention having a five-membered carbocychc core. As is readily apparent to those skilled in the art, these methods may be modified to also prepare compounds having six- or seven- membered carbocychc cores by selection of the appropriate starting materials such as, but not limited to, 2-bromo-3-ethoxycyclohex-2-enone (see J. Org. Chem. 1990, 4025-33) or 3-ethoxycyclohept-2- enone (see Helv. Chim. Acta 2010, 17-24, Synthesis 1995, 1432-4). The foregoing Schemes VIII-X may also be modified to produce compounds of the invention bearing different groups flanking the central core by appropriate choice of a distinct boronic acid or ester for each Suzuki reaction. For example, compounds may be prepared having a benzimidazole moiety on one side and a
phenylimidazole on the other; or a benzimidazole on one side and a phenylamide on the other; or a phenylamide on one side and a phenylimidazole on the other. Compounds (XI-1), where X13 is alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxycarbonyl, etc., can be coupled with an acid (e.g., (5)-l-(te^butoxycarbonyl)pyrrolidine-2-carboxylic acid) using peptide coupling procedures described above to give an amide that can be heated in acetic acid to about 100 °C to give (XI-2). Compounds (XI-2) can be reacted with SEM-C1 and
diisopropylethylamine in dichloromethane to give (XI-3). For convenient illustration, the SEM protecting groups on the benzimidazoles are shown attached to particular nitrogens of the benzimidazole. The actual substitution positions of the SEM groups may be at either nitrogen (i.e., (XI-3) may be a mixture of regioisomers). In subsequent compounds, the positional isomerism of the SEM group results in mixtures of SEM regioisomers that may or may not be separable. In practice the SEM regioisomers can be carried through as mixtures. Compounds (XI-2) and (XI-3) may each, respectively, be converted to the corresponding pinacol boronates by reaction with
bis(pinacolato)diboron in the presence of a base such as potassium acetate, a catalyst such as PdCl2(dppf)-CH2Cl2, in a solvent such as DMSO, dimethoxyethane or dioxane with heating to between 60-100 °C.
Scheme XI
Compound (VIII-2) may react with a variety of boronic acids or esters as mentioned above. Certain boronic acids suitable for reaction with (VIII-2) may be prepared as outlined in Scheme XII, where q is 0, 1, or 2; RA is halo, alkyl, cycloalkyl, alkoxy, haloalkyl, haloalkoxy, etc.; and n is 0, 1, 2, 3, or 4. Bromoanilines may be reacted with a dihaloalkane (e.g., 1,5-dibromopentane) generally in solvents such as benzene, toluene, DMF, etc. with heating to around 50-100 °C to form azetidines, pyrrolidines, or piperidines, etc. (see J. Org. Chem. 1984, 269-276; J. Org. Chem. 1983, 4649-4658). These products may, in turn, be converted to the corresponding pinacol boronates by reaction with bis(pinacolato)diboron, a palladium catalyst such as PdCl2(dppf), a base such as KOAc with heating to around 50-100 °C in a solvent such as DMSO.
Scheme XII
An alternative to the procedures in Scheme VIII wherein compounds of formula (VIII-5) are converted to compounds of formula (VIII-12) is described in Scheme XIII. Compounds of formula (VIII-5) can be hydrogenated in the presence of a palladium on charcoal catalyst in methanol to give compounds of formula (XIII- 1). The cyclopentanol moiety can then be oxidized with a suitable oxidant such as but not limited to Dess-Martin periodinane. Subsequently, the teri-butoxycarbonyl group can be removed under acidic conditions to give compounds of formula (XIII -2). Compounds of formula (XIII-2) can then be reacted with hexane-2,5-dione in the presence of heat and acid to give a pyrrole protecting group. Then treatment with base (e.g., NaH, LiHMDS, KHMDS) followed by reaction with (Tf)2NPh supplies compounds of formula (XIII-3). Compounds of formula (XIII-3) can be converted to compounds of formula (XIII-4) under Suzuki reaction conditions described for the conversion of compounds of formula (XIII-7) to compounds of formula (XIII-8) in Scheme VIII. The protecting groups of compounds of formula (XIII-4) can be removed in a two-step sequence. In the first step, compounds of formula (XIII-4) can be treated with hydroxylamine hydrochloride in the presence of potassium hydroxide in a heated mixture of ethanol and water to remove the 2,4- dimethylpyrrole. Then treatment with acid under conditions known to one skilled in the art removes the teri-butoxycarbonyl protecting group to deliver compounds of formula (VIII-9). Compounds of formula (VIII-9) can be coupled with compounds of formula (XIII-5) under standard amide bond coupling procedures to give compounds of formula (VIII-12). Compounds of formula (VIII-12) can be further transformed as described in Scheme VIII.
Scheme XIII
In the foregoing Schemes, compounds are shown wherein an aromatic ring (e.g., phenyl) is substituted with groups in a particular regiochemistry (e.g., para). A starting material or intermediate with para-substitution provides a final product with para-substitution in the foregoing Schemes. It is understood by one of skill in the art that substitution in the foregoing Schemes of a starting material or intermediate with a different regiochemistry (e.g., meta) would provide a final product with a different regiochemistry. For example, replacement of a para-substituted starting material or intermediate in the foregoing Schemes with a meta substituted starting material or intermediate would lead to a meta- substituted product. If a moiety described herein (e.g., -NH2 or -OH) is not compatible with the synthetic methods, the moiety may be protected with a suitable protecting group that is stable to the reaction conditions used in the methods. The protecting group may be removed at a suitable point in the reaction sequence to provide a desired intermediate or target compound. Suitable protecting groups and methods for protecting or deprotecting moieties are well know in the art, examples of which can be found in Greene and Wuts, supra. Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants employed and substituents present in the reactants used. Solvents, temperatures and other reaction conditions may be readily selected by one of ordinary skill in the art based on the present invention.
Other compounds of the invention can be similarly prepared according to the above-described schemes as well as the procedures described in following examples, as appreciated by those skilled in the art. It should be understood that the above-described embodiments and schemes and the following examples are given by way of illustration, not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the present description.
Example compounds below were named using either ChemDraw version 9.0 or ACD/Name release 12.00 12 (ACD vl2). Final compounds for Examples 1-8 were named using ChemDraw unless otherwise indicated as being named using ACD vl2. Intermediates were named using ChemDraw, unless otherwise indicated as being named using ACD vl2.
Example compounds below were named using ACD Name version 12 (ACD Name vl2).
Other compounds were named using ChemDraw version 9.0 (v9), unless otherwise indicated as being named using ACD Name vl2. Both naming programs may provide a chemical name that depends on the tautomeric structure chosen for naming. Structures may be shown or named as any chemically distinct tautomer.
For example, the tautomeric structure:
(1S)-5,5'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(2-((.S)-pyrrolidin-2-yl)-li7- benzo [i/]imidazole) given the following names (.S)-5,5'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(2-((5)-pyrrolidin
benzo [J] imidazole) (Chemdraw v9);
5-(2-[4-(benzyloxy)phenyl]-3-{2-[(25)-pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopropyl)-2- pyrrolidin-2-yl]-l f-benzimidazole (ACD Name vl2).
The tautomeric s
is given the following names:
(1S)-6,6'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(2-((.S)-pyrrolidin-2-yl)-l f- benzo [J] imidazole) (Chemdraw v9);
6,6'-{3-[4-(benzyloxy)phenyl]cyclopropane-l,2-diyl}bis{2-[(25)-pyrrolidin-2-yl]-l f-benzimidazole}
(ACD Name vl2).
The tautomeric structure:
is given the following names:
(1S)-6,6'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(2-((.S)-pyrrolidin-2-yl)-l f- benzo [J] imidazole) (Chemdraw v9);
5-(2-[4-(benzyloxy)phenyl]-3-{2-[(25)-pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopropyl)-2-[(25)- pyrrolidin-2-yl]-l f-benzimidazole (ACD Name vl2).
Certain compounds in the Examples below were purified using reverse-phase HPLC.
Purification was conducted using either a CI 8 or C8 reverse-phase column. Compounds were eluted using a gradient of about 10-100% acetonitrile in 0.1% aqueous trifluoroacetic acid; about 60-100%o methanol in 10 mM aqueous ammonium acetate; or about 10-95% methanol in 10 mM aqueous ammonium acetate. For purifications conducted with trifluoroacetic acid, the product thus obtained may be in the form of a trifluoroacetic acid salt. Compounds may be characterized as the trifluoroacetic acid salt or as the free base following neutralization, extraction and isolation.
Certain compounds in the Examples below can be purified using normal phase silica gel chromatography including traditional flash chromatography or an automated purification system (e.g., Isco CombiFlash®, Analogix Intelliflash) using pre-packed silica gel columns (55 or 35 μιη silica gel, Isco gold columns). Compounds can also be purified by preparative thin-layer chromatography. Typical solvents for silica gel chromatography include: Ethyl acetate in hexanes, diethyl ether in hexanes, tetrahydrofuran in hexanes, ethyl acetate in methylene chloride, methanol in methylene chloride, methanol in methylene chloride with ammonium hydroxide, acetone in hexanes, and methylene chloride in hexanes. Representative compounds contemplated as part of the invention:
dimethyl ([2-(4-teri-butylphenyl)cyclopent- 1 -ene- 1 ,3-diyl]bis {benzene-4, 1 - diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate;
dimethyl (2S,2,S)-l,l'-((2S,2,S)-2,2,-(4,4,-(2-(4-tert-butylphenyl)cyclopent-3-ene-l,3-diyl)bis(4,l- phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate;
dimethyl ([2-(4-teri-butylphenyl)cyclopentane- 1 ,3-diyl]bis {benzene-4, 1 - diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate;
dimethyl ([2-(4-cyclopropylphenyl)cyclopent-l-ene-l,3-diyl]bis{benzene-4,l- diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate;
dimethyl (2S,2'S)- 1 , 1 ,-((2S,2'S)-2,2,-(4,4,-(2-(4-cyclopropylphenyl)cyclopent-3-ene- 1 ,3-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl-l -oxobutane-2, 1 - diyl)dicarbamate;
dimethyl ([2-(4-cyclopropylphenyl)cyclopentane-l ,3-diyl]bis {benzene-4, 1 - diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate;
dimethyl ( [2-(4-teri-butylphenyl)cyclohex- 1 -ene- 1 ,3 -diyl]bis {benzene-4, 1 - diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate; dimethyl ([2-(4-teri-butylphenyl)cyclohexane-l ,3-diyl]bis {benzene-4, 1 - diylcarbamoyl(2.S)pyrrolidine-2,l-diyl[(21S)-3-methyl-l-oxobutane-l,2-diyl]})biscarbamate;
methyl {(25)-l-[(21S)-2-{5-[2-(4-?er?-butylphenyl)-3-{2-[(21S)-l-{(21S)-2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l-en-l-yl]-l f-benzimidazol-2- yl } pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2 -yl } carbamate; dimethyl (2S,2,5)-l,l'-((2S,2, 1S)-2,2,-(6,6,-(2-(4-ier?-butylphenyl)cyclopent-3-ene-l,3-diyl)bis(l f- benzo[i/]imidazole-6,2-diyl))bis(pyrrolidine-2,l-diyl))bis(3-methyl-l-oxobutane-2,l- diyl)dicarbamate; methyl {(21S)-l-[(21S)-2-{5-[2-(4-?er?-butylphenyl)-3-{2-[(21S)-l-{(21S)-2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopentyl]-l f-benzimidazol-2- yl } pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2 -yl } carbamate; methyl {(25)-l-[(21S)-2-{6-[2-(4-cyclopropylphenyl)-3-{2-[(21S)-l-{(21S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l- en- 1 -yl] - 1 f-benzimidazol-2 -yl } pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2-yl } carbamate ; methyl [(21S)-l-(2-{6-[5-(4-cyclopropylphenyl)-4-{2-[(25)-l-{2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l-en-l-yl]-l f-benzimidazol-2- yl } pyrrolidin- 1 -yl)-3 -methyl- 1 -oxobutan-2 -yl] carbamate ; methyl {(25)-l-[(21S)-2-{6-[2-(4-cyclopropylphenyl)-3-{2-[(21S)-l-{(21S)-2-
[(methoxy carbonyl)amino] -3 -methylbutanoyl } pyrrolidin-2 -yl] - l/f-benzimidazol-6-yl } cy clopentyl] - 1 f-benzimidazol-2 -yl } pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2 -yl } carbamate;
methyl {(25)-1-[(25)-2-{6-[2-(4-ίβΓ?^ί ^6η 1)-3-{5-ΑυοΓθ-2-[(25)-1-{(25)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l- en-l-yl]-5-fluoro-l f-benzimidazol-2-yl}pyrrolidin-l-yl]-3-methyl-l-oxobutan-2-yl}carbamate; methyl [(21S)-l-(2-{6-[2-(4-?er?-butylphenyl)-3-{5-fluoro-2-[(21S)-l-{2-[(methoxycarbonyl)amino]-3- methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-3-en-l-yl]-5-fluoro-l f- benzimidazol-2-yl } pyrrolidin- 1 -yl)-3 -methyl- 1 -oxobutan-2 -yl] carbamate ; methyl {(25)-1-[(25)-2-{6-[2-(4-ίβΓ?^ί ^6η 1)-3-{5-ΑυοΓθ-2-[(25)-1-{(25)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopentyl]-5- fluoro- l f-benzimidazol-2-yl}pyrrolidin-l -yl] -3 -methyl- 1 -oxobutan-2-yl} carbamate; methyl [(21S)-l-{(21S)-2-[6-(2-[3-fluoro-4-(piperidin-l-yl)phenyl]-3-{2-[(21S)-l-{(25)-2- [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l- en- 1 -yl)- 1 f-benzimidazol-2 -yl]pyrrolidin- 1 -yl } -3 -methyl- 1 -oxobutan-2 -yl] carbamate; methyl [(21S)-l-{(21S)-2-[6-(5-[3-fluoro-4-(piperidin-l-yl)phenyl]-4-{2-[(21S)-l-{(21S)-2- [(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-benzimidazol-6-yl}cyclopent-l- en-l-yl)-l f-benzimidazol-2-yl]pyrrolidin-l-yl}-3-methyl-l -oxobutan-2 -yl]carbamate; methyl [(21S)-l-{(21S)-2-[6-(2-[3-fluoro-4-(piperidin-l-yl)phenyl]-3-{2-[(21S)-l-{(21S)-2-
[(methoxy carbonyl)amino] -3 -methylbutanoyl } pyrrolidin-2 -yl] - l f-benzimidazol-6-yl } cy clopentyl)-
1 f-benzimidazol-2 -yl]pyrrolidin- 1 -y 1 } -3 -methyl- 1 -oxobutan-2 -yl] carbamate;
methyl {(2S)-l -[(2S)-2-(5-{4-[2-(4-te^butylphenyl)-3^
[(methoxy carbonyl)amino] -3 -methylbutanoy
en- 1 -y l]phenyl } - l/f-imidazol-2 -yl)pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2 -yl } carbamate; and methyl {(25)-1 -[(25)-2-(5-{4-[5-(4-ίβΓί^ηί ^6η 1)-4-(4-{2-[(25)-1-{(25)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-l f-imidazol-5-yl}phenyl)cyclopent-l- en- 1 -y l]phenyl } - l f-imidazol-2 -yl)pyrrolidin- 1 -y 1] -3 -methyl- 1 -oxobutan-2-yl } carbamate; methyl {(25 -[(25 -2-(5-{4-[2-(4-ier^bu1ylphenyl) -(4-{2-[(2S -{(2S -2- [(methoxy carbonyl)amino] -3 -methylbutanoyl } pyrrolidin-2 -yl] - l f-imidazol-5 - yl } phenyl)cy clopentyljphenyl } - 1 f-imidazol-2 -yl)pyrrolidin- 1 -yl] -3 -methyl- 1 -oxobutan-2- yl} carbamate.
Synthesis of Intermediates
Intermediate 1
(S)-tert-buty\ 2-(4-bromo-l f-imidazol-2-yl)pyrrolidine-l-carboxylate
Intermediate 1A
(S)-tert-buty\ 2-formylpyrrolidine-l -carboxylate
To an oven-dried 500-mL 3-neck flask purged with nitrogen was added oxalyl chloride (5.32 mL, 60.8 mmol) and anhydrous dichloromethane (125 mL), and the solution was cooled to -78 °C. A solution of anhydrous DMSO (7.30 mL, 103 mmol) in anhydrous dichloromethane (25 mL) was added dropwise from a constant-pressure addition funnel over a 20-minute period. A solution of (S)- teri-butyl 2-(hydroxymethyl)pyrrolidine-l -carboxylate (9.41 g, 46.8 mmol) in anhydrous dichloromethane (50 mL) was added dropwise from a constant-pressure addition funnel over a 20- minute period, and then the reaction mixture was stirred at -78 °C for 30 minutes. Triethylamine (32.6 mL, 234 mmol) was added dropwise via syringe over a 5-minute period and the thick white mixture was stirred in an ice-water bath for 30 minutes. The reaction was quenched with 10% (w/v) aq. citric acid (30 mL). The mixture was partitioned in a separatory funnel between Et20 (550 mL) and 10% (w/v) aq citric acid. The layers were separated, and the organic phase was washed with water and brine. The organic phase was dried over anhydrous Na2S04, filtered, and concentrated to afford a yellow oil (9.4 g), which was used directly in the next reaction. Intermediate IB
(5)-teri-butyl 2-(l f-imidazol-2-yl)pyrrolidine-l-carboxylate The product from Intermediate 1A (20 g, 100 mmol) was dissolved in methanol (50.2 mL) and ammonium hydroxide (50.2 mL) was added. To this solution, glyoxal (40% in water; 24.08 mL, 211 mmol) was added, dropwise, over 10 minutes. The reaction was stirred at room temperature overnight. The reaction was concentrated under reduced pressure, diluted with 50 mL of water, and then extracted with ethyl acetate. The organic layer was washed with brine, dried (Na2S04) and concentrated to a tan solid. The solid was treated with ether and concentrated. The solid was then triturated with 2: 1 diethyl ether :hexanes (150 mL) to afford 17 g of solid, which was used directly in the next reaction. 'HNMR (400 MHz, DMSO-i¾) δ ppm 1.14/1.40 (s, 9H), 1.81 -2.12 (m, 4H), 3.32- 3.33 (m, 1H), 3.35-3.50 (m, 1H), 4.72-4.81 (m, 1H), 6.84 (s, 1 H), 1 1.68 (s, 1 H).
Intermediate 1C
(S)-tert-buty\ 2-(4,5 -dibromo- l f-imidazol-2-yl)pyrrolidine- 1 -carboxylate A -Bromosuccinimide (108 mmol) was added to a cold (0 °C) solution of the product from Intermediate IB (12.05 g, 50.8 mmol) in dichloromethane (200 mL). The mixture was stirred in ice bath for 2 hours and then concentrated, dissolved in ethyl acetate (250 mL), washed with water (3 x 150 mL) and brine (1 x 100 mL), dried (MgS04), and concentrated to very dark residue. The residue was mixed with and concentrated from dichloromethane/hexanes (1 : 1) to get brown solid (~19 g). The solid was triturated with ether (-100 mL) and filtered to isolate a tan solid (13.23 g, 65% yield). !H NMR (400 MHz, CDC13) δ ppm 1.49 (s, 9 H), 1.86 - 2.17 (m, 3 H), 2.80 - 2.95 (m, 1 H), 3.30 - 3.44 (m, 2 H), 4.85 (dd, J=7.54, 2.55 Hz, 1 H), 10.82 (s, 1 H); MS (DCI+) m/z 394/396/398 (M+H)+.
Intermediate ID
(S)-tert-buty\ 2-(4-bromo-l f-imidazol-2-yl)pyrrolidine-l -carboxylate The product from Intermediate 1C (6.25 g, 15.82 mmol) was dissolved in dioxane (200 mL) and water (200 mL) in a 1 L round bottom flask equipped with a condenser and glass stopper. A solution of sodium sulfite (22.38 g, 174 mmol) in water (200 mL) was added, and the mixture was heated at reflux for 16 hours. The reaction mixture was cooled to room temperature, and dioxane and some water were removed by rotary evaporation. The residue was extracted with dichloromethane. The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2S04, filtered, and concentrated by rotary evaporation, co-evaporating with 2:1 hexanes/dichloromethane (100 mL) to give a beige foam (4.38 g). The foam was dissolved in dichloromethane (2 mL), hexanes (2 mL) were added, and the resultant solution was applied to a column, and purified by silica gel flash chromatography eluting with 30% to 80% ethyl acetate/hexanes to afford the title compound as a white solid (3.48 g). !H NMR (400 MHz, CDC13) δ ppm 1.48 (s, 9 H), 1.83 - 2.33 (m, 3 H), 2.79 - 3.02 (m, 1 H), 3.37 (dd, J=7.10, 5.37 Hz, 2 H), 4.88 (dd, J=7.59, 2.49 Hz, 1 H), 6.92 (s, 1 H), 10.70 (br s, 1 H); MS (ESI+) m/z 316/318 (M+H)+.
Intermediate 2
(5)-2-(methoxycarbonylamino)-3-methylbutanoic acid
To (5)-2-amino-3-methylbutanoic acid (57 g, 487 mmol) dissolved in dioxane (277 mL) was added & 2 N aqueous sodium hydroxide solution (803 mL, 1606 mmol) followed by the dropwise addition of methyl chloroformate (75 mL, 973 mmol) over 1 hour which caused warming of the solution to occur. After the addition, the mixture was heated at 60 °C for 22 hours, then cooled and extracted with dichloromethane (400 mL). The resultant aqueous layer was cooled in an ice bath, and then 12 /V hydrochloric acid was added dropwise until the pH was 2. The resultant mixture was stirred at 0 °C for 2 hours, and then the resultant solid was collected by vacuum filtration, and dried in a vacuum oven to provide 80g (94%) of the title compound as a colorless solid. !H NMR (400 MHz,
DMSO-i¾) δ ppm 12.50 (bs, 1H), 7.34 (d, J = 8.6 Hz, 1H), 3.84 (dd, J = 8.6, 6.0 Hz, 1H), 3.54 (s, 3H), 2.03 (m, 1H), 0.86 (t, J = 7.0 Hz, 6H).
Intermediate 4
methyl (1S)-l-((5)-2-(5-bromo-l f-imidazol-2-yl)pyrrolidin-l-yl)-3-methyl-l-oxobutan-2-ylcarbamate Intermediate 4A
(5)-5-bromo-2-(pyrrolidin-2-yl)-l f-imidazole hydrochloride
A mixture of Intermediate ID (5.0g, 15.8 mmol) in 4 M HCl/dioxane (40 mL) was allowed to stir for one hour. The mixture was concentrated to afford 3.99 g (100%) of the title compound. MS (ESI) m/z 217 (M+H)+.
Intermediate 4B
methyl (.S)-l-((5)-2-(5-bromo-l /-imidazol-2-yl)pyrrolidin-l-yl)-3-methyl-l-oxobutan-2-ylcarbamate A mixture of Intermediate 4A (3.99g, 15.8 mmol), Intermediate 2 (2.77 g, 15.8 mmol), N-(3- dimethylaminopropyl)-A '-ethylcarbodiimide hydrochloride (3.63 g, 19.0 mmol), 1 -hydroxy - benzotriazole hydrate (2.90 g, 19.0 mmol) and N-methylmorpholine (12.2 mL, 111.0 mmol) in DMF (150 mL) were allowed to stir overnight. The mixture was diluted with H20 and extracted with EtOAc (3χ300 mL). The organic was washed with ¾0 and brine. The organic phase was then dried (MgSOt), filtered and concentrated. Purification by chromatography (silica gel, 75% EtOAc in hexanes) afforded 5.2 g (88%) of the title compound. !H NMR (400 MHz, DMSO-i¾) δ ppm 0.79 (dd, J=6.67, 3.63 Hz, 6 H), 1.84 - 1.96 (m, 3 H), 2.02 - 2.14 (m, 2 H), 3.51 (s, 3 H), 3.66 - 3.80 (m, 2 H), 3.96 - 4.03 (m, 1 H), 4.91 - 4.99 (m, 1 H), 7.06 (d, J=1.52 Hz, 1 H), 7.26 (d, J=8.46 Hz, 1 H), 12.01 (s, 1 H); MS (ESI) m/z 373 (M+H)+.
Intermediate 8
(25,45)- 1 -(?er?-butoxycarbonyl)-4-(ieri-butyldimethylsilyloxy)pyrrolidine-2-carboxylic acid (21S',41S)-l-(ieri-Butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (5.31 g, 22.96 mmol) and imidazole (7.82 g, 115 mmol) were combined in dichloromethane (106 mL) and dimethylformamide (22 mL) at ambient temperature and treated with portionwise addition of tert- butylchlorodimethylsilane (7.61 g, 50.5 mmol). The mixture was stirred for 18 hours then diluted with water and extracted into ethyl acetate and concentrated to provide the title compound.
Intermediate 9
(S)- 1 -((5)-2-(met ioxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylic acid Intermediate 2 (150 g, 856 mmol), HOBt hydrate (138 g, 899 mmol) and DMF (1500 mL) were charged to a flask. The mixture was stirred for 15 minutes to give a clear solution. EDC hydrochloride (172 g, 899 mmol) was charged and mixed for 20 minutes. The mixture was cooled to 13 °C and (Z)-proline benzyl ester hydrochloride (207 g, 856 mmol) was charged. Triethylamine (109 g, 1079 mmol) was then charged in 30 minutes. The resulting suspension was mixed at room temperature for 1.5 hours. The reaction mixture was cooled to 15 °C and 1500 mL of 6.7% NaHC(¾ was charged in 1.5 hours, followed by the addition of 1200 mL of water over 60 minutes. The mixture was stirred at room temperature for 30 minutes, an then it was filtered and washed with water/DMF mixture (1 :2, 250 mL) and then with water (1500 mL). The wetcake was dried at 55 °C for 24 hours to give 282 g of product (5)-benzyl l -((5)-2-(methoxycarbonylamino)-3- methylbutanoyl)pyrrolidine-2-carboxylate as a white solid (90%).
(5)-Benzyl l-((.S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate (40 g) and 5% Pd/alumina were charged to a Parr® reactor followed by THF (160 mL). The reactor was sealed and purged with nitrogen (6><20 psig) followed by a hydrogen purge (6x30 psig). The reactor was pressurized to 30 psig with hydrogen and agitated at room temperature for approximately 15 hours. The resulting slurry was filtered through a GF/F filter and concentrated to approximately 135 g solution. Heptane (120 mL) was added, and the solution was stirred until solids formed. After an addition 2-3 hours, additional heptane (240 mL) was added drop-wise, the slurry was stirred for approximately 1 hour, then filtered. The solids were dried to afford the title compound (5)-1-((5)-2- (methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylic acid.
Intermediate 1 1A
A^-(4-bromo-5-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide
To a flask containing trifluoroacetic anhydride (10.0 mL, 70.5 mmol) at 0 °C was added 4- bromo-3-fluoroaniline (2.0,g, 10.5 mmol) and stirring was continued for 30 minutes (Charifson, P.S.; et al. J. Med. Chem. 2008, 51 , 5243-5263). Potassium nitrate (1.3 g, 12.6 mmol) was added and the solution was allowed to warm to 25 °C. The solution was concentrated, the residue dissolved in EtOAc and washed with 10% NaHCC^, brine, dried (Na2S04), and filtered. The filtrate was concentrated to give the title compound (3.5 g, 10.5 mmol, 100%o).
Intermediate 1 IB
4-bromo-5 -fluoro-2-nitroaniline
To A^-(4-bromo-5-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide (3.5 g, 10.5 mmol) was added CH3OH (30mL) followed by 1.0 K2CO3 (10.5mL, 10.5 mmol), and the solution was stirred for 30 minutes (Charifson, P.S.; et al. J. Med. Chem. 2008, 51, 5243-5263). The solution was diluted with H20 and stirred for 1 hour. The resulting orange solid was collected by filtration and dried in a vacuum oven to give the title compound (2.1,g, 8.8 mmol, 84%). Intermediate 11C
4-bromo-5 -fluorobenzene- 1 ,2-diamine
To a solution of 4-bromo-5-fluoro-2-nitroaniline (1.0 g, 4.3 mmol) in THF (9.0 mL), EtOH (9.0 mL) and H20 (3 mL) was added iron powder (1.2 g, 21.3 mmol) and ammonium chloride (0.34 g, 6.4 mmol), and the mixture was heated at 95 °C for 4 hours. The cooled mixture was diluted with EtOH, filtered through diatomaceous earth until no further color came through the filter, and concentrated. The residue was dissolved in EtOAc, washed with H20, brine, dried (Na2S04), filtered and concentrated. Hexane was added and the resulting solid collected by filtration to give the title compound (710 mg, 3.5 mmol, 81%). Intermediate 12
4-bromo-3-chlorobenzene-l,2-diamine
Intermediate 12A
4-bromo-3-chloro-2-nitroaniline
3-Chloro-2-nitroaniline (5.00 g, 29.0 mmol) was dissolved in glacial acetic acid (258 mL). N-
Bromosuccinimide (5.06 g, 28.4 mmol) was added and the resulting mixture was refluxed for 1 hour. The reaction was cooled to room temperature and poured into water to give a precipitate that was filtered, rinsed with water and dried to constant weight to give the title compound (4.78 g, 67%o). !H NMR (400 MHz, CDCL3) δ ppm 7.46 (d, J= 9.0, 1H), 6.64 (d, J= 9.0, 1H), 4.74 (s, 2H).
Intermediate 12B
4-bromo-3-chlorobenzene-l,2-diamine
4-Bromo-3-chloro-2-nitroaniline (4.78 g, 19.01 mmol) was dissolved in ethanol (112 mL). Tin (II) chloride (14.42 g, 76 mmol) was added, and the resulting mixture was stirred at reflux for 12 hours. The mixture was cooled to room temperature, poured into water, and adjusted to pH 5 with saturated sodium bicarbonate solution. The resulting solid was filtered and rinsed well with ethyl acetate. The filtrate was washed with water and brine, dried over Na2SOt, filtered and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using a solvent gradient of 0-50% EtOAc in hexane to give the title compound (3.32 g, 79%). !H NMR (400 MHz, CDC13) δ ppm 6.94 (d, 1H), 6.51 (d, J= 7.0, 1H), 3.87 (br s, 2H), 3.46 (br s, 2H). Intermediate 13
4-bromo-3-methylbenzene-l,2-diamine
Intermediate 13A
A^-(3-bromo-2-methyl-6-nitrop ienyl)-2,2,2-trifluoroacetamide
To a solution of 3-bromo-2-methylaniline (1.0 g, 5.37 mmol) in CH2CI2 (4.0 mL) at 0 °C was added trifluoroacetic anhydride (2.0 mL, 14.2 mmol). The mixture was stirred at 0 °C for 30 minutes, and solid potassium nitrate (0.679 g, 6.72 mmol) was added. The cooling bath was removed, and the mixture was stirred at room temperature overnight. LCMS showed a single product formed. The mixture was concentrated in vacuo, and the residue was partitioned between water and CH2CI2 (2χ). The organic layers were combined and dried over Na2S04. The drying agent was filtered off and the crude product was purified by crystallization from aq EtOH to give the title compound (1.3 g, 74%).
Intermediate 13B
3 -bromo-2-methyl-6-nitroaniline
A solution of A^-(3-bromo-2-methyl-6-nitrophenyl)-2,2,2-trifluoroacetamide (1.3 g, 3.97 mmol) in CH3OH (30 mL) was treated with potassium carbonate (1.099 g, 7.95 mmol), and the mixture was stirred at 50 °C overnight. The mixture was cooled to room temperature and poured into water, 1 TV HC1 was added to adjust to pH 6, and the mixture was extracted with CH2C12 (3x). The combined extracts were dried over Na2S04, and the drying agent was filtered off and solvent was removed in vacuo to give the title compound as a yellow solid (0.57 g, 62%).
Intermediate 13C
4-bromo-3-methylbenzene-l,2-diamine
To a solution of 3-bromo-2-methyl-6-nitroaniline (0.45 g, 1.95 mmol) in EtOH (6 mL) was added tin(II) chloride (1.48 g, 7.8 mmol), and the resulting solution was stirred at 70 °C for 4 hours. The mixture was cooled to room temperature and poured into water, and 1 N aq. NaOH was added to adjust to pH>7. The resulting mixture was extracted with CH2CI2 (2χ), and the combined extracts were dried over Na2S04. The drying agent was filtered off and solvent was removed in vacuo to give the title compound as an oil (0.34 g, 88%o).
Intermediate 14
5 -bromo-3 -fluorobenzene- 1 ,2 -diamine
To a solution of 4-bromo-2-fluoro-6-nitroaniline (0.5 g, 2.1 mmol) in THF (4.6 mL), EtOH (4.6 mL) and H20 (1.5 mL) was added iron powder (0.6 g, 10.6 mmol) and ammonium chloride (0.17 g, 3.2 mmol). The resulting mixture was stirred at 95 °C for 22 hours. The mixture was cooled to room temperature and filtered through diatomaceous earth. The solid was washed with EtOH until no further color came through the filter. The filtrate was concentrated and the residue was dissolved in EtOAc, washed with H20 and brine, dried over Na2S04, filtered and concentrated to give the title compound (0.43 g, 99%) as a brown, waxy solid.
Intermediate 15
4-bromo-3 -fluorobenzene- 1 ,2-diamine
Intermediate 15A
3-fluoro-2-nitroaniline
To a pressure tube was added 1, 3 -difluoro-2 -nitrobenzene (2.8 mL, 26.4 mmol) and 7 TV NH3 in CH3OH (10 mL, 70 mmol). The tube was sealed and the mixture was stirred at room temperature for 5 days. The solution was diluted with H20, extracted with CH2CI2, and the combined extracts were washed with brine, dried over Na2S04, filtered and concentrated to give an oil. The oil was triturated with hexane and the resulting orange solid was collected by filtration to give the title compound (2.1 g, 51%).
Intermediate 15B
4-bromo-3 -fluoro-2-nitroaniline
To a solution of 3-fluoro-2-nitroaniline (2.1 g, 13.4 mmol) in DMF (30 mL) at 0 °C was added a solution of Λ^-bromosuccinimide (2.4 g, 13.4 mmol) in DMF (20 mL). The resulting solution was stirred at 0 °C for 30 minutes and then warmed to room temperature over 1 hour. The solution was diluted with EtOAc, washed with H20 and brine, dried over MgS04, filtered and concentrated to give the title compound (3.1 g, 97%).
Intermediate 15C
4-bromo-3 -fluorobenzene- 1 ,2-diamine
To a solution of 4-bromo-3-fluoro-2-nitroaniline (3.0 g, 12.8 mmol) in THF (30 mL) was added EtOH (30 mL) and H20 (10 mL) followed by iron powder (3.6 g, 63.8 mmol) and ammonium chloride (1.0 g, 19.2 mmol). The resulting mixture was stirred at 80 °C for 16 hours. The mixture was cooled to room temperature and filtered through diatomaceous earth. The solid was washed with EtOH until no further color came through the filter. The filtrate was concentrated in vacuo and the crude product was purified by column chromatography on silica gel using a solvent gradient of 0-40%o EtOAc in hexane to give the title compound (2.2 g, 84%).
General Procedure 20
(79) (80) (81)
As described above generally in Scheme XI, diamines (XI- 1) can be converted to benzimidazoles (XI-3) in two steps. Illustration of General Procedure 20. General Procedure 20A
(S)-tert-buty\ 2-(6-bromo-5-fluoro-l f-benzo[i/]imidazol-2-yl)pyrrolidine-l-carboxylate To a solution of 4-bromo-5-fluorobenzene-l,2-diamine (1.7 g, 8.4 mmol) in DMSO (42 mL) was added (.S)-l-(ieri-butoxycarbonyl)pyrrolidine-2-carboxylic acid (1.8 g, 8.4 mmol) followed by HATU (3.5 g, 9.3 mmol) and NNf Uisopropyl-N-ethylamine (3.7 mL, 21.1 mmol), and the solution was stirred for 16 hours. The reaction mixture was diluted with EtOAc, washed with H20 and brine, dried (Na2S04), filtered and concentrated. Acetic acid (40 mL) was added, and the mixture was stirred at 60 °C for 4 hours. Then, the reaction mixture was cooled and concentrated. The residue was azeotroped 2 times with toluene to give crude product which was purified by flash
chromatography (0-50% EtOAc/hexane) to give the title compound (2.5g, 6.4 mmol, 77%).
(S)-tert-buty\ 2-(5-bromo-6-fluoro-l -((2-(trimethylsilyl)ethoxy)methyl)-l f-benzo[ii|imidazol-2- yl)pyrrolidine- 1 -carboxylate
To a solution of (S)-tert-buty\ 2-(6-bromo-5-fluoro-l /-benzo[i/]imidazol-2-yl)pyrrolidine-l- carboxylate (2.5 g, 6.4 mol) in THF (32 mL) was added sodium hydride (0.27 g, 6.8 mmol) and stirring was continued for 30 minutes. 2-(Trimethylsilyl)-ethoxymethyl chloride (1.2 mL, 6.8 mmol) was added and stirring was continued for 30 minutes. Water was added to quench the reaction. The mixture was diluted with EtOAc, washed with IN HC1, H20, and brine, dried (Na2S04), filtered and concentrated to an oil. The oil was purified by flash chromatography (0-30% EtOAc/hexane) to give the title compound (2.9 g, 5.7 mmol, 89%).
The following compounds of general formula (XI-3) can be made following General Procedure 20 starting from the appropriate diamine:
(S)-tert-buty\ 2-(5-bromo-l -((2-(trimethylsilyl)ethoxy)methyl)-l /-benzo[i/]imidazol-2-yl)pyrrolidine- 1 -carboxylate;
(S)-tert-buty\ 2-(5-bromo-4-methyl-l -((2-(trimethylsilyl)ethoxy)methyl)-l /-benzo[i/]imidazol-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-4-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-l /-benzo[i/]imidazol-2- yl)pyrrolidine-l -carboxylate; (S)-tert-butyl 2-(5 -bromo-4-fluoro- 1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 f-benzo [i/]imidazol-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(6-bromo-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-ft]pyridin-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-7-methyl-l -((2-(trimethylsilyl)ethoxy)methyl)-l f-benzo[J]imidazol-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-6-methyl-l -((2-(trimethylsilyl)ethoxy)methyl)-l f-benzo[J]imidazol-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-6-(trifluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-l f- benzo[i/]imidazol-2-yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-7-(trifluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-l f- benzo[i/]imidazol-2-yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-6-methoxy-l-((2-(trimethylsilyl)ethoxy)methyl)-l f-benzo[J]imidazol-2- yl)pyrrolidine-l -carboxylate;
(S)-tert-buty\ 2-(5-bromo-7-methoxy-l-((2-(trimethylsilyl)ethoxy)methyl)-l f-benzo[J]imidazol-2- yl)pyrrolidine-l -carboxylate; and
(5)-methyl 5-bromo-2-(l -(?er^butoxycarbonyl)pyrrolidin-2-yl)-l-((2-(trimethylsilyl)ethoxy)methyl^ l f-benzo[i/]imidazole-7-carboxylate.
Example 1
dimethyl (25,2'5)-1 , 1 ,-((2S,2'1S)-2,2,-(4,4,-(3-(4-methoxyphenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
Example 1A (2*,2'S)-ieri-bu1yl 2,2'-(4,4'-((^)-ethene-l ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate
To a solution of 4,4'-diaminostilbene dihydrochloride (0.5 g, 2.38 mmol) in dimethyl sulfoxide (10 mL) was added (5)-l-(te^butoxycarbonyl)pyrrolidine-2-carboxylic acid (1.024 g, 4.76 mmol), 0-(7-azabenzotriazol-l-yl)-A^,A^^V'^V'-tetramethyluronium hexafluorophosphate (HATU) (1.808 g, 4.76 mmol) and Hunig's base (1.66 mL, 9.51 mmol), and the mixture was stirred at room temperature for 3 hours. Then 1 TV aqueous hydrochloric acid (20 mL) was added to the reaction mixture followed by extraction with dichloromethane (2x20 mL). The organic extract was dried, filtered and concentrated. The residue was purified by chromatography (silica gel, methanol in dichloromethane) which afforded 1.09 g, (76%) of the title compound. MS (ESI) m/z 604 (M+H)+.
Example IB
(4-methoxyphenyl)(tributylstannyl)methyl methyl carbonate
To dry tetrahydrofuran (80 mL) cooled to -78 °C was added a solution of lithium diisopropylamide (2.0 M in heptane/tetrahydrofuran/ethylbenzene, 18.36 mL, 37.5 mmol) followed by tri-«-butyltin hydride (9.81 mL, 37.5 mmol) dropwise. After 5 minutes, the mixture was placed in an ice water bath for 0.5 hours, then recooled to -78 °C. 4-Methoxybenzaldehyde (4.45 mL, 37.5 mmol) was added dropwise, and the reaction mixture was stirred at this temperature for 1.5 hours. Afterwards, methyl chloroformate (3.41 mL, 44.1 mmol) was added dropwise, the cooling bath was removed, and the mixture was allowed to stir overnight at room temperature. Then a solution of saturated aqueous ammonium chloride (100 mL) was added followed by extraction with ethyl acetate. The organic extract was dried, filtered and concentrated. The residue was purified by chromatography (silica gel, ethyl acetate in hexanes) which afforded 6.7 g, (38%) of the title compound.
Example 1C
(2S, S)-tert-bn\y\ 2,2'-(4,4'-(3-(4-methoxyphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate The product of Example 1A (100 mg, 0.165 mmol) and the product from Example IB (241 mg, 0.496 mmol) were partially dissolved in dichloromethane (5 mL), and then the mixture was cooled to -25 °C. Boron trifhioride etherate (0.063 mL, 0.496 mmol) was added, and the resultant mixture stirred for 1 hour. The solution was then warmed to room temperature, 0.5 iV aqueous hydrochloric acid (10 mL) was added followed by extraction with dichlorom ethane (2x 10 mL). The organic extract was dried, filtered and concentrated. The residue was purified by chromatography (silica gel, methanol in dichloromethane) which afforded 0.1 15 g, (96%) of the title compound. MS (ESI) m/z 725 (M+H)+.
Example ID
(2S,2'1S)-A^,A''-(4,4'-(3-(4-methoxyphenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 -phenylene))dipyrrolidine-2- carboxamide
The product of Example 1C (115 mg, 0.159 mmol) was dissolved in dioxane (1.5 mL) and hydrochloric acid in dioxane (4.0 N, 0.6 mL, 2.38 mmol), and the mixture was stirred at room temperature for 4 hours. Afterwards, the mixture was concentrated to afford the title compound as a hydrochloride salt. MS (ESI) m/z 548 (M+H)+.
Example IE
dimethyl (2S,TS)-\ , 1 ,-((2S,2'1S)-2,2,-(4,4,-(3-(4-methoxyphenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
The product from Example ID (83 mg, 0.158 mmol), (,S)-2-(methoxycarbonylamino)-3- methylbutanoic acid (55 mg, 0.316 mmol), A^-(3-dimethylaminopropyl)-A^'-ethylcarbodiimide hydrochloride (67 mg, 0.348 mmol), 1 -hydroxybenzotriazole hydrate (53 mg, 0.348 mmol) and 4- methylmorpholine (1.38 mL, 1.27 mmol) were dissolved in Λ^,Λ^-dimethylformamide (3 mL), and the mixture stirred at room temperature for 3 hours. Afterwards, 1 N aqueous hydrochloric acid (10 mL) was added followed by extraction with dichloromethane (2x 10 mL). The combined organic extracts were dried, filtered and concentrated. The residue was purified by chromatography (silica gel, methanol in dichloromethane) which afforded 60 mg, (45%) of the title compound. !H NMR (400 MHz, DMSO-i¾) δ ppm 9.96 (s, IH), 9.87 (s, IH), 7.96 (d, J=8.1 Hz, IH), 7.70 (d, J=8.5 Hz, IH), 7.55 (m, 2H), 7.32 (m, 4H), 6.98 (m, 4H), 6.72 (d, J=8.6 Hz, 2H), 4.43 (m, IH), 4.39 (m, IH), 4.02 (m, 2H), 3.65 (s, 3H), 3.62 (m, 2H), 3.53 (s, 3H), 3.52 (s, 3H), 2.87 (m, IH), 2.70 (m, 2H), 2.15 (m, 2H), 1.90 (m, 8H), 0.90 (m, 12H); MS (ESI) m/z 839 (M+H)+.
Example 2
dimethyl (2S, S)-\ , 1 ,-((2S,2'1S)-2,2,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
Example 2 A
(4-(benzyloxy)phenyl)(tributylstannyl)methyl methyl carbonate A solution of lithium diisopropylamide (2.0 in heptane/tetrahydrofuran/ethylbenzene, 10.5 mL, 21 mmol), tri-«-butyltin hydride (5.55 mL, 21 mmol), 4-benzyloxybenzaldehyde (4.24 g, 20 mmol), and methyl chloroformate (1.86 mL, 24 mmol) were processed using the method described in Example IB to afford 4.6 g (41%) of the title compound.
Example 2B
(2S, S)-tert-bn\y\ 2,2'-(4,4'-(3-(4-(benzyloxy)prienyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate The product from Example 2A (0.34 g, 0.6 mmol), the product from Example 1A (0.12 g, 0.2 mmol), and boron trifluoride etherate (0.076 mL, 0.6 mmol) were processed using the method described in Example 1C to afford 108 mg (67%) of the title compound.
Example 2C
(2S,2'.S)-AyV-(4,4'-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 -phenylene))dipyrrolidine-
2-carboxamide
The product from Example 2B (100 mg, 0.125 mmol) was processed using the method described in Example ID to afford 75 mg (100%) of the title compound.
Example 2D dimethyl (25,2'5)-1 , 1 ,-((2S,2'1S)-2,2,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
The product from Example 2C (75 mg, 0.125 mmol), and (5)-2-(methoxycarbonylamino)-3- methylbutanoic acid (46 mg, 0.263 mmol), were processed using the method described in Example IE to afford 70 mg (59%) of the title compound. 1H NMR (400 MHz, DMSO-i¾) d ppm 0.88 (t, J=6.07 Hz, 6 H) 0.93 (t, J=7.26 Hz, 6 H) 1.77 - 2.20 (m, 10 H) 2.70 (d, J=5.86 Hz, 2 H) 2.90 (t, J=5.75 Hz, 1 H) 3.52 (s, 3 H) 3.53 (s, 3 H) 3.57 - 3.67 (m, 2 H) 3.75 - 3.85 (m, 2 H) 4.03 (q, J=8.35 Hz, 2 H) 4.39 (dd, J=7.92, 4.88 Hz, 1 H) 4.44 (dd, J=8.13, 4.77 Hz, 1 H) 4.99 (s, 2 H) 6.80 (d, J=8.57 Hz, 2 H) 6.98 (dd, J=8.78, 2.28 Hz, 4 H) 7.26 - 7.42 (m, 11 H) 7.53 (d, J=8.57 Hz, 2 H) 9.87 (s, 1 H) 9.96 (s, 1 H); MS (ESI) m/z 915 (M+H)+.
Example 3
dimethyl (2S,2'1S)-l,l,-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-methoxyphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(l H-imidazole-4,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3-methyl-l -oxobutane-2, 1 - diyl)dicarbamate
Example 3A
(ii)-l,2-bis(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)ethane A solution of (£)-l,2-bis(4-bromophenyl)ethene (10 g, 29.6 mmol), 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(l,3,2-dioxaborolane) (16.53 g, 65.1 mmol), potassium acetate (8.71 g, 89 mmol) and [l,l '-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (2.42 g, 2.96 mmol) in dioxane (550 mL) was heated at 100 °C for 18 hours. The mixture was then filtered through diatomaceous earth, the filtrate was concentrated, and the residue was dissolved in ethyl acetate and extracted with brine. The organic extract was concentrated to a small volume, passed through a short pad of silica gel, and then concentrated which afforded 9.6 g, (75%) of the title compound. MS (ESI) m/z 433 (M+H)+.
Example 3B
2,2'-(4,4'-(3-(4-methoxyphenyl)cyclopropane-l ,2-diyl)bis(4,l -phenylene))bis(4,4,5,5-tetramethyl-
1 ,3,2-dioxaborolane)
The product from Example 3A (1.0 g, 2.31 mmol), the product from Example IB (1.18 g, 2.43 mmol), and boron trifluoride etherate (0.308 mL, 2.43 mmol) were processed using the method described in Example 1C to afford 100 mg (8%) of the title compound.
Example 3C
(S)-tert-buty\ 2-formylpyrrolidine-l -carboxylate
Oxalyl chloride (5.32 mL, 60.8 mmol) and anhydrous dichloromethane (125 mL) were combined under nitrogen, and the solution was cooled to -78 °C. A solution of anhydrous dimethyl sulfoxide (7.30 mL, 103 mmol) in anhydrous dichloromethane (25 mL) was added dropwise over 20 minutes. A solution of (S)-tert-buty\ 2-(hydroxymethyl)pyrrolidine-l -carboxylate (9.41 g, 46.8 mmol) in anhydrous dichloromethane (50 mL) was added dropwise over 20 minutes, and then the reaction mixture was stirred at -78 °C for 30 minutes. Triethylamine (32.6 mL, 234 mmol) was then added dropwise over a 5 minutes, and the reaction mixture was stirred in an ice-water bath for 30 minutes. The reaction was quenched with 10% (w/v) aqueous citric acid (30 mL), and the resultant mixture was partitioned between diethyl ether (550 mL) and 10%o (w/v) aqueous citric acid. The organic phase was subsequently washed with water and brine. The organic phase was dried over anhydrous Na2S04, filtered, and concentrated to afford the title compound (9.4 g), which was used directly in the next reaction.
Example 3D
(5)-teri-butyl 2-(l f-imidazol-2-yl)pyrrolidine-l -carboxylate The product from Example 3C (20 g, 100 mmol) was dissolved in methanol (50.2 mL) and ammonium hydroxide (50.2 mL) was added. To this solution glyoxal (40% in water; 24.08 mL, 21 1 mmol) was added, dropwise, over 10 minutes. The reaction was stirred at room temperature overnight. The reaction was concentrated under reduced pressure, diluted with 50 mL of water, and then extracted with ethyl acetate. The organic layer was washed with brine, dried (Na2SC>4), and concentrated. The residue was treated with ether and concentrated. The solid was then triturated with 2:1 diethyl ethenhexanes (150 mL) to afford 17 g of solid which was used directly in the next reaction.
Example 3E
(S)-tert-buty\ 2-(4,5 -dibromo- 1 H-imidazol-2-yl)pyrrolidine- 1 -carboxylate A -Bromosuccinimide (108 mmol) was added to a cold (0 °C) solution of the product from Example 3D (12.05 g, 50.8 mmol) in dichloromethane (200 mL). The reaction mixture was stirred in an ice bath for 2 hours and then concentrated. The residue was dissolved in ethyl acetate (250 mL), and the resultant solution was extracted with water (3>< 150 mL) and brine (l x l 00 mL). The organic phase was dried (MgS04) and concentrated. The residue was treated with dichloromethane/hexanes (1 : 1) to get brown solid (~19 g). The solid was triturated with diethyl ether (-100 mL), and the title compound was collected by filtration (13.23 g, 65% yield).
Example 3F
(S)-tert-buty\ 2-(5-bromo-lH-imidazol-2-yl)pyrrolidine-l-carboxylate or (S)-tert-buty\ 2-(4-bromo-
1 H-imidazol-2 -yl)pyrrolidine- 1 -carboxylate
The product from Example 3E (6.25 g, 15.82 mmol) was dissolved in dioxane (200 mL) and water (200 mL). A solution of sodium sulfite (22.38 g, 174 mmol) in water (200 mL) was added, and the reaction mixture was heated at reflux for 16 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and extracted with dichloromethane. The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2S04, filtered, and concentrated under reduced pressure, co-evaporating with 2: 1 hexanes/dichloromethane (100 mL) to give the crude title compound (4.38 g). The crude product was dissolved in dichloromethane (2 mL) and hexanes (2 mL) were added. The solution was purified by silica gel flash chromatography eluting with 30% to 80%o ethyl acetate/hexanes to afford the title compound (3.48 g, 70%o yield).
Example 3G
(2S,2'5)-ie^butyl 2,2,-(4,4,-(4,4,-(3-(4-metrioxyprienyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis( 1 H-imidazole-4,2-diyl))dipyrrolidine- 1 -carboxylate
The product from Example 3B (100 mg, 0.181 mmol), the product from Example 3F (172 mg, 0.543 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14.8 mg, 0.018 mmol), and a solution of sodium carbonate (1.0 in water, 0.543 mL, 0.543 mmol) was heated in a solution of ethanol (1.5 mL) and toluene (1.5 mL) at 85 °C for 18 hours. Water (10 mL) was added followed by extraction with ethyl acetate (2x 10 mL). The combined organic washes were dried, filtered and concentrated. The residue was purified by chromatography (silica gel, methanol in dichloromethane) which afforded 70 mg, (50%) of the title compound. MS (ESI) m/z 111 (M+H)+.
Example 3H
(1S)-4,4'-(4,4'-(3-(4-methoxyphenyl)cyclopropane-l,2-diyl)bis(4,l-phenylene))bis(2-((.S)-pyrrolidin-2- yl)-l H-imidazole)
The product from Example 3G (70 mg, 0.091 mmol) was processed using the method described in Example ID to afford 52 mg (100%) of the title compound.
Example 31
dimethyl (2S,2'1S)-l,l,-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-methoxyphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(l H-imidazole-4,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3-methyl-l -oxobutane-2, 1 - diyl)dicarbamate
The product from Example 3H (50 mg, 0.088 mmol), and (,S)-2-(methoxycarbonylamino)-3- methylbutanoic acid (30 mg, 0.171 mmol) were processed using the method described in Example IE to afford 31 mg (40%) of the title compound. !H NMR (400 MHz, DMSO-i¾) δ ppm 14.5 (bs, 2H), 7.98 (bs, 1H), 7.90 (bs, 1H), 7.78 (m, 2H), 7.64 (m, 4H), 7.29 (t, J=7.8 Hz, 2H), 7.18 (m, 2H), 7.05 (m, 2H), 6.72 (m, 2H), 5.09 (m, 2H), 4.07 (m, 2H), 3.83 (m, 4H), 3.54 (s, 3H), 3.53 (s, 6H), 3.18 (m, 1H), 2.92 (m, 2H), 2.35 (m, 2H), 2.01 (m, 8H), 0.88 (m, 12H); MS (ESI) m/z 885 (M+H)+.
Example 4
dimethyl (2S,2'1S)-l,l,-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2- diyl)bis(4, 1 -phenylene))bis( 1 H-imidazole-4,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3-methyl-l- oxobutane-2, 1 -diyl)dicarbamate
Example 4 A
2,2'-(4,4'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(4,l-phenylene))bis(4,4,5,5-tetramethyl-
1 ,3,2-dioxaborolane)
The product from Example 3A (0.25 g, 0.578 mmol), the product from Example 2A (1.62 g, 2.89 mmol), and boron trifluoride etherate (0.367 mL, 2.89 mmol) were processed using the method described in Example 1C to afford 150 mg (41%) of the title compound. MS (ESI) m/z 629 (M+H)+.
Example 4B (2S,2'S)-tert-buiy\ 2,2,-(4,4,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis( l f-imidazole-4,2-diyl))dipyrrolidine- 1 -carboxylate The product from Example 4A (150 mg, 0.239 mmol), the product from Example 3F (303 mg, 0.955 mmol), and [l ,l '-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (24.4 mg, 0.03 mmol) were processed using the method described in Example 3G to afford 130 mg (64%) of the title compound. MS (ESI) m/z 847 (M+H)+.
Example 4C
(S)-4,4'-(4,4'-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 -phenylene))bis(2-((5)- pyrrolidin-2 -yl)- 1 H-imidazole)
The product from Example 4B (125 mg, 0.148 mmol) was processed using the method described in Example ID to afford 95 mg (100%) of the title compound.
Example 4D
dimethyl (2S,2'1S)-l ,l ,-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2- diyl)bis(4,l -phenylene))bis(l f-imidazole-4,2-diyl))bis(pyrrolidine-2,l-diyl))bi
oxobutane-2, 1 -diyl)dicarbamate
The product from Example 4C (95 mg, 0.148 mmol) and (,S)-2-(methoxycarbonylamino)-3- methylbutanoic acid (52 mg, 0.296 mmol) were processed using the method described in Example IE to afford 57 mg (40%) of the title compound. !H NMR (400 MHz, DMSO-i¾) δ ppm 14.6 (bs, 2H), 7.99 (bs, 1H), 7.93 (bs, 1H), 7.79 (d, J=7.9 Hz, 2H), 7.59 (d, J=7.9 Hz, 2H), 7.56 (m, 2H), 7.31 (m, 7H), 7.20 (m, 2H), 7.04 (m, 2H), 6.81 (m, 2H), 5.14 (m, 2H), 4.99 (s, 2H), 4.10 (m, 2H), 3.83 (m, 4H), 3.54 (s, 3H), 3.53 (s, 6H), 3.20 (m, 1H), 2.95 (m, 2H), 2.35 (m, 2H), 2.05 (m, 8H), 0.91 (m, 12H); MS (ESI) m/z 961 (M+H)+.
Example 5
dimethyl (25,2'S)- 1 , 1 ,-((25,2'5)-2,2'-(5 ,5 '-(3 -(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis( IH- benzo [d]imidazole-5 ,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate
Example 5A
teri-butyl 4-bromo-l,2-phenylenedicarbamate
A suspension of 4-bromo-l ,2-diaminobenzene (5.61 g, 30 mmol) and saturated sodium bicarbonate solution (100 mL) in tetrahydrofuran (150 mL) was treated with di-teri-butyl dicarbonate (17.5 g, 80 mmol) followed by stirring under nitrogen for 3 days. The mixture was diluted with ethyl acetate and extracted with water (2x) and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded the crude product as a brown oil. This material was dissolved in ethyl acetate and treated with Darco G-60. The mixture was filtered through diatomaceous earth and the red filtrate was treated again with Darco G-60 and filtered through diatomaceous earth. The filtrate was concentrated in vacuo to afford a peach-colored solid, which was triturated with hexanes and collected by filtration. After drying in a vacuum oven at 50 °C for 18 hours, these procedures afforded the title compound (10.23 g, 88%) as a very light peach-colored solid. !H NMR (400 MHz, CDC13) δ ppm 7.76 (s, 1 H), 7.32 (s, 1 H), 7.24 (m, 1 H), 6.73 (s, 1 H), 6.54 (s, 1 H), 1.52 (s, 9 H),1.51 (s, 9 H); MS (ESI-) m/z (relative abundance) 385 (100, M-H), 387 (92).
Example 5B
teri-butyl 4-((trimethylsilyl)ethynyl)- 1 ,2-phenylenedicarbamate In a microwave tube, a solution of the compound of Example 5 A (2.0 g, 5.16 mmol) in triethylamine (17 mL) was degassed by nitrogen sparge for 20 minutes. The solution was then treated with bis(triphenylphosphine)palladium (II) chloride (181 mg, 0.26 mmol) and copper (I) iodide (98 mg, 0.52 mmol) followed by sparging with nitrogen for another 10 minutes. The mixture was treated with trimethylsilylacetylene (1.09 mL, 761 mg, 7.75 mmol). The microwave tube was sealed and the mixture was warmed at 70 °C for 18 hours. The mixture was cooled and diluted with ethyl acetate and extracted with water and saturated sodium chloride solution. The solution was dried (Na2S04) and stirred with 3-(mercaptopropyl) silica gel for 1 hour. Filtration and concentration in vacuo afforded an oil, which was chromatographed over a 120 g silica gel cartridge, eluting with 0-20% ethyl acetate in hexanes. These procedures afforded the title compound (1.65 g, 79%) as a white solid. !H NMR (400 MHz, CDC13) δ ppm 7.56 (m, 2 H), 7.27 (s, 1 H), 6.77 (s, 1 H), 6.56 (s, 1 H), 1.52 (s, 18 H), 0.23 (m, 9 H); MS (ESI+) m/z (relative abundance) 405 (8, M+H)+, 421 (36, M+NH4)+, 826 (100, 2M+NH4)+.
Example 5C
teri-butyl 4-ethynyl-l,2-phenylenedicarbamate
A solution of the compound of Example 5B (1.68 g, 4.16 mmol) in 2:1 methanol- tetrahydrofuran was treated with potassium carbonate (402 mg, 2.91 mmol) followed by stirring at room temperature for 3 hours. The solution was diluted with ethyl acetate and extracted with water and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded an oil which was chromatographed over a 120 g silica gel cartridge eluting with 5-40% ethyl acetate in hexanes. These procedures afforded the title compound (1.21 g, 88%) as a white solid. !H NMR (400 MHz, CDC13) δ ppm 7.58 (s, 2 H), 7.26 (m, 1 H), 6.80 (s, 1 H), 6.56 (s, 1 H), 3.02 (s, 1 H), 1.51 (s, 18 H). MS +ESI m/z (relative abundance) 333 (16, M+H)+, 350 (100, M+NH4)+, 682 (38, 2M+NH4)+.
Example 5D
(E)-3 ,4-bis(tert-butoxycarbonylamino)styrylboronic acid A solution of borane methyl sulfide complex (384 μΐ,, 307 mg, 4.04 mmol) in dry tetrahydrofuran (0.67 mL) at 0 °C was treated with (1 ?)-(+)-a-pinene (1.28 mL, 1.10 g. 8.09 mmol) followed by warming to room temperature for 3 hours. The milky white solution was cooled to -40 °C and treated dropwise over 10 minutes with a solution of the compound of Example 5C (1.12 g, 3.37 mmol) in dry tetrahydrofuran (7 mL; 2 mL was used to rinse addition funnel) followed by warming to room temperature for 2 hours. The mixture was cooled to 0 °C and treated with acetaldehyde (2.66 mL, 2.08 g, 47.2 mmoL) followed by warming to room temperature and then warming at reflux for 18 hours. The mixture was cooled to room temperature and concentrated in vacuo to afford an oil. This material was treated with water (5.0 mL, 280 mmol) and tetrahydrofuran (2 mL) followed by stirring at ambient temperature for 3 hours. The mixture was diluted with ethyl acetate and extracted with water and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded an oil, which smell ed like a-pinene. This material was triturated with hexanes and collected by filtration. After drying in a vacuum oven at 50 °C for 2 hours, these procedures afforded the title compound (699 mg, 55%) as a buff-colored powder. !H NMR (400 MHz, DMSO-4) δ ppm 8.52 (m, 3 H), 7.75 (s, 2 H), 7.47 (m, 2 H), 7.18 (m, 3 H), 6.00 (d, J = 18.4 Hz, 1 H), 1.47 (s, 18 H); MS (ESI-) m/z (relative abundance) 377 (100, M-H)\
Example 5E (E)-tert-butyl 4,4'-(ethene- 1 ,2-diyl)bis(benzene-4,2, 1 -triyl)tetracarbamate
In a microwave tube, a suspension of the compound of Example 5D (866 mg, 2.29 mmol), the compound of Example 5A (739 mg, 1.91 mmol), tribasic potassium phosphate (810 mg, 3.82 mmol), and Cytec® PA-Ph (G. Adjabeng, et al. Org. Lett. 2003, 5, 953; G. Adjabeng, et al. J. Org. Chem. 2004, 69, 5082) (56 mg, 0.19 mmol) in 4:1 tetrahydrofuran- water (9.5 mL) was degassed by nitrogen sparge for 30 minutes. The mixture was treated with tris(dibenzylideneacetone) dipalladium (0) (35 mg, 0.038 mmol) followed by degassing for another 5 minutes. The microwave tube was sealed and the mixture warmed at 80 °C for 18 hours. The mixture was cooled and diluted with ethyl acetate and extracted with water, 1 TV tribasic potassium phosphate solution, and saturated sodium chloride solution. The solution was dried (Na2S04) and stirred with 3-(mercaptopropyl) silica gel for 1 hour. After filtration and concentration in vacuo, the residue was chromatographed over a 120 g silica gel cartridge, eluting with 10-70% ethyl acetate in hexanes. These procedures afforded an oil, which was crystallized from dichloromethane-hexanes to afford the title compound (794 mg, 65%) as a white solid after drying in a vacuum oven at 50 °C for 18 hours. !H NMR (400 MHz, CDC13) δ ppm 7.62 (s, 2 H), 7.47 (s, 2 H), 7.25 (dd, J= 10.2, 1.4 Hz, 2 H), 6.96 (s, 1 H), 6.71 (s, 4 H), 1.53 (s, 18 H), 1.52 (s, 18 H); MS (ESI-) m/z (relative abundance) 639 (100, M-H)\
Example 5F
teri-butyl 4,4'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(benzene-4,2,l-triyl)tetracarbamate A solution of the compound of Example 5E (794 mg, 1.24 mmol) and the compound of Example 2A (3.48 g, 6.20 mmol) in 3:1 (dry) dichloromethane-toluene (20 mL) at -25 °C was treated with boron trifluoride etherate (785 L, 879 mg, 6.20 mmol) followed by stirring at -25 °C for 1 hour. The mixture was quenched by addition of 5 mL saturated sodium bicarbonate solution followed by warming to ambient temperature. The mixture was diluted with ethyl acetate and extracted with saturated sodium bicarbonate solution. Drying (Na2S04) and concentration in vacuo afforded an amber oil, which was chromatographed over a 320 g silica gel cartridge, eluting with 10-60%o ethyl acetate in hexanes. These procedures afforded the title compound (520 mg, 50%) as an off-white rigid foam. !H NMR (400 MHz, CDC13) δ ppm 7.33 (m, 15 H), 6.98 (m, 4 H), 6.76 (m, 4 H), 6.63 (m, 4 H), 4.98 (s, 2 H), 2.72 (d, J = 7.5 Hz, 1 H), 2.68 (t, J = 9.8 Hz, 2 H), 1.50 (m, 9 H), 1.49 (s, 9 H), 1.48 (s, 18 H); MS (ESI+) m/z (relative abundance) 854 (100, M+NH4)+.
Example 5G
4,4'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)dibenzene-l,2 -diamine The compound of Example 5F (520 mg, 0.62 mmol) was dissolved in a solution of hydrogen chloride in dioxane (4 N, 15 mL) followed by stirring at room temperature for 2 hours. The mixture was diluted with ether and the solids collected by filtration, followed by washing with ether. After air drying, the solid was dried in a vacuum oven at 50 °C for 18 hours. These procedures afforded the title compound (283 mg, 78%) as a light brown solid. !H NMR (400 MHz, DMSO-4) δ ppm 7.39 (m, 1 1 H), 6.98 (m, 8 H), 6.81 (m, 9 H), 6.51 (m, 2 H), 5.00 (s, 2 H), 2.76 (m, 1 H), 2.61 (m, 2 H); MS (ESI+) m/z (relative abundance) 437 (100, M+H)+, 873 (50, 2M+H)+.
Example 5H
(2S, S)-tert-hm \ 2,2'-(5,5'-(3-(4-(benzyloxy)phenyl)cyclopropane-l ,2-diyl)bis(2-amino-5,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine- 1 -carboxylate
And (2S)-tert-buty\ 2-(2-amino-4-(2-(4-amino-3-((5)-l-(?er?-butoxycarbonyl)pyrrolidine-2- carboxamido)phenyl)-3-(4-(benzyloxy)phenyl)cyclopropyl)phenylcarbamoyl)pyrrolidine-l- carboxylate
A solution of the compound of Example 5G (209 mg, 0.36 mmol), 1 -(teri-butoxycarbonyl)-L- proline (158 mg, 0.74 mmol), and 0-(7-azabenzotriazol-l-yl)-A^^V,A^',A^'-tetramethyluronium hexafluorophosphate (HATU, 280 mg, 0.74 mmol) in dry dimethyl sulfoxide (1.8 mL) was treated with diisopropylethylamine (627 L, 464 mg, 3.59 mmol) followed by stirring at room temperature for 2 hours. The mixture was diluted with ethyl acetate and extracted with water (3X) and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded a brown solid, which was used directly in the next step.
Example 51
(2S,2'1S)-tert-butyl 2,2'-(5,5'-(3-(4-(benzyloxy)phenyl)cyclopropane-l,2-diyl)bis(l f- benzo[i/]imidazole-5,2-diyl))dipyrrolidine- 1 -carboxylate
A suspension of the compound of Example 5H in toluene (2 mL) and tetrahydrofuran (0.5 mL) was treated with glacial acetic acid (150 μί) followed by warming at 70 °C for 1 hour. The mixture was cooled and concentrated in vacuo (3X) with toluene to remove acetic acid. The solid obtained was chromatographed over an 80 g silica gel cartridge, eluting with 3-12% methanol in dichloromethane. These procedures afforded an oil, which solidified upon trituration with ether- hexanes. The solids were collected by filtration and washed with hexanes. After drying in a vacuum oven at 50 °C for 24 hours, these procedures afforded the title compound (59 mg, 21%> from Example 5G) as a buff-colored solid. !H NMR (400 MHz, CDC13) δ ppm 7.33 (m, 5 H), 6.92 (m, 2 H), 6.72 (d, J = 8.5, 1 H), 5.09 (m, 1 H), 4.94 (s, 1 H), 3.40 (s, 2 H), 3.04 (s, 1 H), 2.92 (d, J = 8.4, 1 H), 2.78 (m, 0.5 H), 2.17 (s, 2 H), 2.00 (s, 1 H), 1.62 (s, 4 H), 1.51 (s, 9 H), 1.50 (s, 9 H), 1.30 (m, 2 H); MS (ESI+) m/z (relative abundance) 795 (100, M+H)+, 796 (44), 1589 (52, 2M+H)+.
Example 5J
(S)-5,5'-(3-(4-(benzyloxy)phenyl)cyclopropane-^
benzo [JJimidazole)
The compound of Example 51 (59 mg, 0.074 mmol) was dissolved in a solution of hydrogen chloride in dioxane (4 N, 6 mL) with methanol (4 mL) followed by stirring at room temperature for 1 hour. The mixture was concentrated in vacuo followed by drying under high vacuum. The product was used directly in the next step.
Example 5K
dimethyl (2S,2'S)- 1 , 1 ,-((25,2'5)-2,2'-(5 ,5 '-(3 -(4-(benzyloxy)phenyl)cyclopropane- 1 ,2-diyl)bis( IH- benzo [d]imidazole-5 ,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate A solution of the compound of Example 5J (55 mg, 0.074 mmol), 7V-(methoxycarbonyl)-L- valine (33 mg, 0.19 mmol), A^-(3-dimethylaminopropyl)-A^'-ethylcarbodiimide hydrochloride (36 mg, 0.19 mmol), and 1 -hydro xybenzotriazole (28 mg, 0.19 mmol) in dry AyV-dimethylformamide (400 |jL) at 0 °C was treated with A -methylmorpholine (163 L, 150 mg, 1.49 mmol). The solution was stirred at 0 °C for 30 minutes and was allowed to warm to room temperature for 2 hours. The solution was then diluted with ethyl acetate and extracted with water (3 X) and saturated sodium chloride solution. Drying (Na2S04) and concentration in vacuo afforded an oil, which was chromatographed over a 10 g silica gel cartridge, eluting with 1 -12% methanol in dichloromethane. These procedures afforded the title compound (35 mg, 52%) as an off-white solid, after being concentrated with chloroform-hexanes. !H NMR (400 MHz, CDC13) δ ppm 10.44 (s, 1 H), 10.26 (s, 1 H), 7.68 (s, 1 H), 7.53 (m, 1 H), 7.30 (m, 10 H), 6.93 (m, 4 H), 6.70 (d, J = 6.7, 2 H), 5.41 (m, 5 H), 4.93 (s, 2 H), 4.33 (m, 2 H), 3.85 (m, 2 H), 3.70 (s, 6 H), 3.63 (s, 4 H), 3.08 (s, 2 H), 2.83 (m, 3 H), 2.37 (s, 2 H), 2.18 (m, 4 H), 1.94 (m, 3 H), 1.24 (m, 2 H), 1.05 (m, 2 H), 0.86 (m, 12 H); MS (ESI+) m/z (relative abundance) 909 (100, M+H)+.
Example 6
dimethyl (2S,2'S)-l ,l'-((2S,2,S)-2,2,-(4,4,-(3-(4-cyclohexylphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
Example 6 A
(2S,2'S)-N,N'-(4,4'-(3-(4-hydroxyphenyl)cyclopropane- 1 ,2-diyl)bis(4, 1 -phenylene))dipyrrolidine-2- carboxamide
To the product from Example 2B (850 mg, 1.06 mmol) was added a solution of boron tribromide (1.0 M in dichloromethane, 2.34 mL, 2.34 mmol) in dichloromethane (25 mL) at room temperature for 0.25 hours. Then methanol (25 mL) was added to the solution and the mixture concentrated to afford 540 mg (76%) of the title compound as a bis-hydrobromide salt. MS (ESI) m/z 51 1 (M+H)+.
Example 6B
(2S,2'S)-tert-butyl 2,2'-(4,4'-(3-(4-riydroxyprienyl)cyclopropane- 1 ,2-diyl)bis(4, 1 - phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate To the bis-hydrobromide salt of the product from Example 6A (600 mg, 0.893 mmol) was added di-teri-butyl dicarbonate (487 mg, 2.23 mmol) and triethylamine (2.49 mL, 17.86 mmol) in dioxane (25 mL) and methanol (3 mL) and the mixture stirred at room temperature for 1 hour. The mixture was then concentrated. A solution of 1 N HC1 (10 mL) was added to the residue followed by extraction with dichloromethane (2x 10 mL). The organic extract was dried, filtered and concentrated. Then the residue was purified by chromatography (silica gel, methanol in dichloromethane) which afforded 425 mg, (67%) of the title compound. MS (ESI) m/z 111 (M+H)+. Alternatively, the benzyl group in the product of Example 2B can be removed to provide Example 6B (without removal of the teri-butoxycarbonyl groups) by employing Raney® nickel and hydrogen under a high pressure environment.
Example 6C
(2S,2'S)-tert-butyl 2,2'-(4,4'-(3-(4-(trifluoromethylsulfonyloxy)phenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate To the product from Example 6B (50 mg, 0.07 mmol) dissolved in dichloromethane (3 mL) was added triethylamine (0.098 mL, 0.702 mmol). Then a solution of trifluoromethanesulfonic anhydride (0.059 mL, 0.352 mmol) in dichloromethane (2 mL) was added dropwise at room temperature. After 1 hour, a solution of 1 N HC1 (5 mL) was added followed by extraction with dichloromethane (10 mL). The organic extract was dried, filtered and concentrated which afforded 60 mg, (100%) of the title compound. MS (ESI) m/z 843 (M+H)+.
Example 6D
(2S,2'S)-tert-butyl 2,2'-(4,4'-(3-(4-cyclohexenylphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate
To the product from Example 6C (60 mg, 0.070 mmol), 1-cyclohexen-yl-boronic acid pinacol ester (16.3 mg, 0.078 mmol), sodium bicarbonate (29.9 mg, 0.356 mmol) and [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(II) (13 mg, 0.018 mmol) in dimethoxyethane (3 mL) and water (1 mL) was heated at 80 °C for 17 hours. Water (5 mL) was then added to the mixture followed by extraction with ethyl acetate (2x5 mL). The organic extract was dried, filtered and concentrated. Then the residue was purified by chromatography (silica gel, ethyl acetate in hexanes) which afforded 20 mg, (36%) of the title compound. MS (ESI) m/z 776 (M+H)+.
Example 6E
(2S,2'S)-tert-butyl 2,2'-(4,4'-(3-(4-cyclohexylphenyl)cyclopropane-l ,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)dipyrrolidine-l-carboxylate To the product from Example 6D (20 mg, 0.026 mmol) in methanol (3 mL) was added 10% palladium on carbon (1 1 mg, 0.103 mmol), and the mixture was placed under an atmosphere of hydrogen (balloon). After hydrogenation at room temperature for 24 hours, the mixture was filtered through diatomaceous earth, and the filter cake was washed with methanol. The filtrate was concentrated to afford 20 mg (100%) of the title compound. MS (ESI) m/z 778 (M+H)+.
Example 6F (2S,2'S)-N,N'-(4,4'-(3-(4-cyclohexylphenyl)cyclopropane-l,2-diyl)bis(4,l-phenylene))dipyrr^
2-carboxamide
The product from Example 6F (20 mg, 0.026 mmol) was processed using the method described in Example ID to afford 15 mg (100%) of the title compound.
Example 6G
dimethyl (2S,2'S)-l,l,-((2S,2,S)-2,2,-(4,4,-(3-(4-cyclohexylphenyl)cyclopropane-l,2-diyl)bis(4,l- phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2, 1 -diyl))bis(3-methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
The product from Example 6F (15 mg, 0.026 mmol), and (,S)-2-(methoxycarbonylamino)-3- methylbutanoic acid (9 mg, 0.052 mmol), were processed using the method described in Example IE to afford 9 mg (40%) of the title compound. !H NMR (400 MHz, DMSO-i/6) δ ppm 9.96 (s, 1H), 9.87 (s, 1H), 7.53 (d, J=8.6 Hz, 2H), 7.33 (m, 5H), 6.98 (m, 5H), 4.43 (m, 1H), 4.39 (m, 1H), 4.02 (m, 2H), 3.80 (m, 4H), 3.61 (m, 2H), 3.54 (m, 6H), 2.90 (m, 1H), 2.74 (m, 1H), 2.68 (m, 1H), 2.12 (m, 2H), 1.80 (m, 14H), 1.26 (m, 5H), 0.88 (m, 12H); MS (ESI) m/z 891 (M+H)+.
Example 7
dimethyl (2S,2, 1S)-l,l'-((2S,2, 1S)-2,2,-(4,4,-(2-(4-?eri-butylphenyl)cyclopent-3-ene-l,3-diyl)bis(4,l- phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
Example 7 A
3 -methoxycyclopent-2-enone
A mixture of 1,3-cyclopentanedione (15.0 g, 153 mmol) and I2 (1.164 g, 4.59 mmol) in methanol (150 mL) was stirred at 25 °C for 16 hours. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (200 mL) and washed with aqueous Na2S203 solution (100 mL), water (100 mL) and brine (100 mL) successively. The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue was used in the next step without further purification. LC/MS (ESI) m/z 113 (M+H)+.
Example 7B
2-bromo-3-methoxycyclopent-2-enone
A mixture of Example 7A (500 mg, 4.46 mmol) and Λ^-bromosuccinimide (794 mg, 4.46 mmol) in dichloromethane (5 mL) was stirred at 25 °C for 16 hours. The mixture was concentrated in vacuo. The residue was purified on a silica column (dichloromethane/methanol = 200:1, v/v) to afford the title compound (650 mg, 3.40 mmol, 76% yield) as a solid. !H NMR (400 MHz, CDC13) δ ppm 4.12 (s, 3H), 2.79-2.82 (m, 2H), 2.62-2.65 (m, 2H); LC/MS (ESI) m/z 191 (M+H)+.
Example 7C
2-(4-teri-butylphenyl)-3-methoxycyclopent-2-enone
A mixture of Example 7B (440 mg, 2.303 mmol), 4-teri-butylphenylboronic acid (492 mg, 2.76 mmol), [l,l '-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (188 mg, 0.230 mmol) and K2CO3 (637 mg, 4.61 mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was stirred at 100 °C for 16 hours. The mixture was diluted with ethyl acetate (100 mL) and washed with brine (30 mL> 4). The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by column chromatography (on silica gel, eluted with petroleum ether/ethyl acetate = 5:1, v/v) to afford the title compound (445 mg, 1.821 mmol, 79% yield) as a white solid. LC/MS (ESI) m/z 245 (M+H)+.
Example 7D
3-bromo-2-(4-teri-butylphenyl)cyclopent-2-enone
To a solution of Example 7C (245 mg, 1.003 mmol) in 1,2-dichloroethane (5 mL) was added PBr3 (0.142 mL, 1.504 mmol). The resulting mixture was heated to reflux for 1 hour, then cooled to ambient temperature, and poured over cracked ice. The organic layer was separated, washed with saturated aqueous NaHC03 (5 mL), and dried over MgSOμ The solvent was removed under reduced pressure, and the residue was purified by column chromatography (on silica gel, eluted with dichloromethane/methanol=200:l, v/v) to afford the title compound (200 mg, 0.682 mmol, 68.0% yield) as a light yellow solid. !H NMR (400 MHz, CDC13) δ ppm 7.38 (s, 4H), 3.00-3.03 (m, 2H), 2.62-2.65 (m, 2H), 1.26 (s, 9H); LC/MS (ESI) m/z 293 (M+H)+.
Example 7E
teri-butyl 4-(2-(4-tert-butylphenyl)-3-oxocyclopent-l-enyl)phenylcarbamate A mixture of Example 7D (88 mg, 0.300 mmol), teri-butyl 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenylcarbamate (105 mg, 0.330 mmol), [1,1 '- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (24.51 mg, 0.030 mmol) and K2C03 (83 mg, 0.600 mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was stirred at 100 °C for 16 hours. The mixture was diluted with ethyl acetate (30 mL) and washed with brine (10 mL> 4). The organic layers were dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (eluted with petroleum ether/ethyl acetate = 2:1, v/v) to afford the title compound (60 mg, 0.148 mmol, 493% yield) as a white solid. !H NMR (400 MHz, CDC13) δ ppm 7.28-7.36 (m, 6H), 7.14 (d, J = 8.0 Hz, 2H), 6.52 (s, 1H), 3.00-3.03 (m, 2H), 2.66-2.69 (m, 2H), 1.51 (s, 9H), 1.32 (s, 9H); LC/MS (ESI) m/z 406 (M+H)+.
Example 7F
teri-butyl 4-(2-(4-?eri-butylphenyl)-3-riydroxycyclopentyl)prienylcarbamate A mixture of Example 7E (20 mg, 0.049 mmol) and 10% palladium on carbon (5.25 mg, 0.049 mmol) in methanol (4 mL) was stirred at 25 °C under a hydrogen atmosphere (balloon) for 16 hours. The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was directly used in the next step without further purification. !H NMR (400 MHz, CDC13) δ ppm 6.67-7.25 (m, 8H), 6.26 (s, 1H), 4.53 (brs, 1H), 3.52 (brs, 1H), 3.29 (br, 1H), 1.82-2.24 (m, 4H), 1.45 (s, 9H), 1.20 (s, 9H); LC/MS (ESI) m/z 408 (M-H)\
Example 7G
teri-butyl 4-(2-(4-tert-butylphenyl)-3-oxocyclopentyl)phenylcarbamate A mixture of crude Example 7F (263 mg, 0.641 mmol) and Dess-Martin periodinane (299 mg, 0.705 mmol) in dichloromethane (4 mL) was stirred at 25 °C for 30 minutes. The mixture was diluted with ethyl acetate (30 mL) and washed with saturated NaHCC^ solution (10 mL> 4) and then saturated Na2S204 solution (10 mL> 4). The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (eluted with dichloromethane/methanol = 200:1, v/v) to afford the title compound (60 mg, 0.147 mmol, 22.97% yield) as a light yellow oil. !H NMR (400 MHz, CDC13) δ ppm 7.18-7.20 (m, 4H), 7.05 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 6.33 (s, 1H), 3.32-3.42 (m, 2H), 2.57-2.63 (m, 1H), 2.33-2.41 (m, 2H), 1.95-1.98 (m, 1H), 1.44 (s, 9H), 1.18 (s, 9H); LC/MS (ESI) m/z 406 (M-H)\
Example 7H
3-(4-aminophenyl)-2-(4-teri-butylphenyl)cyclopentanone A mixture of Example 7G (1.3 g, 3.19 mmol) in dichloromethane (12 mL) and trifluoroacetic acid (4 mL) was stirred at ambient temperature for 1 hour. The mixture was diluted with ethyl acetate (100 mL) and washed with saturated NaHCC solution (30 mL> 3) and brine (30 mL). The organic layer was dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (petroleum ether/ethyl acetate=2:l, v/v) to afford the title compound (586 mg, 1.906 mmol, 59.8% yield) as a solid. LC/MS (ESI) m/z 308 (M+H)+.
Example 71
2-(4-?er?-butylphenyl)-3-(4-(2,5-dimethyl-l f-pyrrol-l-yl)phenyl)cyclopentanone
A mixture of Example 7H (300 mg, 0.976 mmol), hexane-2,5-dione (134 mg, 1.171 mmol) and >-toluenesulfonic acid (1.856 mg, 9.76 μιηοΐ) in toluene (2 mL) was stirred at 110 °C for 1 hour. The mixture was concentrated in vacuo. The residue was directly used in the next step without further purification. LC/MS (ESI) m/z 386 (M+H)+.
Example 7J
5-(4-?er?-butylphenyl)-4-(4-(2,5-dimethyl-l f-pyrrol- 1 -yl)phenyl)cyclopent- 1 -enyl
trifluoromethanesulfonate To a solution of crude Example 71 (376 mg, 0.976 mmol) in tetrahydrofuran (10 mL) was added lithium bis(trimethylsilyl)amide (1.171 mL, 1.171 mmol, tetrahydrofuran) dropwise at -78 °C. After stirring at ambient temperature for 30 minutes, l,l,l-trifluoro-/V-phenyl-/V- [(trifluoromethyl)sulfonyl]methanesulfonamide (418 mg, 1.171 mmol) was added to the reaction mixture at -78 °C in one portion. The mixture was then allowed to warm to room temperature and stirred overnight. The reaction was quenched with saturated NH4C1 solution. The organic layer was separated and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (eluted with petroleum ether/ethyl acetate=20:l, v/v) to afford the title compound (300 mg, 0.580 mmol, 59.4% yield) as an oil. LC/MS (ESI) m/z 518 (M+H)+.
Example 7K
teri-butyl 4-(5-(4-?er?-butylphenyl)-4-(4-(2,5-dimethyl-l f-pyrrol-l-yl)phenyl)cyclopent-l- enyl)phenylcarbamate
A mixture of Example 7J (373 mg, 0.721 mmol), teri-butyl 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenylcarbamate (253 mg, 0.793 mmol), K2CO3 (299 mg, 2.162 mmol) and [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (58.8 mg, 0.072 mmol) in 1,4-dioxane (4 mL) and water (1 mL) was heated at 100 °C for 16 hours. The mixture was concentrated in vacuo, the residue was purified by column chromatography (on silica gel, eluted with dichloromethane/petroleum ether = 2:1, v/v) to afford the title compound (386 mg, 0.688 mmol, 95% yield) as a solid. LC/MS (ESI) m/z 561 (M+H)+.
Example 7L
teri-butyl 4-(4-(4-aminophenyl)-5 -(4-teri-butylphenyl)cyclopent- 1 -enyl)phenylcarbamate A mixture of Example 7K (475 mg, 0.847 mmol), hydroxylamine hydrochloride (353 mg, 5.08 mmol) and KOH (143 mg, 2.54 mmol) in ethanol (6 mL) and water (2 mL) was stirred at 65 °C for 48 hours. The mixture was concentrated in vacuo. The residue was diluted with ethyl acetate (20 mL) and washed with brine (6 mL> 2). The organic layer was dried over Na2S04, filtered and concentrated. The residue was used directly in the next step without further purification. LC/MS (ESI) m/z 483 (M+H)+.
Example 7M
4,4'-(2-(4-?er?-butylphenyl)cyclopent-3-ene-l,3-diyl)dianiline A mixture of crude Example 7L (372 mg, 0.771 mmol) in dichloromethane (3 mL) and trifluoroacetic acid (1 mL) was stirred at room temperature for 16 hours. The mixture was neutralized with aqueous NaHCC^ solution and extracted with dichloromethane (10 mL> 2). The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by column chromatography (on silica gel, eluted with dichloromethane/methanol = 50:1, v/v) to afford the title compound (240 mg, 0.627 mmol, 81% yield) as a brown solid. !H NMR (400 MHz, methanol-^) δ ppm 7.12 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 6.57 (d, J= 8.4 Hz, 2 H), 6.43 (d, J = 8.4 Hz, 2H), 6.12 (s, 1H), 4.49 (s, 1H), 3.02-3.05 (m, 1H), 2.87-2.93 (m, 1H), 2.41-2.45 (m, 1H), 1.16 (s, 9H); LC/MS (ESI) m/z 383 (M+H)+.
Example 7N
dimethyl (2S,2, 1S)-l,l'-((2S,2, 1S)-2,2,-(4,4,-(2-(4-?eri-butylphenyl)cyclopent-3-ene-l,3-diyl)bis(4,l- phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
A mixture of Intermediate 9 (103 mg, 0.376 mmol), Example 7M (80 mg, 0.188 mmol), (benzotriazol-l-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP®, 215 mg, 0.414 mmol) and diisopropylethylamine (0.197 mL, 1.129 mmol) in N,N-dimethylformamide (2 mL) was stirred at ambient temperature for 16 hours. The mixture was then purified by preparative HPLC (Instrument Gilson 281( PHG008); Column Waters Xbridge™ OBD™ C18 19*250 mm, 10 μιη; Mobile Phase A water(10 ppm NH4HCO3) B acetonitrile Gradient 32-80% B in 8 minutes, stop at 15 minutes; Flow Rate (mL/minute) 30.00; Detective Wavelength (nm) 214\254 Retention Time(minutes) 7.6; Number of Injections 2.00; Purity of crude sample (%>) 17.82) to afford the title compound (30 mg, 0.034 mmol, 8.94% yield) as a white solid. !H NMR (400 MHz, methanol-i/4) δ ppm 7.02-7.47 (m, 12H), 6.43 (s, 1H), 4.49-4.57 (m, 2H), 4.20-4.27 (m, 3H), 3.93-3.98 (m, 2H), 3.65- 3.75 (m, 8H), 3.06-3.15 (m, 1H), 2.63-2.67 (m, 2H), 2.03-2.31 (m, 10H), 1.27 (s, 9H), 0.95-1.06 (m, 12H); LC/MS (ESI) m/z 891 (M+H)+.
Example 8
dimethyl (2S,2, 1S)-l,l'-((2S,2, 1S)-2,2,-(4,4,-(2-(4-?eri-butylphenyl)cyclopentane-l,3-diyl)bis(4,l- phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane-2, 1 - diyl)dicarbamate
A mixture of Example 7N (50 mg, 0.056 mmol) and 10% palladium on carbon (5.97 mg,
0.056 mmol) in methanol (1 mL) was stirred under hydrogen (balloon) for 16 hours at 30 °C. The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC: Instrument Waters 2767 PHW003; Column Boston C18 10 μιη 21 *250mm; Mobile Phase A: water(0.05% NH4HC03); B: acetonitrile Gradient 55-85% B in 8 minutes, stop at 14 minutes; Flow Rate(mL/minute) 30.00; Detective Wavelength(nm) 214\254; Retention Time(minutes) 8.18; Number of Injections 2.00; Purity of Crude Sample (%>) 70, to afford the title compound (31 mg,
0.035 mmol, 61.9% yield) as a white solid. !H NMR (400 MHz, methanol-i/4) δ ppm 6.70-7.37 (m, 12H), 4.51-4.53 (m, 2H), 4.20-4.23 (m, 2H), 3.95-3.98 (m, 2H), 3.49-3.73 (m, 10H), 3.15-3.18 (m, 1H), 2.01-2.55 (m, 14H), 1.18-1.22 (m, 9H), 0.96-1.05 (m, 12H); LC/MS (ESI) m/z 893 (M+H)+.
The title compounds of Examples 2, 3, 4, and 6 showed an EC50 value of less than about 0.1 nM in HCV lb-Conl replicon assays in the presence of 5% FBS. The title compounds of Examples
1, 5 and 8 showed an EC50 value of from about 0.1 to about 1 nM in HCV lb-Conl replicon assays in the presence of 5% FBS. The title compound of Examples 7 showed an EC50 value of from about 1 to about 5 nM in HCV lb-Conl replicon assays in the presence of 5% FBS.
The present invention also contemplates pharmaceutically acceptable salts of each compound in Examples 1-8, as well as pharmaceutically acceptable salts of each compound described hereinbelow. Likewise, the following compounds of Formula I or pharmaceutically acceptable salts thereof can be similarly prepared according to the schemes and procedures described above,
I
wherein A is selected from Table la, B is selected from Table lb, D is selected from Table 2, Y and Z are each independently selected from Table 3, and X Ϊ3 L2 [s selected from Table 4, and A, B, D and X are each independently optionally substituted with one or more RA, and D is optionally substituted with J, and wherein J, L L2, L3 and RA are as described above. Preferably, L L2 and L3 are bond.
 T/US2011/065501
Table 2. D
ı92 Table 3. Y and Z (continued)
Table 3. Y and Z (continued)
Table 4. L-,— X— L2
ΛΑΛ A ^'Ά Each compound's anti-HCV activity can be determined by measuring the activity of the luciferase reporter gene in the replicon in the presence of 5% FBS. The luciferase reporter gene is placed under the translational control of the poliovirus IRES instead of the HCV IRES, and HuH-7 cells are used to support the replication of the replicon.
The inhibitory activities of the compounds of the present invention can be evaluated using a variety of assays known in the art. For instance, two stable subgenomic replicon cell lines can be used for compound characterization in cell culture: one derived from genotype la-H77 and the other derived from genotype lb-Conl, obtained from University of Texas Medical Branch, Galveston, TX or Apath, LLC, St. Louis, MO, respectively. The replicon constructs can be bicistronic subgenomic replicons. The genotype la replicon construct contains NS3-NS5B coding region derived from the H77 strain of HCV (la-H77). The replicon also has a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker. These two coding regions, separated by the FMDV 2a protease, comprise the first cistron of the bicistronic replicon construct, with the second cistron containing the NS3-NS5B coding region with addition of adaptive mutations E1202G, K1691R, K2040R and S2204I. The lb-Conl replicon construct is identical to the la-H77 replicon, except that the HCV 5' UTR, 3' UTR, and NS3-NS5B coding region are derived from the lb-Conl strain, and the adaptive mutations are K1609E, K1846T and Y3005C. In addition, the lb-Conl replicon construct contains a poliovirus IRES between the HCV IRES and the luciferase gene. Replicon cell lines can be maintained in Dulbecco's modified Eagles medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 200 mg/ml G418 (Invitrogen).
The inhibitory effects of the compounds of the invention on HCV replication can be determined by measuring activity of the luciferase reporter gene. For example, replicon-containing cells can be seeded into 96 well plates at a density of 5000 cells per well in 100 μΐ DMEM containing
5% FBS. The following day compounds can be diluted in dimethyl sulfoxide (DMSO) to generate a
200x stock in a series of eight half-log dilutions. The dilution series can then be further diluted
100-fold in the medium containing 5% FBS. Medium with the inhibitor is added to the overnight cell culture plates already containing 100 μΐ of DMEM with 5% FBS. In assays measuring inhibitory activity in the presence of human plasma, the medium from the overnight cell culture plates can be replaced with DMEM containing 40% human plasma and 5% FBS. The cells can be incubated for three days in the tissue culture incubators after which time 30 μΐ of Passive Lysis buffer (Promega) can be added to each well, and then the plates are incubated for 15 minutes with rocking to lyse the cells. Luciferin solution (100 μΐ, Promega) can be added to each well, and luciferase activity can be measured with a Victor II luminometer (Perkin-Elmer). The percent inhibition of HCV RNA replication can be calculated for each compound concentration and the EC50 value can be calculated using nonlinear regression curve fitting to the 4-j3aram.et.er logistic equation and GraphPad Prism 4 software. Using the above-described assays or similar cell-based replicon assays, representative compounds of the present invention showed significantly inhibitory activities against HCV replication.
The present invention also features pharmaceutical compositions comprising the compounds of the invention. A pharmaceutical composition of the present invention can comprise one or more compounds of the invention, each of which has Formula I (or IA, ¾, Ic, ID, IE, IF or IG).
In addition, the present invention features pharmaceutical compositions comprising pharmaceutically acceptable salts, solvates, or prodrugs of the compounds of the invention. Without limitation, pharmaceutically acceptable salts can be zwitterions or derived from pharmaceutically acceptable inorganic or organic acids or bases. Preferably, a pharmaceutically acceptable salt retains the biological effectiveness of the free acid or base of the compound without undue toxicity, irritation, or allergic response, has a reasonable benefit/risk ratio, is effective for the intended use, and is not biologically or otherwise undesirable.
The present invention further features pharmaceutical compositions comprising a compound of the invention (or a salt, solvate or prodrug thereof) and another therapeutic agent. By way of illustration not limitation, these other therapeutic agents can be selected from antiviral agents (e.g., anti-HIV agents, anti-HBV agents, or other anti-HCV agents such as HCV protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, IRES inhibitors or NS5A inhibitors), anti -bacterial agents, anti-fungal agents, immunomodulators, anti-cancer or chemotherapeutic agents, anti- inflammation agents, antisense RNA, siRNA, antibodies, or agents for treating cirrhosis or inflammation of the liver. Specific examples of these other therapeutic agents include, but are not limited to, ribavirin, a-interferon, β-interferon, pegylated interferon-a, pegylated interferon-lambda, ribavirin, viramidine, R-5158, nitazoxanide, amantadine, Debio-025, NIM-811 , R7128, R1626, R4048, T-1106, PSI-7851 (Pharmasset) (nucleoside polymerase inhibitor), PSI-938 (Pharmasset) (nucleoside polymerase inhibitor), PF-00868554, ANA-598, IDX184 (nucleoside polymerase inhibitor), IDX102, IDX375 (non-nucleoside polymerase inhibitor), GS-9190 (non-nucleoside polymerase inhibitor), VCH-759, VCH-916, MK-3281, BCX-4678, MK-3281, VBY708, ANA598, GL59728, GL60667, BMS-790052 (NS5A inhibitor), BMS-791325 (protease Inhibitor), BMS- 650032, BMS-824393, GS-9132, ACH-1095 (protease inhibitor), AP-H005, A-831 (Arrow Therapeutics) (NS5A inhibitor), A-689 (Arrow Therapeutics) (NS5A inhibitor), INX08189 (Inhibitex) (polymerase inhibitor), AZD2836, telaprevir (protease Inhibitor), boceprevir (protease Inhibitor), ITMN-191 (Intermune/Roche), BI-201335 (protease Inhibitor), VBY-376, VX-500 (Vertex) (protease Inhibitor), PHX-B, ACH-1625, IDX136, IDX316, VX-813 (Vertex) (protease Inhibitor), SCH 900518 (Schering-Plough), TMC-435 (Tibotec) (protease Inhibitor), ITMN-191 (Intermune, Roche) (protease Inhibitor), MK-7009 (Merck) (protease Inhibitor), IDX-PI (Novartis), BI-201335 (Boehringer Ingelheim), R7128 (Roche) (nucleoside polymerase inhibitor), MK-3281 (Merck), MK-0608 (Merck) (nucleoside polymerase inhibitor), PF-868554 (Pfizer) (non-nucleoside polymerase inhibitor), PF- 4878691 (Pfizer), IDX-184 (Novartis), IDX-375 (Pharmasset), PPI-461 (Presidio) (NS5A inhibitor), BILB-1941 (Boehringer Ingelheim), GS-9190 (Gilead), BMS-790052 (BMS), Albuferon (Novartis), ABT-450 (Abbott/Enanta) (protease Inhibitor), ABT-333 (Abbott) (non-nucleoside polymerase inhibitor), ABT-072 (Abbott) (non-nucleoside polymerase inhibitor), ritonavir, another cytochrome P450 monooxygenase inhibitor, or any combination thereof.
In one embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates or prodrugs thereof), and one or more other antiviral agents.
In another embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates or prodrugs thereof), and one or more other anti-HCV agents. For example, a pharmaceutical composition of the present invention can comprise a compound(s) of the present invention having Formula I, IA, ¾, Ic, ID, IE, IF or IG (or a salt, solvate or prodrug thereof), and an agent selected from HCV polymerase inhibitors (including nucleoside or non-nucleoside type of polymerase inhibitors), HCV protease inhibitors, HCV helicase inhibitors, CD81 inhibitors, cyclophilin inhibitors, IRES inhibitors, or NS5A inhibitors.
In yet another embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates or prodrugs thereof), and one or more other antiviral agents, such as anti-HBV, anti-HIV agents, or anti-hepatitis A, anti-hepatitis D, anti -hepatitis E or anti-hepatitis G agents. Non-limiting examples of anti-HBV agents include adefovir, lamivudine, and tenofovir. Non-limiting examples of anti-HIV drugs include ritonavir, lopinavir, indinavir, nelfmavir, saquinavir, amprenavir, atazanavir, tipranavir, TMC-114, fosamprenavir, zidovudine, lamivudine, didanosine, stavudine, tenofovir, zalcitabine, abacavir, efavirenz, nevirapine, delavirdine, TMC-125, L-870812, S-1360, enfuvirtide, T-1249, or other HIV protease, reverse transcriptase, integrase or fusion inhibitors. Any other desirable antiviral agents can also be included in a pharmaceutical composition of the present invention, as appreciated by those skilled in the art.
In a preferred embodiment, a pharmaceutical composition of the invention comprises a compound of the invention (e.g.., a compound of Formula I, IA, ¾, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1-8, or a salt, solvate or prodrug thereof), and a HCV protease inhibitor. In another preferred embodiment, a pharmaceutical composition of the invention comprises a compound of the invention (e.g.., a compound of Formula I, IA, IB, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1 -8, or a salt, solvate or prodrug thereof), and a HCV polymerase inhibitor (e.g., a non-nucleoside polymerase inhibitor, or preferably a nucleoside polymerase inhibitor). In yet another preferred embodiment, a pharmaceutical composition of the present invention comprises (1) a compound of the invention (e.g.., a compound of Formula I, IA, ½, Ic, ID, IE, If or IG, or preferably a compound selected from Examples 1-8, or a salt, solvate or prodrug thereof), (2) a HCV protease inhibitor, and (3) a HCV polymerase inhibitor (e.g., a non-nucleoside polymerase inhibitor, or preferably a nucleoside polymerase inhibitor). Non-limiting examples of protease and polymerase inhibitors are described above.
A pharmaceutical composition of the present invention typically includes a pharmaceutically acceptable carrier or excipient. Non-limiting examples of suitable pharmaceutically acceptable carriers/excipients include sugars (e.g., lactose, glucose or sucrose), starches (e.g., corn starch or potato starch), cellulose or its derivatives (e.g., sodium carboxymethyl cellulose, ethyl cellulose or cellulose acetate), oils (e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil or soybean oil), glycols (e.g., propylene glycol), buffering agents (e.g., magnesium hydroxide or aluminum hydroxide), agar, alginic acid, powdered tragacanth, malt, gelatin, talc, cocoa butter, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, or phosphate buffer solutions. Lubricants, coloring agents, releasing agents, coating agents, sweetening, flavoring or perfuming agents, preservatives, or antioxidants can also be included in a pharmaceutical composition of the present invention.
The pharmaceutical compositions of the present invention can be formulated based on their routes of administration using methods well known in the art. For example, a sterile injectable preparation can be prepared as a sterile injectable aqueous or oleagenous suspension using suitable dispersing or wetting agents and suspending agents. Suppositories for rectal administration can be prepared by mixing drugs with a suitable nonirritating excipient such as cocoa butter or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drugs. Solid dosage forms for oral administration can be capsules, tablets, pills, powders or granules. In such solid dosage forms, the active compounds can be admixed with at least one inert diluent such as sucrose lactose or starch. Solid dosage forms may also comprise other substances in addition to inert diluents, such as lubricating agents. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs containing inert diluents commonly used in the art. Liquid dosage forms may also comprise wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents. The pharmaceutical compositions of the present invention can also be administered in the form of liposomes, as described in U.S. Patent No. 6,703,403. Formulation of drugs that are applicable to the present invention is generally discussed in, for example, Hoover, John E., REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Co., Easton, PA: 1975), and Lachman, L., eds., PHARMACEUTICAL DOSAGE FORMS (Marcel Decker, New York, N.Y., 1980). Any compound described herein, or a pharmaceutically acceptable salt thereof, can be used to prepared pharmaceutical compositions of the present invention.
In a preferred embodiment, a compound of the invention (e.g., a compound of Formula I, IA, IB, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1 -8, or a salt, solvate or prodrug thereof) is formulated in a solid dispersion, where the compound of the invention can be molecularly dispersed in an amorphous matrix which comprises a pharmaceutically acceptable, hydrophilic polymer. The matrix may also contain a pharmaceutically acceptable surfactant. Suitable solid dispersion technology for formulating a compound of the invention includes, but is not limited to, melt-extrusion, spray-drying, co-precipitation, freeze drying, or other solvent evaporation techniques, with melt-extrusion and spray-drying being preferred. In one example, a compound of the invention is formulated in a solid dispersion comprising copovidone and vitamin E TPGS. In another example, a compound of the invention is formulated in a solid dispersion comprising copovidone and Span 20.
A solid dispersion described herein may contain at least 30% by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of such hydrophilic polymers. Preferably, the solid dispersion contains at least 40% by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of such hydrophilic polymers. More preferably, the solid dispersion contains at least 50%> (including, e.g., at least 60%>, 70%>, 80%> or 90%>) by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of such polymers. A solid dispersion described herein may also contain at least 1 % by weight of a pharmaceutically acceptable surfactant or a combination of such surfactants. Preferably, the solid dispersion contains at least 2% by weight of a pharmaceutically acceptable surfactant or a combination of such surfactants. More preferably, the solid dispersion contains from 4% to 20% by weight of the surfactant(s), such as from 5% to 10% by weight of the surfactant(s). In addition, a solid dispersion described herein may contain at least 1% by weight of a compound of the invention, preferably at least 5%, including, e.g., at least 10%. In one example, the solid dispersion comprises 5%> of a compound of the invention (e.g., a compound of Formula I, IA, ¾, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1-8, or a salt, solvate or prodrug thereof), which is molecularly dispersed in a an amorphous matrix comprising 7% Vitamin E-TPGS and 88%o copovidone; the solid dispersion can also be mixed with other excipients such as mannitol/aerosil (99: 1), and the weight ratio of the solid dispersion over the other excipients can range from 5 : 1 to 1 :5 with 1 : 1 being preferred. In another example, the solid dispersion comprises 5% of a compound of the invention (e.g., a compound of Formula I, IA, ¾, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1 -8, or a salt, solvate or prodrug thereof), which is molecularly dispersed in a an amorphous matrix comprising 5%> Span 20 and 90%o copovidone; the solid dispersion can also be mixed with other excipients such as mannitol/aerosil (99: 1), the solid dispersion can also be mixed with other excipients such as mannitol/aerosil (99: 1), and the weight ratio of the solid dispersion over the other excipients can range from 5:1 to 1 :5 with 1 :1 being preferred.
Various additives can also be included in or mixed with the solid dispersion. For instance, at least one additive selected from flow regulators, binders, lubricants, fillers, disintegrants, plasticizers, colorants, or stabilizers may be used in compressing the solid dispersion to tablets. These additives can be mixed with ground or milled solid dispersion before compacting. Disintegrants promote a rapid disintegration of the compact in the stomach and keeps the liberated granules separate from one another. Non-limiting examples of suitable disintegrants are cross-linked polymers such as cross- linked polyvinyl pyrrolidone, cross-linked sodium carboxymethylcellulose or sodium croscarmellose. Non-limiting examples of suitable fillers (also referred to as bulking agents) are lactose monohydrate, calcium hydrogenphosphate, microcrystalline cellulose (e.g., Avicell), silicates, in particular silicium dioxide, magnesium oxide, talc, potato or corn starch, isomalt, or polyvinyl alcohol. Non-limiting examples of suitable flow regulators include highly dispersed silica (e.g., colloidal silica such as Aerosil), and animal or vegetable fats or waxes. Non-limiting examples of suitable lubricants include polyethylene glycol (e.g., having a molecular weight of from 1000 to 6000), magnesium and calcium stearates, sodium stearyl fumarate, and the like. Non-limiting examples of stabilizers include antioxidants, light stabilizers, radical scavengers, or stabilizers against microbial attack.
The present invention further features methods of using the compounds of the present invention (or salts, solvates or prodrugs thereof) to inhibit HCV replication. The methods comprise contacting cells infected with HCV virus with an effective amount of a compound of the present invention (or a salt, solvate or prodrug thereof), thereby inhibiting the replication of HCV virus in the cells. As used herein, "inhibiting" means significantly reducing, or abolishing, the activity being inhibited (e.g., viral replication). In many cases, representative compounds of the present invention can reduce the replication of HCV virus (e.g., in an HCV replicon assay as described above) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more.
The compounds of the present invention may inhibit one or more HCV subtypes. Examples of HCV subtypes that are amenable to the present invention include, but are not be limited to, HCV genotypes 1, 2, 3, 4, 5 and 6, including HCV genotypes la, lb, 2a, 2b, 2c, 3a or 4a. In one embodiment, a compound or compounds of the present invention (or salts, solvates or prodrugs thereof) are used to inhibit the replication of HCV genotype la. In another embodiment, a compound or compounds of the present invention (or salts, solvates or prodrugs thereof) are used to inhibit the replication of HCV genotype lb. In still another embodiment, a compound or compounds of the present invention (or salts, solvates or prodrugs thereof) are used to inhibit the replication of both HCV genotypes la and lb.
The present invention also features methods of using the compounds of the present invention
(or salts, solvates or prodrugs thereof) to treat HCV infection. The methods typically comprise administering a therapeutic effective amount of a compound of the present invention (or a salt, solvate or prodrug thereof), or a pharmaceutical composition comprising the same, to an HCV patient, thereby reducing the HCV viral level in the blood or liver of the patient. As used herein, the term "treating" refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition, or one or more symptoms of such disorder or condition to which such term applies. The term "treatment" refers to the act of treating. In one embodiment, the methods comprise administering a therapeutic effective amount of two or more compounds of the present invention (or salts, solvates or prodrugs thereof), or a pharmaceutical composition comprising the same, to an HCV patient, thereby reducing the HCV viral level in the blood or liver of the patient.
A compound of the present invention (or a salt, solvate or prodrug thereof) can be administered as the sole active pharmaceutical agent, or in combination with another desired drug, such as other anti-HCV agents, anti-HIV agents, anti-HBV agents, anti-hepatitis A agents, anti- hepatitis D agents, anti-hepatitis E agents, anti-hepatitis G agents, or other antiviral drugs. Any compound described herein, or a pharmaceutically acceptable salt thereof, can be employed in the methods of the present invention. In one embodiment, the present invention features methods of treating HCV infection, wherein said methods comprise administering a compound of the invention (e.g., a compound of Formula I, IA, ¾, Ic, ID, IE, IF or IG, or preferably a compound selected from Examples 1 -8, or a salt, solvate or prodrug thereof), interferon and ribavirin to an HCV patient. The interferon preferably is a-interferon, and more preferably, pegylated interferon-a such as PEGASYS (peginterferon alfa-2a).
A compound of the present invention (or a salt, solvent or prodrug thereof) can be administered to a patient in a single dose or divided doses. A typical daily dosage can range, without limitation, from 0.1 to 200 mg/kg body weight, such as from 0.25 to 100 mg/kg body weight. Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose. Preferably, each dosage contains a sufficient amount of a compound of the present invention that is effective in reducing the HCV viral load in the blood or liver of the patient. The amount of the active ingredient, or the active ingredients that are combined, to produce a single dosage form may vary depending upon the host treated and the particular mode of administration. It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.
The present invention further features methods of using the pharmaceutical compositions of the present invention to treat HCV infection. The methods typically comprise administering a pharmaceutical composition of the present invention to an HCV patient, thereby reducing the HCV viral level in the blood or liver of the patient. Any pharmaceutical composition described herein can be used in the methods of the present invention.
In addition, the present invention features use of the compounds or salts of the present invention for the manufacture of medicaments for the treatment of HCV infection. Any compound described herein, or a pharmaceutically acceptable salt thereof, can be used to make medicaments of the present invention.
The compounds of the present invention can also be isotopically substituted. Preferred isotopic substitution include substitutions with stable or nonradioactive isotopes such as deuterium, 1 C, 15N or 180. Incorporation of a heavy atom, such as substitution of deuterium for hydrogen, can give rise to an isotope effect that could alter the pharmacokinetics of the drug. In one example, at least 5 mol % (e.g., at least 10 mol %) of hydrogen in a compound of the present invention is substituted with deuterium. In another example, at least 25 mole % of hydrogen in a compound of the present invention is substituted with deuterium. In a further example, at least 50, 60,70, 80 or 90 mole % of hydrogen in a compound of the present invention is substituted with deuterium. The natural abundance of deuterium is about 0.015%. Deuterium substitution or enrichment can be achieved, without limitation, by either exchanging protons with deuterium or by synthesizing the molecule with enriched or substituted starting materials. Other methods known in the art can also be used for isotopic substitutions.
The foregoing description of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to the precise one disclosed. Modifications and variations are possible in light of the above teachings or may be acquired from practice of the invention. Thus, it is noted that the scope of the invention is defined by the claims and their equivalents.

Claims

What is claimed is:
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,
D
I
L3
I
Y— A— L— X— L2— B— Z
I
wherein:
X is C3-C8cycloalkyl or C5-C8cycloalkenyl, and is optionally substituted with one or more RA;
Li and L2 are each independently selected from bond; or Ci-Cealkylene, C2-Cealkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL;
L3 is bond or -Ls-K-Ls'-, wherein K is selected from bond, -0-, -S-, -N(RB)-, -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20- -S(0)0-, -C(0)0-, -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0-, -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2- -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-, -N(RB)S02N(RB')-, or -N(RB)S(0)N(RB')-;
A and B are each independently C3-Ci2carbocycle or 3- to 12-membered heterocycle, and are each independently optionally substituted with one or more RA;
D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Ci2carbocycle or 3- to 12-membered heterocycle and is optionally substituted with one or more RA, or J is -SF5; or D is hydrogen or RA;
Y is selected from -T'-C(R1R2)N(R5)-T-RD, -T'-C(R3R4)C(R6R7)-T-RD, -LK-T-Rd, or
Ri and R2 are each independently Rc, and R5 is RB; or Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
R3, R4, R6, and R7 are each independently Rc; or R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12- membered carbocycle or heterocycle which is optionally substituted with one or more RA;
Z is selected from -T'-C(R8R9)N(R12)-T-RD, -T'-C(R10Rn)C(Ri3Ri4)-T-RD, -LK— T— RD or Rs and Rg are each independently Rc, and R12 is RB; or R8 is Rc, and Rg and R12, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
Rio, Rn, Ri3, and RM are each independently Rc; or Ri0 and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
T and T are each independently selected at each occurrence from bond, -Ls- -Ls-M-Ls'-, or -Ls-M-Ls'-M'-Ls"-, wherein M and M' are each independently selected at each occurrence from bond, -0-, -S-, — N(RB)— , -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20- -S(0)0-, -C(0)0-, -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0- -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2-, -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-, -N(RB)S02N(RB')-, -N(RB)S(0)N(RB')-, C3-Ci2carbocycle or 3- to 12-membered heterocycle, and wherein said C3-Ci2carbocycle and 3- to 12-membered heterocycle are each independently optionally substituted at each occurrence with one or more RA;
LK is independently selected at each occurrence from bond, -Ls-N(RB)C(0)-Ls'- or -Ls-C(0)N(RB)-Ls'-; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; or C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more RA;
E is independently selected at each occurrence from C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is independently optionally substituted at each occurrence with one or more RA;
RD is each independently selected at each occurrence from hydrogen or RA;
RA is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE, wherein two adjacent RA, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle;
RB and RB' are each independently selected at each occurrence from hydrogen; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 12- membered carbocycle or heterocycle; or 3- to 12-membered carbocycle or heterocycle; wherein each 3- to 12-membered carbocycle or heterocycle in RB or RB' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl;
Rc is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 12-membered carbocycle or heterocycle; or 3- to 12-membered carbocycle or heterocycle; wherein each 3- to 12-membered carbocycle or heterocycle in Rc is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl;
RE is independently selected at each occurrence from
-0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), P(0)(ORs)2 or -C(0)N(Rs)C(0)-Rs'; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or
C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs, -N(RSRS') or RF, wherein RF is C3-Ci2carbocycle or 3- to 12-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-Cealkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RsRs'); RF is independently selected at each occurrence from Ci-Cioalkyl, C2-Cioalkenyl or C2-Ci0alkynyl, each of which contains 0, 1, 2, 3, 4 or 5 heteroatoms selected from O, S or N and is optionally substituted with one or more RL; or -(RX-RY)Q-(RX-RY'), wherein Q is 0, 1 , 2, 3 or 4, and each Rx is independently O, S or N(RB), wherein each RY is independently Ci-Cealkylene, C2-Cealkenylene or C2-C6alkynylene each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, and wherein each RY' is independently Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl each of which is independently optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano;
RL is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs') or -N(Rs)C(0)Rs'; or C3-Ci2carbocycle or 3- to 12- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl;
Ls, Ls' and Ls" are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; and
Rs, Rs' and Rs" are each independently selected at each occurrence from
hydrogen; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 12-membered carbocycle or heterocycle; or
-(RG-RH)n-(RG-RH')> wherein each n is independently 0, 1 , 2, 3 or 4; each RG is independently O, S or N(RB); each RH is independently Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 12- membered carbocycle or heterocycle; and each RH' is independently Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 12-membered carbocycle or heterocycle; or
3- to 12-membered carbocycle or heterocycle;
wherein each 3- to 12-membered carbocycle or heterocycle in Rs , Rs' or Rs" is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl.
2. The compound or salt of claim 1 , wherein:
selected from C5-C6carboc cle 5- to 6-membered heteroc cle
B is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or and is optionally substituted with one or more RA;
D is selected from C5-C6carbocycle or 5- to 6-membered heterocycle, and is optionally substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-C6carbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA;
Zi is independently selected at each occurrence from O, S, NH or CH2;
Z2 is independently selected at each occurrence from N or CH;
Z3 is independently selected at each occurrence from N or CH;
Z4 is independently selected at each occurrence from O, S, NH or CH2; and
Wi, W2, W3, W4, W5 and W6 are each independently selected at each occurrence from CH or N.
3. The compound or salt of claim 1 , wherein: selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or
B is selected from C5-C6carbocycle, 5- to 6-membered heterocycle, or is optionally substituted with one or more RA;
D is selected from C5-C6carbocycle or 5- to 6-membered heterocycle, and is optionally substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA;
Zi is independently selected at each occurrence from O, S, NH or CH2;
Z2 is independently selected at each occurrence from N or CH; and
Wi, W2, W3, W4, W5 and W6 are each independently selected at each occurrence from CH or N.
4. The compound or salt of claim 1 , wherein:
A and B are each independently C5-C6carbocycle or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more RA; and
D is selected from C5-C6carbocycle or 5- to 6-membered heterocycle, and is optionally substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA.
5. A compound of Formula I, or a pharmaceutically acceptable salt thereof,
D
Y— A— L-i— X— L2— B— Z
I wherein:
X is C3-C8cycloalkyl or C5-C8cycloalkenyl, and is optionally substituted with one or more RA; Li, L2 and L3 are each a bond;
A and B are each independently * and are each independently optionally substituted with one or more RA;
D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Ci2carbocycle or 3- to 12-membered heterocycle and is optionally substituted with one or more RA;
Y is -G-C(R!R2)N(R5)-T-RD, -G-C(R3R4)C(R6R7)-T-RD, -N(RB)C(0)C(R!R2)N(R5)-T-RD, or -N(RB)C(0)C(R3R4)C(R6R7)-T-RD;
Z is -G-C(R8R9)N(R12)-T-RD, -G-C(R10Rn)C(R13R14)-T-RD,
-N(RB)C(0)C(R8R9)N(R12)-T-RD, or -N(RB)C(0)C(R1oRn)C(R13R14)-T-RD;
Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
R8 is Rc, and R9 and Ri2, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
Rio and Ri3 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
G is each independently C5-C6carbocycle or 5- to 6-membered heterocycle, and is each independently optionally substituted with one or more RA;
T is each independently selected at each occurrence from bond, -Ls- -Ls-M-Ls'-, or -Ls-M-Ls'-M'-Ls"-, wherein M and M' are each independently selected at each occurrence from bond, -0-, -S-, — N(RB)— , -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20- -S(0)0- -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0-, -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2-, -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-
-N(RB)S02N(RB')-, -N(RB)S(0)N(RB')-, C3-Ci2carbocycle or 3- to 12-membered heterocycle, and wherein said C3-Ci2carbocycle and 3- to 12-membered heterocycle are each independently optionally substituted at each occurrence with one or more RA; RD is each independently selected at each occurrence from hydrogen or RA;
RA is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE;
RB and RB' are each independently selected at each occurrence from hydrogen; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RB or RB' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-Cehaloalkenyl or C2-Cehaloalkynyl;
Rc is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in Rc is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl;
RE is independently selected at each occurrence from
-0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), P(0)(ORs)2 or -C(0)N(Rs)C(0)-Rs'; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS'); RL is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs') or -N(Rs)C(0)Rs'; or C3-C6carbocycle 3- to 6- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; Ls, Ls' and Ls" are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-Cealkenylene or C2-Cealkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; and
Rs, Rs' and Rs" are each independently selected at each occurrence from
hydrogen; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or
-(RG-RH)n-(RG-RH')> wherein each n is independently 0, 1, 2, 3 or 4; each RG is independently O, S or N(RB); each RH is independently Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; and each RH' is independently Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or
3- to 6-membered carbocycle or heterocycle;
wherein each 3- to 6-membered carbocycle or heterocycle in Rs, Rs1 or Rs» is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-C6haloalkenyl or C2-C6haloalkynyl.
6. The compound or salt of claim 5, wherein:
is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"- or -N(RB)C(0)-Ls'-M'-Ls"-; and
' is each independently Ci-C6alkylene, and is independently optionally substituted at each occurrence with one or more RL.
7. The compound or salt of claim 5, wherein:
Y is -N(RB)C(0)C(R1R2)N(R5)-T-RD;
Z is -N(RB)C(0)C(R8R9)N(R12)-T-RD;
T is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"-; and
D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA.
8. The compound or salt of claim 7, wherein T is independently selected at each occurrence from -C(0)-Ls'-N(RB)C(0)-Ls"- or -C(0)-Ls'-N( "-; and R2 and R5, taken
together with the atoms to which they are attached,
substituted with one or more RA; and Rg and R12, taken together with the atoms to which they
are attached, form which is optionally substituted with one or more RA.
The compound or salt of claim 5, wherein:
Y is -G-C(RiR2)N(R5)-T--RD;
Z is -G-C(R8R9)N(R12)-T-RD;
G is each independently , and is each independently optionally substituted with one or more RA;
T is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"-; and D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA.
The compound or salt of claim 9, wherein T is independently selected at each occurrence from -C(0)-Ls'-N(RB)C(0)-Ls"- or -C(0)-Ls'-N(RB)C( "-; and R2 and R5, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA; and Rg and R12, taken together with the atoms to which they
are attached, form which is optionally substituted with one or more RA. 1. A compound of Formula I, or a pharmaceutically acceptable salt thereof,
D
I
L3
I
Y— A— L— X— L2— B— Z
I
wherein:
X is C3-C8cycloalkyl or C5-C8cycloalkenyl, and is optionally substituted with one or more RA; Li, L2 and L3 are each a bond;
A is selected from B is selected from or s Zi is independently selected at each occurrence from O, S, NH or CH2, Z2 is independently selected at each occurrence from N or CH, and Wi, W2, W3, W4, W5 and W6 are each independently selected at each occurrence from CH or N, wherein A and B are each independently optionally substituted with one or more RA; D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more RA; or D is C3-Ci2carbocycle or 3- to 12-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Ci2carbocycle or 3- to 12-membered heterocycle and is optionally substituted with one or more RA;
Y is -C(R!R2)N(R5)-T-RD, or -C(R3R4)C(R6R7)-T-RD;
Z is -C(R8R9)N(R12)-T-RD, or -C(R10Rn)C(R13R14)-T-RD;
Ri is Rc, and R2 and R5, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
Rs is Rc, and R9 and R12, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RA;
RIO and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more RA;
T is each independently selected at each occurrence from bond, -Ls- -Ls-M-Ls'-, or -Ls-M-Ls'-M'-Ls"-, wherein M and M' are each independently selected at each occurrence from bond, -0-, -S-, — N(RB)— , -C(O)-, -S(0)2- -S(O)-, -OS(O)-, -OS(0)2- -S(0)20- -S(0)0- -C(0)0- -OC(O)-, -OC(0)0- -C(0)N(RB)-, -N(RB)C(0)-, -N(RB)C(0)0- -OC(0)N(RB)-, -N(RB)S(0)-, -N(RB)S(0)2-, -S(0)N(RB)-, -S(0)2N(RB)-, -C(0)N(RB)C(0)-, -N(RB)C(0)N(RB')-
-N(RB)S02N(RB')-, -N(RB)S(0)N(RB')-, C3-Ci2carbocycle or 3- to 12-membered heterocycle, and wherein said C3-Ci2carbocycle and 3- to 12-membered heterocycle are each independently optionally substituted at each occurrence with one or more RA;
RD is each independently selected at each occurrence from hydrogen or RA;
RA is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -LS-RE;
RB and RB' are each independently selected at each occurrence from hydrogen; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in RB or RB' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-Cealkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-Cehaloalkynyl;
Rc is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in Rc is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl;
RE is independently selected at each occurrence from
-O-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs'), -N(Rs)C(0)Rs', -N(Rs)C(0)N(Rs'Rs"), -N(Rs)S02Rs', -S02N(RsRs'), -N(Rs)S02N(Rs'Rs"), -N(Rs)S(0)N(Rs'Rs"), -OS(0)-Rs, -OS(0)2-Rs, -S(0)2ORs, -S(0)ORs, -OC(0)ORs, -N(Rs)C(0)ORs', -OC(0)N(RsRs'), -N(Rs)S(0)-Rs', -S(0)N(RsRs'), P(0)(ORs)2 or -C(0)N(Rs)C(0)-Rs'; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or
C3-C6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-C6haloalkyl, C2-C6haloalkenyl, C2-C6haloalkynyl, C(0)ORs or -N(RSRS');
RL is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -0-Rs, -S-Rs, -C(0)Rs, -OC(0)Rs, -C(0)ORs, -N(RSRS'), -S(0)Rs, -S02Rs, -C(0)N(RsRs') or -N(Rs)C(0)Rs'; or C3-C6carbocycle 3- to 6- membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Q-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl; Ls, Ls' and Ls" are each independently selected at each occurrence from bond; or Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is independently optionally substituted at each occurrence with one or more RL; and
Rs, Rs' and Rs" are each independently selected at each occurrence from
hydrogen; or
Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or
-(RG-RH)II-(RG-RH')5 wherein each n is independently 0, 1, 2, 3 or 4; each RG is independently O, S or N(RB); each RH is independently Ci-C6alkylene, C2-C6alkenylene or C2-C6alkynylene, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6- membered carbocycle or heterocycle; and each RH' is independently Ci-C6alkyl, C2-C6alkenyl or C2-C6alkynyl, each of which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or
3- to 6-membered carbocycle or heterocycle;
wherein each 3- to 6-membered carbocycle or heterocycle in Rs, Rs. or Rs» is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cealkyl, C2-Cealkenyl, C2-C6alkynyl, Ci-Cehaloalkyl, C2-Cehaloalkenyl or C2-C6haloalkynyl.
The compound or salt of claim 1 1 , wherein:
T is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"- or
-N(RB)C(0)-Ls'-M'-Ls"-; and
Ls' is each independently Ci-C6alkylene, and is independently optionally substituted at each occurrence with one or more RL.
13. The compound or salt of claim 1 1 , wherein:
Y is -C(R1R2)N(R5)-T-RD;
Z is -C(R8R9)N(R12)-T-RD; T is independently selected at each occurrence from -C(0)-Ls'-M'-Ls"-; and
D is C5-C6carbocycle, 5- to 6-membered heterocycle, or 6- to 10-membered bicycles, and is substituted with one or more RA; or D is C5-C6carbocycle or 5- to 6-membered heterocycle, and is substituted with J and optionally substituted with one or more RA, wherein J is C3-Cecarbocycle or 3- to 6-membered heterocycle and is optionally substituted with one or more RA.
The compound or salt of claim 13, wherein T is independently selected at each occurrence from -C(0)-Ls'-N(RB)C(0)-Ls"- or -C(0)-Ls'-N(RB)C( "-; and R2 and R5, taken
together with the atoms to which they are attached, form which is optionally substituted with one or more RA; and Rg and R12, taken together with the atoms to which they
are attached, form which is optionally substituted with one or more RA.
15. The compound of claim 14, wherein A is and A and
B are each independently optionally substituted with one or more R ■A-
16. The compound of claim 1 , wherein the compound is selected from the group consisting of: dimethyl (2S,2'1S)-l,l '-((2S,2, 1S)-2,2,-(4,4,-(3-(4-methoxyphenyl)cyclopropane-l ,2- diyl)bis(4,l -phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,l-diyl))bis(3- methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate;
dimethyl (2S,2'S)- 1 , 1 ,-((2S,2'1S)-2,2,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2- diyl)bis(4,l -phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,l-diyl))bis(3- methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate;
dimethyl (2S,2'1S)-l,l '-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-methoxyphenyl)cyclopropane-l ,2- diyl)bis(4, 1 -phenylene))bis( 1 H-imidazole-4,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 - oxobutane-2, 1 -diyl)dicarbamate;
dimethyl (2S,2, 1S)-l,l '-((2S,2, 1S)-2,2,-(4,4,-(4,4,-(3-(4-(benzyloxy)phenyl)cyclopropane-l ,2- diyl)bis(4, 1 -phenylene))bis( 1 H-imidazole-4,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 - oxobutane-2, 1 -diyl)dicarbamate; dimethyl (2S,2'S)- 1 , 1 '-((25,2'5)-2,2'-(5 ,5 '-(3-(4-(benzyloxy)phenyl)cyclopropane- 1 ,2- diyl)bis( 1/f-benzo [d]imidazole-5 ,2-diyl))bis(pyrrolidine-2, 1 -diyl))bis(3 -methyl- 1 -oxobutane- 2, 1 -diyl)dicarbamate;
dimethyl (2S,2'S)-l,l '-((2S,2,S)-2,2,-(4,4,-(3-(4-cyclohexylphenyl)cyclopropane-l,2- diyl)bis(4,l -phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-2,l-diyl))bis(3- methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate;
dimethyl (2S,2,S)-l,l '-((2S,2,S)-2,2,-(4,4,-(2-(4-tert-butylphenyl)cyclopent-3-ene-l,3- diyl)bis(4,l -phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2,l-diyl))bis(3- methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate; and
dimethyl (2S,2'S)- 1 , 1 ,-((2S,2, 1S)-2,2,-(4,4,-(2-(4-?eri-butylphenyl)cyclopentane-l ,3- diyl)bis(4,l -phenylene)bis(azanediyl)bis(oxomethylene))bis(pyrrolidine-2,l-diyl))bis(3- methyl- 1 -oxobutane-2, 1 -diyl)dicarbamate.
17. A pharmaceutical composition comprising a compound or salt according to claim 1.
18. A pharmaceutical composition comprising a compound or salt according to claim 1 and another anti-HCV agent.
18. A method of treating HCV infection, comprising administering to an HCV patient a compound or salt according to claim 1.
19. A process of making a compound according to claim 1, comprising a step described in one of the schemes or examples described hereinabove.
EP11806100.1A 2010-12-16 2011-12-16 Anti-viral compounds Ceased EP2651885A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42390610P 2010-12-16 2010-12-16
PCT/US2011/065501 WO2012083170A1 (en) 2010-12-16 2011-12-16 Anti-viral compounds

Publications (1)

Publication Number Publication Date
EP2651885A1 true EP2651885A1 (en) 2013-10-23

Family

ID=45464913

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11806100.1A Ceased EP2651885A1 (en) 2010-12-16 2011-12-16 Anti-viral compounds

Country Status (6)

Country Link
EP (1) EP2651885A1 (en)
JP (1) JP5906253B2 (en)
CN (1) CN103354808B (en)
CA (1) CA2819894A1 (en)
MX (1) MX2013006951A (en)
WO (1) WO2012083170A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2651923A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
SI3043803T1 (en) 2013-09-11 2022-09-30 Emory University Nucleotide and nucleoside compositions and their uses
CN104610332B (en) * 2015-02-26 2019-11-08 成都安斯利生物医药有限公司 A method of preparing three potassium fluoborate of tetrahydrofuran -3-
CN104672261A (en) * 2015-02-27 2015-06-03 成都安斯利生物医药有限公司 Method for preparing tetrahydrofuran-3-boric acid pinacol ester
CN104592278A (en) * 2015-02-28 2015-05-06 成都安斯利生物医药有限公司 Method for preparing tetrahydropyrane-3-boronic acid pinacol ester
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
TWI791251B (en) 2015-08-26 2023-02-01 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
EA201892031A1 (en) 2016-03-10 2019-02-28 Янссен Фармацевтика Нв SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
MD3433234T2 (en) 2016-03-22 2022-02-28 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
US11098062B2 (en) 2016-10-03 2021-08-24 Janssen Pharmaceutica Nv Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
IL268842B2 (en) 2017-02-27 2024-09-01 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
AU2018370903B2 (en) 2017-11-24 2023-09-21 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
BR112020010815A2 (en) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv spirobicyclic analogs
TW202112375A (en) 2019-06-06 2021-04-01 比利時商健生藥品公司 Methods of treating cancer using prmt5 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AU2004231538A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
KR20140072101A (en) * 2005-06-24 2014-06-12 바이오트론 리미티드 Antiviral compounds and methods
BRPI0708942A2 (en) * 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc apoptosis promoting compound, use and method of production thereof and pharmaceutical composition
BRPI0713025A2 (en) 2006-06-16 2012-04-17 Syngenta Participations Ag ethenyl carboxamide-derived compounds useful as microbiocides, method of controlling or preventing plant infestation useful by phytopathogenic microorganisms and composition for controlling and preventing said microorganisms
EP2373168A4 (en) * 2008-12-03 2012-08-01 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
SG174146A1 (en) * 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
TWI476190B (en) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) * 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
EP2337781B1 (en) 2009-06-11 2014-07-23 AbbVie Bahamas Ltd. Anti-viral compounds to treat hcv infection
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
BR112012022311A2 (en) * 2010-03-04 2016-08-23 Enanta Pharm Inc combination pharmaceutical agents as inhibitors of hcv replication.

Also Published As

Publication number Publication date
WO2012083170A1 (en) 2012-06-21
CN103354808B (en) 2016-08-10
JP2014504296A (en) 2014-02-20
CA2819894A1 (en) 2012-06-21
CN103354808A (en) 2013-10-16
JP5906253B2 (en) 2016-04-20
MX2013006951A (en) 2013-10-03

Similar Documents

Publication Publication Date Title
US9394279B2 (en) Anti-viral compounds
JP5906253B2 (en) Antiviral compounds
US10039754B2 (en) Anti-viral compounds
US8921514B2 (en) Anti-viral compounds
US20120115918A1 (en) Anti-Viral Compounds
JP6790202B2 (en) Antiviral compound
AU2016238925B2 (en) Anti-viral compounds
AU2014203655B2 (en) Anti-viral compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188450

Country of ref document: HK

17Q First examination report despatched

Effective date: 20140905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20161013

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1188450

Country of ref document: HK